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Introduction
Partly based on “van Hagen, Roos-Hesselink. Pregnancy in women with 
congenital heart disease. South African Heart Journal, 2013;10:616-624” and 
“Care during pregnancy’, van Hagen, Roos-Hesselink, book chapter in ‘Adult 
Congenital Heart Disease’, 2016.
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Thankfully, in the vast majority of pregnancies no severe problems occur. But the woman’s 
body is exposed to major changes throughout pregnancy and subsequently some preg-
nant women may experience serious events, such as (pre)eclampsia, haemorrhage and 
even death. The fifth millennium goal from the World Health Organization is to reduce 
global maternal mortality rates, and as a consequence of improved maternal health care, 
the number of deaths have declined over the past decades1. Remarkably, maternal mortality 
due to cardiovascular disease showed a paradoxical increase2,3. Cardiovascular disease is the 
leading cause of mortality in pregnant women in countries with an advanced economy. 
Obstetric complications, such as haemorrhage and sepsis, are the major cause of maternal 
mortality in Sub-Saharan countries. Apart from these direct obstetric causes, heart disease is 
the main non-obstetric cause of death also in emerging countries4.
Haemodynamic physiology of pregnancy
Growing a fetus in the womb requires development and maintenance of a sufficient 
uteroplacental and fetal circulation. Establishment of this new circulatory system warrants 
adaptation of the maternal cardiovascular system. Hormonal changes significantly influence 
circulating volume, vascular resistance and heart rate. Both the heart and the great vessels 
are subject to structural changes. Pregnancy is a major challenge to the cardiovascular 
system even in healthy women. 
Cardiac output and plasma volume start to raise in the first weeks of gestation, and 
increase up to 50% above normal values up to the end of the second trimester, together 
with a 10-20% increase of the heart rate, a 30% increase of stroke volume, and a 30-40% de-
crease of vascular resistance5-7. Left ventricular diastolic dimensions are known to increase 
approximately 7-12% throughout pregnancy and to return to preconception values 6–12 
months after pregnancy in healthy women8. Systolic dimensions remain stable, allowing for 
the increment of stroke volume. Maximum haemodynamic adaptation is generally reached 
beyond 20 weeks of gestation up to the end of the second trimester5.
The aortic wall undergoes both functional and structural changes. Aortic dimensions may 
be influenced by physiological haemodynamic alterations, hormonal changes, but also by 
hypertensive conditions9. In Marfan syndrome, an aortic diameter growth of 3 mm during 
pregnancy has been described and a decrease after pregnancy was reported, but without 
full recovery to prepregnancy values10. In a post-mortem histology study of pregnant 
women, loss of medial layer integrity has been shown in the aorta11. Hormonal changes are 
suggested to play a role. Oestrogen and progesterone induce an increase of vascular matrix 
metalloproteinases (MMPs) and elastin, and a decrease of collagen, resulting in reduced 
systemic artery stiffness12,13. This physiological phenomenon of vascular remodelling is 
probably key to various pathophysiologic issues during pregnancy14.
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Maternal cardiovascular disease and pregnancy 
In patients with heart disease, the capacity of the heart to adapt may be insufficient, leading 
to cardiac deterioration during pregnancy, and thus a higher risk of complications such as 
arrhythmias or heart failure. Patients with compromised ventricular function, severe valve 
disease, pulmonary hypertension or cyanosis are particularly at risk. While pregnancy itself 
forms a thrombogenic state, pregnancy introduces an additional risk for thrombosis but also 
for haemorrhage in women with a mechanical valve who require anticoagulation. Also, the 
risk of aortic dissection and rupture may be elevated during pregnancy due to the vascular 
wall changes15,16. Aortic dissection during pregnancy in healthy pregnant women is rare, 
but women with aortic disease, such as Marfan syndrome or Loeys Dietz syndrome, clearly 
are at increased risk. Acute aortic pathology is the most important cause of cardiovascular 
maternal death in the general pregnant population2. Such a devastating event not only 
involves the life of the mother, but also the life of the fetus is at risk17. In women with cardiac 
disease, there is a higher chance of miscarriage, preterm birth, low birth weight and fetal 
congenital (heart) disease. Treatment strategy should therefore always be determined by a 
multidisciplinary team, including at least an obstetrician, a cardiologist and an anaesthetist, 
with careful consideration of both lives. 
Guidelines and need for evidence 
Recommendations on the management of pregnancy in women with heart disease have 
been published in 2003 and first guidelines were published in 2011 by the European Society 
of Cardiology (ESC)18,19. While great efforts have been made to provide evidence based 
statements, the majority of recommendations were based on level of evidence class C: 
expert opinion. With an increasing number of women with heart disease getting pregnant 
it is important to provide solid evidence to support future guidelines. Clearly there are large 
gaps in knowledge and evidence from randomized-controlled trials is lacking and difficult 
to obtain.
What we do know is that preconception counselling is of utmost importance and a class 
I recommendation for all women with known heart disease. In each individual woman, risk 
stratification may help to determine further approach of counselling and management 
before, during and after pregnancy. Several risk models have been proposed. The CARPREG 
(CARdiac disease in PREGnancy) risk score, developed by dr. Siu and his team in Toronto, 
Canada, was the first tool developed in 2001 for women with cardiac disease in general, 
based on retrospective data and validated in a prospective cohort20,21. The cohort consisted 
mainly of women with congenital heart disease; few had valvular or other type of heart dis-
ease. Four predictors could be identified. These included -a prior cardiac event, -diminished 
functional class (New York Heart Association class >2) or cyanosis, -left heart obstruction and 
-left ventricular ejection fraction below 30%. In the presence of 0, 1 or more than 1 predictor 
the maternal cardiac event rate was 5%, 27% and 75%, respectively. In 2006, the modified 
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WHO (World Health Organization) risk stratification model was proposed, based on expert 
opinion (Table 1)22,23. It included cardiac diagnosis, New York Heart Association class and 
ventricular function. The ESC guidelines for pregnancy and cardiac disease adopted this risk 
tool. But prospective data to validate this tool was missing. The ZAHARA (Zwangerschap bij 
Aangeboren HARtAfwijking) risk score has been developed in 2010 in a large retrospective 
cohort of women with congenital heart disease in the Netherlands24. The group of research-
ers, led by dr. Pieper, found 3 new predictors: cardiac medication, atrioventricular valve 
regurgitation, and mechanical valve prosthesis. In women with congenital heart disease, 
the modified WHO classification seems to be the best tool to predict maternal outcome25,26. 
table 1 WHO classification. 
  Risk Diagnosis
mWHO I No to mild increased risk in morbidity Repaired simple lesion
compared to normal population ASD or VSD
  PDA
  PAPVR
  Mild valvular disease
  Uncomplicated PDA
mWHO II Small increased risk of maternal mortality Unrepaired uncomplicated ASD or VSD
and moderate increased risk in morbidity Repaired tetralogy of Fallot
   
   
   
mWHO II-III   Mild systemic ventricular dysfunction
  Repaired coarctation
  Native or tissue valve disease 
  Marfan (<40 mm)
  BAV (<45 mm)
mWHO III Significantly increased risk of maternal 
mortality and severe morbidity
Mechanical valve
Systemic right ventricle
  Fontan circulation
  Unrepaired cyanotic heart disease
  Other complex congenital heart disease
  Marfan (40-45 mm)
 BAV (45-50 mm)
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Large prospective cohorts in women with any type of cardiac disease are required to sup-
port guidelines recommendations. 
Gaps in current knowledge
There is a specific need for data on high risk pregnancies and pregnancies in less prevalent 
conditions: numbers of women included in studies are generally low, which may hamper 
drawing firm conclusions. Conditions such as pulmonary hypertension and severe left sided 
obstructive lesions are a reason to avoid pregnancy. But whether a mildly elevated right 
ventricular systolic pressure or moderate stenotic lesions are associated with much better 
outcome allowing for a positive advice regarding pregnancy is unknown. And what about 
women with an artificial heart valve? Young women requiring valve replacement and their 
treating cardiologist face a difficult dilemma:  a mechanical valve lasts hopefully a lifetime, 
but warrants adequate anticoagulation for the same timespan; and a bioprosthesis, without 
the need for anticoagulation, requires reoperation after approximately 15 years. Pregnancy 
may further complicate the decision, as data about adequate and safe anticoagulation is 
currently lacking, while the effect of pregnancy on bioprosthetic valve function also awaits 
elucidation. Evidence in order to answer such questions should come from large prospec-
tive studies. 
The majority of current evidence comes from Western countries, while in emerging 
countries a different distribution of cardiac morbidity is present with valvular heart disease 
being much more common in young adults than congenital heart disease27. Therefore, 
future guidelines will benefit from improved knowledge about the outcome of pregnancy 
in women with heart disease from more remote areas. While randomized controlled trials 
provide the strongest level of evidence, ethically it is hard to perform such studies during 
pregnancy. This is why real world observational data are required. 
table 1 WHO classification.  (continued)
  Risk Diagnosis
mWHO IV Extremely high risk of maternal mortality or 
severe morbidity
Pulmonary arterial hypertension
Severe systemic ventricular dysfunction
  Severe mitral stenosis
  Severe symptomatic aortic stenosis
  Marfan (>45 mm)
  BAV (>50 mm)
  Native severe coarctation
ASD = atrial septal defect; BAV = bicuspid aortic valve; mWHO = modified WHO classification; PAPVR = partial 
anomalous pulmonary venous return, PDA = persistent ductus arteriosus, VSD = ventricular septal defect
Adapted from: Care during pregnancy. van Hagen, Roos-Hesselink, book chapter in ‘Adult Congenital Heart 
Disease’ 2016
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An evolving and potentially high risk group are women with Turner syndrome con-
templating pregnancy. Turner syndrome is caused by a partial or total monosomy of the 
X-chromosome and it is characterised by subfertility in some women and even infertility 
in others28. In the past decades In Vitro Fertilization and oocyte donation have soared, and 
are now widely used, also in women with Turner Syndrome. But pregnancy in these women 
may put them at risk of serious events: Turner syndrome is associated with aortic pathology. 
An increasing number of reports became available showing an alarming relation between 
Turner syndrome and aortic dissection during pregnancy29,30. How many women contem-
plate pregnancy, and whether some are restrained by their own concerns for cardiovascular 
complications is unknown. Important questions, such as whether prophylactic aortic sur-
gery puts these women at low(er) risk of aortic complications remain unanswered.
Registry Of Pregnancy And Cardiac disease (ROPAC)
The worldwide prospective ROPAC was initiated in 2007 by a joint effort of the European 
Society of Cardiology working group on ‘valvular heart disease’ and working group on 
‘congenital heart disease’. Principal investigators Professor Roger Hall from the United 
Kingdom and Professor Jolien Roos-Hesselink from the Netherlands aimed to prospectively 
observe a large number of women with structural heart disease during pregnancy. ROPAC 
forms the basis of this thesis. Participating doctors could enter their (anonymous) cases in 
an online database. Cardiac diagnoses include congenital disorders, valvular heart disease, 
cardiomyopathy, ischemic heart disease, aortic disease or pulmonary hypertension31. By 
collecting data from all over the world, ROPAC provides a solid basis for risk stratification 
and future recommendations on specific patient groups. As for all registries, ROPAC has 
some limitations that need to be appreciated while interpreting the results: women were 
included only when visiting a participating centre, which means that a selection bias is 
probably introduced: those who decided not to visit a doctor and do not have any preg-
nancy complication may be underrepresented in our cohort. Also, participating centres are 
likely to represent a clinic involving a cardiologist or obstetrician with an interest in the field 
of pregnancy and heart disease. This may also explain the underrepresentation of emerging 
countries, where acquisition of specialised clinics is presumably hard to achieve.
The registry is ongoing, but interim analyses were performed in 2011, including 1321 
pregnancies in women with cardiovascular disease. The results were published by the 
principal investigators, dr. Titia Ruys (who wrote a thesis on the first ROPAC results) and 
participating investigators. Maternal mortality occurred in 1% of pregnancies of women 
with cardiac disease. Heart failure appears to occur in about 13% of women, mainly by the 
end of the second trimester, and in the first week after delivery32.  Another important find-
ing is the fact that caesarean section was not superior to vaginal delivery in most women, 
while fetal adverse events were more common after caesarean section33. Fetal outcome is 
also influenced by maternal cardiac medication: beta-blockers in particular, are associated 
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with a significant lower birth weight34. In 2014, 2966 pregnancies from 99 hospitals in 39 
countries were included and form the basis of several chapters in this thesis. The ongoing 
collaboration with centers from all over the world,  will enable to shed a light on many other 
maternal and fetal topics. 
Aims
The overall aim of this thesis is to provide real world registry data on pregnancy outcome in 
women with cardiac disease to support the current guidelines, and to create awareness of 
maternal and fetal pregnancy risks in specific patient groups. To reach these goals, this thesis 
will focus on the following subjects:
- risk stratification both for maternal as well as for fetal outcome 
- incidence and impact of common complications such as arrhythmias 
- investigate the outcome of high risk conditions, such as mechanical heart valves 
- investigate the impact of socioeconomic factors 
- investigate the pregnancy wish in women with Turner Syndrome
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PART I 
Risk prediction and complications
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AbstrAct 
Aims To validate the modified World Health Organization (mWHO) risk classification in 
advanced and emerging countries, and to identify additional risk factors for cardiac events 
during pregnancy.
Methods and Results The ongoing prospective worldwide Registry Of Pregnancy And 
Cardiac disease (ROPAC) included 2742 pregnant women (mean age 29.2 (±5.5) years ) with 
established cardiac disease: 1827 from advanced countries and 915 from emerging coun-
tries. In patients from advanced countries, congenital heart disease was the most prevalent 
diagnosis (70%) while in emerging countries valvular heart disease was more common 
(55%). A cardiac event occurred in 566 patients (20.6%) during pregnancy: 234 (12.8%) in 
advanced countries and 332 (36.3%) in emerging countries. The mWHO-classification had a 
moderate performance to discriminate between women with and without cardiac events 
(c-statistic 0.711  and 95%CI 0.686-0.735). However, its performance in advanced countries 
(0.726) was better than in emerging countries (0.633). The best performance was found in 
patients with acquired heart disease from developed countries (0.712). Pre-pregnancy signs 
of heart failure and, in advanced countries, atrial fibrillation and no prior cardiac interven-
tion added prognostic value to the mWHO-classification, with a c-statistic of 0.751 (95%CI 
0.715-0.786) in advanced countries and of 0.724 (95%CI 0.691-0.758) in emerging countries. 
Conclusion The mWHO risk classification is a useful tool for predicting cardiac events during 
pregnancy in women with established cardiac disease in advanced countries, but seems 
less effective in emerging countries. Data on pre-pregnancy cardiac condition including 
signs of heart failure and atrial fibrillation, may help to improve preconception counselling 
in advanced and emerging countries. 
Cardiac risk assessment in women with heart disease 23
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Cardiovascular disease is the most prevalent cause of maternal mortality1-3. As awareness 
of this fact has increased over recent decades, guidelines on the management of women 
with cardiac disease have been composed and updated4,5. These state that preconception 
counselling is essential and should be based on the past history, underlying condition and 
an assessment of the current physical state. The aim is to provide an estimation of individual 
risk, allowing a patient to make an informed choice about whether or not to embark on 
pregnancy.
Morbidity and mortality risks in pregnancy for both mother and offspring depend on 
the underlying type and severity of cardiac disease6,7. Further, there may be differences in 
outcome between centres from advanced and emerging countries. There is likely to be 
geographic variation in both the epidemiology of maternal cardiac disease and access to 
health care.
Several risk stratification models have been published: the CARPREG-risk score was derived 
in 2001 from a large single country cohort8,9; the ZAHARA-risk score, which was derived 
from women with congenital heart disease10; and the modified WHO(mWHO) classification, 
which is based mainly on expert consensus11. A recent comparison of these models in a 
cohort of patients with congenital heart disease showed that the mWHO-classification was 
optimal in predicting adverse outcome in this patient group12, although the accuracy of the 
model could still be improved. 
The primary aim of the current study was to validate the mWHO-classification to predict 
an adverse outcome in a large global patient cohort of women with both congenital and 
acquired structural cardiac disease including patients from both advanced and emerging 
countries. Secondly, we evaluated the predictive value of additional clinical features in order 
to develop a modified risk model with improved discriminative power. 
methods
The Registry Of Pregnancy And Cardiac disease (ROPAC) was established to prospectively 
study a large number of pregnant women with structural cardiac disease. The ROPAC is 
an ongoing worldwide Registry. An extensive description of the data collection has been 
published previously6. The first patients were included in January 2008 and for this study 
we included the data of patients with a term date up to October 2013, and follow-up up 
to April 2014. Informed consent was obtained from patients when required by the local 
independent review board. For this analysis only patients with known cardiac disease were 
included, while patients in whom cardiac disease had been diagnosed during pregnancy 
were excluded. 
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Data 
The patient characteristics collected at baseline (before pregnancy) included age, ECG 
rhythm, diagnosis, risk factors for cardiovascular disease (smoking, diabetes, hypertension), 
previous interventions, medication, parity, obstetric history and if available echocardio-
graphic parameters. Follow-up was available for all patients up to one week after delivery. 
The originating countries were divided into advanced and emerging economies according 
to the International Monetary Fund (IMF) classification of economies13 (online supplemental 
Table). 
Every patient was stratified according to the mWHO-classification, as stated in the latest 
guidelines5,11 by two authors (IH;JRH). Modified WHO-class I implicates no increased risk of 
events during pregnancy, compared to the general pregnant population. The mWHO-class II 
has a small increased risk, class II-III a moderate increased risk, and class III has a ‘significantly’ 
increased risk. Class IV bears an unacceptable high risk of complications and consensus 
suggests that pregnancy should be avoided.
Endpoints
The composite primary endpoint was any cardiac event (defined as cardiac arrest, cardiac 
death, new episode of arrhythmia requiring treatment, heart failure, thromboembolic event, 
aortic dissection, endocarditis, acute coronary syndrome, hospitalisation for cardiac reason, 
or a cardiac intervention) during pregnancy and up to one week following. Previous analysis 
of this registry has shown that the most common cardiac events were heart failure and 
arrhythmia6 and hence subanalysis was performed separately for these endpoints. Heart 
failure was defined according to ACC/AHA guidelines14,15, as a clinical syndrome that is 
characterised by specific symptoms (dyspnea and fatigue) and signs (of fluid retention, such 
as oedema, rales) on the physical examination as judged by the treating cardiologist. The 
heart failure episode was only registered when signs or symptoms of HF were present which 
required new treatment, change of treatment or hospital admission.
Patient characteristics and events were reported by the individual sites and did not un-
dergo centralised adjudication. However, all events were predefined in the CRF.
Statistical analysis
Continuous variables are presented as mean and standard deviation, and differences were 
assessed with Student’s t-test. Median and quartiles are provided when data were not nor-
mally distributed. Categorical variables are presented as percentages and differences were 
assessed using Chi-square tests. 
First the mWHO-classification was validated for prediction of cardiac events in the total 
cohort. Further analyses were performed for advanced and emerging countries separately. 
Subgroup analysis was performed for congenital heart disease (CHD) and patients with 
acquired heart disease. All analyses were performed per pregnancy; in other words, a 
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1pregnancy was defined as eventful when at least one cardiac event occurred.  Possible new predictors were identified by performing univariable logistic regression analyses. Baseline 
variables that are integral part of the mWHO-classification (e.g. mechanical valve prosthesis, 
NYHA-classification and cyanotic heart disease) were excluded from univariable analysis. All 
variables with a p-value<0.20 were entered into multivariable logistic regression analysis. 
Variables that were still significantly (p<0.05) associated with outcome in the multivariable 
analysis using backward selection, were entered in a new model together with the mWHO-
classification. Results of regression analyses are reported as an odds ratio (OR), 95%confi-
dence interval, and p-value. 
The predicted and observed probabilities were plotted in a calibration plot and Hosmer-
Lemeshow Goodness-of-fit tests were checked. A receiver operating characteristic (ROC) 
curve and c-statistic was computed. Internal validation was done using 1000 bootstrap 
samples and reporting the potential optimism of the c-statistic. A c-statistic of 0.5-0.7 
represents low discriminative power; a c-statistic of 0.7-0.9 represents moderate discrimina-
tive power; a c-statistic of >0.9 represents a high discriminative power16,17. A risk chart was 
produced showing the risk of an event (in tertiles) in our cohort within the different mWHO-
classes and in the presence or absence of significant independent predictors. 
Multiple imputation was used to handle missing data within the following baseline vari-
ables: age, body mass index, parity, singleton or multiple pregnancy, atrial fibrillation, signs 
of heart failure, hypertension, diabetes mellitus, smoking and prior cardiac intervention. 
Data were missing in no more than 5% of pregnancies, except for smoking (14% missing). It 
was assumed to be plausible that all these variables were missing at random. We generated 
20 imputed data sets. Estimates were pooled and 95%confidence intervals were generated 
after calculating the standard error following Rubin’s method18,19.
Statistical tests were considered significant if a p-value was less than 0.05 (two-sided). 
All analyses, except for bootstrapping, were performed with SPSS version 21.0 (IBM Corp., 
Armonk, NY). Bootstrapping was performed in R version 2.3.0. 
results
The ROPAC included 2966 pregnant women with cardiac disease from 99 centres (84% 
tertiary centres) in 39 countries, of whom 2742 had a diagnosis known before conception. 
The other 224 pregnancies were excluded because cardiac disease was discovered only 
during pregnancy. Cardiac diagnoses were: congenital heart disease (58.2%), valvular heart 
disease (31.4%), cardiomyopathy (5.9%), ischemic heart disease (0.6%), aortopathy (3.7%) 
and pulmonary hypertension (0.3%). Baseline characteristics and distribution of characteris-
tics among the mWHO-classes are presented in Table 1. 
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Cardiac events
A cardiac event occurred in 566 (20.6%) pregnancies: 9.9% of patients in mWHO-I; 7.7% of 
patients in mWHO-II; 17.7% of patients in mWHO-II/III; 28.9% of patients in mWHO-III and 
50.3% of patients in mWHO-IV. Maternal mortality up to 1 week postpartum occurred in 
11 (0.4%) of pregnancies. Figure 1 presents the frequency and type of events per mWHO-
class and Figure 2 presents the percentage of events within centres from emerging and 
advanced countries. The overall risk of a cardiac event in pregnancy was higher in all 
mWHO-classes in centres from emerging compared to advanced countries. Figure 3 shows 
the risk of events per mWHO class in congenital and acquired heart disease in emerging and 
advanced countries.
table 1 Baseline characteristics
Overall mWHO-I mWHO-II mWHO-II/III mWHO-III mWHO-IV p-value
mWHO 
classesn=2742 n=547 n=504 n=849 n=470 n=372
Age-years(SD) 29.2(±5.5) 29.3(±5.5) 29.0(±5.3) 29.7(±5.7) 29.0(±5.3) 28.8(±5.8) 0.037
BMI-kg/m2(SD) 25.3(±4.8) 24.5(±4.5) 24.5(±4.6) 25.3(±4.8) 25.8(±4.4) 25.8(±5.3) 0.51
Nulliparous 45.4% 49.5 54.0 44.3 40.2 36.8 <0.001
Singleton pregnancy 97.9% 98.3 98.5 97.4 98.1 97.0 0.49
Atrial fibrillation 2.4% 0.6 0.4 1.7 4.7 6.6 <0.001
Hypertension 6.0% 3.6 2.6 9.6 5.8 5.8 <0.001
Diabetes mellitus 1.4% 1.1 1.4 1.7 1.3 1.4 0.93
Signs of heart failure 9.3% 3.5 3.6 6.7 10.7 30.1 <0.001
Current smoking 4.1% 6.0 3.9 4.5 2.6 2.6 0.07
Prior cardiac intervention 56.5% 68.0 59.2 47.8 73.8 33.7 <0.001
Emerging country 33.4% 23.9 18.1 27.7 48.1 62.4 <0.001
Cardiac diagnosis   <0.001
Congenital heart disease 58.2% 77.3 99.4 45.2 39.6 27.7
Valvular heart disease 31.4% 22.7 0.6 35.1 49.8 54.6
Cardiomyopathy 5.9% 0 0 10.6 7.0 10.2
Ischemic heart disease 0.6% 0 0 1.4 0.9 0.3
Aortic disease 3.5% 0 0 7.7 2.8 5.1
Pulmonary hypertension 0.3% 0 0 0 0 2.2
NYHA class   <0.001
I 74.6% 86.7 82.0 78.0 72.3 41.8
II 22.7% 13.3 18.0 21.8 27.7 38.3
III 2.5% 0 0 0 0 18.6
IV 0.2% 0 0 0 0 1.4
BMI=Body Mass Index; mWHO=modified WHO classification
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figure 2 Observed cardiac events in emerging and advanced countries. 
mWHO, modified World Health Organization; classes are indicated by Roman numerals.
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figure 3 Cardiac event rate in patients with acquired or congenital heart disease. 
mWHO, modifiedWorld Health Organization; classes are indicated by Roman numerals.
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Validation of mWHO-classification
The c-statistic of the mWHO-classification was 0.711 (95%CI:0.686-0.735) for the entire 
cohort and the ROC curve is presented in Figure 4. The c-statistic was 0.726 (95%CI:0.690-
0.762) for centres from advanced countries and 0.633 (95%CI:0.595-0.671) for those from 
emerging countries. 
In patients with CHD, the c-statistic of the mWHO classification to predict cardiac events 
was 0.659 (95%CI:0.598-0.720) for centres from advanced countries and 0.645 (95%CI:0.577-
0.712) for centres from emerging countries. In patients with acquired heart disease, the 
c-statistic was  0.712 (95%CI:0.661-0.763) for centres from advanced countries and  0.619 
(95%CI:0.572-0.666) for centres from emerging countries.
No differences were found in the accuracy of the mWHO classification between left and 
right sided lesions. The accuracy of the mWHO classification predicting those patients with 
more than one cardiac event was similar to the accuracy of predicting any event.
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figure 4 Receiver operating characteristic (ROC) curve of modified World Health Organization (mWHO) clas-
sification. 
CI, confidence interval.
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1Additional predictive variablesThe associations between baseline characteristics and cardiac events are demonstrated in 
Table 2. The final combinations of predictors are shown for centres from advanced and 
emerging countries separately. In both advanced and emerging countries, “signs of heart 
failure before pregnancy” was predictive, independently from the mWHO-classification. In 
advanced countries, “atrial fibrillation before pregnancy” and “no prior cardiac intervention” 
were additionally found to be predictive of cardiac events during pregnancy. The probability 
of events in the absence or presence of the additional risk factors is depicted in Figure 5. 
The additional predictive variables were combined in a model for emerging and advanced 
countries. The calibration plot and ROC curves for both models are presented in Figure 6. 
The c-statistic for the model was 0.751 (95%CI:0.715-0.786) for advanced countries and 0.724 
(95%CI:0.691-0.758) for emerging countries and both were similar in the unimputed dataset. 
Bootstrapping revealed an optimism in de c-statistic of 0.01 in advanced countries and an 
optimism in the c-statistic of 0.02 in emerging countries. 
table 2 Predictors of cardiac events during pregnancy
Advanced countries 
(n=1827)
Emerging countries 
(n=915)
Univariable analysis OR 95%CI p-value   OR 95%CI p-value
Age 1.02 1.00-1.05 0.09* 0.99 0.97-1.02 0.55  
BMI 1.02 0.96-1.08 0.57  1.00 0.96-1.04 0.90  
Nulliparous 0.90 0.69-1.19 0.46  0.99 0.74-1.32 0.95  
Singleton 1.22 0.47-3.19 0.69  0.82 0.33-2.02 0.66  
Atrial fibrillation 11.3 4.32-29.4 <0.001* 1.75 0.97-3.15 0.06*
Hypertension 1.42 0.85-2.38 0.17* 1.53 0.86-2.75 0.15*
Diabetes mellitus 1.33 0.45-3.91 0.61  0.98 0.33-2.94 0.97  
Signs of heart failure 7.09 3.83-13.1 <0.001* 5.15 3.70-7.17 <0.001*
Current smoking 0.72 0.34-1.52 0.39  1.23 0.49-3.09 0.66  
Prior cardiac intervention 0.66 0.50-0.87 0.003* 0.61 0.46-0.80 <0.001*
 
Multivariable analysis
mWHO II** 1.09 0.59-2.03 0.78 0.56 0.28-1.12 0.10
II-III 2.21 1.31-3.73 0.003 1.25 0.76-2.05 0.38
III 6.79 3.95-11.7 <0.001 1.25 0.75-2.06 0.39
IV 10.1 5.64-18.0 <0.001 2.48 1.50-4.11 <0.001
Age 1.02 0.99-1.05 0.22  
Atrial fibrillation 4.89 1.40-17.0 0.014 1.44 0.76-2.74 0.26
Hypertension 1.08 0.62-1.88 0.80 1.28 0.66-2.48 0.46
Signs of heart failure 3.34 1.68-6.66 0.001 4.22 2.99-5.94 <0.001
Prior cardiac intervention 0.67 0.49-0.90 0.009   0.75 0.55-1.03 0.08
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Risk chart
A risk chart was produced based on the probabilities of events in the different mWHO-
classes and in the presence or absence of signs of heart failure and/or atrial fibrillation 
before pregnancy. The chart is shown in Table 3 for both advanced and emerging countries. 
“No prior cardiac intervention” was not included, because of the limited additional value as 
shown in Figure 5.
table 2 Predictors of cardiac events during pregnancy (continued)
Advanced countries 
(n=1827)
Emerging countries 
(n=915)
New model of mWHO and significant additional predictors
mWHO II** 1.08 0.58-2.02 0.80 0.57 0.29-1.14 0.11
II-III 2.24 1.33-3.77 0.002 1.34 0.82-2.20 0.24
III 6.77 3.95-11.6 <0.001 1.19 0.72-1.96 0.49
IV 10.2 5.68-18.1 <0.001 2.77 1.70-4.53 <0.001
Atrial fibrillation 5.07 1.44-17.8 0.012  
Signs of heart failure 3.33 1.68-6.62 0.001 4.22 3.00-5.93 <0.001
Prior cardiac intervention 0.66 0.48-0.89 0.007      
BMI=body mass index;mWHO=modified WHO classification. 
*Variables with p<0.20 were entered in multivariable analysis.
**mWHO I is the reference category.
table 3 Risk chart for a cardiac event
Emerging countries Advanced countries
Pre-pregnancy: No AF HF HF+AF No AF HF HF+AF
mWHO-IV 43 51 76 82 35 73 65 90
mWHO-III 24 31 58 66 25 62 53 84
mWHO-II/III 27 34 61 69 11 37 29 67
mWHO-II 14 18 40 48 5 22 16 49
mWHO-I 22 28 54 62 5 20 15 46
  <35%
  35-65%
  >65%
AF = atrial fibrillation; HF = signs of heart failure; mWHO = modified World Health Organization classification
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Sub analysis of arrhythmic and heart failure events
Arrhythmic events occurred in 94 (3.4%) pregnancies. Regression analysis is presented in 
Supplemental Table 1 and 2. An independent predictor of a new arrhythmic event during 
pregnancy was “atrial fibrillation before pregnancy” in centres from both advanced and 
emerging countries. In emerging countries, also “nulliparity” and “signs of heart failure 
before pregnancy” were predictive of an arrhythmic event. The c-statistic of the mWHO-
classification for an arrhythmic event was 0.652 in centres from advanced countries and 
0.688 in those from emerging countries. These c-statistics improved by adding the indepen-
dent predictors (Supplemental Table 3).
Heart failure complicated pregnancy in 313 women (11.4%). Regression analysis is shown 
in the Supplemental tables. Independent predictors were “signs of heart failure before preg-
nancy” and “no prior cardiac intervention”, for centres from both advanced and emerging 
countries. The c-statistic of the mWHO-classification for prediction of heart failure was 0.758 
for advanced countries, and 0.627 for emerging countries and could be improved by adding 
“signs of heart failure before pregnancy” to the model (Supplemental Table 3).
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
80,0%
90,0%
100,0%
WHO I WHO II WHO II-III WHO III WHO IV
Total observed events
No signs of heart failure
Signs of heart failure
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
80,0%
90,0%
100,0%
WHO I WHO II WHO II-III WHO III WHO IV
Total observed events
No signs of heart failure
Signs of heart failure
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
80,0%
90,0%
100,0%
WHO I WHO II WHO II-III WHO III WHO IV
Total observed events
No prior atrial ﬁbrillation
Prior atrial ﬁbrillation
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
80,0%
90,0%
100,0%
WHO I WHO II WHO II-III WHO III WHO IV
Total observed events
No prior cardiac intervention
Prior cardiac intervention
A. Advanced countries 
B. Emerging countries 
Signs of heart failure before pregnancy Atrial ﬁbrillation before pregnancy 
Prior cardiac intervention Signs of heart failure before pregnancy 
figure 5 Risks within modified World Health Organization (mWHO) classes (Roman numerals), in the presence 
and absence of additional risk factors.
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discussion
This prospective study validates the modified WHO risk classification in a large cohort of 
women with different types of structural cardiac disease from centres all over the world. 
The mWHO-classification appeared to perform reasonably well, but better in centres from 
advanced countries than those from emerging countries. By adding “atrial fibrillation before 
pregnancy” and “signs of heart failure before pregnancy” to this risk model, estimation of risk 
improves. This is attributable mainly to the strong association of atrial fibrillation at baseline 
with the occurrence of an arrhythmic event, and of signs of heart failure at baseline and the 
occurrence of a heart failure event. Although the mWHO proves to be a useful tool, the risk 
prediction in women with heart disease can be further improved by using our risk chart, a 
simple tool for clinicians (see Table 1). 
figure 6 Calibration plots and receiver operating characteristic (ROC) curves of modified World Health Organi-
zation (mWHO) classification and enhanced model. 
AF, atrial fibrillation; CI, confidence interval; HF, signs of heart failure.
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1Cardiac eventsThe cardiac event rate was relatively high compared to the event rate in other studies9,10,12,20-25, 
which is not surprising as ROPAC included more high-risk patients, reflecting the high risk 
caseload of participating centres. At baseline, there were more patients with NYHA class 
greater than 1, mWHO-class greater than 1 and the percentage of patients with any type of 
medication preconception is higher in our study population than in other studies6,9,10,12,20-25. 
The most prevalent events were heart failure and arrhythmic events, while mortality oc-
curred in only 0.4%, even though 372 patients were in mWHO-class IV.
Modified WHO-classification
The mWHO-classification was proposed in the latest guidelines5, and stratifies patients 
based on their underlying diagnosis together with few echocardiographic and clinical 
parameters and is based on expert opinion11. It is striking that in our study, in centres from 
advanced and emerging countries the rate of cardiac events in mWHO-class I was as high as 
5 and 22% respectively, in the absence of heart failure or atrial fibrillation before pregnancy. 
The guidelines state that there is no increased risk of complications in this group compared 
to the general pregnant population. In literature this percentage is 0 to 2.5%12,24,26. However, 
previous studies included less than 100 pregnancies in this mWHO-class, while in our study 
547 pregnancies were included. We included patients from emerging countries, while up 
until now most studies were performed in advanced countries. Although the risk in mWHO-I 
is limited, women in this group should not be told that the risks are negligible. The percent-
age of complications in this group indicates that some women in mWHO-class I, in particular 
in emerging countries, need more careful and frequent follow-up during pregnancy and 
should be followed and delivered in specialised centres as is advised for women who are 
assigned to mWHO-class II or higher. This holds for both women with congenital as well as 
acquired heart disease. Further research is warranted to better subdivide women in mWHO-
class I. Remarkably, we did not observe a higher risk in mWHO-class II compared to class I, 
so probably it is difficult to establish a clear cut off between these two “low risk” categories. 
Two other risk stratifications have been proposed in the literature: the CARPREG-risk score, 
which was conducted in a retrospective study cohort of women with cardiac disease from 
Canada8; and the ZAHARA-risk score, which was developed in a retrospective Dutch study of 
pregnant women with congenital heart disease10, both validated in two prospective studies 
from the same groups9,12.
Overestimation of risks was found in the validation of both CARPREG and ZAHARA in the 
intermediate and high-risk groups, due to a relatively low number of patients within these 
groups9,10. In our study, there were 842 (30.7%) patients in mWHO-class III and IV combined. 
The mWHO-classification with additional predictors shows a relatively good agreement 
between predicted probability and observed events also for patients with a higher mWHO-
class, although overestimation of risks is still present.
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We did not compare the mWHO-classification with the CARPREG-risk score, since we do 
not have  information about the patients history of having had a stroke for instance. A recent 
single centre study validating the CARPREG, ZAHARA and mWHO-risk scores in 179 women 
with cardiac disease showed that the mWHO-classification was most accurate in predicting 
cardiac events26.  Two other studies showed that the mWHO-classification performs better 
than the other risk scores in patients with congenital heart disease12,24. The discriminative 
accuracy of the mWHO-classification appeared to be better in the congenital heart disease 
population, compared to our study. This may be related to the fact that our cohort is more 
heterogenous regarding the underlying cardiac diagnosis. Secondly, our study has a mul-
ticenter and multicountry design, providing the first global estimation of accuracy of the 
mWHO-classification. Indeed, the separate analysis of data from centres in advanced and 
emerging countries did reveal a distinct difference in accuracy of the mWHO-classification, 
with the mWHO-classification performing better in advanced countries. This demonstrates 
the need for additional risk predictors, enabling a more accurate estimation of risks espe-
cially in emerging countries.
Advanced and emerging countries
The difference between centres from advanced and emerging countries in accuracy of the 
mWHO-classification for prediction of cardiac events is remarkable. The low discriminative 
power found in emerging countries is attributable to the varying frequency of events per 
mWHO class, whereas the event rate in advanced countries shows the expected gradual 
increase of events per mWHO class. The discriminative power was similar in CHD patients 
from advanced and emerging countries, but appeared to be better in patients with ac-
quired heart disease from advanced countries. The event rate is low in CHD patients from 
advanced countries, in particular in the lower mWHO classes, which may have led to a less 
distinct difference in event rate between the mWHO classes. This might contribute to a 
lower discriminative power of the mWHO classification in this patient group. The majority 
of patients from advanced countries have congenital heart disease6,25, which is a reflection 
both of good survival rates of congenital heart disease patients and of the lead taken by 
congenital heart disease cardiologists in establishing heart disease in pregnancy services. 
Acquired heart disease is underrepresented in some mWHO classes, with a subsequent 
different event rate than expected, which probably influenced the discriminative power. 
The majority of these patients have valvular disease. However, the mWHO classification is 
based on Western specialists experience and thus may underestimate the risks in women 
with rheumatic valvular heart disease. 
Indeed, a previous South African study of pregnant women with cardiac disease suggested 
that these women had a different disease pattern than those in the developed world7. They 
experienced a higher maternal mortality rate, probably attributable to differences in the 
underlying diagnosis and late presentation or referral to a medical facility. 
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1The number of women in mWHO-class IV is remarkably high in centres from advanced countries (n=140) but even higher in those from emerging countries (n=232). Expert con-
sensus recommends that pregnancy should be avoided in these patients. Given the fact that 
the mWHO-classification has been in use for several years now, it is possible that patients 
included in mWHO-class IV in our registry (after clinical implementation of the guidelines), 
are women with less severe disease than in earlier years. In addition, in some parts of the 
world, giving birth improves a woman’s status and hence a patient might decide to accept 
a high risk and to even avoid seeing a doctor prior to pregnancy. 
Arrhythmic and heart failure events
Heart failure during pregnancy occurs far more often in emerging countries6. Not surpris-
ingly, “signs of heart failure before pregnancy” was strongly predictive of heart failure during 
pregnancy. The accuracy of prediction of events was improved by adding this factor to the 
mWHO-classification, which holds particularly for emerging countries and for the separate 
heart failure endpoint. In a large cohort of African heart failure patients, it appeared that 
patients were often young women with valvular heart disease27. Early detection of cardio-
vascular disease was emphasized, and our study stresses the importance of recognition of 
signs of heart failure well before conception to minimize the risk of severe deterioration 
during pregnancy. 
For prediction of arrhythmic events we show a fairly high accuracy in emerging countries 
of the mWHO-classification in combination with the presence of paroxysmal atrial fibrilla-
tion prior to pregnancy. It has been shown previously that recurrence of arrhythmias was 
often seen during pregnancy and, more importantly, that it is associated with an increased 
risk of adverse fetal events28.  
Introduction in clinical setting 
This study implies that adding signs of heart failure and atrial fibrillation before pregnancy to 
the established mWHO-classification, may be of potential benefit for better risk estimation 
especially in emerging countries. Our risk chart is a simple tool for clinicians, which is of use 
after the mWHO-classification has been applied (see Table 1). It may be useful for clinicians 
during counselling of women with cardiac disease contemplating pregnancy.
Limitations 
Our conclusions are mainly applicable to women with heart disease under the care of a 
heart disease in pregnancy clinic, and extrapolation to those cared for in other settings 
should be done cautiously. Although our registry included patients prospectively, it only 
includes those patients seeking medical counselling or support. This does introduce poten-
tial inclusion bias. For example patients with mild cardiac defects may be underreported.
36 Chapter 1
The diagnosis of heart failure was reported by the individual centres. Mild peripheral oe-
dema and dyspnoea are frequently encountered during normal pregnancy without actual 
heart failure. Thus an overestimation of events may be present. However, an event of heart 
failure was only registered when it required new treatment, change of treatment or hospital 
admission.
Finally, although this study is the largest cohort to date, the maternal mortality rate did 
not allow for regression analysis. It would be interesting to have maternal mortality as sole 
endpoint as this would potentially provide additional evidence for contraindications to 
pregnancy. 
Conclusion 
The mWHO-classification is a moderately accurate tool for the prediction of cardiac events 
during pregnancy, in centres from advanced countries but suboptimal in centres from 
emerging countries. Signs of heart failure and atrial fibrillation before pregnancy are addi-
tional independent risk factors, improving the accuracy of the mWHO-classification. This has 
clear implications for preconception counselling of women with cardiac disease, especially 
of those with signs of heart failure or atrial fibrillation, who are at substantially higher risk 
regardless of their mWHO-risk class. A further modification of the mWHO criteria, based on 
our findings, merits further independent validation. 
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AbstrAct 
Objective Women with cardiac disease becoming pregnant have an increased risk of 
obstetric and fetal events.  The aim of this study was to study the incidence of events, to 
validate the modified World Health Organization (mWHO) risk classification and to search 
for event-specific predictors. 
Methods The Registry Of Pregnancy And Cardiac disease (ROPAC) is a worldwide ongoing 
prospective registry that has enrolled 2742 pregnancies in women with known cardiac 
disease (mainly congenital and valvular disease) before pregnancy, from January 2008 up 
to April 2014. 
Results Mean age was 28.2±5.5 years, 45% were nulliparous and 33.3% came from emerging 
countries.  Obstetric events occurred in 231 pregnancies (8.4%). Fetal events occurred in 651 
pregnancies (23.7%).  The mWHO-classification performed poorly in predicting obstetric 
(c-statistic=0.601) and fetal events (c-statistic=0.561). In multivariable analysis, aortic valve 
disease was associated with pre-eclampsia (OR=2.6, 95%CI=1.3-5.5). Congenital heart 
disease (CHD) was associated with spontaneous preterm birth (OR=1.8, 95%CI=1.2-2.7). 
Complex CHD was associated with small-for-gestational-age neonates (OR=2.3, 95%CI=1.5-
3.5). Multiple gestation was the strongest predictor of fetal events: fetal/neonatal death 
(OR=6.4, 95%CI=2.5-16), spontaneous preterm birth (OR=5.3, 95%CI=2.5-11) and small-for-
gestational age (OR=5.0, 95%CI=2.5-9.8).
Conclusion The modified WHO classification is not suitable for prediction of obstetric and 
fetal events in women with cardiac disease. Maternal complex CHD was independently 
associated with fetal growth restriction and aortic valve disease with pre-eclampsia, poten-
tially offering an insight into the pathophysiology of these pregnancy complications. The 
increased rates of adverse obstetric and fetal outcomes in women with pre-existing heart 
disease should be highlighted during counseling.
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introduction
The physiological changes that occur to ensure adequate blood perfusion of the utero-
placental circulation during pregnancy require significant cardiovascular adaptations. A 
normal heart has the reserve to adjust to these requirements, but the capacity of an already 
functionally compromised cardiovascular system is uncertain. Indeed, several studies have 
highlighted the risk of deterioration in cardiac function in pregnant women with heart dis-
ease and documented an increased risk of obstetric and fetal events.1 Cardiac events have 
been studied in depth and can be partly predicted by the modified World Health Organiza-
tion (mWHO) risk classification.2,3 The mWHO stratifies patients mainly according to their 
cardiac diagnosis and on some clinical parameters such as ventricular function and New 
York Heart Association (NYHA) class. The expected risk of an adverse event is low compared 
to the normal population in mWHO-class I, but the risk rises progressively with each class 
and women in mWHO IV are at extremely high risk and should avoid pregnancy. 
In women with congenital heart disease, increased adverse neonatal events have been 
reported, including preterm birth and low birth weight in particular.4,5 Genetic and epigen-
etic causes have been hypothesized to play a role in the pathophysiologic mechanism of 
preterm birth6 and myocardial dysfunction and cyanosis were predictors of overall adverse 
neonatal outcome in women with congenital heart disease.4 Interestingly, previous studies 
found an association between cardiac function and abnormal uteroplacental blood flow, 
suggesting that pre-existing heart disease may cause abnormal placental development 
or perfusion.7 These data suggest that the mWHO-classification may be able to predict 
obstetric and fetal risk in women with pre-existing heart disease.  The aim of our study 
was to report the incidence of obstetric and fetal events in patients with cardiac disease, 
and to evaluate the discriminative power of the mWHO-classification in predicting adverse 
obstetric or fetal outcome. In addition we will search for event-specific predictors.
methods
The Registry Of Pregnancy And Cardiac disease (ROPAC) is a large, prospective and global 
registry. A detailed report of study design has been published previously.3,8 Patients in this 
interim analysis were included from January-2008 to April-2014. Patients in whom cardiac 
disease had been diagnosed during pregnancy were excluded. Patient informed consent 
was obtained when required by the local independent review board. 
Data collection
Patient characteristics collected before pregnancy included age, diagnosis, electrocardio-
gram rhythm, risk factors (smoking, diabetes, hypertension), previous interventions, medi-
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cation, parity, obstetric history and if available echocardiographic parameters. Follow-up 
was available for all patients up to one week after delivery. The originating countries were 
divided into developed and emerging countries according to the International Monetary 
Fund (IMF).9 Country of residence was included as an independent variable in further analy-
sis (defined as ‘living in an emerging country’).
Every patient was stratified according to the mWHO-classification, as stated in the lat-
est guidelines by two authors(IH;JRH).10 Modified WHO-class I implies no increased risk of 
events during pregnancy, compared to the general pregnant population; class II has a small 
increased risk; class II-III a moderate increased risk; class III a significantly increased risk; class 
IV bears an unacceptable high risk of complications and consensus suggests that pregnancy 
should be avoided.
Endpoints
Obstetric events were defined as maternal non-cardiac death up to one week postpartum, 
pregnancy induced hypertension (new-onset >140/90mmHg at two occasions), pre-
eclampsia (including pre-eclampsia, eclampsia or HELLP syndrome), and haemorrhagic 
complication, which could be either postpartum haemorrhage (defined as increased blood 
loss, >500mL after vaginal delivery or >1000mL after Caesarean delivery, up until 24 hours 
postpartum) or other major haemorrhage (defined as a bleeding resulting in at least 1g/
dL decrease in hemoglobin, the need for blood transfusion or end-organ damage such as 
haemorrhagic cerebrovascular accident or retinal bleeding). A fetal event was either prema-
ture birth <37weeks, small-for-gestational-age(<10th percentile), poor Apgar score(<7 at 1 
minute), fetal death ≥14weeks of gestation, or neonatal death up to one week after delivery. 
Induced and spontaneous preterm birth were also analysed separately. 
A cardiac event was defined as a combined endpoint, including: cardiac arrest, cardiac 
death, new episode of arrhythmia requiring treatment, heart failure, thromboembolic event, 
aortic dissection, endocarditis, acute coronary syndrome, hospitalisation for cardiac reason, 
or a cardiac intervention. Cardiac event rates are published elsewhere.3
Analysis
Categorical variables are presented as frequencies and percentages and differences be-
tween groups were assessed using chi-square tests. Continuous variables are presented as 
mean and standard deviation, or as median and first and third quartiles as appropriate, and 
differences were assessed using Student’s t-test or Mann-Whitney U tests depending on the 
data distribution.
The mWHO-classification was assessed for its ability to predict obstetric and fetal 
events in the total cohort, and also in patients with congenital and valvular heart disease 
separately. The discriminative power of the mWHO-classification was checked by receiver 
operating characteristic (ROC) curves and c-statistics. A c-statistic of 0.5-0.7 represents low 
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discriminative power; 0.7-0.9 represents moderate discriminative power; >0.9 represents a 
high discriminative power.11
In the total cohort, and in congenital heart disease and valvular heart disease separately, 
predictors of separate endpoints were searched for by univariable logistic regression analy-
sis. Variables with a p-value<0.10 were entered into multivariable logistic regression analysis, 
provided that there was no collinearity between independent variables. One independent 
variable could be entered per 10 events. Results are presented as odds ratio (OR), 95% 
confidence interval (95%CI) and p-value. Multiple imputation was used to handle missing 
data within the following baseline variables: age, systemic ventricular dysfunction (ejection 
fraction<40%), hypoxia (<90%), parity, singleton or multiple pregnancy, atrial fibrillation, 
hypertension, diabetes mellitus, signs of heart failure, smoking, and NYHA class. It was 
assumed to be plausible that all these variables were missing at random. The Bonferroni 
method was used to correct for multiple hypothesis testing in the multivariable analysis 
of the separate endpoints (corrected α=0.05/n, with n=number of hypotheses/endpoints 
tested). All analyses were performed with SPSS version 21.0(IBM Corp., Armonk, NY).
results
This registry included 2966 pregnancies in women with structural cardiac disease from 99 
centres in 39 countries, between January 2008 and April 2014. The cardiac diagnosis was 
known before conception in 2742 pregnancies, and these pregnancies were included in 
this analysis. Baseline characteristics are shown in Table 1. Congenital heart disease was 
table 1 Baseline characteristics
Overall CHD VHD
N 2742 1599 862
Age, years (SD) 29.2 (±5.5) 28.9 (±5.3) 29.5 (±5.9)
BMI, kg/m2 (SD) 25.3 (±4.8) 24.3 (±4.5) 26.2 (±4.7)
Nulliparous 45.4% 52.8% 31.8%
Singleton pregnancy 97.9% 98.5% 96.8%
Systemic ventricle dysfunction 6.5% 5.5% 2.7%
Hypoxia 4.0% 6.5% 1.4%
Atrial Fibrillation 2.4% 0.4% 6.5%
Hypertension 6.0% 5.9% 4.1%
Diabetes Mellitus 1.4% 1.4% 1.4%
Signs of heart failure before pregnancy 9.3% 5.6% 15.7%
NYHA III or IV 2.7% 1.3% 4.6%
Current smoking 4.1% 4.6% 2.4%
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present in 1599 (58.3%, Table 2) women; valvular heart disease in 862 (31.4%, Table 2); a 
cardiomyopathy in 161 (5.9%); ischemic heart disease in 17 (0.6%); aortopathy in 95 (3.5%); 
and idiopathic pulmonary arterial hypertension in 8 (0.3%) women. 
table 1 Baseline characteristics (continued)
Overall CHD VHD
Prior cardiac intervention 56.5% 69.4% 43.9%
Anticoagulants in therapeutic dosage 12.4% 4.8% 28.1%
Emerging country 33.4% 20.1% 58.2%
SD = Standard Deviation; BMI = Body Mass Index.
table 2 Specific congenital and valvular heart diseases
Number of patients
Complex congenital heart disease:
Eisenmenger 8
Univentricular heart 5
Tricuspid atresia 11
Pulmonary atresia 16
Double outlet right ventricle 19
Double outlet left ventricle 7
Transposition of the great arteries 100
Congenitally corrected transposition of the great arteries 24
Congenital heart disease of mild/moderate complexity:
Tetralogy of Fallot 241
Aortic coarctation 156
Atrioventricular septal defect 80
Atrial septal defect 214
Ventricular septal defect 220
Morbus Ebstein 47
Aortic valve abnormality 126
Pulmonary valve abnormality 135
Mitral valve abnormality 48
Pulmonary vein abnormality 18
Patent ductus arteriosus 50
Other congenital heart disease 74
Valvular heart disease:
Aortic valve disease 189
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Obstetric and fetal complications 
Of the 2742 pregnancies, 231 (8.4%) pregnancies were complicated by one or more obstet-
ric events, and one or more fetal events occurred in 651 (23.7%) pregnancies. Table 3 shows 
obstetric and fetal events in women with and without a cardiac event during pregnancy.
table 2 Specific congenital and valvular heart diseases (continued)
Number of patients
Mitral valve disease 537
Pulmonary valve disease 52
Tricuspid valve disease 15
Other valvular heart disease 69
Ischemic heart disease 17
Cardiomyopathy 161
Aortic disease 95
Pulmonary hypertension 8
Total 2742
table 3 obstetric and fetal events in women with and without a cardiac event
 
Women without a cardiac event 
(n=2176)
Women with a cardiac event* 
(n=566) p-value
Preeclamptic toxaemia 1.7% 4.4% <0.001
Pregnancy induced hypertension 1.9% 3.4% 0.037
Postpartum hemorrhage 3.1% 4.1% 0.24
Other major hemorrhage 0.8% 3.4% <0.001
Spontaneous preterm birth 4.7% 5.2% 0.60
Induced preterm birth 5.1% 14.8% <0.001
Fetal/neonatal death 1.7% 3.4% 0.010
Small for gestational age 8.6% 15.8% <0.001
Poor Apgar (<7) 5.9% 10.4% <0.001
Median birth weight, gr (Q1-Q3) 3070 (2762-3420) 2900 (2486-3198) <0.001
*Defined as cardiac arrest, cardiac death, new episode of arrhythmia requiring treatment, heart failure, throm-
boembolic event, aortic dissection, endocarditis, acute coronary syndrome, hospitalisation for cardiac reason, 
or a cardiac intervention
Q1-Q3 = first to third quartile
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Maternal non-cardiac mortality
Non-cardiac maternal mortality occurred in two patients (0.07%). One patient with 
rheumatic aortic and mitral valve disease and elevated pulmonary arterial pressures was 
delivered by Caesarean section at 35+3 weeks because of fetal distress. The neonate died 
shortly after delivery. Frank pus was found in the uterus, and the mother died of septic shock 
two days later. The second patient had idiopathic pulmonary arterial hypertension. She was 
treated with heparin in the first trimester and with warfarin during the second and third 
trimester before she was switched back to unfractionated heparin before term. An elective 
Caesarean section was performed at 38+0 weeks. During delivery, she developed shock due 
to an acute pulmonary embolism and the patient died shortly after delivery. The neonate 
survived and was healthy.
Modified WHO classification
Figure 1 shows the adverse obstetric and fetal events that occurred in each mWHO-class. The 
c-statistic for the mWHO-classification was 0.601 (95%CI=0.563-0.639) for obstetric events 
and 0.561 (95%CI=0.536-0.586) for fetal events, which means a low discriminative power. 
The ROC curves are presented in Figure 2. The ROC curves of the mWHO-classification for 
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figure 1 Obstetric and fetal events per mWHO-class
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prediction of obstetric and fetal events in patients with congenital heart disease and valvular 
heart disease separately all show a poor discriminative power (Figure S1, online supplement). 
The mWHO classification did not perform better in emerging or advanced countries.
Predictors of separate events
The frequency of separate events within each diagnostic group and in relation to baseline 
characteristics are shown in Table S1 (online supplement). The results of the univariable and 
multivariable analyses are shown in Table S2 and S3 (online supplement), for all patients in this 
cohort, and for patients with congenital heart disease and valvular heart disease separately. 
C-statistics for the new models are shown in Table S3. Indeed, part of the models showed 
a better discriminative power for predicting the separate endpoints, than the mWHO-
classification predicted combined endpoints.  
Obstetric events c-statistic 0.601, 95%CI 0.563-0.639
Fetal events c-statistic 0.561, 95%CI 0.536-0.586
figure 2 ROCs mWHO-classification
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The results for pre-eclampsia, fetal/neonatal death, spontaneous preterm birth and 
small-for-gestational-age are depicted in Figure 3. The main findings of the multivariable 
analysis in patients with congenital heart disease and valvular heart disease are presented 
in Figure 4 and Figure 5.
      
  
      
     
    
      
      
     
        
     
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figure 3 Predictors of obstetric and fetal events
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figure 4 Predictors of obstetric events in patients with congenital heart disease
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figure 5 Predictors of obstetric events in patients with valvular heart disease
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discussion
This is the largest prospective cohort of pregnant women with known structural heart 
disease to date, reporting an obstetric event rate of 8.4% and fetal event rate of 23.7%. The 
mWHO-classification failed to accurately predict these events, although a gradual increase of 
events can be observed throughout the mWHO-classes. As in the general population, twin 
pregnancy and pre-gestational diabetes are important predictors of adverse fetal outcome. 
Pre-eclampsia is more often seen in women with aortic valve disease, while spontaneous 
preterm birth is more common in patients with congenital heart disease and small-for-
gestational-age neonates in particular in complex congenital heart disease. Women who 
suffer from a cardiac event during pregnancy are at increased risk of most obstetric and 
fetal complications. These findings may help to accurately inform women about the risks of 
obstetric and fetal problems when they contemplate pregnancy.
modified Who risk clAssificAtion
The obstetric and fetal event rates are in line with findings of a previous prospective study 
in patients with any type of cardiac disease.12 Based on the gradual increase of event rate 
in each mWHO-class, there seemed to be a relationship between the mWHO-classification 
and fetal and obstetric outcome, as was also shown in a previous publication.8 The high 
incidence of obstetric events in mWHO-class III is mainly due to hemorrhagic complications 
in women with a mechanical valve who are treated with anticoagulants.13 Unfortunately, 
overall, the mWHO-classification failed to show a sufficient discriminative power. This agrees 
with the results of a previous validation study in congenital heart disease patients.14 Several 
explanations may explain the poor predictive power of the mWHO-classification. First, it 
seems that a cardiac diagnosis as a risk factor is subordinate to the well-established risk fac-
tors for obstetric and fetal events in the general population, such as maternal age, multiple 
pregnancy and nulliparity. The majority of the obstetric and fetal events are associated with 
these known risk factors, which may have a bigger impact in women with heart disease. This 
is supported by the high rate of events present in mWHO-class I women. Secondly, the com-
bined endpoint may be too inclusive and unsuitable for designing an accurate prediction 
tool. For instance, haemorrhage will usually have a different aetiology than pre-eclampsia. 
In addition, fetal complications can be either the result of primary maternal, fetal or both 
maternal and fetal deteriorating conditions. Combining events may obscure the actual link 
between heart disease and specific pregnancy related events.
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Obstetric complications
Pre-eclampsia was more common in women with aortic valve disease and, as expected, 
in nulliparous women and those with pre-existing hypertension. Also, ventricular dysfunc-
tion was a significant predictor of pre-eclampsia in the univariable analysis, but none of 
these predictors were significant (after correction for multiple hypotheses testing) in the 
multivariable analysis. Subclinical ventricular dysfunction is often seen in patients with 
aortic valve disease, typically in stenotic lesions.15 However, pre-eclampsia, in particular early 
pre-eclampsia, is known to be associated with subclinical cardiac dysfunction, although 
the cardiac dysfunction is probably secondary to pre-eclampsia.16 Previous studies have 
reported poor placental function in association with subclinical ventricular dysfunction.7 
Thus, the link between aortic valve disease and pre-eclampsia warrants further investiga-
tion, as the association may provide a valuable insight into the aetiology of pre-eclampsia 
and these women may benefit from prophylactic medication such as aspirin.17 
Haemorrhage occurred more often in women with a mechanical valve13 and is mainly 
associated with anticoagulation. Another independent predictor of specifically postpartum 
haemorrhage in the sub analysis of patients with congenital heart disease, was complex 
disease, which has been described earlier5. Anaemia, independent of antepartum haemor-
rhage, is a known predictor of postpartum haemorrhage18 and is also often encountered 
outside pregnancy in patients with complex congenital heart disease,19 offering another 
explanation for the predisposition to postpartum haemorrhage. It is unknown whether 
uterine atony, strongly associated with postpartum haemorrhage, is more prevalent in 
patients with complex congenital heart disease, still the more prudent use of oxytocin in 
the third stage and a low threshold to assisted deliveries in this group may contribute to 
the risk.20
Fetal/neonatal complications 
The strongest predictor of fetal and neonatal complications in our cohort was multiple 
pregnancy, being an important predictor of not only fetal demise, but also of preterm birth 
and small-for-gestational-age. In the general population, fetal/perinatal death is reported in 
about 0.8-1.2% and increases in twin pregnancies about 4-5 times.21 In ROPAC fetal/neonatal 
death occurred in 0.8% of singletons and 10.9% of twins, which is an increase of 13.6. Pre-
term birth occurs in almost half of the twin pregnancies in the general population, which is 
at least 7 times more often than reported in singleton pregnancies.21 In the current series, 
preterm delivery occurred in 37% of ROPAC twin and 12% of singleton pregnancies. So 
preterm birth is not more common in twins, in contrast to singletons. But more importantly, 
it seems that cardiac disease further increased the risk of fetal demise. This may be related 
to the higher incidence of small-for-gestational-age babies in ROPAC twins: 34% had a birth 
weight beneath the 10th percentile, compared to 10% of singleton pregnancies. As an il-
lustration, in the general population this rate only increases from about 10-11% to 15%.22,23 
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An obstetric complication occurred in more than 58% of multiple pregnancies (all twin), 
which is not surprising based on the evidence,12,24 but it raises the question how to deal with 
twin pregnancy in women with a severe form of heart disease. Women should certainly be 
counseled about the risks. Twins should be avoided by performing single embryo transfer 
in case of in vitro fertilization, and by carefully monitoring ovulation induction. However, 
it is not possible to prevent the spontaneous conception of twins. To our opinion, reduc-
tion or termination of pregnancy should be reserved for strict maternal reasons or social 
indications. We do not know whether the rate of pregnancy complications is much higher 
in multiple pregnancies in women with heart disease compared to multiple pregnancies in 
the general population, and future research is needed to study this.  
Premature deliveries are either spontaneous or iatrogenic. Symptomatic women (NYHA class 
III-IV), and women taking oral anticoagulants, were more likely to have an induced preterm 
delivery, which is consistent with recommendations made by the guidelines.10 Interestingly, 
women with congenital heart disease tended to go into spontaneous preterm labour. Both 
inflammatory processes, and uteroplacental ischemia can initiate preterm labour.25,26 The 
(subclinical) failure of the heart to fully adapt to pregnancy in congenital heart disease may 
promote inflammation and in more severe cases lead to uteroplacental hypoperfusion and 
ischemia. Certainly, maternal hypoxia increases cytokines and oxygen free radicals, which 
may cause abnormal placentation.27 Indeed, uteroplacental flow has been shown to be 
abnormal in women with congenital heart disease.28 
Small-for-gestational-age babies were mainly seen in women with complex congenital 
heart disease and in symptomatic patients (NYHA class III-IV). Maternal hypoxia was only 
found to be a predictor in univariable analysis, but its effect may have been influenced by 
the co-existence of complex congenital heart disease. Women with congenital heart dis-
ease and those with ventricular dysfunction should be very closely monitored with regard 
to fetal growth; preventative treatment like aspirin may need further investigation in this 
patient group.29 It is expected to be of less benefit if these women indeed rather suffer from 
low cardiac output as a cause of growth restriction, instead of insufficient deep placentation 
due to ischemia.
Intrauterine death is associated with oral anticoagulant use as has been reported in a 
previous ROPAC study, describing pregnancy in women with a mechanical valve.13 Oral anti-
coagulant use in the first trimester predisposed women to an increased risk of fetal death in 
both the second and third trimester. Miscarriages in the first trimester were excluded from 
this analysis, but have been reported in several groups of heart disease to be up to 40% in 
women with a Fontan circulation.5 Certainly, this excessive rate should be mentioned to 
women with complex disease. 
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Emerging countries
In this cohort, 33% of women came from a country with an emerging economy. In these 
women, fetal loss was more common, which is in line with previous studies of global preg-
nancy outcome and is partly explained by the limited access to obstetric and neonatal care, 
increased rates of prolonged pregnancies and infectious disease.30 
In emerging countries, both induced and spontaneous preterm birth were less common 
than in developed countries. This is interesting as generally, spontaneous preterm birth is 
thought to be more common in low-income countries.31 Specialists in developed countries 
may be more likely to induce preterm birth as soon as the maternal condition deteriorates 
and women from these countries may have better and quicker access to obstetric care facili-
ties. Also, a higher prevalence of spontaneous preterm birth was related to advanced age 
in a large global cohort,32 which may be the result of uterine dysfunction.33 However, in our 
study, age was not related to spontaneous preterm birth. Differences between emerging 
and developed countries in maternal and fetal outcome in women with cardiac disease are 
intriguing and deserve attention in future research.
Limitations 
Data were missing in no more than 5% of pregnancies, except for smoking(14% missing), 
systemic ventricular function(37.4% missing) and hypoxia(59.7% missing). These questions 
were added in the adjusted online case report form in 2012, and data are therefore missing 
at random. In previous studies, systemic ventricular function and hypoxia were suggested 
as potential important predictors4 and therefore we decided to include this predictor in the 
analysis. Missing variables were handled using multiple imputation, which is considered 
a reliable tool in such situations where large amounts of data are missing. However, firm 
conclusions cannot be drawn.
Miscarriage before 14 weeks was excluded from the analysis. The incidence of miscar-
riage widely ranges in literature concerning the overall healthy population. It is strongly 
influenced by inclusion bias and therefore hard to interpret. That is why, in line with previous 
literature, we chose not to include miscarriage in the first trimester as an endpoint. 
Being aware of its inferiority, we analysed Apgar score at 1 minute rather than at 5 min-
utes, because the first value was complete in almost all cases, while Apgar at 5 minutes was 
missing in more than half.
Conclusion
Women with cardiac disease are at high risk of adverse obstetric and fetal events. The 
modified WHO classification, conducted for women with structural heart disease is a good 
predictor for maternal outcome, but does not perform as well for obstetric and fetal events. 
The majority of events are associated with more general predictors such as twin pregnancy. 
Other associations were complex congenital heart disease leading to small-for-gestational-
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age babies, aortic valve disease predisposing to pre-eclampsia, and the use of anticoagu-
lants leading to fetal demise. Whether factors like twin pregnancy lead to a greater obstetric 
and fetal risk in women with heart disease than their healthy peers needs to be determined 
and may influence the counseling of these patients.
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ABSTRACT
Objectives  To describe the incidence, onset, predictors and outcome of ventricular tachyar-
rhythmia (VTA) in pregnant women with heart disease.
Background  VTA during pregnancy will cause maternal morbidity and even mortality and 
will have impact on fetal outcome. Insufficient data exist on the incidence and outcome of 
VTA in pregnancy. 
Methods and Results  From January 2007 up to October 2013, 99 hospitals in 39 countries 
enrolled 2966 pregnancies in women with structural heart disease. Forty-two women (1.4%) 
developed clinically relevant VTA during pregnancy, which occurred mainly in the third tri-
mester (48%). NYHA class >1 before pregnancy was an independent predictor for VTA. Heart 
failure during pregnancy was more common in women with VTA than in women without 
VTA (24% vs. 12%, p=0.03) and maternal mortality was respectively 2.4% and 0.3% (p=0.15). 
More women with VTA delivered by Caesarean section than women without VTA (68% vs. 
47%, p=0.01). Neonatal death, preterm birth (<37 weeks), low birthweight (<2500 gram) and 
Apgar score <7 occurred more often in women with VTA (4.8% vs. 0.3%, p=0.01; 36% vs. 16%, 
p=0.001; 33% vs. 15%, p=0.001 and 25% vs. 7.3%, p=0.001, respectively). 
Conclusions  VTA occurred in 1.4% of pregnant women with cardiovascular disease, mainly 
in the third trimester, and was associated with heart failure during pregnancy. NYHA class 
before pregnancy was predictive. VTA during pregnancy had clear impact on fetal outcome.
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INTRODUCTION
Heart disease is an important cause of maternal death and, surprisingly, rates are increas-
ing1,2. Interim analysis of the Registry Of Pregnancy and Cardiac disease (ROPAC) reported 
a 100 times higher maternal mortality rate in women with heart disease compared to the 
general pregnant population3. This raises serious safety concerns for women with structural 
heart disease and makes it imperative to identify those at greatest risk of complications 
during pregnancy.
Potentially life-threatening ventricular tachyarrhythmia (VTA) is rare during normal preg-
nancy (2 per 100,000 pregnancies)4,5, but may be associated with maternal hemodynamic 
compromise causing adverse consequences for both mother and fetus6. This data, par-
ticularly in women with structural heart disease, however is scarce and is generally poorly 
reported in the literature. The incidence of VTA in pregnant women with heart disease has 
been documented ranging from 1.0% to 1.4%1,7. In patients with congenital heart disease, 
VTA occurs in up to 1.6%1,8, whereas there are hardly any reports on the incidence of VTA 
in pregnant women with valvular heart disease, ischemic heart disease or cardiomyopathy. 
Also, insufficient data exist on the outcome of VTA during pregnancy. Previous studies 
mostly report on arrhythmias in general, but it is of major importance to distinguish poten-
tially life-threatening VTA from the mostly benign supraventricular tachycardia. This study 
describes the incidence, onset, predictors and outcome of VTA during pregnancy in women 
with structural heart disease.
methods
Study design
The Registry Of Pregnancy And Cardiac disease (ROPAC) is part of the EURObservational 
Research Programme (EORP of the European Society of Cardiology) and was initiated in 
2007. From January 2008 pregnant women with heart disease were included prospectively. 
Patients from 2007 were included retrospectively, assuming that the complete data were 
available and reliable. All patients included up to October 2013 were included in the current 
interim analysis. In this period, 99 hospitals in 39 countries contributed to the registry and a 
total of 2966 pregnant women with congenital heart disease (CHD), valvular heart disease 
(VHD), cardiomyopathy (CMP), ischemic heart disease (IHD), aortic pathology (AOP) or pul-
monary hypertension were enrolled. Non-structural heart disease, for example arrhythmia 
occurring in the context of a structurally normal heart, was excluded. The study protocol 
and first results of this registry were published in 20133. Informed consent was obtained 
from the patients and the study protocol conforms to the ethical guidelines of the 1975 
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Declaration of Helsinki as reflected in a priori approval by the institution’s human research 
committee.
Data
VTA has been defined as three or more consecutive ventricular beats with a mean rate of 
more than 100 beats per minute; however, only clinically relevant VTA (when the patient 
had physical complaints, needed treatment for VTA or when the patient had more than 100 
consecutive beats) was included. Onset of VTA, given in weeks of gestation, was calculated 
using the expected date of delivery. Data up to one week after delivery was available for all 
patients. Baseline characteristics before pregnancy were analyzed, including cardiac diag-
nosis, maternal age, parity, clinical signs of heart failure, hypertension, smoking status, medi-
cation use and New York Heart Association (NYHA) functional class. The following cardiac 
diagnoses were included: CHD, VHD, IHD, CMP, AOP and pulmonary hypertension. The type 
of cardiac lesions were divided into three categories for the univariable logistic regression 
analysis: right sided lesions (e.g. Ebstein anomaly, tetralogy of Fallot, pulmonary stenosis), left 
sided lesions (e.g. aortic valve disease, mitral valve disease and most cardiomyopathies) and 
shunt lesions (e.g. atrial septal defects and ventricular septal defects). Participating countries 
were classified as developed or developing according to the International Monetary Fund 
classification9. 
Statistical methods
Categorical data are presented as frequencies (numbers) and percentages. Normality of 
continuous data was checked by one-sample Kolmogorov-Smirnov tests and histograms. 
Continuous data are presented as mean values +/- one standard deviation (SD) when nor-
mally distributed. The chi-squared test was used to compare differences in categorical data 
between independent patient groups. Fisher’s exact tests were applied if any expected cell 
count was less than 5. The Student’s t-test was used to compare differences in continuous 
data between independent patient groups. Mean birthweight was corrected for gestational 
age, fetal sex, maternal age and diabetes, using linear regression. The birthweight was not 
normally distributed; therefore both the median birthweight and the corrected mean 
birthweight are shown in this article. Baseline patient characteristics associated with VTA 
were identified with univariable logistic regression analysis. Available echocardiographic 
data (moderate or severely impaired systemic ventricular function) were also analyzed in 
the univariable logistic regression analysis. The multivariable analysis consists of variables 
that were associated with an increased incidence of the studied endpoint (P<0.15). For each 
10 cases/patients, one of the most significant univariable predictors was included in the 
multivariable analysis. A p-value <0.05 (2-sided test) was considered statistically significant. 
All statistical analyses were performed using SPSS 21.0 (SPSS Inc., Chicago).
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RESULTS
Baseline characteristics
Of the 2966 patients included in the registry, 42 (1.4%) patients developed clinically relevant 
VTA during pregnancy. One patient had ventricular fibrillation (VF), the other patients had 
ventricular tachycardia. Baseline characteristics of pregnant patients with and without VTA 
are shown in Table 1. The incidence of VTA was 1.2% in CHD patients, 0.6% in VHD patients, 
5.9% in CMP patients, 2.1% in IHD patients and 3.0% in AOP patients. VTA was not observed 
in patients with pulmonary hypertension. The diagnoses per cardiac disease category are 
shown in Figure 1. Before pregnancy, three patients had pacemaker-dependent rhythm. All 
others were in sinus rhythm.
table 1 Baseline characteristics of cardiac patients with and without ventricular tachyarrhythmia.
Total group Patients with VTA* Patients without VTA
(n=2966) (n=42) (n=2924) p-value
Mean age in years (SD†) 29.3 (5.6) 28.9 (5.7) 29.3 (5.6) 0.78
Nulliparity (%) 45 55 45 0.21
Clinical signs of heart failure (%) 10 21 10 0.02
Hypertension (%) 6.5 4.9 6.5 1.00
Current smoker (%) 4.3 5.1 4.3 0.68
Developing countries (%) 35 45 35 0.17
NYHA class‡ 0.002
NYHA class 1 (%) 73 50 73
NYHA class 2 (%) 22 38 22
NYHA class 3 (%) 2.9 11.9 2.8
NYHA class 4 (%) 0.3 0 0.3
Type of heart disease
Congenital heart disease (%) 56 48 56 0.28
Valvular heart disease (%) 32 14 32 0.01
Ischemic heart disease (%) 1.6 2.4 1.6 0.68
Cardiomyopathy (%) 7 29 7 <0.001
Aortic pathology (%) 3.4 7.1 3.4 0.18
Pulmonary arterial 
hypertension(%)
0.4 0 0.4 1.00
Medication use before pregnancy 
Beta-blocker (%) 12 17 12 0.39
Other anti-arrhythmic drugs (%) 3.1 0 3.1 0.64
Diuretics (%) 5.8 9.5 5.7 0.30
ACE inhibitors§ (%) 3.9 4.8 3.9 0.68
Calcium antagonists (%) 0.2 0 0.2 0.34
* VTA = ventricular tachyarrhythmia, † SD = Standard deviation,  ‡ NYHA = New York Heart Association, 
§ ACE = Angiotensin Receptor Enzyme
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Onset of VTA
Figure 2 shows that VTA mainly occurred in the third trimester (48%). Figure 3 shows the 
onset of VTA per cardiac disease category. 
VTA patients (n=42) 
CHD (n=20) CMP (n=12) VHD (n=6) AOP (n=3) IHD (n=1) 
 
Eisenmenger syndrome (n=3) 
Tetralogy of Fallot (n=3) 
Transposition of the great arteries  
(TGA, n=2) 
Congenitally corrected TGA (n=1) 
Mitral valve abnormality (n=3) 
Aortic stenosis with bicuspid valve (n=1) 
Subvalvular aortic stenosis with aortic 
regurgitation (n=1) 
Pulmonary atresia (n=1) 
Pulmonary valve abnormality (n=1) 
Secundum atrial septal defect (n=2) 
Ventricular septal defect (n=1) 
Infundibular stenosis with ASD (n=1) 
 
 
Hypertrophic obstructive 
CMP (n=5) 
Dilated CMP (n=4) 
Arrhythmogenic right 
ventricular CMP (n=2) 
Other unspecified CMP 
(n=1) 
 
 
Mitral regurgitation (n=4) 
Mixed mitral disease (n=1) 
Aortic stenosis (n=1) 
 
 
Marfan syndrome (n=1) 
Aortic dilatation with 
bicuspid valve (n=1) 
Aortic dilatation, no 
etiology (n=1) 
 
 
ST-segment elevation 
myocardial infarction 
developed during 
pregnancy (n=1) 
 
figure 1 Diagnoses per cardiac disease category.
CHD=congenital heart disease, VHD=valvular heart disease, CMP=cardiomyopathy, AOP=aortic pathology
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figure 2 The occurrence (onset) of VTA during pregnancy in women with heart disease.
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Predictors
The results of the univariable and multivariable logistic regression are shown in Table 2. 
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figure 3 The occurrence of VTA during pregnancy per cardiac disease category.  
The number of patients per category is shown between brackets.
CHD=congenital heart disease, VHD=valvular heart disease, CMP=cardiomyopathy, AOP=aortic pathology, All 
cardiac=CHD+VHD+CMP+AOP.
* The time of onset of VTA was missing in four CHD patients. 
table 2 Pre-pregnancy predictors for VTA
Univariable Odds ratio 95% CI p-value
Congenital heart disease 0.72 (0.39-1.32) 0.28
Valvular heart disease 0.35 (0.15-0.84) 0.02
Cardiomyopathy 5.76 (2.90-11.4) <0.001
Right sided lesion 0.72 (0.32-1.62) 0.43
Left sided lesion 1.71 (0.91-3.20) 0.09
Shunt lesion 0.61 (0.26-1.46) 0.27
NYHA class>1 2.98 (1.62-5.49) <0.001
Nulliparity 1.48 (0.80-2.72) 0.21
Hypertension 0.74 (0.18-3.08) 0.68
Clinical signs of pre-pregnancy heart failure 2.59 (1.23-5.47) 0.01
Developing countries 1.53 (0.83-2.82) 0.17
Any medication use before pregnancy 1.16 (0.60-2.24) 0.66
Beta-blocker use before pregnancy 1.43 (0.63-3.24) 0.39
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Medication before and during pregnancy
Of the 42 patients with VTA, 31% used cardiac medication before pregnancy. The medica-
tion used before pregnancy is shown in Table 1. During pregnancy, 74% of the VTA patients 
used medication: 57% used beta-blockers, 12% used other anti-arrhythmic drugs and 12% 
used diuretics. Amiodarone was used in 3 of the 42 patients with VTA.
Maternal outcome
Pregnancy outcome until one week after delivery is presented in Table 3. Heart failure was 
diagnosed in 10 VTA patients (24%), occurring after VTA in three patients, before in three 
and at the same time in one and in the remaining three patients the temporal relationship 
was unclear. Maternal death occurred in one patient (2.4%). This was a 36-year-old woman 
with pulmonary atresia, who had a bioprosthetic pulmonary valve replacement before 
pregnancy. She was taking beta-blockers because of aortic dilatation and used LMWH 
throughout pregnancy. At 17 weeks of pregnancy, she had an out of hospital cardiac arrest 
due to VF. She survived resuscitation, but was left in a persistent vegetative state. She was 
ventilated until delivery at 32 weeks and died one week postpartum. 
table 2 Pre-pregnancy predictors for VTA (continued)
Univariable Odds ratio 95% CI p-value
Echo prior to pregnancy
Systemic ventricular dysfunction 4.59 (1.92-10.96) 0.001
moderate/severely impaired
Multivariable       
Cardiomyopathy 2.70 (0.95-7.69) 0.06
NYHA class>1 2.64 (1.12-6.20) 0.03
Clinical signs of pre-pregnancy heart failure 0.88 (0.29-2.64) 0.82
Systemic ventricular dysfunction 2.25 (0.78-6.48) 0.13
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Delivery and fetal outcome
Fetal outcome is shown in Table 3. Mode of delivery in patients with VTA was by emergency 
Caesarean section in 20%, elective Caesarean section in 48% and vaginally in 32%. No fetal 
death occurred in VTA patients (Table 3), but there were two neonatal deaths. A 28-year-old 
patient with non-obstructive CMP developed VTA in week 6 of pregnancy. She underwent 
Caesarean section at 29 weeks for cardiac reasons, followed by an unexplained neonatal 
death. The second neonatal death was due to acute respiratory distress syndrome (ARDS) 
one week postpartum. The mother of this child had subaortic stenosis and a history of heart 
failure before pregnancy.
table 3 Pregnancy outcome in cardiac patients with and without VTA. Outcome until one week after preg-
nancy.
Total group Patients with VTA Patients without VTA
p-value(n=2966) (n=42) (n=2924)
     
Maternal mortality (%) 0.4 2.4 0.3 0.15
Cardiac
Heart failure (%) 13 24 12 0.03
Thromboembolic events (%) 0.8 0 0.8 1.00
Endocarditis (%) 0.2 0 0.2 1.00
Bleeding during pregnancy (%) 6.2 4.8 6.2 1.00
Obstetric
Intra-uterine growth retardation (%) 4.6 4.8 4.6 0.72
Pregnancy induced hypertension (%) 2.3 0 2.4 0.63
(Pre)eclampsia (%) 2.4 0 2.5 0.63
Caesarean section (%) 48 68 47 0.01
Fetal outcome
Miscarriage (<24 weeks; %) 2.7 0 2.7 0.26
Late fetal death (≥24 weeks; %) 0.7 0 0.7 1.00
Neonatal death (%) 0.3 4.8 0.3 0.01
Median pregnancy duration (weeks) 38.2 37.4 39.0 <0.001
Apgar score <7 (%) 7.6 25 7.3 0.001
Preterm birth (<37 weeks; %) 16 36 16 0.001
Low birthweight (<2500 g; %) 15 33 15 0.001
Median birthweight (g) - 2730 3020 0.006
Corrected mean birthweight (g)* - 3283 3289 0.94
Birthweight corrected for: gestational age, fetal sex, maternal age, and diabetes.
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discussion
This is the first detailed study of pregnancy outcome after VTA in patients with cardiovas-
cular disease. In this large prospective international registry of 2966 pregnancies with heart 
disease, the incidence of VTA during pregnancy was 1.4% and occurred mainly in the third 
trimester. NYHA class >1 before pregnancy was an independent predictor of VTA. VTA was 
associated with a marked increase in the neonatal death rate, preterm birth rate, low birth-
weight rate and poor Apgar score.
Incidence of VTA
Existing data on the incidence of VTA during pregnancy in patients with heart disease is 
scarce. Siu et al. studied pregnancy outcome in two cohorts of women with heart disease. 
VTA occurred in 4 cases in the cohort of 276 pregnancies and in 6 patients in the cohort of 
599 pregnancies1,7. The incidence of VTA in our study (1.4%) was comparable to the inci-
dence of Siu et al.’s retrospective (1.4%) and prospective (1.0%) studies. 
Congenital heart disease – VTA during pregnancy in women with CHD is rare. We observed 
VTA in 1.2% of CHD patients, in keeping with the reported incidence range from 0.4 to 
1.6%1,8. Patients with repaired CHD in the study of Niwa et al.10 had a significantly higher inci-
dence of VTA than healthy pregnant women. In their study, the prevalence of non-sustained 
VTA was 14% with the highest incidence in patients with previous surgical correction of 
Tetralogy of Fallot (TOF) 8,10,11. In our study, VTA occurred in 2.5% of TOF patients (3 out of 119 
patients), however, we only included patients with symptomatic VTA.
Cardiomyopathy – VTA occurred remarkably often in patients with CMP (7.4%) in our study. 
In the study of Grewal et al.12, VTA occurred in 3% of dilated CMP patients. In patients with 
hypertrophic CMP, the incidence of arrhythmias (including VTA) was not increased during 
pregnancy13. However, in hypertrophic CMP patients with an Implantable Cardioverter De-
fibrillator (ICD), VTA is a common complication with an observed incidence of 22% during 
pregnancy14. Some case reports of VTA in patients with peripartum cardiomyopathy (PPCM) 
have been published previously15-17. In our study VTA did not occur in the 33 PPCM patients.
Valvular heart disease – We found that 0.7% of the patients with VHD developed VTA 
during pregnancy and the majority had mitral valve disease. In the literature, ventricular 
arrhythmia, not further defined, has been described in 1.5% of pregnant women with VHD18 
and occurred in 1.2% in Siu et al.’s prospective study. 
Ischemic heart disease – Although seldom encountered during pregnancy, IHD is a major 
and increasing cause of maternal death19. In the existing literature, cases of VF, but not 
ventricular tachycardia, have been reported during pregnancy in patients with a myocardial 
infarction 20,21. In our registry, VTA occurred in only one patient with IHD (2.1%). 
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Predictors for VTA
Women with a limited exercise tolerance are at higher risk of developing complications 
during pregnancy4, and consequently, we were not surprised to find that NYHA class>1 
before pregnancy is an independent predictor of VTA. Any disease process that affects the 
ventricular myocardium causing hypertrophy, infiltration or scarring may disrupt the electri-
cal integrity of the myocardium and induce VTA11. CMP in general is known to be associated 
with ventricular arrhythmias as it is often associated with diminished ventricular function22. 
In accordance with this, we found that a diagnosis of CMP showed a borderline significance 
(0.06) in the multivariable analysis. 
Onset during pregnancy
Nakagawa et al.23 studied 11 pregnant women who experienced a new onset of ventricu-
lar tachycardia during pregnancy. In their study, the onset of ventricular tachycardia was 
distributed equally over the three trimesters and did not occur in the postpartum period. 
Overall, VTA occurred throughout pregnancy but more in the third trimester in our study, 
with CHD patients experiencing VTA more in the second and third trimester, while CMP 
patients typically present with VTA at the end of pregnancy (≥32 weeks), perhaps reflecting 
a different threshold for VTA. These findings raise a number of hypotheses regarding the 
mechanism of VTA during pregnancy. Cardiac output, induced by a decline in systemic 
vascular resistance, rises rapidly through the first and second trimesters reaching a peak 
at around 26 weeks and remaining at this level until the end of pregnancy24. The increase 
in cardiac output is due to an increase in heart rate and stroke volume. The greater filling, 
resulting in an increase in cardiac end diastolic volumes, will result in myocardial stretch 
which has been shown to induce VTA25. In addition to these physiological changes during 
normal pregnancy, women with structural heart disease have limited ability to adjust to 
the hemodynamic requirement of pregnancy, and this may become manifest as systolic 
and diastolic cardiac dysfunction during pregnancy24, which again may increase the risk of 
VTA. Finally, the increased sympathetic activity observed during pregnancy has also been 
suggested to be responsible for the increased incidence of arrhythmias and it is well known 
that high plasma catecholamine concentrations and adrenergic receptor sensitivity may 
trigger VTA26. In all patients, the hemodynamic overload may well have contributed to the 
development of VTA, while the increased sympathetic activity may be more important in 
specific groups such as cardiomyopathy patients, which may be more susceptible.
Maternal outcome
VTA, outside of pregnancy, is associated with sudden cardiac death, especially in the pres-
ence of cardiomyopathy22,27. Previous publications on VTA during pregnancy were either 
case reports or studies which have only reported on its incidence. Therefore, it is not well 
known whether VTA during pregnancy carries an extra high risk for mortality. We did not 
70 Chapter 3
detect a significant increase in maternal mortality, but it must be noted that, although 
our series is by far the largest, our mortality numbers are still small and we have analyzed 
outcome only until one week after pregnancy. The timing of heart failure and VTA seemed 
to be associated in our study. However, a clear cut pattern was not found as some patients 
developed heart failure shortly after VTA, while others developed heart failure prior to VTA.
Delivery and fetal outcome
Women with VTA during pregnancy had higher rates of neonatal death, preterm birth and 
poor Apgar score. Certainly, low birthweight was more common in patients with VTA than 
in patients without VTA and the median birthweight was significantly lower in VTA patients. 
However, the corrected mean birthweight did not significantly differ between the two 
groups, suggesting that the difference in birthweight is primarily due to the higher preterm 
birth rate. Physicians often opt for preterm delivery in women with VTA, partly to shorten 
the period of hemodynamic compromise and also to be able to institute a more aggressive 
therapy for VTA, which might have an adverse effect on the fetus. Equally, the decision for 
early delivery may have a negative impact on neonatal development28. 
Management of VTA during pregnancy
In general, the management of VTA in pregnancy is similar to that outside of pregnancy. 
For VTA with hemodynamic compromise, immediate cardioversion, which is reported to be 
safe in all phases of pregnancy, is recommended4. When the patient is not hemodynamically 
compromised, medication should be considered. The concerns with anti-arrhythmic drug 
use during pregnancy relate to their effects on fetal growth and development. Beta-blockers 
are the drug of choice for hemodynamically well-tolerated VTA. The use of beta-blockers 
during pregnancy is generally well tolerated by both mother and fetus, even though it 
has been associated with a decrease in fetal heart rate, low blood glucose and reduced 
birthweight22,29. In our study, most patients with VTA (57%) were treated with a beta-blocker, 
other antiarrhythmic drugs were prescribed in 12% of the patients. Amiodarone was used 
in 3 of the 42 patients with VTA in our study and may have had a deleterious effect on one 
fetus, perhaps causing growth retardation requiring earlier delivery22. A multidisciplinary 
approach with close monitoring of mother and baby with timely intervention for both is 
required to optimize maternal and fetal outcomes.
Implications on clinical practice
The significance of VTA during pregnancy in women with heart disease lies in the fact 
that it carries a higher preterm birth rate and, consequently, lower birthweight and poor 
Apgar score. Cardiac patients in NYHA class>1 and patients with CMP are at particular risk 
and should be counselled about the risks before pregnancy and followed closely during 
pregnancy. 
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Study Limitations
This dataset, like in other registry collected datapoints, was limited by the availability of in-
formation on the past history. In our registry missing data concerning the current pregnancy 
ranged from 0% to 4% for all parameters except two: smoking (14%) and left ventricular 
dysfunction (36%). Although VTA is an important complication especially in women with 
underlying heart disease, its incidence is low, reflected in the number of cases. This makes 
it difficult to draw any firm conclusions. The severity of the VTAs was not reported in detail. 
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ABSTRACT 
Background The incidence, timing and consequences of atrial fibrillation or flutter (AF/Afl) 
during pregnancy in patients with heart disease are not well known. 
Objectives AF/Afl during pregnancy in these women is associated with adverse outcome 
of pregnancy.
Methods Between 2007 and 2011, 60 hospitals in 28 countries prospectively enrolled 1321 
pregnant women with congenital heart disease, valvular heart disease, ischemic heart 
disease or cardiomyopathy in the Registry Of Pregnancy And Cardiac disease (ROPAC). We 
studied the incidence, onset and predictors of AF/Afl during pregnancy and assessed the 
pregnancy outcome. An overview of the existing literature is provided.
Results Seventeen women (1.3%) developed AF/Afl during pregnancy, mainly in the second 
trimester (61.5%). Univariable analysis identified the following pre-pregnancy risk factors 
for AF/Afl in pregnancy; AF/Afl before pregnancy (OR 7.1, 95% CI 1.5-32.8), mitral valvular 
heart disease (OR 6.9, 95% CI 2.6-18.3), beta-blocker use (OR 3.3, 95% CI 1.2-9.0), and left 
sided lesions (OR 2.9, 95% CI 1.0-8.3). Maternal mortality was higher in women with than in 
women without AF/Afl (11.8% vs. 0.9%, p=0.01), although heart failure was not seen more 
often. Low birth weight (<2500 gram) occurred more often in women with than in women 
without AF/Afl (35% vs. 14%, p=0.02). 
Conclusions AF/Afl occurs in 1.3% of pregnant patients with structural heart disease with 
a peak at the end of the second trimester. AF/Afl during pregnancy in cardiac patients is 
associated with unfavorable maternal outcome and also has impact on fetal birth weight. 
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introduction 
Major cardiovascular adaptations occur in women during pregnancy1. Cardiac output 
increases 30-50% above baseline during normal pregnancy. In early pregnancy, increased 
cardiac output is primarily related to the rise in stroke volume. In late pregnancy, heart rate is 
the major factor2. Pregnancy is also a hypercoagulable state3. These physiological alterations 
have more impact in patients with pre-existing heart disease4,5. 
Arrhythmia, especially supraventricular tachycardia (SVT), is a known complication during 
pregnancy in patients with heart disease6 7. The incidence of SVT seems to increase dur-
ing pregnancy due to hemodynamic and maybe also hormonal changes, but evidence is 
scarce8. Atrial fibrillation is the most common clinically significant cardiac arrhythmia in the 
general population. Even though atrial fibrillation or atrial flutter (AF/Afl) is rarely directly 
life-threatening, it increases the risk of thrombo-embolism and may worsen cardiac func-
tion9-11.  Starting medical treatment for AF/Afl presents a difficult choice in practice, since 
most anti-arrhythmic drugs can be regarded as potential harmful to the fetus6,9.
Current literature on the occurrence of arrhythmia during pregnancy and its effect in 
women with cardiac disease is limited. Therefore, we studied the incidence, onset and 
predictors of AF/Afl in pregnant patients with heart disease, and report on the maternal and 
fetal outcome. In addition, we present an overview of the current literature.
methods 
Study design
The European Registry on Pregnancy and Cardiac disease (ROPAC) was established in 2008 
by the European Society of Cardiology (ESC). Pregnant patients from 2007 were included 
retrospectively, assuming that the complete data of these patients were available and reli-
able. From January 2008 up to June 2011 patients were included prospectively with follow-
up of six months. In this period, 60 hospitals in 28 countries have contributed to the registry 
and 1321 pregnant patients with structural heart disease were enrolled. Non-structural 
heart diseases, for example arrhythmias occurring in the context of a normal heart, were 
excluded. 
Data
The study protocol and first results of this registry were published in 20137. 
Onset of AF/Afl was displayed as weeks of gestational age. Baseline characteristics before 
pregnancy were analyzed, including cardiac diagnosis, maternal age, nulliparity, clinical 
signs of heart failure, atrial fibrillation before pregnancy, hypertension, smoking status, 
beta-blocker use before pregnancy and New York Heart Association (NYHA) functional class. 
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Recorded cardiac diagnoses were congenital heart disease (CHD), valvular heart disease 
(VHD), cardiomyopathy (CMP) and ischemic heart disease (IHD). Countries were divided into 
developed or developing nations according to the International Monetary Fund Classifica-
tion. 
The type of cardiac lesion was classified in three categories for the univariable logistic 
regression analysis: right sided lesions (e.g. Ebstein anomaly, tetralogy of Fallot, pulmonary 
stenosis), left sided lesions (e.g. aortic valve disease, mitral valve disease and cardiomyopa-
thies) and shunt lesions (e.g. atrial septal defects and ventricular septal defects). Fractional 
shortening <30 on echocardiography was also analyzed with the univariable logistic regres-
sion analysis.
Statistical methods
Categorical data are presented as frequencies and percentages. Continuous data are 
presented as mean values +/- one standard deviation (SD) when considered normally dis-
tributed as was checked using Kolmogorov-Smirnov tests. The chi-squared test or Fisher’s 
exact tests were used to compare differences in categorical data between independent 
patient groups, whereas student’s t-test was used to compare differences in continuous 
data between independent patient groups. It was the intention to adjust birth weight by a 
linear regression for multiple factors. However due to the small number of cases in the AF/
AFl group, adjustment was only applied for gestational age. Baseline patient characteristics 
associated with AF/Afl were identified with univariable logistic regression analysis. Multivari-
able analysis was not done because of the small number of cases. A p-value <0.05 (2-sided 
test) was considered statistically significant. All statistical analyses were performed using 
SPSS 21.0 (SPSS Inc., Chicago).
results
Baseline characteristics
Of the 1321 patients included in the registry, 17 (1.3%) developed AF/Afl during pregnancy. 
Two of these 17 had one episode of AF before pregnancy, and experienced a new event 
during pregnancy, while 5 others had pre-existing paroxysmal AF/Afl. Baseline character-
istics of patients with and without AF/Afl are shown in Table 1. Differences were found in 
underlying diagnoses. VHD was the most common underlying problem in patients with 
AF/Afl. No patients with ischemic heart disease developed AF/Afl. The incidence of AF/Afl 
within each cardiac diagnosis category is depicted in Figure 1.
Detailed information on the patients with AF/Afl is provided in Table 2.
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table 1 Baseline characteristics of patients with and without AF or AFl
Total group Patients with AF/Afl Patients without AF/Afl p value
(n=1321) (n=17) (n =1304)
Mean age in years 30 ± 5.6 32 ± 5.0 30 ± 5.6 0.09
Nulliparity 50 41 50 0.47
Clinical signs of heart failure 11 18 10 0.41
Episode of AF at baseline 2.0 11.8 1.8 0.04
Hypertension 6.7 0 6.7 0.62
Smoking 3.3 0 3.3 1.00
Beta-blocker before pregnancy 14 35 14 0.026
NYHA functional class
I 70 59 70 0.30
II 25 29 25 0.58
III 3 12 3 0.10
IV 0.3 0 0.3 1.00
Type of heart disease
Congenital heart disease 66 35 66 0.01
Valvular heart disease 25 59 25 0.003
Cardiomyopathy 6.7 5.9 6.7 1.00
  Ischemic heart disease 1.9 0 1.9 1.00
Values are mean ± SD or %
AF = atrial fibrillation; Afl = Atrial flutter; NYHA = New York Heart Association
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figure 1 Percentage of patients with AF/Afl within each diagnosis category
The number of patients per group is shown between brackets.
AF/Afl=atrial fibrillation or flutter, All cardiac=CHD+VHD+CMP+IHD, CHD=congenital heart disease, VHD=valvular 
heart disease, CMP=cardiomyopathy, IHD=ischemic heart disease
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Predictors and onset of AF/Afl
The results of the univariable logistic regression are shown in Table 3. It appeared that 
patients enrolled in centers with at least one AF/Afl event had different characteristics than 
the remaining patients. Unfortunately, due to the low number of endpoint events, it was 
not possible to correct for the differences between the centers. Table 1 of the online supple-
ment shows the differences between centers with AF/Afl events and centers without AF/Afl 
events. Of the univariable predictors, only pre-pregnancy atrial fibrillation and beta-blocker 
use were not different in the centers with or without AF/Afl.
In all patients, AF/Afl occurred during pregnancy and once after delivery (Figure 2). Onset 
of AF/Afl was mainly at the end of the second trimester. 
table 3 Univariable predictors for AF/AFl
Odds ratio   95% CI p value
Congenital heart disease 0.3 (0.1-0.8) 0.01
Mitral valve disease 6.9 (2.6-18.3) <0.001
Cardiomyopathy 0.9 (0.1-6.7) 0.90
Right sided lesion 0.2 (0.03-1.5) 0.12
Left sided lesion 2.9 (1.0-8.3) 0.046
Shunt lesion 0.9 (0.3-2.9) 0.89
NYHA class > II 3.9 (0.9-17.6) 0.08
Nulliparity 0.7 (0.3-1.9) 0.48
Developing countries 2.6 (0.9-7.5) 0.08
Clinical signs of heart failure 1.8 (0.5-6.5) 0.34
Rhythm: Atrial fibrillation before pregnancy 7.1 (1.5-32.8) 0.01
Mechanical valve 1.5 (0.2-11.8) 0.68
Beta-blocker before pregnancy 3.3 (1.2-9.0) 0.02
Echo prior to pregnancy: Fractional Shortening < 30% 2.2 (0.2-24.6) 0.53
CI = Confidence interval, other abbreviations as in Table 1
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Medication before and during pregnancy
During pregnancy 14 patients (82%) used medication. Details concerning antiarrhythmic 
medication and anticoagulants are listed in Table 2.
Delivery
Mode of delivery in patients with AF/Afl was vaginally in 9 (53%), by elective Cesarean sec-
tion (CS) in 7 (41%) and by emergency CS in one patient, because of cardiac reasons. Elective 
CS was for cardiac reasons in 7 patients and for obstetric reasons in one.
Maternal and fetal outcome
Maternal mortality occurred in 2 of the 17 patients (12%). The first patient was 29 years old 
and had moderate mitral stenosis and mitral regurgitation before pregnancy. After delivery 
anticoagulation was stopped because of severe bleeding. She suddenly died 1 week after 
delivery and was highly suspected based on clinical judgement of a thromboembolic com-
plication. The second patient was 25 years old and also had a combination of severe mitral 
stenosis and mitral regurgitation. Early spontaneous abortion occurred in this patient and 
she died 6 weeks after the expulsion of the pregnancy due to sepsis, which was followed 
by the event of atrial fibrillation. Both patients did not suffer from heart failure prior to their 
demise.
There were no significant differences in cardiac and obstetric complications during preg-
nancy in the patients with versus without AF/Afl (Table 4). Hospitalization during pregnancy 
was needed for 12 patients (71%). All hospital admissions were for cardiac reasons. 
Fetal outcome is summarized in Table 4. 
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figure 2 Onset of AF/Afl during pregnancy in patients with heart disease
Exact timing of onset is missing in 4 patients.
AF/Afl=atrial fibrillation or flutter 
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discussion
This is the first study to examine in detail the incidence, predictors and outcome of AF/Afl in 
pregnant patients with heart disease. In this large prospective international registry of 1321 
patients with heart disease, 1.3% experienced documented AF/Afl, which occurred most 
frequently at the end of the second trimester. Pre-pregnancy predictors of AF/Afl were AF 
before pregnancy, mitral valve disease, beta-blocker use, and left sided lesions. AF/Afl was 
associated with higher rates of maternal mortality and lower fetal birth weight.
Literature and Incidence of AF/Afl
Existing data on the incidence of AF/Afl, during pregnancy in patients with heart disease 
is limited and based on small case series and individual case reports (online supplement 
Table 1)12-22. Silversides et al did report on the recurrence rate of SVT during pregnancy in 
patients with a history of SVT17. Li et al18 reported the prevalence of cardiac arrhythmia 
table 4 Pregnancy outcome in patients with and without AF/AFl
Total group
Patients with 
AF/Afl
Patients without 
AF/Afl 
p value
(n =1321) (n=17) (n=1304)  
Maternal mortality 1.0 11.8 0.9 0.01
Cardiac
Heart failure 13 12 13 1.00
Thrombo-embolic events 0.5 0 0.5 1.00
Endocarditis 0.2 0 0.2 1.00
Bleeding complications during pregnancy 1.6 5.9 1.5 0.34
Bleeding complications postpartum 4.9 5.9 4.9 0.58
Obstetric
Intra-uterine growth retardation 5.8 17.6 5.6 0.07
Pregnancy induced hypertension 2.4 0 2.5 1.00
(Pre-)eclampsia 3.3 0 3.3 1.00
Caesarean section 41 47 41 0.58
Fetal outcome
Mean pregnancy duration (weeks) 38.0 37.5 38.0 0.25
Fetal death 1.7 0 1.7 1.00
Neonatal death 0.6 0 0.6 1.00
Apgar score < 7 10 6 10 1.00
Premature birth < 37 weeks 15 29 15 0.16
Birth weight < 2500 gram 14 35 14 0.02
Adjusted mean birth weight (grams) - 3026 3358 <0.001
Values are %. Abbreviations as in Table 1
Atrial fibrillation or flutter during pregnancy 85
4
among 136,422 pregnant females hospitalized in a single center. Out of 226 patients who 
had an arrhythmia, 3 had AF and all these patients had structural heart disease. Two out of 
the three patients had a previous episode of AF and none of the patients died. Huisman et 
al23 assessed the incidence and risk factors for severe maternal morbidity and cardiovascular 
mortality during pregnancy, delivery and puerperium in the general Dutch population 
between 2004 and 2006. Out of 2552 cases of severe maternal morbidity, 84 (3.3%) involved 
the cardiovascular system among which two cases had AF, neither of whom died. 
Congenital heart disease – We observed AF/Afl in 0.7% of CHD patients. There was one previ-
ous report12 that assessed the progress and outcome of 482 pregnancies in 232 patients 
with CHD. Afl occurred in that study in 2 patients (0.4%).
Cardiomyopathy – We report on one patient with CMP who developed AF in the second 
trimester. The patient delivered in the third trimester by Cesarean section without fetal 
or maternal complications. There are no prior data in the literature on pregnancy in CMP 
developing AF/Afl. 
Valvular heart disease – AF/Afl occurred in 10 patients with mitral VHD (3%) in our study7, 4 of 
them had valve surgery in the past. Available literature on AF/Afl in VHD and pregnancy is in 
the form of case series reports and incidence varies from 2 to 17.5%13,14,16. 
We also collected the literature regarding AF/Afl in pregnancy in women without structural 
cardiac disease. This is summarized in online supplement Table 2, which is available in the 
supplementary material. In summary, these studies are mainly case reports of women 
experiencing AF during the third trimester, with good outcome of both mother and fetus.
Predictors for AF/Afl
It was not surprising to find that AF before pregnancy was an independent predictor of 
AF/Afl during pregnancy. Silversides et al17 found a recurrence rate of arrhythmia during 
pregnancy of 50% in patients with SVT in general and 52% in patients with AF. Adverse fetal 
events occurred in 35% of patients with paroxysmal AF/Afl and 50% with permanent AF. 
Other pre-pregnancy predictors of AF/Afl were mitral valve disease, and left sided lesions, 
although these associations might be explained by the fact that the centers reporting AF/
Afl in these patients were a predilection site for these underlying diagnoses. The physiologi-
cal changes that occur during pregnancy producing a state of high volume, high output 
and low cardiovascular resistance are likely responsible mechanisms. These changes may 
amplify wall stress, which, combined with the prior cardiac abnormalities, causes electro-
physiological imbalance and lowers the threshold for onset of arrhythmias. To our surprise, 
we found no correlation with heart failure.
 Patients in our study who had been prescribed medication before pregnancy, in particu-
lar beta-blockers, probably had more severe cardiac disease, accounting for the increased 
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risk of developing AF/Afl in this group. This might be related to the fact that some of the 
patients were administered beta-blockers before pregnancy because of prior arrhythmias. 
Onset during pregnancy
Most of AF/Afl was found in the second trimester in our study, with a peak of occurrence 
between week 23 and 26. In contrast, previously reported cases of AF in pregnancy were 
commonly observed in the third trimester. Most comparable is the cohort of Silversides et al 
and our results do agree with theirs.  
Maternal and fetal outcome
We report an increase in maternal deaths in cardiac patients with AF/Afl during or shortly 
after pregnancy (11.8%). This is probably attributable partly to the severity of the underlying 
cardiac condition and in addition the thrombo-embolic risk might play a role. As we report 
on two mortality cases only, a definitive conclusion on causative mechanisms cannot be 
drawn. Only one previous report13 has described mortality in a patient due to heart failure. 
We did not find any increase in fetal loss in women with AF/Afl. A low birth weight was 
more common in the offspring of patients with than without AF/Afl. Adjusted for pregnancy 
duration, the absolute birth weight remained to be remarkably lower in patients suffering 
AF/Afl during pregnancy. However, it was not appropriate to statistically correct for factors 
like the use of beta-blockers during pregnancy and type of underlying cardiac disease, 
which might influence the birth weight as well.
Management of AF/Afl during pregnancy
In the management of patients with AF/Afl in pregnancy several issues should be taken 
into consideration. First, the teratogenic potential of anti-arrhythmic drugs limits the use 
of these agents during pregnancy. From many of these drugs, information on safety in 
pregnancy is lacking and most pharmaceutical companies advice not taking these drugs 
during pregnancy. Secondly, the hemodynamic alteration during pregnancy can alter the 
pharmacokinetics of the anti-arrhythmic drugs. For instance, for digoxin the dose needed 
for adequate serum levels during pregnancy is higher than outside pregnancy.  In addi-
tion, anticoagulation needs consideration because pregnancy is a thrombogenic state 6. 
However, bleeding complications are also more often encountered, in particular during 
delivery. Anticoagulants and beta-blockers constitute the medications of first choice in the 
management of patients with AF/Afl in pregnancy and both were used in two thirds of 
our patients.  No increase in bleeding complication rates was observed in our patients on 
anticoagulants. Finally, electrical cardioversion is reported to be safe during pregnancy, but 
anesthetic management needs careful consideration in the pregnant woman. In our study 
this was not reported.
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To achieve a more definite management of the arrhythmia in case of poor tolerance and 
drug resistance, radiofrequency (RF) catheter ablation might be considered. RF ablation for 
AF/Afl during pregnancy has not been reported to date. There is limited evidence from case 
reports and series24,25 on RF ablation being safe in pregnant women suffering from atrial or 
atrioventricular re-entry tachycardia provided that an electroanatomical mapping system is 
used instead of fluoroscopy. 
Implications for clinical practice and research
Although rare in pregnancy, the management of AF/Afl in women with heart disease poses 
a unique challenge to physicians. A multidisciplinary approach with close monitoring of 
mother and baby, and timely therapy is required to optimize maternal and fetal outcomes. 
Despite our data, experience with the management of such arrhythmias remains limited 
and further studies in larger numbers of patients are still awaited. In addition, there is re-
cent evidence that non-pregnant patients at risk for AF may have asymptomatic AF which 
exposes them to the risk of ischemic stroke and other thromboembolic events26,27. The 
observation that most of our patients developed the arrhythmia in the second trimester 
alerts us to the period of highest risk. 
Limitations
As with all registries there was some missing information, which comprised 4% in our 
registry. Some of the previously identified predictors (e.g. hypothyroidism and stress) were 
neither confirmed nor contradicted in this study, because these data were not collected. 
Although AF/Afl is an important complication especially in women with underlying heart 
disease, its incidence during pregnancy is low. It is difficult to draw firm conclusions for the 
different cardiac diseases as the numbers of patients with AF/Afl per cardiac disease cat-
egory were small. Also, the hierarchical structure (60 hospitals within 28 countries), should 
ideally be accounted for in the analysis. However, unfortunately, due to the low number of 
AF/Afl events, adequate estimates of hierarchical model parameters could not be obtained. 
Hence, we were not able to adjust for differences in clinical characteristics between patient 
populations.  Interpretation of our data should be done against this background. Our find-
ings should be seen as first results needing confirmation in larger populations. 
Conclusions 
In this large prospective international registry of women with heart disease, the incidence of 
AF/Afl during pregnancy was 1.3% and occurred mainly at the end of the second trimester. 
AF/Afl before pregnancy, mitral valve disease, beta-blocker use, and left sided lesions were 
predictors of AF/Afl. Our data suggest an increase in maternal mortality and low birth weight 
in patients with AF/Afl during pregnancy.
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Online Supplementary Information
Table 1 Differences between patients enrolled in centers with and without AF/Afl events
Table 2 Atrial fibrillation in pregnant women with structural heart disease as reported in the 
medical literature 
Table 3 Atrial fibrillation in pregnant women without structural heart disease as reported in 
the medical literature
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introduction
Reducing maternal mortality was a major component of the fifth millennium development 
goal. A drop of 47%, was achieved mainly through reductions in sepsis and haemorrhage.1 
Maternal mortality related to cardiovascular causes did not decrease and, in developed 
countries, may even have increased.2,3 Most of these women are not known to have an 
underlying cardiovascular problem, and the majority die from acute events including 
aortic dissection, acute coronary syndrome or an arrhythmia. Others have an underlying, 
pre-existing heart condition, which deteriorates with the increased demands of pregnancy, 
most commonly resulting in heart failure.4 
In the group of women with a known cardiac condition, a preconception assessment by 
an experienced team of specialists is essential in order to minimize the risk of complications 
during pregnancy. The aim of this assessment is to identify those who may benefit from an 
operative intervention, to optimize medical treatment, to identify potential complications 
and to put in place plans to deal with these eventualities. It involves a combination of his-
tory, physical examination, VO2 max exercise testing, echocardiography and in some cases 
cardiac CT or MR. In addition, the thorough evaluation informs pre-conception counseling, 
which should occur at the same time and which should consider the potential impact of 
the cardiac condition on pregnancy outcome and, conversely, the potential impact of the 
pregnancy on the cardiac condition. 
The evaluation of maternal risks can be based on several risk tools.5-7 Of these, the modi-
fied World Health Organization (WHO) risk stratification model seems to be the best predic-
tor of overall risk. Women in modified WHO class IV (a severely dilated aorta, pulmonary 
hypertension, severe systemic ventricular dysfunction, symptomatic left heart obstruction) 
are at such high risk of complications that they should be advised not to conceive.
In women who present in pregnancy with a major cardiac event, early diagnosis and 
prompt treatment is essential. Immediate referral to a specialised center is strongly advised. 
The balance between the maternal condition and fetal maturity will determine whether a 
conservative or invasive approach is adopted. However, in life-threatening circumstances 
the health of the mother is always the primary concern. This strategy is usually in the best 
interest of the fetus.
In this review, the most common acute cardiac complications during pregnancy are 
discussed. The incidence, diagnosis and management are outlined. A summary flow chart 
for practical use is provided for each complication.
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Incidence and timing
In two large prospective cohorts of pregnant women with cardiac disease, heart failure 
was the most common cardiac complication 4,6 and in the largest study it was the most 
important cause of cardiac death. 8 The incidence varies depending on the underlying 
cardiac condition, ranging, in a review of series and case reports, from 4.8% in women 
with congenital heart disease in general, to more than 21.1% in patients with Eisenmenger 
syndrome.9 In prospective studies of patients with any cardiac disease, the overall incidence 
was up to 13.1%,4 but was highest women with shunt lesions, diminished cardiac function 
and pulmonary hypertension (41%). Other patients at particular risk are those with a left 
heart obstruction.10-13 In patients with congenital heart disease with a baffle or conduit in 
situ, prosthesis related problems should be ruled out.
Heart failure typically occurs at the end of the second trimester or immediately postpar-
tum. At the end of the second trimester, the cardiovascular adaptation to pregnancy, with 
increase in cardiac output and plasma volume, reaches its maximum 14, while immediately 
post partum, uterine contraction is associated with an auto-transfusion of between 500-
1000ml of blood results into the maternal circulation. These events may explain the timing 
of heart failure during pregnancy and are summarised in Figure 1.8,14,15 The timing of heart 
failure varies with the underlying cardiac diagnosis: shunt lesions (atrial and ventricular 
septal defects) show a peak incidence of heart failure at the end of the second trimester, 
cardiomyopathies and stenotic lesions at the end of pregnancy and postpartum.8
NT-proBNP levels predict cardiovascular events during pregnancy, but are also elevated 
in pre-eclamptic women without any cardiac abnormality, which is probably attributable 
to the pressure overload and associated cardiac dysfunction.16-18 Therefore, while a low NT-
proBNP does have a strong negative predictive value, a high value does not have a strong 
positive predictive value. There is a remarkable association between pre-eclampsia and 
heart failure. A study assessing cardiac function by echo in patients with either preterm or 
term pre-eclampsia and compared with normotensive controls showed signs of diastolic 
and systolic ventricular dysfunction mainly in women with preterm pre-eclampsia which 
is the more severe form.19 Interestingly, 30% of cardiac patients with pre-eclampsia, also 
developed heart failure during pregnancy.8 Whether the (subclinical) cardiac dysfunction is 
the cause or result in this situation is uncertain, however, the pathogenesis of peripartum 
cardiomyopathy has been related to endothelial dysfunction which also occurs in pre-
eclampsia mediated through VEGF and TGFβ antagonism; this possibility needs further 
investigation.20,21  
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Management (Figure 2)
An experienced center from Germany published their management algorithm for use in 
pregnant patients with acute heart failure.22 A multidisciplinary team decides on the man-
agement plan based on the maternal and fetal condition: if the fetus is viable, the choice 
is between immediate delivery or continuing the pregnancy with heart failure therapy. If 
the heart failure is severe and the fetus is showing signs of distress, then the advice will be 
to deliver. If, on the other hand, the heart failure is mild and the fetal assessment reassur-
ing, then the advice will be to continue. As gestation advances, the threshold for delivery 
will reduce. The final decision is determined by the parents.5 If the fetus is not viable, then 
maximum heart failure therapy is administered directly.  
In case of acute heart failure, bedrest is advised and with few exceptions, the pharma-
cological management of acute heart failure during pregnancy follows the guidelines for 
non-pregnant patients.23,24 Management should always be determined in cooperation with 
an obstetrician. Diuretics can be given and are considered safe during pregnancy,25 but the 
dosage should be increased with caution, to avoid intravascular volume depletion.  ACE 
inhibitors and angiotensin receptor blockers are contraindicated during pregnancy due to 
their fetotoxic effects26 and can only be used in exceptional circumstances as stated by the 
U.S. Food and Drug Administration (FDA category D). The FDA classification is commonly 
used in the setting of pregnancy, but decisions in the emergency situation should always be 
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figure 1 Cardiac output change and timing of heart failure during pregnancy, delivery and postpartum. 
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individualised.  An acute pharmacological intervention can be justified while long-term use 
of the same medication is contraindicated. Hydralazine and nitrates can be used for after-
load reduction 27 and low dose beta-blockers can be considered to control sinus tachycardia 
and maintain sinus rhythm or for the treatment of hypertension. Inotropic therapy may be 
used in those who are haemodynamically unstable: dopamine and levosimendan are then 
first choice agents, although their use in pregnant women Is controversial as evidence of 
efficacy and safety is limited.5,28,29 In patients with ventricular dysfunction, due to the risk of a 
cardiac thrombus and systemic embolisation, therapeutic anticoagulation is recommended 
with either low molecular weight heparin or unfractionated heparin with strict monitoring 
of coagulation. Sinus rhythm should be aimed for in all patients with heart failure. Extensive 
Non-viable fetus:
Postpone delivery
Viable fetus:
Consider induction of
(preterm) delivery
Pregnant patient with
acute heart failure
Medical treatment:
Diuretic
Hydralazine
Nitrate
Low dose beta-blocker
Dopamine and/or levosimendan
In Pulmonary hypertension:
Prostanoid
PDE5 inhibitor
Nitric Oxide inhalation
In PPCM:
Bromocriptine
Gather a multidisciplinary team of:
Cardiologist
Intensivist
Obstetrician
Perinatologist
Anaesthesiologist
If required a cardiac surgeon
Diagnostics:
History + Physical examination
ECG
Laboratory tests
Echocardiography
Delivery:
Contraindicated drugs:
ACE-inhibitor
Angiotensin receptor blocker
Endothelin receptor antagonist
Caution with oxytocin
Congenital heart disease
Acquired valve dysfunction
Cardiomyopathy
Myocarditis
Pulmonary hypertension
Stabilise the
patient as
outside
pregnancy
Pregnancy related problems:
- failure to process the cardiac output increase
- thromboembolic complication
- tachycardia/-arrhythmia
Surgery and other interventions:
Depending on underlying problem
Try to postpone any surgery or intervention until after delivery
Otherwise perform surgery preferably in the 2nd trimester
figure 2 Management of pregnant patients with acute heart failure
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information about cardiac medication is available in the ESC guidelines on the manage-
ment of cardiovascular disease during pregnancy.5
If the pharmacological treatment achieves stabilization of the maternal condition, a 
vaginal delivery is preferred as close as possible to term. A Caesarean section (CS) confers no 
benefit in most women with cardiac disease and increases the risk of infection, thrombosis 
and haemorrhage.30,31 However, in individual cases, a CS might be considered, especially in 
those women with further deterioration in cardiac function, in whom heart function is so 
precarious that it might not cope with the strain of substantial fluctuations in cardiac output 
accompanying contractions during delivery.5 Because of the large volume shifts shortly 
after delivery, women with a history of heart failure should still be monitored intensively for 
at least 48 hours.
Heart failure in patients with pulmonary hypertension
In patients with heart failure due to pulmonary arterial hypertension, treatment with pul-
monary vasodilators should be considered to lower the pulmonary pressure. Some of these 
agents have teratogenic effects, in particular endothelin receptor antagonists, and are con-
traindicated. Experience with the use of other advanced pulmonary arterial hypertension 
therapies, such as prostaglandin therapy and PDE5 inhibitors during pregnancy is limited, 
but seem to be safe and their use associated with improved maternal survival.32 Nitric oxide 
(NO) inhalation is considered as a last resort; but it may acutely reduce pulmonary vascular 
resistance and its use has been associated with a maternal survival in the region of 68%.33-35 
The decision regarding the mode of delivery should be made on an individual basis. During 
delivery, vaginal or a Caesarean section, every effort should be made  to prevent major 
haemodynamic changes. The two key points are the delivery of the placenta, which is as-
sociated with the return of 500-1000mls of blood into the maternal circulation, and the 
immediate post-partum period, when inadequate use of uterotonics may result in an in-
creased risk of post-partum haemorrhage. The presence of an experienced team, including 
a cardiac anaesthetist is essential.
Heart failure in patients with peripartum cardiomyopathy
Women with no cardiac history, who present in the last month of pregnancy or first months 
after delivery with symptoms and signs of heart failure and who are found to have diminished 
left ventricular function  should be considered to have peripartum cardiomyopathy. It is the 
diagnosis of exclusion and is probably related to dilated cardiomyopathy. Prolactin has been 
suggested to play an important role in the pathophysiology.36,37 Heart failure management 
is the same as in other pregnant patients, but in addition, bromocriptine, a dopamine-2D 
agonist that inhibits prolactin secretion, has shown to improve left ventricular function in 
small studies, 38,39 and is currently being investigated in a randomised controlled trial.38 
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ArrhythmiAs  
Supraventricular tachycardia (Figure 3)
Palpitations, dizziness and (near)syncopal events, occur commonly during normal preg-
nancy and are mostly benign: only 10% of symptomatic episodes are actually caused by an 
arrhythmia.40 In women with an arrhythmic event before pregnancy, the recurrence rate of 
supraventricular arrhythmia during pregnancy is approximately 50%.41 The occurrence of 
new onset symptomatic supraventricular tachycardia during pregnancy is rare. An incidence 
of 1.3% has been reported in women with cardiac disease. In pregnant women without 
cardiac history the incidence of supraventricular arrhythmia is presumably much lower and 
mainly described in case reports, often in the third trimester.42 The workup in new onset 
atrial fibrillation is the same as outside pregnancy and includes a careful history and physical 
examination, an ECG, serum electrolytes and thyroid function and an echocardiography to 
identify any underlying abnormality.
Antiarrhythmic agents should be considered to be potentially fetotoxic.5 Also, the 
haemodynamic changes during pregnancy influence drug pharmacokinetics, meaning 
that dose adjustments may be necessary in pregnant women. Similar to the situation 
outside pregnancy, treatment decisions depend on the maternal condition, the duration 
of the arrhythmia and hemodynamic status. Most therapeutic approaches are based on 
observational data, these have been reviewed extensively by Tan and Lie in 2001.43 Current 
treatment recommendations are summarised in Figure 3.
In the case of an atrioventricular (nodal) re-entrant tachycardia, vagal manoeuvres are 
the first line followed by adenosine. Both are reported to be safe in pregnancy.44,45 Atrial 
tachycardia, including intra-atrial re-entry tachycardia, may also be treated with adenosine 
and if unsuccessful, a beta-blocker or digoxin can be started as rate control. Most beta-
blockers are FDA category C, except for atenolol, which is considered FDA category D, and 
should be avoided. 
For atrial fibrillation, sotalol can be used for rhythm control and is considered FDA class 
B. Alternatives include intravenous ibutilide46 or flecainide (FDA class C). In haemodynamic 
unstable patients or if pharmacological cardioversion failed, immediate direct current car-
dioversion should be performed, which is considered safe during pregnancy.  Cardioversion 
should be performed under strict fetal and maternal monitoring and with an obstetric team 
and facilities available for immediate emergency Caesarean section if necessary.47 Agents 
that are not first choice treatment but can be considered because of their effectiveness 
outside pregnancy are: amiodarone (only for short-term use, FDA D),48 procainamide (FDA 
C, limited experience), propafenon (FDA C, limited experience), and verapamil (FDA C, risk of 
maternal hypotension and subsequent placental hypoperfusion).
The indications for anticoagulant therapy are the same during pregnancy,49 but since 
pregnancy and the puerperium are thrombogenic states a lower threshold for treatment 
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should be used. Vitamin K antagonists (VKA, FDA category D) have severe teratogenic ef-
fects and changing to heparin, usually lower molecular weight (LMWH, FDA category B), 
should be considered as soon as pregnancy is confirmed, particularly when high doses are 
needed.50,51 There are minimal data for new oral anticoagulation (NOAC) therapy during 
pregnancy. In rats, most NOACs have been shown to cross the placenta, consequently 
NOACs should not be used, although short-term use of rivaroxaban in the first trimester did 
not reveal severe problems.52 
Ventricular tachycardia
Although the incidence of ventricular arrhythmia is less than supraventricular tachycardia, 
they are associated with worse outcome. Overall, the incidence of ventricular tachycardia 
in women with cardiac disease is approximately 1.0-1.4%.6,53 Hormonal changes are sug-
gested to play a role in the pathophysiological mechanism.54,55 A ventricular arrhythmia in 
the third trimester or postpartum period in previously healthy woman, may also be the first 
presentation of peripartum cardiomyopathy.56,57 A remarkable reduced risk of events in long 
Atrial fibrillation or atrial flutter
Rhythm control:
Sotalol
IV Ibutilide
IV Flecainide
Alternatively (short term):
Amiodarone
Procainamide
Propafenon
Verapamil
Rate control:
Beta-blocker
Verapamil
Alternatively:
Digoxin
Supraventricular
tachycardia
ECG
Laboratory (serum electrolytes +
thyroid function)
Echocardiography
Atrial tachycardia/
intra-atrial re-entry
tachycardia
Adenosine
Beta-blocker
Digoxin
AVNRT/AVRT
Vagal
Manoeuvre
Adenosine
Preexcitation
tachycardia
(WPW)
AF/Afl:
IV Ibutilide
IV Flecainide
IV Procainamide
Reentry
tachycardia:
Vagal manoeuvre
Adenosine
If diagnosis
uncertain:
IV Procainamide
DC cardioversion
Haemodynamically stable: medical treatment Haemodynamically unstableor failed medical treatment
Avoid: Atenolol
IV heparin or LMWH:
Pericardioversion
or
In AF/Afl >48hrs:
3 wks before + 4 wks after elective cardioversion
Anticoagulation:
Preferably low-molecular-
weight-heparin
Alternatively unfractionated
heparin or oral anticoagulation
figure 3 Management of supraventricular tachycardia during pregnancy
LMWH, low-molecular-weight heparin.
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QT syndrome has been observed during the course of pregnancy, whilst the postpartum 
period seems to be associated with an increased risk.58    
In all patients, the aim is to achieve and maintain haemodynamic stability, for the benefit 
of the mother and fetus. In a haemodynamically unstable patient with any type of ven-
tricular tachycardia, immediate defibrillation is indicated.59 If a patient is stable, chemical 
cardioversion can be considered. First choice drugs in a monomorphic ventricular tachy-
cardia, without signs of long-QT syndrome, is IV sotalol (FDA B) or procainamide (FDA C).60 
In the case of sustained refractory or recurrent ventricular tachyarrhythmias, not directly 
responding to defibrillation, IV amiodarone is an alternative. In patients with idiopathic right 
ventricular outflow tract tachycardia, which is probably the most common ventricular ar-
rhythmia in an otherwise healthy pregnant woman, verapamil or beta-blockers are usually 
Monomorphic VT
sotalol
procainamide
--------------------
Specific conditions
Idiopathic RVOT VT
verapamil
β-blockers
Brugada
quinidine
Long QT
mexiletine
ARVC
sotalol
Ventricular tachycardia
ECG
Laboratory (serum electrolytes + cardiac biomarkers)
Echocardiography
Polymorphic VT
β-blockers
Correction of electrolytes
Stop precipitating drugs
Consider temporary overdrive pacing
----------------------
In acute coronary syndrome
Consider lidocaine
Defibrillation
Haemodynamically stable: medical treatment Haemodynamically unstableor failed medical treatment
Avoid Amiodarone if possible for long term use
Consider
radiofrequency ablation
------------------
Preferably in 2nd
trimester
Consider IV amiodarone
in monomorphic VT when
repeated defibrillation is
required
FDA classification:
A: controlled studies show no risk (none)
B: chance of foetal harm is remote sotalol, lidocaine
C: potential benefits outweigh the risk procainamide, verapamil, β-blockers, quinidine, mexiletine,
disopyramide, propafenone
D: positive evidence of risk amiodarone
X: contraindicated
figure 4 Management of ventricular tachycardia during pregnancy
FDA, US Food and Drug Administration.
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effective for the prevention of recurrence. 43 The management of ventricular arrhythmias is 
summarised in Figure 4.61,62
In patients with a poorly tolerated and drug resistant tachyarrhythmia, radio frequency 
ablation can be considered. Evidence of safety during pregnancy is lacking and limited to 
case reports. The general advice is to perform the ablation in the second trimester if possible 
under ultrasound guidance, to minimise the potential influence of radiation on the fetus.59,63 
Limited experience with an implantable cardioverter-defibrillator (ICD) during pregnancy 
has revealed no major problems.64-66 Reports of experience with ICD implantation during 
pregnancy are lacking, but a subcutaneous ICD is a promising technique as fluoroscopy is 
not required.59
Resuscitation
Several guidelines provide practical advices concerning the treatment of maternal cardiac 
arrest, which are summarised in Table 1. 67,68 Immediate basic life support and, when available, 
advanced life support should be initiated as outside pregnancy. After, 20 weeks, aortocaval 
compression should be avoided by left lateral manual displacement of the gravid uterus 
or by putting a wedge under her right side. If resuscitation is not successful by 4 minutes, 
emergency perimortem Caesarean section should be performed immediately with the aim 
of improving the chance of successful resuscitation by relieving aortocaval compression 
and creating a sudden autotransfusion of blood from the uteroplacental circulation. As an 
additional benefit it increases fetal survival as the uteroplacental perfusion is poor during 
arrest and chest compressions.69,70 
The hand position for chest compressions has been studied recently. Previously, it was 
suggested that the hands should be placed in a higher sternal position during pregnancy 
table 1 Resuscitation of pregnant women
   
BLS and position Supine position
Chest compressions as usual
Left uterine displacement to relieve aortocaval compression (in obvious gravid 
uterus)
Remove fetal monitors
ACLS As usual
Provide intravenous therapy 
above diaphragm level
Experienced provider for advanced airway placement is preferred
If patient received IV/IO magnesium prearrest, stop magnesium and give IV/
IO calcium chloride 10mL in 10% solution, or calcium gluconate 30mL in 10% 
solution
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on the basis that the maternal heart is displaced superiorly in the third trimester.71 However, 
an MRI in 34 pregnant females, showed no significant displacement of the heart, suggesting 
that there is no need to adjust the hand position. 
The outcome of cardiopulmonary resuscitation during pregnancy has been described 
by a population-based cohort study from Canada. The authors reported a survival of 36.9%, 
which was better than the survival in matched non-pregnant women.72
Acute myocArdiAl infArction 
Acute myocardial infarction (AMI) occurs 3 to 4 times more often during pregnancy.73 In 
population-based studies, the incidence ranges from 1:35,700 74 to a more recent estimation 
of 1:17,000 73 with a maternal mortality rate of 5-7%. Older pregnant women, in particular 
those >40 years, women with a history of pre-eclampsia and women with cardiovascular 
table 1 Resuscitation of pregnant women (continued)
   
Bleeding/DIC
Embolism: coronary, pulmonary, amniotic
Anesthetic complications
Uterine atony
Possible contributing factors BEAU-CHOPS Cardiac disease (MI/ischemia/aortic 
dissection/cardiomyopathy)
Hypertension/preeclampsia/eclampsia
Other: differential diagnosis of standard 
ACLS guidelines
Placenta abruptio/previa
Sepsis
Obstetric intervention If no ROSC by 4 minutes, consider performing immediate CS
Aim for delivery within 5 minutes of onset
Post resuscitation
Temperature management Depends on individual
If used, than follow the guidelines in non-pregnant women and monitoring of 
fetus should take place
Fetal considerations
Post resuscitation continuous 
fetal monitoring
In case of maternal shock, the uterus/fetus is considered a non-vital organ: 
consider to perform emergency delivery
Partly adapted and modified from AHA algorithm cardiac arrest in pregnancy basic and advanced life support  2015
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risk factors, such as smoking and diabetes, are at highest risk of AMI.73,74 Patients with known 
ischemic heart disease have a 10% risk of a cardiac event (cardiac arrest, heart failure, acute 
coronary syndrome, or ventricular arrhythmia) in a subsequent pregnancy.75
Diagnostic tests
The first presentation of an acute myocardial infarction may be cardiogenic shock (38%) or 
with a ventricular arrhythmia (12%).76 The initial assessment in suspected acute coronary 
syndrome (ACS) should be the same as in non-pregnant patients as the time to intervention 
is as critical in an ST-elevation myocardial infarction (STEMI) as in non-pregnant patients. 
The key is to maintain a high index of suspicion of ACS and so to perform an ECG promptly. 
Subsequently, cardiac markers may support the diagnosis, as may wall motion abnormali-
ties on echocardiography. Pregnancy does not influence Troponin I and an elevated level is 
indicative of an AMI.77-79 Urgent imaging of the underlying coronary anatomy by coronary 
angiography is key to the further management of a STEMI; however, iatrogenic dissection 
has been reported. The most common diagnosis is an acute coronary dissection.80 In a 
review of literature between 2006 and 2011, the angiogram showed: coronary dissection in 
43% (mainly postpartum); atherosclerosis in 27%; coronary thrombus in 17% (both mainly 
in second or third trimester); normal in 9%; vasospasm in 2%; Tako tsubo in 2% (postpartum) 
of AMI.76 The risk of iatrogenic dissection has lead some to advise a non-invasive approach 
in stable, low-risk women with a non-ST-elevation myocardial infarction.
Treatment of myocardial infarction
Treatment of pregnant women with an AMI depends on the aetiology and is further 
delineated in Figure 5. In case of a coronary dissection, thrombolysis should be avoided 
because of the increased risk of local bleeding, which might exacerbate the situation.76 
Percutaneous coronary intervention (PCI) is the first choice intervention. Although PCI does 
expose the fetus to radiation, the potential benefits outweigh the risks.81 Most experience 
exists with bare-metal stents because knowledge on (prolonged) antiplatelet therapy such 
as clopidogrel in pregnancy is limited (FDA class B). The use of low dose aspirin is safe. 
Glycoprotein IIb/IIIa should be avoided as there is a lack of experience with its use during 
pregnancy. Nitrates are widely used in pregnant women for tocolysis and have proven to 
be safe.82 Nifedipine is the calcium antagonist that has been used most frequently dur-
ing pregnancy for hypertension and tocolysis83 and is the drug of choice in women with 
vasospasm-associated complaints. Statins are currently contraindicated during pregnancy 
(FDA class X). 
Coronary artery bypass grafting (CABG) is associated with high fetal loss, and should be 
performed after delivery if the fetus is viable. Cardiac surgery during pregnancy has mainly 
been reported in valvular or aortic disease while CABG experience consists of case reports 
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Acute myocardial infarction
Urgent diagnosis and start of treatment
as in other AMI patients
ECG
Laboratory, cardiac markers
(Echocardiography)
Coronary
dissection Atherosclerosis Vasospasm
Other findings:
Normal angiogram
Tako Tsubo
Thrombolysis
contraindicated
Significant obstruction:
Percutaneous coronary intervention
(caution of iatrogenic dissection)
---------------------------
Low dose aspirin
Consider
thrombolysis:
Streptokinase
rtPA
Coronary angiogram
Caution of iatrogenic dissection
Minimize intracoronary contrast injections
Consider non-invasive approach
in stable, low-risk women
Nitrates
Very limited data available for the use of clopidogrel and glycoprotein IIb/IIIa, reserve for substantial indication (stent)
Contraindicated: statins
Nifedipine
If CABG is required:
In viable fetus,
consider caesarean section first
NSTEMI STEMI
Thrombus
Non-significant obstruction:
Conservative treatment
Conservative
treatment
figure 5 Management of acute myocardial infarction during pregnancy
CABG, coronary artery bypass grafting; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocar-
dial infarction.
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only.84 When unavoidable, the second trimester is probably the safest period and surgery is 
best performed in the left lateral position in normothermic condition with high pump flow. 
In patients with a coronary thrombus, thrombolysis may be considered. The available evi-
dence of thrombolysis during pregnancy for myocardial infarction is limited,85 and is mainly 
based on the use of recombinant tissue plasminogen activator. Most experience during 
pregnancy for other reasons than AMI, involved the use of streptokinase.86 
After the course of a successfully treated ischemic event during pregnancy, the preferred 
mode of delivery is vaginal, with Caesarean section reserved for obstetric indications.87,88 
Aortic dissection 
Incidence 
Pregnancy induces not only induces marked haemodynamic changes, but it can also 
influence the integrity of the vessel wall. A morphological study showed marked fragmenta-
tion of reticular fibres in the tunica media of the aorta in pregnant women without aortic 
disease.89 Also, smooth muscle cells in the aortic media were subject to both hypertrophy 
and hyperplasia, compared to non-pregnant women. These adaptations are usually well 
tolerated by healthy women: the incidence of aortic dissection in women of reproductive 
age is low (0.4 per 100,000 person years).90 But women with aortic disease are at increased 
risk . It was the most important cause of cardiac maternal death in the UK 2006-8.2 Women 
with Marfan syndrome, an autosomal dominant connective tissue disease, are at high risk 
with a reported rate of pregnancy-related aortic dissection of up to 4.5% in prospective 
studies 91-93 and up to 6.4% in retrospective studies.94-98 Women with Loeys-Dietz,99 vascular 
type Ehlers Danlos,100 SMAD3 mutation or Aneurysm Osteoarthritis Syndrome,101,102 ACTA2 
mutation,103 TGFB3 mutation,104 unspecified familial thoracic aortic aneurysm and dissection 
syndrome, Turner syndrome105,106 and bicuspid aortic valve need careful preconception 
assessment and follow-up during pregnancy.107 Studies reporting vascular complications 
during pregnancy in these women are scarce and small; the largest studies included mainly 
women with Marfan syndrome. Important and independent risk factors are initial aortic size 
and rate of diameter change during pregnancy.98 5 
Management of type A aortic dissection (Figure 6)
As mortality due to aortic dissection remains high,108 each symptomatic pregnant patient 
with known aortic disease or with signs or symptoms of aortic dissection should be 
immediately evaluated. Echocardiography should be done promptly, followed by com-
puted tomography if necessary. Although MRI avoids fetal radiation exposure, CT can be 
performed much faster in the acute situation. The management of aortic dissection is the 
same as outside pregnancy and has been recently described in detail.109 Recommendations 
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for the management of aortic dissection during pregnancy are limited, probably due to 
lack of evidence. Type A aortic dissection warrants emergency aortic surgery. Whether this 
should be performed before, together with or after delivery depends on the viability of the 
fetus and the local situation (Figure 6).110 A high intraoperative fetal mortality rate has been 
reported in many case reports and series, suggesting that delivery before surgery in case of 
a viable fetus is preferable.5
Management of type B aortic dissection (Figure 6)
The guidelines recommend conservative management in type B aortic dissections. Strict 
blood pressure regulation is warranted, with bedrest until delivery. Fetal demise is as high 
as 35%, probably due to compromised uteroplacental perfusion.111,112 Frequent monitoring 
of the aortic status by MRI should be done during follow-up. An alternative approach in 
complicated dissections of the descending aorta is an endovascular procedure (TEVAR). A 
few studies have reported favourable outcomes, some in acute type B aortic dissection.113 
Recently, a successful result with an endograft during pregnancy as a bridging step to an 
open repair was presented.114 More studies are warranted to determine further the safety 
and efficacy of this approach is pregnant women. 
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figure 6 Management of acute aortic dissection during pregnancy
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Although the role of beta-blockers in prevention of aortic dissection is equivocal, the ben-
efit of use in patients with aortic dissection is clearer. In the IRAD study, beta-blockers were 
associated with better survival mainly after type A aortic dissection.115 During pregnancy, 
first choice beta-blockers are labetalol or metoprolol. Labetalol combines alpha and beta 
blocking properties, also reducing vascular resistance. During pregnancy, beta-blockers can 
be administered safely, with close monitoring of fetal growth.116 Calcium channel blockers 
also reduced mortality but ACE inhibitors had no effect.  Interestingly, calcium channel 
blockers exacerbated aneurysm growth in a mouse model outside pregnancy,117 and should 
be used with caution. Hydralazine is an alternative, but again used with caution as it can 
induce marked hypotension and compromise uteroplacental perfusion.118 Methyldopa, is 
another alternative, but there is little or no evidence on its use with aortic dissection.  
mechAnicAl vAlve thrombosis 
Incidence 
Pregnancy is a hypercoagulable state, with decreased levels of anticoagulant proteins such 
as protein S and increased levels of clotting factors and fibrinogen.119,120 The risk of mechani-
cal valve thrombosis is increased and can lead to a catastrophic outcome of both mother 
and child. The reported incidence of valve thrombosis varies from 3.7% to 9.4%.121-127 Women 
with a mechanical valve in mitral or tricuspid position or with low flow due to ventricular 
dysfunction are at higher risk.128 Meticulous attention to anticoagulation is essential, particu-
larly when switching anticoagulant agents in the first trimester and peripartum period.129 
Diagnostics and Management (Figure 7)
Valve thrombosis should be suspected in a pregnant patient with a mechanical valve pros-
thesis who presents with dyspnea, fatigue, palpitations, signs of heart failure, soft or absent 
prosthetic valve sounds or a systemic emboli. 129,130 Transthoracic echocardiography should 
be performed initially, if the diagnosis cannot be confirmed, and/or the patient is haemo-
dynamically stable, a transoesophageal echocardiography (TOE) provides higher resolution 
images, better views of the atrial edge and a more accurate assessment of thrombus size, 
which predicts embolic risk.131 If the diagnosis is still not clear, fluoroscopy might provide 
more insight with little radiation exposure to the fetus.81,129
In a haemodynamically unstable patient, with an obstructive thrombosis, emergency 
surgery is indicated, preceded by Caesarean section if the fetus is viable.132 In a haemody-
namically stable woman, different strategies are available, broadly in line with the approach 
of non-pregnant patients. Oral anticoagulant therapy or heparin may be continued and 
optimised in patients with a recent sub therapeutic INR, APTT or anti-Xa level, and non-
obstructive left sided valve thrombosis.5,133 In other patients, thrombolysis or surgery should 
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be considered. Outside pregnancy, the advantages of thrombolysis make it the first choice, 
134,135 however, randomised controlled trials are not yet available,133 and the estimated 
sample size for a definitive studies will be hard to achieve.134
Fibrinolytic therapy either does not cross the placenta or does so to a limited extent, 
but experience is insufficient during human pregnancy, in particular in women with 
a mechanical valve. However, the main concern is that fibrinolysis may release systemic 
emboli, consequently, it should be avoided in patients with large, mobile thrombi, a left 
atrial thrombus as determined by TOE 130,136 or with evidence of a recent systemic embolus. 
Outside pregnancy, thrombolysis has shown to be an effective therapy, with high success 
rate in selected patients.137 In patients with a right-sided valve thrombosis or when surgery 
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figure 7 Management of mechanical valve thrombosis during pregnancy
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is contra-indicated in a severely ill patient, it is the first choice therapy.132 One study of 24 
consecutive women (2004-2012) with valve thrombosis during pregnancy, treated with a 
specific thrombolysis protocol had reassuring results.130 Patients were treated with slow 
infusion of low dose tissue plasminogen activator (t-PA, 25 mg) over 6 hours, which was 
repeated up to 6 times, to a maximum dose of 150mg. The need for repeated treatment 
was determined by serial TOE, which is also current practice outside pregnancy.136,138,139 
Complete thrombolysis was achieved in all case with no maternal mortality, however five 
early pregnancies miscarried between 1 and 5 weeks after thrombolytic therapy. The results 
of this study are encouraging, but the authors also emphasise that these treatment op-
tions are complementary: high-risk patients or those with a contraindication to or failure 
of thrombolysis, should still be considered for surgical therapy. In addition, delivery of a 
woman with recent thrombolysis would be a very unattractive option.
Surgical valve replacement or thrombectomy is preferred in patients with obstructive 
thrombosis and those who are critically ill.132 Also, immediate surgery may be considered for 
large and mobile thrombi. 140 However, surgery is associated with a high rate of fetal mortal-
ity (20-30%) and considerable morbidity,141 although outcomes seem to have improved over 
time, 142-144 which is why a viable fetus should be delivered prior to surgery. Uteroplacental 
hypoperfusion is the reason for the high rate of fetal demise.145 Normothermic surgery may 
have lower risks for the fetus than hypothermia.146 Surgery should be performed in left 
lateral position and a higher pump flow is desired to maintain placental perfusion.
summAry
A multidisciplinary, high-risk team should evaluate all pregnant women presenting with 
an acute cardiac event. Such events are potentially devastating if not recognised early and 
treated by experienced specialists. Management decisions are determined by the severity 
the maternal condition and fetal viability. The management of most cardiac complications 
is similar in pregnant and non-pregnant women. There are no large studies investigating the 
management of cardiac emergencies in pregnant women, hence, therapeutic strategies are 
mainly based on expert opinion and small observational studies. Risks and benefits for both 
mother and child need to be balanced, with the over-riding aim to achieve and maintain 
maternal haemodynamic stability.  
key Points
•	 Treating pregnant women for a cardiac event means that there are two lives to save. 
Generally, the same therapeutic approach should be used in pregnant and non-
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pregnant patients. If the fetus is viable, urgent delivery should be performed, if safe for 
the mother, as this will broaden the therapeutic options for the mother and reduce the 
cardiac burden.
•	 Heart failure is the most common cardiac complication during pregnancy. Preconcep-
tion, cardiomyopathy and a WHO class of 3 or 4 are strong predictors of the occurrence 
of heart failure during pregnancy. The treatment of cardiac failure should be optimised 
before conception. ACE inhibitors and angiotensin receptor blockers are contraindi-
cated, but otherwise, heart failure treatment is similar in pregnant and nonpregnant 
women.
•	 The main aim of treating arrhythmias is to achieve or maintain  haemodynamic stabil-
ity. Immediate defibrillation is therefore indicated in any haemodynamically unstable 
patient. Safety data for antiarrhythmic agents are scarse, but a life threatening maternal 
event justifies their use in the acute setting. 
•	 In the case of a maternal cardiac arrest, if resuscitation is unsuccessful after 4 minutes, a 
perimortem emergency Caesarean section should be performed.
•	 Acute myocardial infarction is a potential catastrophic event and, in the case of a STEMI, 
the underlying coronary anatomy should be imaged urgently, as this has therapeutic 
implications. A coronary dissection is the most common cause, which is a contraindica-
tion for thrombolysis. 
•	 An acute aortic dissection should be managed in the same way as in a non-pregnant 
patient. In Type A dissection, fetal viability determines whether delivery should be per-
formed before aortic surgery.
•	 For a mechanical valve thrombosis, thrombolysis should be considered using the same 
criteria as used outside of pregnancy, namely: patients with a right-sided prosthesis, 
with recent subtherapeutic anticoagulation and non-critically ill patients. Emergency 
surgical replacement, performed directly after Caesarean section, is reserved for left-
sided lesions and haemodynamically unstable patients.
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AbstrAct 
Aims Cardiac disease is the leading cause of indirect maternal mortality. The aim of this 
study was to analyse to what extent socioeconomic factors at a country level, such as in-
come inequality (Gini coefficient), health expenditure, and birth rate, influence the outcome 
of pregnancy in women with heart disease. 
Methods and results The Registry Of Pregnancy And Cardiac disease (ROPAC) is a global 
prospective registry. For this analysis, countries that enrolled at least 10 patients were 
included. A total of 30 countries enrolled 2924 patients from 89 centres. Countries were 
grouped into human development index (HDI) categories, with 74% of the women living 
in countries with a very high HDI. A combined cardiac endpoint included maternal cardiac 
death, arrhythmia requiring treatment, heart failure, thromboembolic event, aortic dissec-
tion, endocarditis, acute coronary syndrome, hospitalisation for cardiac reason or a cardiac 
intervention; which occurred in 645 women (22.1%). Age, New York Heart Association, and 
modified World Health Organization risk classification, were associated with the combined 
endpoint and explained 37% of variance in outcome in a three-level model (patient-centre-
country). Gini coefficient and country-specific birth rate explained an additional 4%. There 
were large differences between the individual countries, but the need for multilevel model-
ling to account for these differences disappeared after adjustment for patient characteristics, 
Gini and country specific birth rate.
Conclusion While there are definite interregional differences in pregnancy outcome in 
women with cardiac disease, these differences seem to be mainly driven by individual 
patient characteristics. Adjustment for country characteristics refined the results to a limited 
extent, but maternal condition seems to be the main determinant of outcome.
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introduction
Cardiac disease is an important cause of maternal mortality and morbidity. An increasing 
amount of research on this topic has been published in the past decades, mainly from 
advanced but also from emerging countries. From pregnancy research in the general popu-
lation it is known that outcome does depend on demography 1,2. The Registry Of Pregnancy 
And Cardiac disease (ROPAC) is a global cohort including pregnant patients from both 
advanced and emerging countries. Several analyses from ROPAC data have been published 
with marked differences between advanced and emerging countries3-5. These differences 
could be partly explained by variations in underlying cardiac condition, with acquired val-
vular disease being more prevalent in emerging countries6 and congenital heart disease in 
advanced countries. In addition, the demographic differences may also influence outcome. 
For instance, in some cultures women gain status by having (many) children and thus they 
may be reluctant to take a doctor’s advice to avoid pregnancy. Also, there is widespread 
difference in the availability of health care and access to female contraception. Although 
tertiary care is provided in the urban areas, many women in less developed countries are 
from rural areas and, consequently, might present with pregnancy complaints much later 
than their peers from rural areas in countries with more advanced economies7.
Interpretation of ROPAC results needs to be done with caution in the light of these dif-
ferences. Insights in country level socioeconomic data and the associated pregnancy out-
comes will help interpreting existing and future analyses. Such an analysis could define the 
influence of socioeconomic background on pregnancy outcome exerted by the countries 
of residence, the alternative approach, of an in depth analysis of individual socioeconomic 
data, is not possible.
The aim of this study was to elucidate the interregional differences in the countries 
contributing to ROPAC, by analysing to what extent socioeconomic factors on country 
level,  such as GDP, income distribution (Gini-coefficient), HDI, health expenditure, birth rate, 
number of hospital beds and schooling, influence the outcome of pregnancy in women 
with heart disease. We hypothesized that country level socioeconomic indices do influence 
pregnancy outcome and that cardiac status (such as severity of disease and NYHA) affects 
the outcome of mother and baby to a greater extent.  
methods
The Registry Of Pregnancy And Cardiac disease (ROPAC) is an ongoing prospective world-
wide registry that includes all consecutive pregnant women with structural heart disease. 
Study design and methods have been described in detail previously3. Patient enrollment 
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started from January 2008 and for this interim analysis we included patients with a term 
date up to October 2013, and 6 months follow-up in April 2014. 
Data 
The patient characteristics collected at baseline (before pregnancy) included age, ECG 
rhythm, New York Heart Association (NYHA) functional classification, diagnosis, risk factors 
for cardiovascular disease (smoking, diabetes, hypertension), previous interventions, medi-
cation, parity, obstetric history and if available echocardiographic parameters. Every patient 
was stratified according to the modified World Health Organization (WHO) classification, 
as stated in the latest guidelines8,9 by two authors (IH;JRH). Modified WHO-class I implies 
no increased risk of events during pregnancy, compared to the general pregnant popula-
tion. Modified WHO-class II has a small increased risk, class II-III a moderate increased risk, 
and class III has a ‘significantly’ increased risk. Class IV bears an unacceptable high risk of 
complications and consensus suggests that pregnancy should be avoided.
For the current study, pre-pregnancy patient characteristics that were included in sta-
tistical modelling were age, nulliparity, modified WHO class, NYHA class and signs of heart 
failure.
Socioeconomic data on patient level were not available. As a result, pre-defined socio-
economic factors were assigned to represent country characteristics, and included: human 
development index (HDI), Gini-coefficient, health expenditure, schooling, gross domestic 
product per capita based on purchasing power parity (GDP), birth rate per 1,000, and hospital 
beds per 1,000. Definitions and sources of these characteristics are listed in Supplementary 
Material Appendix 1. HDI is a combination of three factors; life expectancy from birth, mean 
years of schooling and the country standard of living.  As these factors correlate with the 
other predefined country characteristics, the HDI was not included in further modelling. The 
HDI categories (low, medium, high, very high) were only used to categorize and understand 
the frequency of events within the different categories. 
Endpoints 
The following endpoints that occurred up to one week after delivery were studied: combined 
cardiac endpoint (including maternal cardiac death, arrhythmia requiring treatment, heart 
failure, thromboembolic event, aortic dissection, endocarditis, acute coronary syndrome, 
hospitalisation for cardiac reason, or a cardiac intervention), heart failure, fetal or neonatal 
mortality (excluding miscarriage in the first trimester), and small-for-gestational-age (SGA, 
birth weight <10th percentile). All-cause mortality data was also collected, but not used for 
statistical modelling due to low numbers. Heart failure was defined according to ACC/AHA 
guidelines10, as a clinical syndrome that is characterised by specific symptoms (dyspnea and 
fatigue) and signs (of fluid retention, such as oedema, rales) on the physical examination 
as judged by the treating cardiologist. The heart failure episode was only registered when 
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signs or symptoms of HF were present which required new treatment, change of treatment 
or hospital admission.
Statistical analysis
Categorical variable differences were tested using chi-square tests and are presented as 
percentages. Continuous variables are presented as mean and standard deviation (SD), or 
as median and first and third quartile (Q1-Q3), as appropriate. Differences were tested using 
Student’s t-tests. 
Generalized linear mixed models (GLMM) were used as a result of the multilevel structure 
in the data. The  ROPAC database consists of three levels: patients (level 1) were nested in 
centres (level 2), and centres were nested in countries (level 3). To account for differences in 
outcome between countries and between centres, random effects for country and centre 
were added to the model. Patient and country characteristics were entered as fixed effects 
and those with a significant trend (p<0.10) in univariable analysis were assessed in multivari-
able analysis. Countries that included less than 10 patients were excluded from this study. 
To determine the influence of fixed and random effects in our cohort, we further analysed 
the model for the combined cardiac endpoint. A conditional R2 (for GLMM) was derived 
from the model before and after including the fixed effects (patient characteristics, followed 
by country characteristics) 11. This is an estimate of the percentage explained variance by the 
complete model (fixed and random effects). The random effect estimates of the individual 
countries for the combined cardiac endpoint were plotted with 95% confidence intervals 
(caterpillar plot), unadjusted and adjusted for the fixed effects.  
The rate of missing patient and country characteristics was relatively low, and therefore a 
complete case analysis approach was taken (96%). All analyses, except for multilevel model-
ling, were performed in SPSS version 21.0 (IBM Corp., Armonk, NY). Multilevel modelling was 
performed in R version 3.1, package lme4 12.
results
From January 2008 until April 2014, 2966 patients were included, from 99 centres in 39 
countries. Nine countries enrolled less than 10 patients, and were excluded. The remain-
ing 30 countries enrolled 2924 patients from 89 centres. An overview of the countries is 
presented and arranged according to the HDI categories in Table 1. Socioeconomic indexes, 
including HDI, Gini coefficient, health expenditure, schooling, GDP, birth rate per 1,000 and 
hospital beds per 1,000 are presented for all countries in Supplemental material Table S1.
Baseline characteristics are presented for patients per HDI category (Table 2). Maternal 
age at conception was higher in women from countries with a very high HDI, while these 
women were also more often nulliparous. Fewer women from countries with a medium or 
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table 1 Human development index categories
  Low Medium High Very high
Human development 
index* <0.555 0.555-0.699 0.700-0.799 ≥0.800
(n=634) (n=118) (n=2130)
Countries in ROPAC Egypt Azerbaijan Argentina
South-Africa Russian Federation Australia
Austria
Belgium
Canada
Czech Republic
France
Greece
Germany
Hungary
Italy
Japan
Lithuania
Israel
Malta
Netherlands
Norway
Poland
Portugal
Slovenia
Spain
Sweden
Switzerland
United Arab Emirates
United Kingdom
United States
<10 patients per 
country
<10 patients per 
country
<10 patients per 
country
Brazil Ireland
Bulgaria
Georgia
Macedonia
Romania
Serbia&Montenegro
Turkey
         
*Human development index for female according to United Nations Development Report 2013. No value was 
available for Bosnia&Herzegovina (<10 inclusions)
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table 2 Baseline characteristics
Total* Low HDI Medium HDI High HDI Very High HDI p
N (% of total inclusions) 2966   0 634 21.7% 118 4.0% 2172 74.3%  
 
Mean age (sd) 29.3 ±5.6   27.7 ±5.9 26.4 ±5.3 29.9 ±5.4 <0.001
Nulliparous 1334 45.2%   160 25.2% 57 48.3% 1099 50.7% <0.001
Pre-existent hypertension 188 6.5%   26 4.1% 18 16.2% 139 6.5% <0.001
Current smoker 110 4.3%   11 1.8% 4 3.6% 95 5.3% 0.001
Pre-existent diabetes 46 1.6%   10 1.6% 1 0.8% 34 1.6% 1.000
Prior cardiac intervention 1585 53.6%   223 35.2% 44 37.3% 1304 60.1% <0.001
 
NYHA functional class   <0.001
NYHA I 2154 74.1%   399 62.9% 48 42.1% 1686 79.3%
NYHA II 659 22.7%   191 30.1% 62 54.4% 395 18.6%
NYHA III 86 3.0%   42 6.6% 4 3.5% 39 1.8%
NYHA IV 7 0.2%   2 0.3% 0 0.0% 5 0.2%
 
Signs of HF before pregnancy 283 9.7%   138 21.8% 66 58.4% 74 3.5% <0.001
AF before pregnancy 68 2.3%   47 7.4% 1 0.9% 20 0.9% <0.001
 
Prior medication 824 27.9%   292 46.1% 17 14.4% 510 23.5% <0.001
Beta-blocker 365 12.3%   75 11.8% 7 5.9% 280 12.9% 0.073
Anti-arrhythmic 90 3.0%   58 9.1% 3 2.6% 28 1.3% <0.001
ACE-inhibitor 116 3.9%   38 6.0% 9 7.6% 67 3.1% 0.001
Diuretic 170 5.8%   93 14.7% 7 5.9% 68 3.1% <0.001
 
Cardiac diagnosis   <0.001
Congenital heart disease 1654 55.9%   88 13.9% 91 77.1% 1458 67.1%
Valvular heart disease 942 31.8%   489 77.1% 15 12.7% 424 19.5%
Ischemic heart disease 47 1.6%   7 1.1% 0 0.0% 40 1.8%
Cardiomyopathy 201 6.8%   45 7.1% 4 3.4% 151 7.0%
Aortic pathology 101 3.4%   3 0.5% 6 5.1% 90 4.1%
Pulmonary hypertension 13 0.4%   2 0.3% 2 1.7% 9 0.4%
 
WHO classification   <0.001
WHO class I 583 19.7%   73 11.5% 27 22.9% 474 21.8%
WHO class II 520 17.6%   18 2.8% 17 14.4% 481 22.1%
WHO class II-III 932 31.5%   150 23.7% 34 28.8% 735 33.8%
WHO class III 486 16.4%   187 29.5% 8 6.8% 286 13.2%
WHO class IV 437 14.8%   206 32.5% 32 27.1% 196 9.0%  
Percentages are of total valid cases, excluding missing cases.*Total cohort includes countries with less than 10 patients. ACE 
= Angiotensin Receptor Enzym; AF = Atrial fibrillation; HDI = Human development index; HF = Heart failure; NYHA = New 
York Heart Association; WHO = World Health Organization.
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high HDI had a prior cardiac intervention and were in NYHA class I, compared to women 
from countries with a very high HDI. Indeed, signs of heart failure prior to pregnancy were 
more common; cardiac medication, mainly diuretics, were more commonly used before 
pregnancy by women from countries with a medium or high HDI compared to those from 
countries with a very high HDI. Valvular heart disease was much more common in women 
from countries with a medium HDI, while women from countries with a high or very high 
HDI more often had congenital heart disease.
Women with modified WHO class III or IV more often came from countries with a medium 
or high HDI, while women with a lower risk WHO class more often came from countries with 
a very high HDI.
Frequency of endpoints
Clinical event rates are presented for each HDI group (Figure 1) and for all countries sepa-
rately (Table 3). A combined cardiac endpoint occurred in 645 women (22.1%); heart failure 
in 365 (12.5%);  fetal/neonatal loss in 60 (2.1%); small-for-gestational age in 270 (10.6%). 
Maternal mortality up to one week postpartum occurred in 11 cases (0.9% medium HDI, 
0.8% high HDI, and 0.2% very high HDI, p=0.016) and was not included in the univariable or 
multivariable analysis. 
0%
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40%
50%
60%
70%
80%
90%
Human development
index: Medium
Human development
index: High
Human development
index: Very high
p=0.016     p<0.001      p<0.001       p<0.001     p=0.055
figure 1 Event rate for HDI categories
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table 3 Events per country
Maternal mortality 
(all cause) Heart failure
Combined cardiac 
endpoint
Fetal/neonatal 
mortality (no 
miscarriage)
Small for 
gestational age
  total n n % n %   n %   n % n %
ARGENTINA 10 0 0,0% 0 0,0% 0 0,0% 0 0,0% 1 10,0%
AUSTRALIA 19 0 0,0% 2 10,5% 4 21,1% 0 0,0% 2 10,5%
AUSTRIA 83 0 0,0% 1 1,2% 4 4,8% 1 1,2% 1 1,2%
AZERBAIJAN 10 0 0,0% 2 20,0% 2 20,0% 0 0,0% 0 0,0%
BELGIUM 125 0 0,0% 2 1,6% 5 4,0% 0 0,0% 3 2,4%
CANADA 57 1 1,8% 3 5,3% 6 10,5% 2 3,5% 2 3,5%
CZECH REPUBLIC 14 0 0,0% 0 0,0% 0 0,0% 0 0,0% 1 7,1%
EGYPT 573 6 1,0% 120 20,9% 198 34,6% 31 5,4% 30 5,2%
FRANCE 58 0 0,0% 13 22,4% 26 44,8% 0 0,0% 10 17,2%
GERMANY 229 0 0,0% 3 1,3% 10 4,4% 1 0,4% 23 10,0%
GREECE 27 0 0,0% 3 11,1% 11 40,7% 0 0,0% 6 22,2%
HUNGARY 44 0 0,0% 0 0,0% 1 2,3% 1 2,3% 4 9,1%
ISRAEL 61 0 0,0% 19 31,1% 25 41,0% 1 1,6% 7 11,5%
ITALY 238 1 0,4% 12 5,0% 33 13,9% 3 1,3% 28 11,8%
JAPAN 33 0 0,0% 2 6,1% 2 6,1% 0 0,0% 6 18,2%
LITHUANIA 60 0 0,0% 5 8,3% 5 8,3% 1 1,7% 8 13,3%
MALTA 19 0 0,0% 0 0,0% 1 5,3% 0 0,0% 2 10,5%
NETHERLANDS 299 0 0,0% 9 3,0% 38 12,7% 2 0,7% 23 7,7%
NORWAY 28 0 0,0% 4 14,3% 6 21,4% 0 0,0% 1 3,6%
POLAND 113 0 0,0% 11 9,7% 27 23,9% 3 2,7% 13 11,5%
PORTUGAL 13 0 0,0% 0 0,0% 0 0,0% 1 7,7% 0 0,0%
RUSSIAN FEDERATION 108 1 0,9% 57 52,8% 90 83,3% 0 0,0% 13 12,0%
SLOVENIA 128 0 0,0% 2 1,6% 10 7,8% 3 2,3% 12 9,4%
SOUTH AFRICA 61 0 0,0% 30 49,2% 34 55,7% 5 8,2% 8 13,1%
SPAIN 221 1 0,5% 20 9,0% 32 14,5% 3 1,4% 29 13,1%
SWEDEN 33 0 0,0% 5 15,2% 7 21,2% 1 3,0% 6 18,2%
SWITZERLAND 45 0 0,0% 2 4,4% 5 11,1% 0 0,0% 5 11,1%
UNITED ARAB EMIRATES 31 0 0,0% 13 41,9% 16 51,6% 0 0,0% 5 16,1%
UNITED KINGDOM 120 1 0,8% 16 13,3% 31 25,8% 0 0,0% 15 12,5%
UNITED STATES 64 0 0,0% 9 14,1%   16 25,0%   1 1,6% 6 9,4%
TOTAL 2924 11 0,4% 365 12,5% 645 22,1% 60 2,1% 270 9,2%
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Associations of patient and country characteristics with clinical endpoints
Univariable analysis of pre-pregnancy patient characteristics for the combined cardiac end-
point is shown in Table 4. The only variable that was not significantly associated with the 
combined cardiac endpoint was nulliparity.  Modified WHO II was not significantly different 
from modified WHO I. Of the country characteristics, Gini coefficient (p=0.017) and birth rate 
(although p=0.050) were independently associated with the combined cardiac endpoint, in 
addition to age, NYHA class, modified WHO class and signs of heart failure before pregnancy. 
The univariable and multivariable analysis of the remaining endpoints are shown in the 
online supplemental data. The results for heart failure as a separate endpoint were largely 
comparable to the results of the combined cardiac endpoint (online supplemental Table S2). 
While schooling, GDP, birth rate and number of hospital beds were associated with fetal/
neonatal mortality in the univariable analysis, only GDP was independently associated 
with this endpoint (online supplemental Table S3). None of the country characteristics were 
table 4 Univariable and multivariable analysis of patient and country characteristics with the combined cardiac 
endpoint
Univariable Multivariable
Variable Estimate p-value   Estimate p-value
Age 0.026 0.004 0.019 0.047
Nulliparity -0.046 0.662
NYHA I NA NA NA NA
NYHA II 1.006 <0.001 0.665 <0.001
NYHA III 2.217 <0.001 1.119 <0.001
NYHA IV 3.258 0.005 2.009 0.079
WHO I NA NA NA NA
WHO II 0.085 0.717 -0.003 0.990
WHO II-III 0.816 <0.001 0.689 <0.001
WHO III 1.470 <0.001 1.351 <0.001
WHO IV 2.126 <0.001 1.600 <0.001
Signs of heart failure 1.427 <0.001
Gini 0.534 <0.001 0.332 0.017
Health expenditure -0.303 0.204
Schooling -0.035 0.924
GDP -0.305 0.220
Birth Rate 1.063 <0.001 0.484 0.050
Hospital beds -0.345 0.143
Data are clustered within hospitals within countries. The categorical variable NYHA classification and WHO are 
tested against the reference category I. WHO II is not significantly different from WHO I. The only variable that is 
not significant is nulliparity. 
GDP = Gross domestic product, NYHA = New York Heart Association, WHO = World Health Organization
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associated with SGA, on top of NYHA II and III, and modified WHO class III and IV (online 
supplemental Table S4). 
Influence of variability between countries and centres
The total explained variability of the model, the conditional R2, for the combined cardiac 
endpoint including patient characteristics only, was 37%. By adding the country charac-
teristics, the R2 increased by 4% to 41%. Without any of these fixed effects in the model 
the conditional R2  including random effects only, was 33%. Figure 2 depicts the estimated 
unadjusted and adjusted odds ratios for a combined cardiac endpoint for each country 
compared to the average odds ratio.  Several countries do not include the 0 in their 95% 
confidence interval in the unadjusted model. But when adjusted for patient and country 
characteristics, the 95% confidence intervals of almost all countries do include 0. This means 
that for the vast majority of the countries, the need to account for random effects (patient 
within centre, within country) disappears when adjusting for patient and country charac-
teristics.

−2 0 2
Random effects
−2 0 2
Random effects
A B
figure 2 Between country differences in outcome, unadjusted for fixed effects (A) and adjusted for fixed ef-
fects (B)
The random effects estimates of the individual countries, plotted with 95% confidence intervals. A country with aver-
age proportion of the combined cardiac endpoint has a random effect (log odds) of 0.
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discussion
The ROPAC registry is the largest recorded cohort of pregnant women with cardiac disease. 
Women from many different countries were included. Results may be influenced by the 
multicenter and multinational nature of the registry. The current study shows that indeed 
there are differences in outcome between centres and countries, but these differences are 
largely explained by differences in individual patient characteristics, such as NYHA classifica-
tion, prior signs of heart failure and modified WHO classification. Only a few country char-
acteristics had some impact: maternal cardiac event was associated with Gini coefficient 
and to a lesser extent with birth rate of the patients’ residential country. Also fetal outcome, 
such as small for gestational age was mainly associated with the maternal condition and to 
a minor extent with country characteristics. 
Maternal outcome and socioeconomic influences
Previous studies have shown that human development index is a strong predictor of 
maternal and fetal mortality rate in the global population13. Inequality of socioeconomic 
determinants within a country further increases the rate of maternal death14. A lower edu-
cational level and lower HDI have been reported to be associated with maternal adverse 
outcome15,16. Less educated women, for instance, have an increased risk of presenting to 
an emergency department in a severe condition15. This may be related to several issues: 
women from emerging countries tend to have a later presentation to a medical centre, 
which is probably associated with limited knowledge and awareness of risks, but also to fac-
tors like a less well developed infrastructure, longer travel-time and perhaps less availability 
of skilled medical staff. To what extent these correlations can be extrapolated to women 
with pre-existent cardiac disease, and whether they need to be taken into account while 
analysing multinational registry data, has not been determined until now.
Although the number of maternal deaths was too low to allow for statistical analysis, the 
risk of a cardiac event (combined endpoint) was indeed associated with income inequality 
(expressed as the Gini-coefficient)  in a country. Also, a higher country birth rate correlated 
with a higher frequency of heart failure. These socioeconomic parameters need to be con-
sidered when interpreting data from registries, however, we feel that the number of factors 
actually showing a relationship to pregnancy outcome in these high risk patients, is actually 
relatively small compared to their impact in the general pregnant population. In fact, the 
most important determinant of pregnancy outcome was the underlying medical condition.
Fetal outcome
With regard to fetal and obstetric outcome, previous reports showed that a higher income 
inequality (Gini coefficient) and educational level, rather than household income, seem to 
be associated with intrauterine growth but not with shorter gestational age at delivery17,18. 
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The exact underlying mechanism is difficult to determine. A recent large prospective cohort 
study of pregnant women showed that women from low socioeconomic subgroups have 
higher placental resistance indices, which may contribute to a higher incidence of preg-
nancy complications19.
In our cohort of women with cardiac disease, country characteristics did not significantly 
influence the SGA rate, while maternal condition expressed as NYHA class and modified 
WHO classification did influence the frequency of SGA. In women with reduced cardiac 
function, an abnormal uteroplacental flow is present, which is an important predictor of 
adverse obstetric and fetal outcome20 and this may explain the association in this study. 
Research and clinical implications 
The results imply that interregional differences need to be acknowledged, also in research, 
but that the maternal condition seems to outweigh the influence of socioeconomic factors 
on reported cardiac and fetal outcome. A clear association between socioeconomic factors 
and events was present in univariable analysis, but it largely disappeared after correction 
for maternal condition. Thus, the higher event rate in emerging compared to advanced 
countries is mainly based on a worse pre-pregnancy condition of patients. Also, the need 
for multilevel modelling in this analysis was lost after adding the patient and country char-
acteristics. 
Data on cultural background were lacking, but would be very interesting to study. Differ-
ences in pregnancy outcome between emerging and advanced countries, may be related 
to for instance religion. Women may have a strong feeling that their fate is predetermined 
and therefore less sensible to a doctor’s advice. But this hypothesis is rather philosophical 
and needs further investigation to determine whether this indeed influences pregnancy 
outcome.
Reducing adverse pregnancy outcome in any region, but in particular in remote areas, 
is an important goal as formulated by the WHO. While this goal resulted in major declines 
in maternal death rates globally, this trend has definitely not been observed in maternal 
death due to cardiac disease21. Creating awareness in young women with cardiac disease 
about the potential high risks of pregnancy should be part of standard care and preferably 
initiated at a young age. The fifth  millennium goal of the World Health Organization is 
reduction of maternal mortality, by means of increasing the number of women receiving at 
least 4 antenatal care visits and the number of births attended by skilled staff22. An increase 
in the number of women receiving this level of care and a decline in maternal death rate 
has been observed in the past 10-15 years, but about 50% of women still do not receive the 
recommended minimum of four antenatal visits. Also, a well-developed infrastructure for 
cardiovascular health screening is warranted to ensure early diagnosis and management23. 
Improvements in these medical resources may also reduce the burden of adverse events in 
pregnant women with cardiac disease.
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Other global observational studies, for instance those dealing with factors influencing 
secondary cardiovascular prevention, did find related socio-economic  factors. One study 
pointed out that the country level socio-economic factors explained two-thirds of the varia-
tion in preventive drug use compared to only a third explained by individual factors (such as 
smoking, gender, education)24. Although these results are not in line with our findings, this 
knowledge needs to be appreciated for our population as well: it does show the between-
country differences in (level of ) health care availability.
Limitations
While ROPAC provides a unique view on global pregnancy outcome, including women from 
39 countries,  the current distribution of countries was within a range of medium to very high 
HDI.  However, the range of country specific characteristics was sufficient to illustrate the 
differences between more developed countries and those with poorer resources. Including 
patients from countries categorised with a low HDI may strengthen this study, but is hard 
to achieve with limited availability of organised/specialised medical care in these countries.
In previous studies, ethnicity was shown to influence maternal outcome25. In particular, 
non-Hispanic black women seem to have an increased risk of pregnancy-related mortality26. 
ROPAC did not include demographic socioeconomic data at a patient level, which is why 
we performed the analysis at a country level. If the socio-economic data (income, educa-
tion,  social status, employment, among others) were available at patient level, it may had 
been possible to find stronger relationships.  Since we performed the statistical analyses at 
three levels (patient, within centre, within country), we believe that meaningful conclusions 
can be drawn from our data.  
The majority of the participating centres were university or tertiary centres (86%). Unfor-
tunately, only 75% responded to the question whether they were a university, community or 
private clinic, which is why we did not include this information in the statistical analysis. But 
it is likely that our data are derived from women cared for in larger centres with a specialised 
department for pregnancy.
ROPAC included 6 months follow-up postpartum. However, due to large differences in 
follow-up availability between countries, it was decided not to include these results to this 
analysis. Follow-up at 1 week was available in all patients. For future research, inclusion of 
long-term follow-up would be favourable. Finally, the number of pregnancies complicated 
by fetal and neonatal mortality was relatively low, which hampered statistical modelling and 
conclusions should be interpreted carefully.
Conclusion
Socioeconomic factors were partly explainable for differences in pregnancy outcome in 
women with cardiac disease, but the main denominator was the individual’s condition. 
Raising awareness and improving access to medical resources as advocated by the World 
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Health Organization, will help to improve the outcome for pregnant women, hopefully also 
for women with heart disease.
Online Supplementary Information
Additional Supporting Information may be found in the online version of this article:
Table S1 Socioeconomic indices per country
Reference numbers from World Bank/ UNDP / UNESCO / HDI UNDESA
Table S2 Univariable and multivariable analysis of patient and country characteristics with 
heart failure 
Table S3 Univariable and multivariable analysis of patient and country characteristics with 
fetal/neonatal mortality
Table S4 Univariable and multivariable analysis of patient and country characteristics with 
small-for-gestational-age
Appendix 1 Definitions
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AbstrAct 
Aims To study pregnancy outcome in women with rheumatic mitral valve disease.
Methods and Results The Registry of Pregnancy and Cardiac Disease is a worldwide pro-
spective registry, and all women with rheumatic mitral valve disease and no pre-pregnancy 
valve replacement were selected(n=390). The majority came from emerging countries(75%). 
Mitral stenosis (MS) with or without mitral regurgitation (MR) was present in 273 women; 
isolated MR in 117. The degree of MS was mild in 20.9%, moderate in 39.2%, severe in 19.8%. 
Maternal death during pregnancy occurred in 1 patient with severe MS. Hospital admission 
occurred in 23.1% of the women with MS, and the main reason was heart failure (mild MS 
15.8%; moderate 23.4%; severe 48.1%,p<0.001). Heart failure occurred in 23.1% of patients 
with moderate or severe MR. An intervention during pregnancy was performed in 16 pa-
tients, 14 had valvular balloon dilatation and 2 had surgical valve replacement (1 for MS; 
1 for MR). Independent pre-pregnancy predictors of maternal cardiac events were NYHA 
class≥II, RVSP>30mmHg, severe MS and older age. Follow-up at 6 months was available for 
53% and three more patients died (1 with severe MS; 1 with moderate MS; 1 with moderate 
to severe MR).
Conclusion Although mortality is low, patients with severe rheumatic MS have a nearly 50% 
risk of developing heart failure. Also, patients with significant MR have an increased risk of 
heart failure. Patients with elevated RVSP and higher NYHA are at highest risk. Pre-pregnancy 
treatment in selected patients is indicated to prevent these complications.
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introduction
Rheumatic heart disease is a major problem, with up to 1.4 million people dying each year, 
and is a leading disease in the young, especially in emerging countries. In more developed 
economies, the diagnosis of rheumatic heart disease is rare and typically found in recent 
immigrants1-3. It poses a particular problem in pregnant women, in whom the diagnosis is 
often delayed. In emerging countries, rheumatic valve disease is the commonest cardiac 
disease in pregnant women and the most important cause of maternal death4-7. Mitral valve 
stenosis in particular is a high risk condition8.
Maternal mortality in general has decreased in the past decade, but over the same period, 
cardiac maternal death has not declined9,10. Large prospective studies in pregnant women 
with heart disease in general and specifically in women with rheumatic heart disease are 
lacking. Such studies are needed to provide evidence for guidelines on the management of 
pregnancy in women with heart disease11,12 and to counsel women with rheumatic heart 
disease who are contemplating a pregnancy. Further, contemporary data on the outcome 
of pregnancy in women with rheumatic mitral valve disease will help to stratify risk, enabling 
high risk women to be identified and appropriately counselled and managed. The aim of 
this study is to assess maternal and fetal outcome of pregnancy in women with rheumatic 
mitral valve disease.
methods
The Registry Of Pregnancy And Cardiac disease (ROPAC) is a worldwide prospective and 
ongoing registry that was established to study a large number of pregnant women with 
structural heart disease. ROPAC was initiated by the European Society of Cardiology (ESC) 
working groups on congenital heart disease and valvular heart disease in 2007. Prospective 
data collection started in January 2008 and for the current study we included data from 
patients with a term date up to October 2013, and follow-up up to April 2014. Informed 
consent was obtained from patients if required by the local independent review board. An 
extensive description of the study protocol and methods has been published previously4. 
For this analysis the outcome of pregnancy for all patients with rheumatic mitral valve dis-
ease in ROPAC was analysed. Women with a mechanical or bioprosthetic valve have already 
been described elsewhere and were excluded from the current study13.
Data collection
Pre-pregnancy patient characteristics that were collected included age, parity, cardiac 
diagnosis, previous interventions, medication, smoking, diabetes, hypertension, obstetric 
history, and if available, echocardiographic parameters. Countries were defined as emerging 
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or advanced, according to the International Monetary Fund (IMF)14. Cardiac, obstetric and 
fetal outcome data were collected. Heart failure was defined according to American College 
of Cardiology (ACC)/American Heart Association (AHA) guidelines15 as a clinical syndrome 
that is characterized by specific symptoms (dyspnoea and fatigue) and signs (of fluid reten-
tion, such as oedema, rales) on physical examination, as judged by the treating cardiologist. 
An episode of heart failure was only registered when signs or symptoms of HF were present 
which required new treatment, change of treatment, or hospital admission.
Maternal cardiac event was defined as cardiac arrest, cardiac death, new episode of ar-
rhythmia requiring treatment, heart failure, thromboembolic  event, endocarditis, hospi-
talisation for cardiac reason, or a cardiac intervention. Fetal adverse outcome was defined as 
fetal death after 14 weeks, or neonatal death < 1 week, low Apgar score, preterm birth, and 
small for gestational age.
Follow-up was available up to 1 week after delivery for all patients. Limited follow-up data 
at 6 months postpartum were available in some patients (53%) and are reported separately. 
Definition of valve disease 
Mitral valve disease was defined according to the European Association of Echocardiography 
and American Society of Echocardiography recommendations for echocardiographic assess-
ment of valve stenosis16. The severity of mitral valve stenosis (MS) was defined as follows:
- Mild MS = valve area >1.5 cm2 or if area not available: mean gradient<6 mmHg
- Moderate MS = valve area 1.0-1.5 cm2 or if area not available: mean gradient 6-12 mmHg
- Severe MS = valve area <1.0 cm2 or if area not available: mean gradient >12 mmHg
Mitral valve regurgitation (MR) quantification was based on visual inspection and quantita-
tive measurements and was determined by the treating cardiologist. NYHA classification 
was used to define whether patients were asymptomatic (NYHA class I) or symptomatic 
(NYHA class ≥II).
Statistical analysis
Continuous variables are presented as mean and standard deviation, or median and first 
and third quartiles (Q1-Q3), and differences between groups were assessed using Students 
t-test or Mann-Whitney test as appropriate. In case of 3 categories (mild, moderate, severe 
stenosis) one-way ANOVA tests were performed. Categorical variables are presented as 
frequencies and percentages, and differences were  studied using chi-square or Fisher’s 
exact test as appropriate. In case of 3 categories  chi square trend tests were performed. We 
compared pregnancy outcome of women with isolated mild mitral valve regurgitation to 
those with moderate/severe mitral valve regurgitation. Similarly, we divided women with 
mitral valve stenosis, (whether or not accompanied by mitral valve regurgitation) into mild, 
moderate or severe stenosis and compared the outcome of these three groups. Separate 
analysis was performed for symptomatic and asymptomatic  patients. Patients with isolated 
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moderate/severe mitral valve stenosis were compared  with those with moderate/severe 
mixed mitral valve disease (MS+MR). Univariable and multivariable logistic regression analy-
sis were performed to search for predictors of maternal cardiac events and of adverse fetal 
outcome. Odds ratios and 95% confidence intervals are provided. Statistical tests were con-
sidered significant if a P-value was less than 0.05 (two-sided). All analyses were performed 
with SPSS version 21.0 (IBM Corp., Armonk, NY). 
results
Of the 2966 patients included in the ROPAC registry from January 2008 until April 2014, 390 
women had rheumatic mitral valve disease. Mean age was 28.9 years (±6.0) and 103 women 
(26.4%) were primigravida. The majority lived in countries with an emerging economy 
(75.2%) and were known to have mitral valve disease before pregnancy (75.1%). The type 
of mitral valve disease is presented in Table 1. MS with or without MR was present in 273 
women, while 117 had MR only. The degree of stenosis was mild in 57 (20.9%), moderate 
in 107 (39.2%), severe in 54 (19.8%) and unknown in 55 (20.1%). Baseline characteristics are 
presented in Table 2, stratified for severity of disease. Before pregnancy, a percutaneous or 
surgical valve repair had been performed in 26.9% of all patients, but in fewer patients with 
MR and severe MS. Women with MS had signs of heart failure before pregnancy more often 
than women with only MR (34.1% vs 10.3%, p=0.019), and in particular those with moderate 
or severe MS. Women with MS also received cardiac medication prior to pregnancy more 
often than women with MR (38.6% vs 24.8%, p=0.009). 
table 1 Severity of rheumatic mitral valve disease
 
No 
mitral valve
regurgitation
Mild 
mitral valve 
regurgitation
Moderate 
mitral valve 
regurgitation
Severe 
mitral valve 
regurgitation
Unknown 
severity 
regurgitation Total
No mitral valve stenosis 0 43 35 30 9 117
Mild mitral valve stenosis 14 20 13 7 3 57
Moderate mitral valve 
stenosis 37 28 27 13 2 107
Severe mitral valve stenosis 19 19 11 5 0 54
Unknown severity stenosis 27 7 4 2 15 55
Total 97 117 90 57 29 390
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Mitral valve stenosis 
The outcome of pregnancy is presented in Table 3, stratified for mild, moderate and severe 
stenosis. Maternal death during pregnancy occurred in 1 patient with MS (1.9% of severe 
MS). This patient died at 35 weeks of pregnancy due to acute heart failure. Two other women 
died during follow-up (after one week postpartum).  One of these two women was a patient 
with severe MS (5.3% of patients with severe MS available for follow-up), who died two 
weeks after spontaneous abortion, complicated by sepsis, atrial fibrillation and cardiogenic 
shock. The other one was a patient with moderate MS (1.7% of patients with moderate MS 
available for follow-up) who developed atrial fibrillation treated with heparin peripartum, 
which was discontinued because of hemorrhage of the Caesarean section wound. In the 
second week postpartum she developed sudden severe abdominal pain and dyspnea and 
she died after a cardiac arrest. An aortic embolism or acute mesenteric vascular occlusion 
was suspected, but autopsy was denied.
Of all patients with MS, hospital admission for a cardiac reason was required in 23.1% 
during pregnancy. The main reason was heart failure, in particular in women with severe MS 
(49.1%). The risk was also significant in moderate MS: 31.8% developed heart failure (22.0% 
of previously asymptomatic women with moderate MS and 41.1% of previously symptom-
atic women with moderate MS, p=0.036). Timing of heart failure in patients with MS was: 
71% during pregnancy only; 14% during pregnancy and up to 1 week after delivery; 15% 
after delivery only. Episodes of heart failure in the presence of mitral stenosis were treated 
mainly with diuretics (59.5%) and/or beta-blockers (41.2%),  and/or ACE-inhibitors (4.7%).
A cardiac intervention was performed during pregnancy in 15 patients with MS (5.9%): 14 
patients had valvular balloon dilatation and one patient had a surgical valve replacement. 
Timing of intervention was during the first trimester in 2 patients, second trimester in 7 
patients, and third trimester in 4 patients (and unknown in 2). The course of pregnancy 
was uneventful after these interventions. Women with mitral stenosis from countries with 
an advanced economy had an intervention during pregnancy more often than those from 
countries with an emerging economy (11.4% versus 3.1%, p=0.015), and this difference 
persisted when assessing women with isolated mitral stenosis only (19.4% versus 4.9%, 
p=0.036).
Miscarriage or fetal death was reported in 5.1% of all women with MS, versus 3.4% of 
women with MR (p=0.46). Women with MS gave birth to small-for-gestational-age babies 
more often compared to women with MR (14.0% vs 3.5%, p=0.009). Women with severe MS 
delivered earlier (p=0.041) and their babies had a lower birth weight (p=0.007).
The outcome of women with moderate or severe MS in the presence and absence of 
significant MR is presented in Table 4. Women with mixed mitral valve disease were more 
likely to have pulmonary hypertension before pregnancy than women with isolated MS 
(48.2% versus 23.6%, p=0.007). A cardiac intervention was performed only in patients with 
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table 4 Isolated mitral valve stenosis versus mixed mitral valve disease 
  Isolated 
moderate/severe MS
Moderate/severe MS 
combined with 
moderate/severe MR
n=56 n=56 p-value
Baseline characteristics
Age (years) 30.0  (±5.8) 28.5  (±6.2) 0.18
Living in an emerging country 39 69.6% 46 82.1% 0.12
Primigravida 17 30.4% 15 26.8% 0.68
Prior intervention 18 32.1% 16 28.6% 0.68
Signs of heart failure before pregnancy 15 26.8% 15 27.8% 0.91
Atrial fibrillation before pregnancy 6 10.7% 5 9.1% 0.78
Cardiac medication before pregnancy 25 44.6% 21 38.2% 0.49
RVSP>30 mmHg 13 23.6% 27 48.2% 0.007
Severe mitral valve stenosis 19 33.9% 16 28.6% 0.54
Pregnancy outcome
Maternal mortality, up to 1 week 
postpartum
0 0.0% 0 0.0% na
Hospital admission for a cardiac reason 16 28.3% 13 23.2% 0.52
Heart failure 24 42.9% 19 33.9% 0.33
Supraventricular tachycardia 6 10.7% 3 5.4% 0.49
Cardiac intervention performed 7 12.5% 0 0.0% 0.013
Caesarean section 30 55.6% 36 65.5% 0.29
Emergency caesarean section for a cardiac 
reason
3 5.4% 5 8.9% 0.72
Miscarriage <24 weeks 1 1.4% 5 8.9% 0.21
Fetal death ≥24 weeks 1 1.8% 0 0.0% 1.00
Low Apgar (<7) 2 4.1% 5 12.5% 0.24
Preterm birth 10 19.2% 5 10.2% 0.20
Birthweight <2500gr 11 19.6% 14 25.0% 0.50
Small for gestational age 6 11.8% 5 11.1% 0.92
Median pregnancy duration, weeks 
(Q1-Q3)
38.4 (37.0-39.4) 38.9 (38.0-39.3) 0.43
Median birthweight, grams (Q1-Q3) 2800 (2600-3100) 2775 (2500-3000) 0.44
Follow-up after 6 months 24 42.9% 24 42.9% 1.00
Mortality after 1 week, <6 months 0 0.0% 2 8.3% 0.49
MR= mitral regurgitation; MS= mitral stenosis; na=not applicable; Q1-Q3 = first and third quartile; RVSP= right 
ventricular systolic pressure
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isolated MS (0% versus 12.5%, p=0.013). The outcome of pregnancy was not different in 
mixed mitral valve disease compared to isolated MS. 
Isolated mitral valve regurgitation
One patient with severe mitral regurgitation died (Table 3, 3.8% of patients available for 
follow-up). She was asymptomatic before pregnancy and had a normal left ventricular func-
tion. She developed a cardiogenic shock pre-delivery at 39 weeks, with the subsequent 
perinatal death of her child. Urgent surgical valve repair was planned directly after preg-
nancy, but she discharged herself against medical advice and she died weeks later due to 
cardiogenic shock.
Hospital admission for cardiac reason was required in 13.7% of women with MR, mainly 
because of heart failure, which occurred in 16.2% compared to 31.1% of MS patients 
(p=0.002). Heart failure in the presence of mitral regurgitation was treated mainly with 
diuretics (47.4%); some received beta-blockers (15.8%), and/or ACE-inhibitors (5.3%). Surgi-
cal valve replacement was performed in one patient (0.9% of MR patients) after 10 weeks 
of gestation. She received a mechanical valve and was treated with vitamin K throughout 
pregnancy, with a switch to heparin before vaginal delivery, with good fetal outcome. 
Outcome of pregnancy is stratified for emerging and advanced economies in Table 5. 
Symptomatic patients
Before pregnancy, 168 patients (43.1%) were in NYHA class ≥II as shown in Table 6. Compared 
to asymptomatic patients (n=217), they had signs of heart failure, pulmonary hypertension, 
took cardiac medication more often and had severe MS more frequently. During pregnancy, 
hospital admission was required in 33.3% of symptomatic patients, mainly for heart failure, 
but also for supraventricular arrhythmias. The majority of cardiac interventions were per-
formed in the symptomatic group. A higher incidence of small for gestational age babies 
was found in symptomatic versus asymptomatic patients (15.1% versus 7.7%, p=0.038).
Predictors of adverse outcome
Results of univariable and multivariable regression analysis are presented in Table 7. Pre-
pregnancy NYHA class of >I, severe mitral stenosis, elevated RVSP and older age were inde-
pendent predictors of maternal cardiac events. Severe mitral stenosis was independently 
associated with adverse fetal outcome. 
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table 6 Baseline and pregnancy outcome in asymptomatic and symptomatic patients
 
 
Asymptomatic Symptomatic
n=217 n=168 p-value
Baseline characteristics
Age (years) 29.2  (±6.2) 28.4  (±5.7) 0.17
Living in an emerging country 162 74.7% 130 77.4% 0.54
Primigravida 46 21.2% 55 32.7% 0.011
Prior intervention 61 28.1% 43 25.6% 0.58
Signs of heart failure before pregnancy 3 1.4% 77 46.4% <0.001
Atrial fibrillation before pregnancy 12 5.6% 13 7.8% 0.37
Cardiac medication before pregnancy 60 27.8% 72 42.9% 0.002
RVSP>30 mmHg 48 22.3% 72 43.6% <0.001
Severe mitral valve regurgitation* 27 17.2% 28 18.4% 0.18
Severe mitral valve stenosis* 21 11.1% 31 22.0% 0.007
Pregnancy outcome
Maternal mortality, up to 1 week postpartum 0 0.0% 1 0.6% 0.44
Hospital admission for a cardiac reason 21 9.7% 56 33.3% <0.001
Heart failure 42 19.4% 60 35.7% <0.001
Supraventricular tachycardia 4 1.8% 12 7.1% 0.010
Cardiac intervention performed 3 1.4% 13 7.7% 0.002
Caesarean section 102 47.9% 93 57.4% 0.07
Emergency caesarean section for a cardiac reason 3 1.4% 7 4.2% 0.11
Miscarriage <24 weeks 8 3.7% 6 3.6% 0.95
Fetal death ≥24 weeks 2 0.9% 2 1.2% 1.00
Low Apgar (<7) 12 7.5% 11 7.8% 0.91
Preterm birth 19 9.7% 12 8.1% 0.59
Birthweight <2500gr 31 14.3% 31 18.5% 0.27
Small for gestational age 13 7.7% 22 15.1% 0.038
Median pregnancy duration, weeks (Q1-Q3) 39.0 (38.0-39.6) 39.0 (38.0-39.6) 0.21
Median birthweight, grams (Q1-Q3) 2900 (2658-3188) 2900 (2600-3000) 0.10
Follow-up after 6 months 104 47.9% 100 59.5% 0.024
Mortality after 1 week, <6 months 1 1.0% 2 2.0% 0.62
             
Q1-Q3 = first and third quartile; RVSP= right ventricular systolic pressure. *Percentage of patients with known 
severity of disease.
152 Chapter 7
discussion
This global prospective registry included the largest number of women with rheumatic mi-
tral valve disease reported to date. It provides contemporaneous data showing that women 
with mild and asymptomatic rheumatic mitral valve disease tolerate pregnancy well, but 
that morbidity and mortality is high especially in women with severe mitral valve stenosis. 
Heart failure occurred in up to 48% of women with severe mitral stenosis, patients with pre-
pregnancy NYHA class II or greater and elevated right ventricular systolic pressure being at 
particularly high-risk of maternal cardiac events. This is not surprising as pregnancy induces 
an expansion of the plasma volume, which is poorly tolerated in the presence of severe 
table 7 Predictors of adverse outcome
Univariable analysis Multivariable analysis
  OR 95%CI   OR 95%CI
Adverse cardiac events* (n= 152, 39.0%)
age 1.03 (1.00-1.07) 1.05 (1.01-1.10)
Primigravida 1.17 (0.74-1.85)
Signs of heart failure before pregnancy 3.12 (1.88-5.18) 1.32 (0.66-2.64)
AF before pregnancy 2.74 (1.21-6.22) 1.02 (0.34-3.03)
NYHA>1 3.32 (2.16-5.09) 2.86 (1.62-5.08)
RVSP>30 mmHg 2.29 (1.47-3.55) 2.14 (1.26-3.64)
Severe mitral stenosis 2.89 (1.59-5.26) 2.35 (1.20-4.62)
Severe mitral regurgitation 1.49 (0.84-2.64)
Adverse fetal outcome^ (n=81, 20.8%)
Age 1.03 (0.99-1.07)
Primigravida 1.23 (0.71-2.11)
Signs of heart failure before pregnancy 0.96 (0.52-1.78)
AF before pregnancy 2.65 (1.15-6.08) 1.10 (0.29-4.22)
NYHA>1 1.29 (0.78-2.13)
RVSP>30 mmHg 1.55 (0.93-2.59)
Severe mitral stenosis 2.62 (1.35-5.07) 2.39 (1.19-4.79)
Severe mitral regurgitation 1.22 (0.62-2.41)
Anticoagulation during pregnancy 2.29 (1.18-4.45) 1.09 (0.36-3.31)
Beta-blocker during pregnancy 1.77 (1.03-3.03) 1.32 (0.69-2.53)
95%CI= 95% confidence interval; AF= episode of atrial fibrillation at baseline; NYHA = New York Heart Association 
functional class; OR= odds ratio; RVSP= right ventricular systolic pressure.
* Defined as cardiac arrest, cardiac death, new episode of arrhythmia requiring treatment, heart failure, throm-
boembolic  event, endocarditis, hospitalisation for cardiac reason, or a cardiac intervention
^ Defined as fetal death after 14 weeks, or neonatal death < 1 week, low apgar score, preterm birth, small for 
gestational age
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left-sided stenosis. The stenotic mitral valve compromises the ability of the heart to increase 
cardiac output, increasing left atrial and pulmonary pressures and resulting in cardiac failure. 
In addition, an increase in cardiac output is required to provide sufficient uteroplacental 
blood flow, when this is compromised fetal growth may be reduced17.
Mitral valve stenosis
While mild stenosis is usually well tolerated outwith pregnancy, this study revealed that 
women with mild disease had a significant risk of heart failure of 15.8%, while those with 
moderate and severe disease had risks of 31.8 and 48.1% respectively. These data are 
consistent with an earlier, smaller study, which reported pulmonary oedema in mild (24%), 
moderate (34%) and severe (56%) mitral valve stenosis during pregnancy18. The degree of 
stenosis, together with NYHA class and RVSP in those with mild or moderate stenosis, may 
help to distinguish between women who are likely to tolerate pregnancy well and those 
who have an unacceptably high risk of pregnancy complications; we found that severe 
MS, RVSP greater than 30 mmHg and NYHA class II or higher were independent significant 
predictors of maternal cardiac events. A previous prospective study reporting on pregnancy 
outcome in 192 patients with rheumatic heart disease, including 61% with a mitral valve 
lesion, also found that heart failure (7 vs. 49%) and arrhythmic (2 vs. 21%) events occurred 
more often in NYHA class III or IV women than in NYHA class I or II women19.
In women with severe mitral valve stenosis and NYHA class III or IV, an increase of pul-
monary capillary wedge pressure immediately postpartum has been described20. In our 
study, 30% of the cases developing heart failure in the presence of MS, occurred in the first 
week after delivery, whether or not preceded by an episode during pregnancy. Thus, close 
monitoring of the hemodynamic situation intrapartum and in the first days after delivery 
is essential, and efforts should be made to limit large fluctuations in pre- and afterload. 
Heart failure should be treated just as in non-pregnant patients, although ACE-inhibitors 
and angiotensin receptor blockers should be avoided during all trimesters because of 
teratogenicity. 
It is noteworthy that 75% of women were known to have mitral valve disease before 
pregnancy. A third of all women with mitral stenosis were symptomatic before pregnancy, 
and half of the women with severe mitral stenosis went on to need hospital admission for 
heart failure during their pregnancy, representing significant morbidity and cost. It is pos-
sible to speculate that if those with isolated severe mitral stenosis had undergone balloon 
mitral valvuloplasty pre conception, they would have had a lower risk pregnancy with less 
chance of morbidity and hospital admission.
We have shown a remarkable difference in birth weight and pregnancy duration between 
emerging and advanced economies. Our data clearly are a reflection of the iatrogenic influ-
ence on pregnancy outcome: physicians from advanced economies are eager to induce 
labour for the benefit of the mother. However, this approach did not result in a significant 
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difference in maternal outcome, although this conclusion is partly restricted by low num-
bers. 
Valve intervention during pregnancy
Sixteen women, almost all of them with MS, had an intervention during pregnancy, most 
commonly (14 of 16 cases) with  a percutaneous balloon mitral commisurotomy (PBMV). 
This is an effective treatment option for selected patients with isolated mitral valve stenosis, 
with rapid decrease of left atrial pressure and pulmonary artery pressure2. PBMV is effective 
and safe during pregnancy21 and is preferred to a surgical procedure, as the latter still carries 
a risk of fetal demise of around 20%22. However, patients with severe mitral valve stenosis 
in the presence of significant mitral valve regurgitation are less suitable for a percutaneous 
intervention23. Treating patients with severe symptomatic mixed disease during pregnancy 
is complex and evidence-based recommendations on the approach are lacking. Indeed, in 
our study, two women with mixed disease died in the second week after pregnancy.
Despite the fact that more women from emerging countries had severe stenotic disease, 
the number of valvular interventions was greater in countries with an advanced economy, 
probably because of the greater access in these countries3. Enhanced flowcharts for the 
choice of intervention in women with valve disease in different settings have been pro-
posed24. Although, ideally, any percutaneous or surgical intervention should be undertaken 
before conception, the threshold for intervention during pregnancy, particularly for PBMV 
in isolated severe mitral stenosis, should be low. The best timing for intervention has been 
suggested to be after the fourth month.11
Isolated mitral valve regurgitation
Mild mitral regurgitation is generally classified as a modified World Health Organization 
(WHO) class I  (no detectable increased risk of maternal mortality and no or mild increased 
risk of morbidity) 11. The results of this study support this statement, with low maternal and 
fetal morbidity. Also, moderate to severe MR is often seen as benign, however, in our study 
it was associated with a surprisingly high rate of heart failure (23%) and should therefore not 
be underestimated. As commented on earlier, there are marked changes in haemodynamic 
function during pregnancy25,26, which may be poorly tolerated in the context of substantial 
mitral valve regurgitation. 
Clinical implications
It might be well that mortality and cardiac deterioration in this cohort could have been 
reduced by appropriate pre-pregnancy assessment and intervention as suggested by 
the guidelines23. A delay in patients seeking help is often the main contributing factor to 
maternal cardiovascular death in emerging countries6. Hence, adequate counselling of ado-
lescents and young women with rheumatic heart disease about the risks of pregnancy is 
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of utmost importance to convince them to see a cardiologist first, before getting pregnant. 
There seems to be a real task here and this societal issue might need political support.
Also, the question remains how to deal with women with asymptomatic moderate MS, 
who are not yet candidates for valve intervention, but who are contemplating pregnancy. 
Pregnancy in these women is associated with a significant risk of heart failure. Most of these 
women seem to have favorable clinical, and probably also anatomical conditions, for bal-
loon commissurotomy. Therefore, the availability of a low-risk intervention is an incentive to 
consider wide indications of balloon commissurotomy in young women with moderate or 
severe MS who have a desire for pregnancy, even if they are asymptomatic.
Limitations
Although this is the largest prospective study about pregnancy in women with rheumatic 
mitral valve disease, it would be desirable to collect data on even more women, specifi-
cally including more patients from low income countries. Definition of valve disease var-
ies between the different guidelines and is subject to updating in newer versions of the 
guidelines. We were restricted to the guidelines used when the majority of the patients 
were included16,23. However, having symptoms of valve disease has direct consequences 
with regard to intervention in current guidelines27, which is why we decided to perform 
a sub-analysis in patients with and without symptoms. This study was conducted from a 
voluntary registry, and therefore potential reporting bias should be taken into account 
when interpreting the results. Furthermore, although follow-up until 1 week postpartum 
was complete in all patients, follow-up until 6 months postpartum was available in only 
53% of the patients. 
In our cohort, mitral valve area, mean gradient and pressure half time were available in 
some patients and at very different time points, which hampered statistical analysis to study 
their potential value as predictors of adverse outcome. 
Conclusion
Women with moderate or severe rheumatic mitral stenosis, who were symptomatic or had 
elevated right ventricular systolic pressures, are at high risk of complications during preg-
nancy. In particular women with symptomatic or severe mitral stenosis should be advised 
against pregnancy until valve intervention has taken place. Women with mild stenosis, and 
those with more than mild mitral regurgitation should be adequately counselled about 
their significant risk of complications. Close follow-up during pregnancy will allow early 
recognition of symptoms and timely intervention to avoid an unfavourable maternal or fetal 
outcome. 
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AbstrAct
Background Controversial results on maternal risk and fetal outcome have been reported in 
women with aortic stenosis (AS). 
Objectives To investigate maternal and fetal outcome in patients with AS in a large cohort.
Methods The Registry on Pregnancy and Cardiac Disease (ROPAC) is a global, prospective 
observational registry of women with structural heart disease providing a uniquely large 
study population. Data of women with moderate (peak gradient 36-63mmHg) and severe 
AS (peak gradient ≥64mmHg) were analyzed. 
Results Out of 2,966 pregnancies in ROPAC, we identified 99 pregnancies in women with AS, 
who had at least moderate AS (34 severe AS). No deaths were observed during pregnancy 
and the first week after delivery. However, 20.8% of women required hospitalisation for car-
diac reasons during pregnancy. This was significantly more common in severe AS compared 
to moderate AS (35.3% vs. 12.9%, p=0.02) and reached the highest rate (42.1%) in severe, 
symptomatic AS. Pregnancy was complicated by heart failure in 6.7% of asymptomatic and 
26.3% of symptomatic patients but could be managed medically except for one patient 
who was symptomatic prior to pregnancy and required balloon valvotomy. Children of 
patients with severe AS had a significantly higher percentage of low birth weight (35.0% vs. 
6.0%; p=0.006). 
Conclusion Mortality in pregnant women with AS, including those with severe AS appears 
to be close to zero in the current era. Symptomatic and severe AS does, however, carry a 
substantial risk of heart failure and is associated with high rates of hospitalisation for cardiac 
reasons although heart failure can nearly always be managed medically. The results high-
light the importance of appropriate preconceptional patient evaluation and counselling.
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introduction
Pregnancy carries a very low risk of death in developed countries, but overall cardiac rea-
sons remain the leading cause of maternal mortality1. Consistent with this, women with 
pre-existing heart disease have a 100 times greater mortality than normal2. Pregnancy is 
associated with profound changes in haemodynamic parameters, perhaps explaining why 
pre-existing heart disease has such an adverse impact on morbidity and mortality in preg-
nant women3. Although there is clear evidence that pregnancy is a high risk endeavour in 
women with complex heart disease and especially those with severe pulmonary hyperten-
sion4,5, available data are limited in women with less complex heart disease. Obstructive 
heart lesions will be aggravated by the increase in stroke volume occurring with pregnancy 
and are therefore of particular concern. Aortic stenosis (AS) is one of these lesions but it is 
relatively uncommon in women of childbearing age. However, when present, it has been 
reported to be associated with increased risk of maternal cardiovascular events – including 
death, obstetric morbidity such as preterm birth, and fetal complications including growth 
restriction, miscarriage, and stillbirth6. The evidence in this setting is nevertheless limited 
and the results of published reports are conflicting. Unfortunately, prior studies either en-
compassed all forms of heart disease7,8 or included mild AS9. In addition, some series report 
on historic patient cohorts6. As a consequence the reported maternal mortality rate ranges 
between 2% and 17.4% and the risk in contemporary cohorts of women presenting with 
severe AS remains unclear6,9. 
The purpose of this study was therefore to investigate maternal and fetal adverse events 
in contemporary patients with moderate or severe AS based on a prospective observational 
study of a large number of pregnancies in patients with AS included in the Registry Of 
Pregnancy And Cardiac disease (ROPAC).
methods
ROPAC is a global, prospective, observational registry of women with heart disease. It was 
initiated by the European Society of Cardiology (ESC) working groups on congenital heart 
disease and valvular heart disease and is part of the EURObservational Research Programme 
of the ESC. The Registry allows for the inclusion of patients with structural or ischaemic heart 
disease, aortic pathology and pulmonary hypertension. The Registry started in January 2008. 
Patients who were pregnant in 2007 could also be included retrospectively, from January 
2008 patients were included prospectively. The overall mortality in the registry has been 
reported at 1%. Further details on the Registry and the Institutional Review Board/ethical 
approval have previously been published2,10. The current study is covered by approval under 
the umbrella of the general ROPAC project.
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The present study retrospectively analyzed the outcome and complications in pregnant 
women with moderate or severe AS included in the Registry up to April 2014. We focused 
exclusively on women with moderate or severe AS. Patients with additional congenital or 
acquired heart disease (with the exception of simple corrected pre-tricuspid shunts, aortic 
coarctation) were not included in the current study. The severity of AS was graded based 
on available transthoracic echocardiographic data at baseline. Moderate AS was defined 
as a peak transaortic gradient ≥36 mmHg (corresponding to a peak velocity of ≥3 m/s), 
while severe AS was defined as a peak aortic gradient ≥64 mmHg (corresponding to a peak 
velocity of ≥4 m/s) based on the simplified Bernoulli equation11,12. This is in agreement with 
current guidelines and general recommendations for assessing the severity of AS in the 
presence of normal flow rate13. Patients who had undergone aortic valve replacement prior 
to pregnancy were included if they fulfilled the haemodynamic criteria described above. 
However, further analyses were also performed and presented separately since prosthetic 
valve related risks require additional consideration. 
Baseline characteristics included maternal age, general cardiovascular risk factors, major 
non-cardiac disease, cardiac diagnosis, prior interventions, cardiac symptoms, medication 
and obstetric history. Heart failure prior to pregnancy was defined according to current 
guidelines clinically, as a syndrome in which patients have typical symptoms (e.g. breathless-
ness, ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, pulmo-
nary crackles, and displaced apex beat)14. Maternal mortality was defined as death during 
pregnancy or up to one week after delivery. Miscarriage was defined as loss of pregnancy up 
to 24 weeks of gestation or a fetus weighting <500 gramm while fetal mortality was defined 
as fetal loss beyond 24 weeks of pregnancy. Outcome measures included maternal mor-
tality, maternal hospital admission (all-cause and admission for cardiac reasons), preterm 
labour (<37 weeks of gestation), neonatal mortality (neonatal death <30 days postpartum), 
low birth weight (defined as a birth weight <2500 grams according to WHO criteria), small 
for gestational age neonates (weight below the 10th percentile for gestational age) and the 
need for Caesarean section.
Statistical analysis
Data are presented as numbers (percentage) for categorical variables or mean±standard 
deviation [SD] or median (interquartile range [IQR], 25th to 75th percentile) for continuous 
variables, depending on data distribution. Groups were compared with the use of Chi-
square, t-tests or nonparametric Mann-Whitney U tests, respectively. The relation between 
baseline parameters and outcome was assessed with the use of univariable and multivari-
able logistic regression analyses and odds ratios (OR) with 95% confidence intervals are pro-
vided. Models were built by including significant univariable parameters into a multivariable 
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analysis. For all analyses, a two-tailed p-value <0.05 was used as the criterion for statistical 
significance. Analyses were performed with the use of Medcalc statistical software version 
14.12.0 (Medcalc Software, Ostend, Belgium).
results
Baseline characteristics
Based on the ROPAC registry, including 2,966 pregnancies from 99 centres in 40 countries 
(enrolled between 2008 and 2014), we identified 99 pregnancies in 96 women with at 
least moderate AS, who had adequate baseline echocardiographic data at a mean(±SD) 
of 52±347 days before conception. Of these 44% were performed before conception. No 
significant difference in the mean peak aortic gradient was seen between patients with and 
without pre-conceptional echocardiographic assessment (59±22mmHg vs. 64±29mmHg, 
p=0.33). Overall, 22 women had already one child, 17 women two children and 13 had three 
or more children. Baseline maternal characteristics are presented in Table 1. The median 
age at pregnancy was 30 years. Before pregnancy 62.5% of AS patients were asymptomatic, 
while 33.3 % were classified as NYHA class II and 4.2% as NYHA class III. Approximately 50% 
of patients had a previous successful pregnancy. Stratifying patients by the severity of the 
underlying AS revealed that the 34 women with severe AS were more likely to be symptom-
atic or to have pre-existing heart failure symptoms (Table 1). In the current study, bicuspid 
aortic valve was the most prevalent aetiology for AS (53.5%). In addition, 18 patients had 
rheumatic aortic valve disease. None of patients had connective tissue disorders such as 
Marfan or Ehlers Danlos syndrome. Two patients had aortic dilatation (45 mm and 50 mm 
aortic diameter). In total 12 patients had repaired aortic coarctation (9 of them with bicuspid 
aortic valve). The peak aortic gradient was (mean±SD) 62.1±26.3 mmHg, while the mean 
aortic gradient was found to be 39.1±17.9 mmHg. With the exception of one woman with 
an ejection fraction of 39%, all patients had a normal left ventricular systolic function. 
Overall, 8 patients had a previously implanted bioprosthesis (7 in aortic position, 1 in 
mitral position). Of these only the patient with the mitral bioprosthesis had severe native 
AS (peak gradient 71 mmHg, mean gradient 49 mmHg), while the patients with aortic 
bioprostheses exhibited only moderate AS (peak gradient 47.1±6.5 mmHg, mean gradient 
28.1±5.4 mmHg). In addition, 13 patients had a previously implanted mechanical heart 
valve (4 in mitral position, 10 in aortic position and 1 in both positions). The peak and 
mean Doppler gradients in those patients with a mechanical aortic valve were 64.4±26.7 
and 39.0±20.2 mmHg, respectively. Anticoagulation was performed with oral vitamin K 
antagonists throughout pregnancy or staged therapy with low molecular heparin during 
the first trimester followed by vitamin K antagonists in 10 patients. Low molecular weight 
heparin was used throughout pregnancy in 3 patients. None of the patients developed a 
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valve thrombosis, neither in the entire cohort, nor specifically in those with a mechanical 
aortic valve.
Maternal cardiac complications
No patient died during pregnancy or within 1 week postpartum. However, cardiovascular 
events and hospitalisations were common. Overall, 35.8% of patients required at least 
one hospital admission during pregnancy; 20.8% admission for cardiac reasons (Table 2). 
Women with severe AS were significantly more likely to be admitted during pregnancy 
(35.3% cardiac admissions) compared to those with only moderate AS (12.9 %, p=0.02). The 
mean gestational week for the occurrence of heart failure was 27.2±7.5 weeks, for the first 
hospital admission for cardiac reasons 24.3±9.7 weeks and for hospital admissions for all 
reasons 26.9±9.5 weeks. The highest rate of hospitalisation for cardiac reasons was seen 
in symptomatic severe AS patients with a rate of 42.1%. Pregnancy was complicated by 
heart failure in 6.7% of patients asymptomatic prior to pregnancy but 26.3% of symptomatic 
patients with severe AS.
The leading cardiac complications were new or worsening heart failure during pregnancy 
and arrhythmias. In contrast, cerebrovascular complications or pulmonary embolism were 
not recorded in this cohort and only one patient was reported to have developed endocar-
ditis during pregnancy. 
Heart failure could be managed medically in all patients, except for one case requiring 
aortic valvotomy. This patient with a history of two previous pregnancies was unaware of 
the severe AS although she had suffered from severe dyspnoea after a previous delivery. 
She presented with critical AS and heart failure at 20 weeks of gestation and had impaired 
left ventricular systolic function. Aortic valvuloplasty was performed, resulting in a reduc-
tion in both peak and mean gradients from 156 and 71mmHg pre-intervention to 113 and 
55mmHg post-intervention, respectively and in moderate aortic regurgitation. The further 
course of the pregnancy and delivery was uneventful. The patient delivered vaginally at 38 
weeks a baby of 3,200 grams. However, one month after delivery, the patient presented 
again with severe symptoms and underwent aortic valve replacement (AVR). 
One patient underwent AVR with a mechanical prosthesis during pregnancy as a conse-
quence of aortic valve endocarditis at 4 months into pregnancy. The further course of the 
pregnancy was uneventful in this patient with a vaginal delivery at 38 weeks.
Obstetric and fetal outcomes
Median pregnancy duration was 38.6 [IQR 37.2-39.8] weeks, and this was significantly 
shorter in patients with severe AS (37.9 [IQR 35.2-39.0] vs. 39.0 [IQR 38.0-40.0] weeks, 
p=0.001, Table 2). Women with severe AS also had a significantly higher rate of Caesarean 
section compared to those with moderate AS (75.0% vs. 48.3%, p=0.008). The main reason 
for Caesarean section was a cardiac indication, recorded in 65.9% of patients. A low Apgar 
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score below 7 was present in 9.0% of neonates (5.2% vs. 16.1% of pts. with moderate and 
severe AS, respectively; p=0.21). Children of patients with severe AS had a significantly lower 
birth weight (3200 [IQR 2932-3490] vs. 3000 [IQR 2145-3227]g, p=0.0025). 
There were 2 miscarriages (both in moderate AS), no fetal losses between 24 weeks and 
delivery and 1 neonatal death (in severe AS). The neonatal death occurred after a pregnancy 
duration of 30 weeks and 2 days. The child that died was delivered by Caesarean section, 
and was small for gestational duration with a weight of 1000 g; the exact reason for delivery 
was not documented but the child died due to respiratory distress syndrome. This event 
occurred in a mother with severe AS, who had a previous unsuccessful pregnancy compli-
cated by heart failure and arrhythmias.
Predictors of maternal or fetal complications
Figure 1-3 present predictors of adverse maternal or fetal outcome. As illustrated in Figure 1, 
the odds ratio of hospitalisation in women with severe AS was 2.77 compared to those with 
only moderate AS. In addition, peak aortic gradient on transthoracic echocardiography was 
significantly associated with a higher risk of maternal hospitalisation during pregnancy (OR 
1.245/10 mmHg, p=0.024). On multivariable analysis, peak aortic gradient emerged as an 
independent predictor of maternal outcome. Regarding fetal outcome, again, severity of 
AS and peak aortic gradient on echocardiography proved to be independent predictors of 
low birth weight (Figure 2) and small for gestational age neonates , respectively (Figure 3). 
figure 1 Predictors of adverse maternal outcome 
Forrest plots illustrating the results of the univariate logistic regression analysis for adverse maternal outcome, defined 
as hospital admission during pregnancy. Severe aortic stenosis and the peak aortic gradient were significantly related 
to worse outcome. An asterisk denotes significant results. CI = confidence interval; NYHA = New York Heart Association.
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Differences between countries of the European Union (EU)/United States (US) and 
non EU countries
Seventy-four pregnancies were reported from inside the EU or the US (Group A) and 25 from 
outside the EU or the US (Group B). Group B included 16 cases from Egypt, 5 from the Russian 
Federation, 2 from the Arab Emirates and one from each Turkey and Serbia/Montenegro. 
Comparing the two cohorts revealed no significant differences between the groups regard-
ing the severity of AS (severe AS 28.3% vs. 52.0% in group A and group B countries, p=0.057), 
the peak aortic gradient (group A: 59.7±25.8 vs. group B: 68.4±25.9 mmHg, p=0.16) or the 
figure 2 Predictors of low birth weight
Forrest plots illustrating the results of the univariate logistic regression analysis for adverse fetal outcome (low birth 
weight, defined as birth weight <2,500 g). Severe aortic stenosis, peak aortic gradient, and NYHA class >1 at baseline 
were predictive of worse fetal outcome. An asterisk denotes significant results. Abbreviations as in Figure 1.
figure 3 Predictors of small for gestational age infants
Forrest plots illustrating the results of the univariate logistic regression analysis for adverse fetal outcome (small for 
gestational age). Severeaortic stenosis and peak aortic gradient were predictive of worse fetal outcome. An asterisk 
denotes significant results. Abbreviations as in Figure 1.
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mean aortic gradient (group A: 37.4±18.1 vs group B: 42.9±16.6 mmHg, p=0.11). Women 
from Group B countries were however more frequently symptomatic at baseline (56.0% vs. 
29.7%, p=0.034) and required more hospital admissions during pregnancy (52.0% vs. 30.1%, 
p=0.049 overall and 48.0% vs. 12.2%, p=0.0005 for cardiac reasons) compared to those from 
Group A countries. The rate of fetal complications such as small for gestational age (group 
A: 9.4% vs. group B: 9.1%, p=0.70) and preterm birth (group A: 21.7% vs. group B: 14.3%, 
p=0.40) was similar between the cohorts.
discussion
The current registry based study suggests that mortality risk in pregnant women with AS, 
including those with severe AS, is close to zero. However, pregnancies may be associated 
with a relatively high burden of morbidity such as hospital admissions for cardiac reasons 
in up to one third of patients with severe AS. The leading maternal complication during 
pregnancy was heart failure which occurred primarily in patients with severe AS, already 
symptomatic prior to pregnancy. In contrast, patients asymptomatic prior to pregnancy 
– even with haemodynamically severe AS – had a relatively low rate of heart failure occur-
rence (6.7%). It is alarming, however, that over 50% of patients with severe AS had symptoms 
and therefore an indication for valve replacement before pregnancy emphasizing the need 
for improvement in cardiac evaluation and appropriate preconceptional counselling of 
patients. Fortunately, heart failure could be managed, in all but one women medically. The 
main predictor of maternal complications besides symptoms of AS prior to pregnancy was 
the haemodynamic severity of AS. Severe fetal complications were rare but preterm birth 
and a low birth weight were observed in approximately one third of patients.
It is well recognised that valvular heart disease patients are more likely than other groups of 
women with structural heart disease to require hospitalisation, suffer from supraventricular 
arrhythmias, or experience postpartum haemorrhagic complications. A previous report 
based on the ROPAC registry found aortic valve disease to be present in 23% of pregnant 
patients with valvular heart disease, with AS being the second most common stenotic 
valve lesion in this cohort2. Current guidelines consider symptomatic severe AS as a high 
risk condition and recommend to avoid pregnancy1,4. In asymptomatic patients a compre-
hensive preconception assessment, including an exercise test evaluating physical capacity 
and blood pressure response to exercise is recommended (see Central Illustration). This 
approach is, however, controversial due to absent/limited data regarding the prognostic 
value of prepregnancy exercise testing in the setting of AS4. 
Even women with AS who remain asymptomatic during pregnancy are subjected to ad-
ditional hemodynamic stress at the time of delivery and the immediate postpartum period. 
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Therefore, these women may become symptomatic at the time of delivery and should be 
managed in a team approach including experienced cardiologists, obstetricians and an-
esthesiologists. In asymptomatic patients in good clinical condition, with normal cardiac 
function, spontaneous labour is generally preferred to induced labour1. In contrast, there is 
less consensus on the recommended mode of delivery in symptomatic patients. Generally, 
vaginal delivery carries a lower risk of complications for mother and fetus. Compared with 
caesarean section, it normally causes smaller shifts in blood volume, less haemorrhage, 
the absence of abdominal surgery, decreased thrombogenic risk and fewer infections. 
Furthermore, the hypertrophied left ventricle in AS may be sensitive to abrupt changes in 
preload (e.g. from anesthetic agents or haemorrhage). Early epidural analgesia is generally 
Vmax <4m/sec 
Peak gradient  
  <64mmHg 
Vmax >4m/sec 
Peak gradient  
  >64mmHg 
Symptoms 
- LVF 
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- BNP 
No Symptoms, normal LVF 
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NOT normal 
No Symptoms 
A 
B 
Vmax >4m/sec 
Peak gradient  
  >64mmHg 
Symptoms 
C Medical  
Therapy 
Balloon 
valvuloplasty AVR 
No Symptoms LVF normal? 
yes 
no 
preconception 
preconception 
during pregnancy 
central illustration  Evaluation of women with moderate or severe aortic stenosis
Figure Legend: A and B: Preconception counseling. Only patients with severe AS and symptoms or asymptomatic pa-
tients with reduced left ventricular function, abnormal exercise test or high brain natriuretic peptide plasma levels 
should be counseled against pregnancy and AS should be treated.
C: Management of women with severe AS during pregnancy. In case of heart failure symptoms patient are first treated 
medically (primarily diuretics in addition to restricting physical activities). If medical treatment is insufficient, percuta-
neous aortic balloon valvuloplasty can be considered to delay surgical valve replacement until the postpartum period. 
In case of persistent severe heart failure symptoms despite valvuloplasty or when patients are not eligible for valvulo-
plasty, aortic valve replacement (AVR) should be considered during pregnancy. Asymptomatic patients with normal 
LVF are followed without treatment. Strenuous physical activities should be avoided.
BNP = brain natriuretic peptide; LVF = left ventricular function; Vmax = peak velocity of blood flow across the valve
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recommended. Caesarean section should be reserved mainly for obstetric indications or 
in case of aortic dilatation or overt heart failure1. Nevertheless in some centers caesarean 
section seems to be a preferred mode of delivery in women with AS. This may be explained 
by various factors related to personal physician and mother’s preferences, cultural aspects, 
local standards and logistical reasons affecting the choice of delivery mode.
While historic series report maternal mortality rates, ranging from 11 to 20%,6,9,15-17 in 
more recent series the cardiac event rates were lower with approximately 10% of patients 
suffering a cardiac event and mortality being rare15,17,18. However, some of these studies 
also included women with mild AS, diluting the clinically interesting group of patients with 
moderate/severe AS. The current multinational study based on 99 pregnancies between 
2007 and 2014 and focusing specifically on moderate or severe AS showed no maternal 
mortality, thus supporting the notion that maternal morbidity rather than mortality is the 
main clinical problem in this setting. Previous studies suggest a risk of heart failure during 
pregnancy of approximately 10%1,15. Our data are consistent with this estimate, showing 
that heart failure occurred in 11.5% of patients with moderate or severe AS. However, in 
patients with pre-existing symptoms pregnancy was complicated by heart failure in 26.3%. 
Arrhythmias are also a recognized common complication during pregnancy in this setting, 
with a reported incidence of 3-25% in previous reports1. In the current series arrhythmias 
were also reported as a complication but with a relatively low rate of around 3%.
Overall, 57% of women included in the current study delivered by Caesarean section. This 
rate is comparable to a recent AS study18 but higher than the overall Caesarean section rate 
of 42% reported in the ROPAC registry19 and higher in comparison to previous AS studies17,20. 
This difference may be related to the fact that the current study included a larger proportion 
of patients with severe AS and a considerable number of patients required anticoagulation. 
While current recommendations support a vaginal delivery with assisted second stage of 
labour in the majority of patients, Caesarean section continues to be advocated by some 
physicians in women with severe AS and in those requiring anticoagulation1. Furthermore, 
country specific preferences may account for some of the differences as discussed in detail 
previously21. 
Severe fetal complications were rare in the current study but preterm birth and low birth 
weight were observed in one third of patients with severe AS. In addition, newborns of 
women with severe AS were more likely to have a low Apgar score, to present with low 
birth weight and to be small for gestational age. The underlying reasons remain speculative 
but are likely multifactorial. Women with severe AS had a significantly shorter pregnancy 
duration compared to those with moderate AS (35.5±6.4 vs. 38.0±4.4; p=0.002), potentially 
related to the higher rate of Caesarean section in this setting. In addition haemodynamic 
compromise due to AS resulting in a reduced utero-placental blood flow is a plausible 
alternative explanation for the impaired intrauterine fetal growth seen in this study and this 
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is supported by the higher prevalence of small for gestational age (accounting for duration 
of pregnancy) newborns in the severe AS cohort22. 
The most important predictor of, both, maternal and fetal adverse events in the current 
study was the haemodynamic severity of AS. In fact, patients with severe AS had an ap-
proximately 2.8-fold increased risk of maternal complications and a 7.6-fold increased risk 
of fetal complications compared to women with only moderate AS. Interestingly, the peak 
aortic gradient before pregnancy - as a continuous variable – emerged as the only indepen-
dent predictor of complications on multivariable logistic regression analysis. This finding, 
although conceivable, is novel as previous studies could not confirm a statistical association 
between baseline severity of AS and outcome in this setting15,17. 
Two women included in this study required aortic valve intervention during pregnancy. 
Both procedures were successful and the patients continued to have uneventful pregnan-
cies with vaginal deliveries of healthy babies. This illustrates that, in experienced hands, 
complications can be managed successfully in the current era, however, the risks associated 
with these procedures (especially the risk of fetal loss) should not be underestimated23. 
Therefore, appropriate preconceptional assessment and counselling are paramount to 
avoid pregnancy complications and to allow for elective procedures to be performed before 
pregnancy especially in symptomatic women with severe AS. On the other hand, the low 
complication rate in asymptomatic patients – even those with haemodynamically severe 
AS – supports a conservative approach and avoidance of prophylactic surgery in this group 
considering the dilemma of managing pregnancy in the presence of a prosthetic valve1. 
Limitations
Due to the multinational nature of the registry we included pregnancies in developed 
and emerging countries. We accept that outcomes may be different in the latter setting. 
However, the vast majority of patients included (74 %) were from resource rich countries 
of the EU or from the US. In addition, obstetric outcomes were not statistically different 
between the EU/US and the remaining countries. Based on the haemodynamic inclusion 
criteria we also enrolled 13 patients with a mechanical heart valve. It is well appreciated 
that mechanical heart valves are associated with increased morbidity during pregnancy 
and worse fetal outcomes24. Under haemodynamic aspects, however, we believe that physi-
ological changes during pregnancy should affect prosthetic and native valves similarly. In 
addition, in this series no prosthetic valve related complication was observed. Furthermore, 
comparing morbidity between patients with severe AS and those with prosthetic valves 
revealed higher rates of complications in the former group (17.6% vs. 11.5%, 35.3% vs. 20.8% 
and 51.5% vs. 35.8% for heart failure and cardiac or all-cause hospitalisation, respectively), 
supporting the notion that the degree of haemodynamic compromise rather than sequalae 
related to previous surgery relate to higher rates of complications during pregnancy. 
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The definition of maternal death employed here differs from the published WHO defini-
tion by considering mortality during pregnancy and within 7 days of delivery as opposed to 
a period of 42 days of termination of pregnancy recommended by the WHO25. In contrast 
to other cardiovascular disorders such as Marfan syndrome, pulmonary hypertension or 
cardiomyopathy, mortality beyond one week post partum nevertheless related directly to 
effect of the pregnancy on the disease is, however, unlikely in AS based on avialble literature 
and our own experience. Thus, a longer observation postpartum should not have signifi-
cantly altered the results. In addition, the causality between pregnancy and later mortality 
may be difficult to establish in AS.
The current study did not investigate the problem of ascending aortopathy, which is 
associated especially with bicuspid aortic valve disease. Nevertheless, we did not observe 
pregnancy-associated aortic dissection in our cohort. Awareness of this potential compli-
cation and appropriate preconception and pregnancy assessment of aortic dimensions 
should be part of routine care for patients with known bicuspid aortic valve.
Not all of the patients had pre-pregnancy echocardiographic assessment. We are aware 
that gradients are expected to increase with increasing cardiac output. Therefore, the clas-
sification of AS severity before pregnancy may have been different in some patients with 
borderline measurements and first presentation during advanced pregnancy (i.e. some of 
the patients classified to have severe AS during pregnancy may have had moderate AS 
when pre-pregnancy data would have been available).
Conclusions
The current multinational study including 99 pregnancies in women with at least moderate 
AS managed in the current era, highlights the ongoing challenge of pregnancy in this set-
ting. Although, maternal mortality rate was zero in this cohort, hospitalisations for cardiac 
reasons were frequent and both preterm birth and low birth weight were observed in one 
third of patients with severe AS. The fact that heart failure – the most frequent maternal 
complication – occurred predominantly in patients with severe AS who had at least mild 
symptoms indicating intervention already before pregnancy, emphasizes the importance of 
appropriate preconception patient evaluation and counselling.
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AbstrAct
Background Pregnant women with a mechanical heart valve (MHV) are at a heightened risk 
of a thrombotic event while their absolute need for adequate anticoagulation puts them at 
considerable risk of bleeding and, with some anticoagulants, fetotoxicity. 
Methods and Results Within the prospective, observational, contemporary, worldwide 
Registry Of Pregnancy And Cardiac disease (ROPAC) we describe the pregnancy outcome of 
212 patients with a MHV. We compare them to 134 patients with a tissue heart valve (THV) 
and 2620 other patients without a prosthetic valve (NoPHV). Maternal mortality occurred in 
1.4% of the MHV patients, in 1.5% of THV patients (p=1.000) and in 0.2% of NoPHV patients 
(p=0.025). Mechanical valve thrombosis complicated pregnancy in 10 (4.7%) MHV patients; 
in five of them the valve thrombosis occurred in the first trimester, and all five had been 
switched to some form of heparin. Hemorrhagic events occurred in 23.1% of MHV patients, 
in 5.1% of THV patients (p<0.001) and in 4.9% of NoPHV patients (p<0.001). Only 58% of the 
MHV patients had a pregnancy free of serious adverse events, versus 79% of THV patients 
(p<0.001) and 78% of NoPHV patients (p<0.001). Vitamin K antagonist use in the first trimes-
ter compared with heparin was associated with a higher rate of miscarriage (28.6% versus 
9.2%, p<0.001) and late fetal death (7.1% versus 0.7%, p=0.016).
Conclusions Women with a MHV have only a 58% chance of experiencing an uncompli-
cated pregnancy with live birth. The markedly increased mortality and morbidity warrants 
extensive pre-pregnancy counseling and centralization of care. 
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introduction
The true extent of the adverse impact of structural heart disease on the outcome of 
pregnancy has become clearer over the last decade1-3. The marked hemodynamic changes 
and the hypercoagulable state in pregnancy increase the risk of complications in patients 
with cardiovascular disease and fetal development can be compromised by a failure of 
cardiac function or the need for cardiac medication. This is particularly true of women with 
a mechanical heart valve prosthesis (MHV), where the hypercoagulable state makes the 
maintenance of effective anticoagulation challenging4,5. More than 200,000 aortic valve 
replacements are performed each year worldwide6, let alone replacements of heart valves in 
other positions. But the exact percentage of women of reproductive age having a mechani-
cal valve is unknown. Indeed, having a MHV has been shown to be a predictor of adverse 
outcome of pregnancy2,7, but studies are scarce and numbers are small.
In women at reproductive age with a MHV, the need to maintain adequate anticoagula-
tion to prevent mechanical valve thrombosis (MVT) has to be balanced against the risks of 
teratogenicity, fetotoxicity and bleeding. Current guidelines recommend Vitamin K Antago-
nists (VKA) in the first trimester for the highest risk patients, while in the other patients dose 
adjusted low-molecular-weight-heparin (LMWH), unfractionated heparin (UFH) or VKA can 
be used8,9. Thereafter, a VKA is recommended until 36 weeks, when it should be replaced 
with (low-molecular-weight) heparin mainly to prevent fetal intracranial hemorrhage dur-
ing vaginal delivery. These guidelines however, are based on weak scientific evidence (level 
C) and the optimal anticoagulation regime to use in pregnancy remains very uncertain2. 
We have carried out a prospective observational study of a large number of pregnancies in 
MHV patients in a broad range of clinical practices from developed and emerging countries. 
We compared them with women with structural heart disease without a prosthetic valve, 
and with women with a tissue heart valve (THV), and looked at the use and impact of the 
different anticoagulation regimes.
methods
Study design
The Registry of Pregnancy and Cardiac Disease (ROPAC) began in January 2008 as part of 
the Euro Heart Survey, which since 2009 is called EURObservational Research Programme 
(EORP) of the European Society of Cardiology. Details of the study design were previously 
published3. Pregnant women with structural heart or aortic disease were prospectively 
enrolled. When a center joined the Registry, they were allowed to include patients up to 6 
months retrospectively. If required, ethical approval or Institutional Review Board approval 
was obtained (e.g. The Netherlands, Germany, USA, Canada, and Belgium) and subjects gave 
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written informed consent. However, in some countries the procedure to obtain ethical ap-
proval was waived because of the anonymized and untraceable nature of the data.
The first term of data collection ran until June 2011 and reports were published on these 
data3,10. The current study reports on the outcome and complications of pregnancy in 
women included in the Registry up to April 1st 2014, who had a MHV compared to the out-
come of  women with a THV and of women with structural heart disease but no  prosthetic 
heart valve (NoPHV). To put the results in perspective, outcome of the normal pregnant 
population is also reported based on available literature3,11. 
Clinical data
Baseline characteristics included maternal age, general cardiovascular risk factors, major 
non-cardiac disease, cardiac diagnosis, prior interventions, cardiac symptoms, medication 
and obstetric history. The countries of origin were subdivided in emerging and developed 
countries according to the International Monetary Fund (IMF) classification12.
Maternal mortality was defined as death during pregnancy and up to one week after 
delivery. Miscarriage was defined as loss of pregnancy up to 24 weeks and fetal mortality as 
fetal loss beyond 24 weeks. Thrombotic events include valve thrombosis, pulmonary embo-
lism, deep vein thrombosis or any ischemic cardio- or cerebrovascular event. Major bleeding 
was defined as a hemorrhage resulting in at least a 1 gm/dl (or 0.62 mmol/l) decrease in 
hemoglobin, need for blood product transfusion, or end-organ damage such as hemor-
rhagic cerebrovascular accident or retina bleeding. Postpartum hemorrhage was defined as 
increased blood loss (more than 500 mL after vaginal delivery or more than 1000 mL after 
caesarean delivery) directly after delivery and up until 24 hours postpartum. Serious adverse 
events were maternal mortality, fetal loss, thrombotic events, major hemorrhagic events, 
supraventricular or ventricular arrhythmia requiring treatment, heart failure, endocarditis, 
acute coronary syndrome, aortic dissection, pre-eclampsia or HELLP (Hemolysis Elevated 
Liver enzymes Low Platelets) syndrome. The endpoint live birth was defined as pregnancies 
resulting in a live neonate.
Further definition of pregnancy outcome is described in the first ROPAC paper3.
Data Analysis 
We focused on the differences of outcome between women with a MHV and women with 
NoPHV. Secondary, we compared patients with a MHV to patients with a tissue heart valve 
(THV)  and we assessed the differences in pregnancy outcome between emerging and 
developed countries. The anticoagulant regime used was analyzed for each patient, sum-
marizing the anticoagulants in three clinically relevant intervals: 
- the first trimester (up to 14 weeks)
- from 14 weeks until 36 weeks (if full-term; otherwise until the pre-delivery period) 
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- the pre-delivery period (36 weeks to delivery; or in case of preterm delivery an 
earlier transition of anticoagulants in view of the approaching labor) 
Clearly, there is no second period of anticoagulation for patients with a pregnancy loss or 
maternal mortality in the first trimester; consequently these cases were excluded from the 
analysis of anticoagulation regimes.  
Categorical data are presented as frequencies and percentages, and chi-square tests or 
Fisher’s exact tests are used, as appropriate, to reveal differences between patients indepen-
dent subgroups. After evaluation of normality by Kolmogorov-Smirnov tests, continuous 
data are presented as mean ± one standard deviation (SD), or median with first and third 
quartiles range (Q1-Q3). Student’s t and Mann Whitney tests are used, as appropriate, to 
study differences between two groups.  Univariable logistic regression analyses are used 
to assess associations between subgroups and outcome, followed by multivariable logistic 
regression to adjust for potential confounders. We adjusted for baseline characteristics that 
were significantly different between the subgroups. Results are presented as odds ratios 
(ORs) with 95% confidence interval. P-values are considered significant if smaller than 0.05 
in context of a 2-sided test. The statistical analysis is carried out using IBM SPSS Statistics 21.0 
(SPSS Inc., Chicago IL, USA). 
results
Among the 2966 pregnancies enrolled in the Registry there were 212 patients with a MHV, 
134 patients with a THV and 2620 patients with NoPHV (Figure 1 and Table 1). MHV patients 
had mainly acquired valvular heart disease, while in other patients congenital heart disease 
was most common. MHV patients were more likely to be multiparous, and to have clinical 
signs of heart failure and atrial fibrillation prior to conception, while NYHA class was similar 
for MHV and NoPHV patients. 
184 Chapter 9
2966 
pregnancies in women with 
structural cardiac disease
Mechanical valve
212
Mitral 130
Aortic 48
Tricuspid 5
Aortic & Mitral 29
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1
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 No delivery reported due to 
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5
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110 (52%)
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 during pregnancy
2
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5
Maternal mortality 
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 0
No prosthetic valve
2620
figure 1 Flowchart of inclusion in the Registry Of Pregnancy And Cardiac disease
table 1: Baseline characteristics
 
 
Normal 
maternal 
population
Mechanical 
valve
No 
prosthetic 
valve
p-value 
mechanical vs no 
prosthetic valve
  n = 212 n = 2620  
Mean age (sd) 30 28.4 (±5.3) 29.3 (±5.7) 0.034
Nulliparous (%) 44% 66 (31.1) 1213 (46.4) <0.001
Pre-existent hypertension (%) 7% 6 (2.8) 176 (6.9) 0.023
Current smoker (%) 10% 4 (2.0) 103 (4.6) 0.087
Pre-existent diabetes (%) 1.8% 3 (1.4) 42 (1.7) 1.00
Prior cardiac intervention (%) <0.5% 212 (100) 1243 (47.5) <0.001
NYHA functional class 0.760
NYHA I (%) 156 (73.9) 1899 (73.8)
NYHA II (%) 50 (23.7) 584 (22.7)
NYHA III (%) 5 (2.4) 81 (3.1)
NYHA IV (%) 0 (0) 8 (0.3)
Clinical signs of HF (%) 0% 32 (15.1) 247 (9.6) 0.010
Left ventricular dysfunction (%) 8 (4.5) 116 (7.2) 0.183
AF before pregnancy (%) 22 (10.4) 46 (1.8) <0.001
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Pregnancy outcomes
Maternal mortality was higher for MHV (1.4%) than for NoPHV (0.2%, p=0.025), which in itself 
was much higher than in the non-cardiac pregnant population (Table 2). In patients with 
a MHV, two of the three deaths were directly prosthetic valve related due to MVT (patients 
1 and 2 in Table 4) and one to pre-existing poor LV function exacerbated by H1N1 flu at 24 
weeks. THV patients are further described below.
table 1: Baseline characteristics (continued)
 
 
Normal 
maternal 
population
Mechanical 
valve
No 
prosthetic 
valve
p-value 
mechanical vs no 
prosthetic valve
  n = 212 n = 2620  
Prior medication
Beta-blocker (%) <0.5% 33 (15.6) 311 (11.9) 0.114
Anti-arrhythmic (%) <0.5% 20 (9.4) 69 (2.6) <0.001
ACE-inhibitor (%) <0.5% 7 (3.3) 107 (4.1) 0.576
Diuretic (%) <0.5% 23 (10.8) 141 (5.4) 0.001
ACE indicates angiotensin-converting enzyme. AF = Atrial fibrillation. HF = Heart failure.  NYHA = New York 
Heart Association. 
table 2 Outcome of pregnancy until 1 week postpartum
 
 
Normal 
maternal 
population
Mechanical 
valve
No 
prosthetic 
valve
p-value 
mechanical vs. 
no prosthetic 
valve
  (n=212), n (%) (n=2620), n (%)  
Maternal mortality 0.007-0.043% 3 (1.4) 6 (0.2) 0.025
Maternal hospital admission 2% 77 (36.7) 621 (24.5) <0.001
Maternal hospital admission for cardiac 
reason
48 (22.6) 328 (12.5) <0.001
Cardiac
Heart failure 0% 16 (7.5) 345 (13.2) 0.018
Endocarditis 0.007% 0 (0.0) 6 (0.2) 1.00
Supraventricular arrhythmias <0.5% 6 (2.8) 47 (1.8) 0.285
Ventricular arrhythmias <0.5% 1 (0.5) 44 (1.7) 0.254
Thrombotic complication, total 13 (6.1) 10 (0.4) <0.001
Mechanical valve thrombosis 10 (4.7)
DVT 0.093% 0 (0.0) 3 (0.1) 1.00
PE 0.037% 0 (0.0) 1 (0.0) 1.00
iCVA 0.0009% 3 (1.4) 2 (0.1) 0.004
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Miscarriage before and fetal death after 24 weeks were both much higher in MHV than in 
NoPHV patients (Table 2) and the percentage of pregnancies ending with a live mother and 
child was significantly less with MHV (81.6%) than with NoPHV (97.7%, p<0.001). When all 
serious adverse events were considered, the chances of an event free pregnancy with a live 
birth was 58.0% for women with MHV and 78.1% for NoPHV (p<0.001). The assessment of 
adjusted ORs for the significant different outcomes are presented in Table 3. 
table 2 Outcome of pregnancy until 1 week postpartum (continued)
 
 
Normal 
maternal 
population
Mechanical 
valve
No 
prosthetic 
valve
p-value 
mechanical vs. 
no prosthetic 
valve
  (n=212), n (%) (n=2620), n (%)  
Hemorrhagic complication, total (%) 49 (23.1) 128 (4.9) <0.001
Major hemorrhagic event 32 (15.1) 81 (3.1) <0.001
Postpartum hemorrhage 1.2% 22 (10.4) 68 (2.6) <0.001
Obstetric
Pregnancy-induced hypertension 2.5% 0 (0.0) 64 (2.5) 0.014
(Pre-)Eclampsia 4% 0 (0.0) 67 (2.6) 0.018
Caesarean Section 23% 96 (46.6) 1212 (48.2) 0.668
Offspring
Miscarriage <24 weeks 12-15% 33 (15.6) 47 (1.7) <0.001
Fetal mortality ≥ 24 weeks 0.35% 6 (2.8) 15 (0.6) 0.003
Therapeutic abortion: maternal 
condition
2 (0.9) 9 (0.3) 0.197
Therapeutic abortion: fetal abnormalities 1 (0.5) 1 (0.0) 0.144
Apgar score < 7 1% 12 (8.0) 171 (7.6) 0.868
Preterm birth < 37 weeks 8% 29 (17.6) 364 (15.6) 0.506
Median pregnancy duration, weeks 
(Q1-Q3)
40 38.7 (37.3-39.4) 39.0 (37.7-39.9) 0.045
Median birth weight, gr (Q1-Q3)
3190
2900 (2600-
3080)
3050 (2700-
3400)
<0.001
         
DVT = Deep Vein Thrombosis. iCVA = Ischemic CerebroVascular Accident. PE = Pulmonary Embolism. Q1-Q3 = 
quartiles 1 to 3
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Thrombotic and hemorrhagic events 
Thrombotic events were significantly more common with MHV than with NoPHV and this 
difference was due to the occurrence of the very serious complication of MVT in ten pa-
tients (4.7%) (Table 4). There was no significant difference in the occurrence of MVT in mitral 
mechanical valves (4.4%) versus aortic mechanical valves (2.6%, p=1.00). MVT emerged at 
all stages of pregnancy and on every possible anticoagulation regime. However, 50% of the 
MVTs occurred in the first trimester and all these five patients had been switched from VKA 
to heparin in some form. No MVTs in the first trimester occurred in patients taking VKA. This 
difference was not statistically significant (MVT in 0% of patients on VKA, versus MVT in 3.6% 
of patients on some form of heparin, p=0.169).
Bleeding complications were also significantly more common in patients with MHV than 
with NoPHV (p<0.001), and were mainly around the time of delivery. Hemorrhage did not 
induce other adverse events such as heart failure, maternal mortality or fetal demise. 
Anti-Xa measurements in patients receiving LMWH were performed and reported in 57% 
of patients receiving LMWH. Most women (60%) had a target level of 1.0 to 1.2 U/ml, versus 
a minority who had a target level of 0.6-1.0 U/ml or 0.8-1.2 U/ml. The number of measure-
ments varied between 3 and 42 times. The percentage of measurements that were within 
the target range was 73%. Three patients experienced a mechanical valve thrombosis while 
having respectively three out of five, four out of five and four out of four anti-Xa measure-
ments within the target range.
table 3 Odds ratios for pregnancy complications in women with a mechanical valve compared to women 
without a prosthetic valve
  OR 95% CI adjusted OR* 95% CI
Maternal mortality** 6.3 1.6-25.1
Hospital admission 1.8 1.3-2.4 1.6 1.2-2.2
Hospital admission for cardiac reason 2.0 1.5-2.9 1.8 1.2-2.6
Heart failure 0.5 0.3-0.9 0.3 0.2-0.6
Thrombotic event** 17 7.4-39
All hemorrhagic event 5.9 4.1-8.4 5.2 3.5-7.6
Major hemorrhagic event 5.6 3.6-8.6 4.7 2.9-7.4
Postpartum hemorrhage 4.3 2.6-7.2 3.8 2.2-6.4
Miscarriage < 24 weeks 10 6.6-17 8.8 5.4-15
Fetal mortality ≥ 24 weeks** 5.1 1.9-13
*adjusted for baseline characteristics: maternal age, nulliparity, hypertension prior to pregnancy, signs of heart 
failure and atrial fibrillation; since there were 35 cases for miscarriage this OR was adjusted for nulliparity, signs 
of heart failure and atrial fibrillation
**due to limited number of events, no adjusted OR could be determined
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Anticoagulation regimes
The anticoagulants and regimes used are summarized in Figure 2 and Figure 3. Heparin, in 
some form, was the most commonly used medication in the first trimester. When UFH was 
used, it was usually given subcutaneously. Most women received VKA from 14-36 weeks and 
the majority of deliveries were covered with UFH. Only 7 women were on VKA at delivery 
and 5 of these were delivered by Cesarean Section (CS).  Two were delivered vaginally 
without an adverse event. The main difference between the regimes (Figure 3) was that 
the use of VKA during pregnancy resulted in fewer live births (p=0.026). Figure 4 depicts 
the association between anticoagulation in the first trimester and fetal mortality. The use 
of VKA in the first trimester was associated with a higher rate of miscarriage (28.6% versus 
9.2% in women receiving heparin, p<0.001) and late fetal death (7.1% versus 0.7%, p=0.016). 
Rates of miscarriage or fetal loss in high versus low dosage VKA (≤ 5mg warfarin or ≤2mg 
acenocoumarol or ≤3mg phenprocoumon) were not significantly different. Complications 
and their relation to the anticoagulant therapy used, is presented in Figure S1 in the online 
supplement.
Aspirin was used in the second and third trimester in only 13 patients in addition to other 
anticoagulation regimes. There were no patients administered on aspirin as monotherapy. 
MVT in the second or third trimester did not occur in the 13 patients (0.0%) on aspirin, while 
five of the 199 patients (2.5%) without aspirin (p=1.00) developed MVT. Hemorrhagic events 
occurred in eight patients (61.5%) on aspirin and in 41 patients (20.6%) without aspirin 
(p=0.002). 
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figure 2 Use of anticoagulants in patients with a mechanical heart valve during pregnancy
LMWH=Low Molecular Weight Heparin. UFH=Unfractionated Heparin. VKA=Vitamin K Antagonist.
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figure 3 Complications in mechanical heart valve patients on different anticoagulation regimes
The intended anticoagulation regime of 26 patients was unknown due to loss of pregnancy in the first trimester. 
Four of these patients had a thrombotic or hemorrhagic complication: 1 patient had a severe hemorrhage related to 
abortion, while receiving UH; 1 patient had a valve thrombosis while receiving UH; 1 patient had a valve thrombosis 
while receiving LMWH, 1 patient had an ischemic stroke while receiving UH. LMWH=Low Molecular Weight Heparin. 
UFH=Unfractionated Heparin. VKA=Vitamin K Antagonist.
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figure 4 Fetal mortality in relation to anticoagulation in the first trimester
LMWH=Low Molecular Weight Heparin. UFH=Unfractionated Heparin. VKA=Vitamin K Antagonist.
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Congenital abnormalities
Two neonates were diagnosed with congenital heart disease. One child of a woman tak-
ing VKA in the first trimester had a combination of atrial septal defect, persistent ductus 
arteriosus and pulmonary stenosis. The heart defect of the other neonate was not specified. 
Hydrocephalus occurred in two children (both mothers took VKA in the first trimester). One 
twin of a mother taking VKA in the first trimester had an unspecified congenital disorder. 
Taken together, congenital abnormalities were present in 6•8% of the live births of mothers 
receiving VKA in the first trimester versus 0•8% when they were receiving some form of 
heparin (p=0•055).
Developed versus emerging countries
There was a clear difference between the anticoagulation regimes used in the different 
parts of the world, with a preference for the use of UFH in any stage of the pregnancy in 
emerging countries (Table 5 and 6). 
Patients with a MHV in developed countries were admitted to the hospital more fre-
quently than patients in emerging countries, also for cardiac reasons. Patients from devel-
oped countries had more hemorrhagic complications, with a similar rate of postpartum 
hemorrhage in developed (11.8%) and emerging countries (10.3%, p=0.214). Patients with 
a MHV in developed countries were more often delivered by CS, which was often preterm 
and resulted in a lower birth weight. The rate of emergency CS was not statistically different 
(14.5% in developed countries and 7.7% in emerging countries, p=0.140). 
table 5 Outcome of pregnancy in women with a mechanical valve in developed and emerging countries
 
Developed countries Emerging countries p-value
(n=56, 26%), n (%) (n=156, 74%), n (%)  
Anticoagulation regimes* <0.001
VKA-VKA-VKA 2 (4.0) 4 (2.9)
VKA-VKA-LMWH/UFH 5 (10.0) 32 (23.5)
LMWH-LMWH-LMWH 14 (28.0) 4 (2.9)
UFH-UFH-UFH 2 (4.0) 19 (14.0)
LMWH-VKA-LMWH/UFH 19 (38.0) 13 (9.6)
UFH-VKA-LMWH/UFH 1 (2.0) 47 (34.6)
Other 7 (14.0) 17 (12.5)
Outcome
Maternal mortality 1 (1.8) 2 (1.3) 1.00
Hospital admission 30 (54.5) 47 (30.3) 0.001
Hospital admission for cardiac reason 18 (32.1) 30 (19.2) 0.048
Heart failure 5 (8.9) 11 (7.1) 0.768
Thrombotic events 6 (10.7) 7 (4.5) 0.110
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Tissue valves
Table 7 and 8 demonstrate the differences between patients with a MHV and patients with 
a THV. There was no significant difference in maternal mortality. However, the two cases of 
death in the MHV group were directly prosthesis related, while this was not the case in the 
THV group: there was one unexplained out of hospital arrest (ventricular fibrillation) and one 
death during emergency Caesarean section (CS) performed for fetal rather than for cardiac 
reasons.
Patients with a MHV had significantly fewer pregnancies resulting in a live mother and 
child than patients with a THV (81.6% versus 97.0%, p<0.001). The chance of a pregnancy 
free of serious adverse events was 58.0% for MHV, compared to 79.1% for women with a 
THV (p<0.001). Overall the risk of complications remained higher for MHV patients, after 
adjustment for baseline characteristics (Table 8).
table 5 Outcome of pregnancy in women with a mechanical valve in developed and emerging countries 
(continued)
 
Developed countries Emerging countries p-value
(n=56, 26%), n (%) (n=156, 74%), n (%)  
Valve thrombosis 5 (8.9) 5 (3.2) 0.134
Hemorrhagic events 23 (41.1) 26 (16.7) <0.001
Cesarean section 33 (64.7) 63 (40.6) 0.003
Miscarriage <24 weeks  6 (10.7) 27 (17.3) 0.243
Fetal mortality ≥ 24 weeks 0 (0.0) 6 (3.8) 0.344
Apgar < 7 7 (16.3) 5 (4.7) 0.039
Preterm birth < 37 weeks 19 (41.3) 10 (8.4) <0.001
Median birthweight (Q1-Q3) 2690 (2265 - 3035) 2945 (2715 - 3100) 0.001
Median pregnancy duration (Q1-Q3) 37.8 (35.1 - 38.9) 39.0 (38.0 - 39.6) <0.001
* regimes could only be determined if a patient had a live pregnancy beyond the first trimester 
   (n=50 in developed countries and n=136 in emerging countries)
 LMWH = Low molecular Weight Heparin. UFH = Unfractionated Heparin. VKA = Vitamin K Antagonist.
table 6 Odds ratios for complications in women with a mechanical valve in emerging countries, compared to 
those in developed countries
  OR 95%CI adjusted OR* 95%CI
Hospital admission 0.4 (0.2-0.7) 0.4 (0.2-0.8)
Hospital admission for cardiac reason 0.5 (0.3-1.0) 0.5 (0.2-1.0)
Hemorrhagic events 0.3 (0.1-0.6) 0.3 (0.1-0.5)
Caesarean Section 0.4 (0.2-0.7) 0.4 (0.2-0.8)
Preterm birth 0.1 (0.1-0.3) 0.2 (0.1-0.4)
Apgar<7** 0.3 (0.1-0.8) 0.4 (0.1-1.2)
*adjusted for maternal age, parity, signs of heart failure and hypertension
**due to limited number of events, adjusted only for gestational age
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table 7 Pregnancy in Women with a Mechanical versus a Tissue Valve
  Mechanical valve Tissue Valve
p-value 
mechanical 
vs tissue valve
Baseline n = 212 n = 134  
Mean age (sd) 28.4 (±5.3) 29.7  (±4.7) 0.029
Nulliparous (%) 66 (31.1) 60 (44.8) 0.010
Current smoker (%) 4 (2.0) 3 (2.8) 0.698
Clinical signs of HF (%) 32 (15.1) 5 (3.8) 0.001
Left ventricular dysfunction (%) 8 (4.5) 4 (4.1) 1.00
AF before pregnancy (%) 22 (10.4) 0 (0.0) <0.001
Outcome      
Maternal mortality (%) 3 (1.4) 2 (1.5) 1.00
Maternal hospital admission (%) 77 (36.7) 37 (27.6) 0.082
Maternal hospital admission for cardiac reason (%) 48 (22.6) 11 (8.2) 0.001
Cardiac
Heart failure (%) 16 (7.5) 11 (8.2) 0.823
Endocarditis (%) 0 (0.0) 1 (0.7) 0.387
Thrombotic complication, total (%) 13 (6.1) 1 (0.7) 0.013
Hemorrhagic complication, total (%) 49 (23.1) 7 (5.1) <0.001
Obstetric
(Pre-)Eclampsia (%) 0 (0.0) 4 (3.0) 0.022
Caesarean Section (%) 96 (46.6) 50 (39.4) 0.196
Offspring
Miscarriage <24 weeks (%) 33 (15.6) 2 (1.5) <0.001
Fetal mortality ≥ 24 weeks (%) 6 (2.8) 0 (0) 0.086
Apgar score < 7 (%) 12 (8.0) 8 (6.6) 0.664
Preterm birth < 37 weeks (%) 29 (17.6) 24 (19.2) 0.723
Median pregnancy duration, weeks (Q1-Q3) 38.7 (37.3-39.4) 38.3 (37.1-39.7) 0.911
Median birth weight, gr (Q1-Q3) 2900 (2600-3080) 2950 (2520-3250) 0.150
AF = Atrial fibrillation. HF = Heart failure. Q1-Q3 = Quartiles 1 to 3.
table 8 Odds ratios for pregnancy complications in women with a mechanical valve compared to women with 
a tissue valve
  OR 95%CI adjusted OR* 95%CI
Hospital admission for cardiac reason 3.3 (1.6-6.6) 3.7 (1.8-7.9)
Thrombotic event** 8.7 (1.1-67)
Hemorrhagic event 5.5 (2.4-12) 6.2 (2.6-15)
Miscarriage 12.2 (2.9-51) 11.0 (2.6-47)
*adjusted for baseline characteristics: maternal age, nulliparity, signs of heart failure and atrial fibrillation; since 
there were 35 cases for miscarriage this OR was adjusted for nulliparity, signs of heart failure and atrial fibrillation
**due to limited number of events, no adjusted OR could be determined
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discussion
In this large contemporary study of 212 women with a MHV, maternal mortality was 1.4%, 
pregnancy loss was 18.4%, valve thrombosis occurred in 4.7% of the pregnancies and 
hemorrhagic complications in 23.1%. Overall, serious complications occurred in over 40% of 
pregnancies in women with a MHV, which is significantly higher compared to other groups 
of cardiac patients. Anticoagulation regimes varied widely but none proved to be superior 
in all respects, however, regimes that included VKA use were associated with a lower live 
birth rate. 
Pregnancy outcomes 
The maternal mortality rate for women with a MHV in this Registry is 1.4%, a 30 to 200-fold 
increase when compared to the normal pregnant population (depending on the country 
from which the normal data were drawn). MVT is the most feared complication and oc-
curred in 4.7% of pregnancies and was associated with 20% mortality. This is consistent with 
the current literature, although the mortality and MVT rates vary in previous studies5,13-16. We 
found a relatively high percentage of hemorrhagic complications (23%) compared to other 
studies where rates of hemorrhage varied between 6 and 23%5,13,15,17. Fetal loss, on the other 
hand, occurred in 18.4% of all pregnancies, which is less frequent than expected, varying in 
literature from 24 to 65%5,13-15,17,18. This might reflect the reduction in VKA use in the past few 
years or that women who lost their child in the first trimester may have been underreported 
in our study. 
Developed versus emerging countries
The outcome of pregnancy in emerging and developed countries was quite comparable, 
regarding maternal and fetal survival and heart failure events. However, patients in devel-
oped countries were more frequently admitted to hospital and had more hemorrhagic 
complications. Hospital admission is expensive and rates might be influenced by financial 
factors and local facilities. The higher rate of hemorrhage was marked, which is just partly 
explained by the higher Cesarean section rate in developed countries, and may be related 
to anticoagulant use. 
The high frequency of preterm CS is an important observation. The current guidelines9 
suggest that Cesarean sections should be performed only for obstetric reasons, unless a 
patient is using VKA in the pre-delivery phase. This is relevant for an emergency CS, which, 
intriguingly, was not performed more frequently in developed countries. 
Anticoagulation 
In the previous literature, heparin, and specifically UFH, was associated with an increased 
thrombotic risk5. Closer examination of our data shows that 50% of the MVTs occurred dur-
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ing the first trimester and that these five patients were being treated with heparin. MVT did 
not occur in any patients on VKA in the first trimester. Although not statistically significant, 
these data are striking. In considering the balance of risk between valve thrombosis and 
hemorrhage, it is clear that MVT was the more serious complication, associated with an 
increase in both maternal and fetal mortality, whereas hemorrhage was not associated with 
such serious sequelae. 
The risk of miscarriage and late fetal death was clearly increased in women receiving VKA 
in the first trimester and in those receiving VKA throughout pregnancy. Although we found 
no difference in miscarriage rates between women receiving low and high dose VKA, there 
is one promising study showing that fetal loss might be lower in women who require a 
low VKA dosage to achieve effective anticoagulation19. This may be important for women 
with new generation aortic mechanical valves, with potentially less need for aggressive 
anticoagulation. However, more data are clearly warranted.
The current anticoagulant regimes differ considerably; despite this there is no clear 
evidence in support of one approach over another. The choice is often driven by physician 
experience and preference and sometimes by economic factors, forcing a choice for the less 
expensive UFH. Although several regimes have been recommended and advised by differ-
ent guidelines, our data do not suggest that one regime is definitively superior. Our study is 
particularly relevant as it reports the current treatments used in 40 different centers across 
the world. Despite the breadth of the study, it is still not possible to recommend a uniform 
approach for all patients. Due to the limited numbers of patients treated with aspirin, it is 
not possible to conclude whether the addition of aspirin is of any benefit. Conversely, it 
appears that the addition of aspirin to other forms of anticoagulation is associated with an 
increased risk of hemorrhage. If the risk of MVT or other thromboembolic complications 
were to be reduced by the addition of aspirin, then the greater risk of hemorrhage may be 
deemed to be acceptable, however as yet, there is no evidence of this.
Our results indicate a stark choice between a lower rate of thrombosis but a much higher 
rate of fetal loss when women remain on VKA in the first trimester, and a probable higher 
thrombosis rate (including MVT) but less fetal loss if they are switched to heparin for the first 
trimester. This decision can only be made by the mother with the aid of careful counseling. 
It is possible that frequent monitoring of peak and trough anti-Xa levels or activated partial 
thromboplastin time will mitigate the risks involved and make the switch to heparin the 
preferable course. Whichever regime is chosen, it is clear that this is a dangerous situation, 
which demands that anticoagulant control should be as near to perfect as possible20,21.
Choice of valve type in women of childbearing age
As previously shown, patients with tissue valves experienced less morbidity and less fetal 
loss than patients with mechanical valves during pregnancy22,23 and this should be discussed 
with women before valve replacement. Currently, the superior durability of a mechanical 
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valve often dominates the discussion7, but consideration should be given to a bioprosthetic 
valve, which would be safer in pregnancy and which could be replaced with a mechanical 
valve when it fails. However, if the availability of cardiac surgery is limited, then it may not 
be possible to offer women two valve replacements. Of course valve repair, when feasible, 
would be the best option. 
Study limitations
This study, as in all registries, provides an insight into the current situation for pregnant 
women with a mechanical valve. Although it is one of the largest studies, the sample size 
is still limited. 
The prospective nature of this study should prevent from selection bias. However, partici-
pation on voluntary basis can always introduce selection bias, which should be kept in mind 
while interpreting our results. 
The outcome of pregnancy in a normal population has been provided to illustrate dif-
ferences; however, as the percentages vary widely throughout the world, extrapolation 
needs to be done with caution. In addition, the relative contribution of individual countries 
to this Registry needs to be considered, however, the numbers of patients from different 
countries are too low for statistical analysis. Despite this, we have been able to show differ-
ences between emerging and developed countries in this and in a previous publication3. 
We aim to provide a global perspective, which, with local studies, will be invaluable in the 
development of future guidelines. 
Conclusions  
Patients with a MHV are at increased risk of maternal and fetal mortality and morbidity, 
particularly thrombotic and hemorrhagic complications during pregnancy. Half of the MVTs 
occurred in the first trimester and all of these on some form of heparin, while the use of 
VKA was associated with miscarriage and fetal death. Current anticoagulation regimes dif-
fer widely and, when considering both the outcome for both mother and fetus, none is 
clearly superior. The outcome of pregnancy in patients with a tissue valve is less hazardous, 
especially for the fetus. Women with a MHV should be counseled about the potential con-
sequences of pregnancy and receive extensive guidance and care throughout pregnancy, 
delivery and the postpartum period, from a specialized multidisciplinary team.
Online Supplementary Information
Figure S1 Complications and anticoagulation
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AbstrAct
In addition to the hemodynamic changes in pregnancy,  hormones also induce changes in 
the aortic wall. Women with diseases like Marfan syndrome, Ehlers-Danlos or other aortic 
abnormalities, have an increased risk of complications during pregnancy. Counseling and 
risk assessment prior to pregnancy is mandatory for all women with known aortic disease. 
Proper information should be provided about the risks of morbidity and mortality during 
pregnancy as well as information on the risks for the fetus, including the potential recur-
rence of disease in the offspring. Evaluation of past medical and family history, the aortic 
size prior to conception and any increase in size before and during pregnancy is essential to 
try and estimate the risk of aortic dissection. If the aorta is dilated, prophylactic repair prior 
to pregnancy may be indicated. In some cases elective surgery during pregnancy may be 
warranted. In patients with a severely dilated ascending aorta, caesarian section is at the 
moment the advised mode of delivery.
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introduction
In young women the occurrence of an aortic complication is fortunately rare, with a re-
ported incidence in the general female population under  45 years of age of 0.4 per 100.000 
person years 1. When acute aortic dissection (AOD) occurs in a person under the age of 40, it 
is frequently caused by an underlying disorder such as Marfan syndrome (MFS) or a bicuspid 
aortic valve (BAV). In this young-age group aortic dissection has a mortality rate of 22%, 
which is similar to the mortality rate in those over 40 years old 2. 
In pregnancy, there are hemodynamic adaptations that influence the vascular system, 
including the aorta. The major cause of maternal mortality in the United Kingdom between 
2006 and 2008 was cardiac disease, with 2.31 deaths per 100.000 maternities. Although the 
incidence of aortic dissection is low, it was one of the most important causes of cardiac death 
3. A challenging situation exists for patients at risk of aortic complications who contemplate 
pregnancy. Moreover, some patients may have AOD during pregnancy as the first presenta-
tion of their aortic disease. High risk patients with known aortopathy reaching reproductive 
age should be counseled about the risks of pregnancy. They should be referred to a tertiary 
center for the purpose of surveillance during pregnancy and management of delivery. 
GenerAl recommendAtions And Guidelines
Taskforces have made great efforts to provide recommendations on this important topic 4,5. 
The two most recent provide helpful advice on how to manage women with aortopathy, 
but prospective studies are needed to assess and provide better data to support the recom-
mendations. The Registry of Pregnancy And Cardiac diseases (ROPAC) is currently the largest 
worldwide prospective study on pregnancy in patients with cardiac disease and includes 
women with aortopathy. The registry is still ongoing 6. 
effect of PreGnAncy on the AortA 
The aorta is subject to structural and functional changes throughout pregnancy. Cardiac 
output, heart rate and circulating volume increase, causing the aortic size to increase. The 
aortic size is also related to hemodynamic conditions and varies in dimension with condi-
tions such as preeclampsia 7. The hormonal changes in pregnancy influence connective 
tissue, changing the microstructure of the medial layer. Analysis of histopathology of the 
tunica media reveals hypertrophy and hyperplasia of smooth-muscle cells and fragmenta-
tion of reticulin which normally surrounds elastic fibers 8. Subsequently, elastic fibers lose 
their organized structure, changes which are most notable in late pregnancy. 
206 Chapter 10
The above effects of pregnancy on the aorta explain why pregnancy itself is thought 
to be a risk factor for acute aortic dissection, although this topic is subject to debate and 
contradictory reports exist. A population based study in Sweden reported on pregnancy 
related AOD, being responsible for 60% of all AOD in young women with a 25-fold increased 
risk of dissection during pregnancy 9, however another population based report in Austria 
demonstrated no increase in risk of aortic dissection 1.  In these population based studies the 
difference in reported outcomes and risk of AOD might be related to different observation 
periods (1987-2007 versus 1994-2004) and the small absolute total numbers of dissections 
(29 versus 15). It is however clear that patients with an increased risk of aortic dissection are 
those with connective tissue diseases such as Marfan syndrome, Ehlers-Danlos  and other 
genetic conditions pre-disposed to developing thoracic aneurysms and aortopathy. Aortic 
abnormalities in the context of bicuspid aortic valves will be reviewed elsewhere.
Pre-concePtionAl counselinG
Every patient at increased risk of aortic complications, including patients with known Marfan 
syndrome, Ehlers-Danlos syndrome (EDS), Loeys-Dietz syndrome (LDS) or familial thoracic 
aorta dissection syndrome (FTAAS), should be counseled prior to pregnancy. Preferably, 
counseling should be done once a female patient reaches reproductive age. Maternal and 
fetal risks should be discussed, as well as recurrence risk of the disease in the offspring and 
of the possible effect of medication use. It is also important that patients are made aware 
of the value of CT and MRI imaging of the aorta prior to pregnancy, because the results if 
abnormal may mean that pregnancy is inadvisable or elective aortic surgery is warranted 4,5. 
The risk of aortic dissection is most likely due to a combination of pregnancy effects, pre-
existance of an abnormal aortic wall and an increased aortic size at baseline. Hypertension 
is a significant risk factor in a healthy patient affected by an aortic dissection, but is less 
common in younger patients suffering from aortic dissection during pregnancy 2.  
PrenAtAl diAGnosis
The recurrence risk of Marfan, Ehlers-Danlos and Loeys-Dietz syndrome is 50% in the off-
spring, due to an autosomal dominant inheritance pattern in all of these conditions. If the 
disease-causing mutation in a family has been identified, then prenatal testing is possible 
using chorion villus sampling or amniocentesis (cell culture) providing information on the 
presence or absence of the mutation 10,11. However, in Marfan syndrome the mutation does 
not predict the severity of the clinical disease spectrum and moreover sampling is associ-
ated with a 1% risk of miscarriage. Foetal echocardiography is therefore an alternative lower 
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risk diagnostic tool looking for atrioventricular valve regurgitation and dilatation of the 
aortic root and pulmonary artery 12. However, this technique is not 100% predictive.
sPecific diseAses
Marfan
Marfan syndrome is a connective tissue disorder with an autosomal dominant inheritance 
pattern, with an incidence of 2-3 per 10.000 in the general population. The mutation affects 
the Fibrillin gene (FBN-1), the gene encoding extracellular matrix protein or glycoprotein 
fibrillin-1 on chromosome 15. In patients with Marfan syndrome, approximately 75% have 
a family history; the other quartile have a sporadic or de novo mutation. There is recent 
evidence that excessive signaling of TGF-β (transforming growth factor B) is also associated 
with Marfan syndrome and these findings might play a key role in future treatment strate-
gies 13,14. 
The mutation of FBN-1 causes a decrease in the amount of elastin and also loss of the 
organized structure of elastin itself 15. The subsequent weakness of the supportive tissue 
affects the cardiovascular system (aorta, AV valves and conduction system), skeletal system, 
eyes and the dural sac of the spinal cord). Since there are more than a 1000 different muta-
tions known, the diagnosis is based on a combination of clinical criteria and genetic findings 
as described by Loeys et al, in the revised Ghent nosology. Other important factors to be 
taken into account include a family history of AOD, aortic root aneurysm, ectopia lentis, an 
identifiable FBN-1 mutation or a combination of systemic manifestations 16. Cardiovascular 
involvement is present in 80% of cases with aortic dilatation, aortic regurgitation and mitral 
or tricuspid valve prolapse with or without regurgitation all being seen. Cardiac complica-
tions are the main cause of morbidity and mortality although life-expectancy has improved 
dramatically in the past two decades, mainly due to the treatment with elective cardiac 
surgery.
Maternal risk
Numerous retro- and prospective reports on the maternal outcome of pregnancy in pa-
tients with Marfan syndrome is available. Table 1 presents an overview of the reported rates 
of aortic dissection 17-24. The outcomes vary, partly because treatment has changed over 
the years. More women are treated with beta blockers or undergo elective aortic root re-
placement prior to pregnancy. In addition, some studies included only women with known 
Marfan syndrome, while others retrospectively included those diagnosed during pregnancy 
when they presented with a complication (aortic dilatation or dissection). Subsequently, it 
seems that nowadays the dissection rate is relatively low.
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The first large report (retrospective study) on maternal risks was published by Pyeritz 17, 
who demonstrated a low risk of dissection during pregnancy in women with MFS. Since 
this was the first large study of its kind, the recommendations in this article have long been 
accepted into clinical practice to guide management, whereby pregnancy is discouraged 
when the aortic diameter exceeds 40-45 mm. These recommendations were further sup-
ported by 2 reports in the nineties: when the aortic diameter is smaller than 40mm the risk 
of dissection is approximately 1% in what was the first prospective study 18, while an aortic 
root diameter exceeding 40mm was associated with a 10% risk of aortic dissection 19. 
More recent studies, one of which was prospective, demonstrated a low risk of AOD if the 
aortic diameter was less than 45 mm 21,23. A low risk was also confirmed in a recent, smaller 
prospective study 24 describing patients managed according to the French guidelines. From 
these studies it would appear that the risk of aortic dissection is higher in patients not 
previously diagnosed before pregnancy and therefore were not managed according to the 
guidelines. This highlights the importance of recognition of the disease signs and its early 
diagnosis along with family screening programs for genetic disorders.  
Aortic diameter growth during pregnancy
The aortic diameter is known to increase during pregnancy particularly in a hypertensive 
state 7. Progressive aortic dilatation and dissection outside pregnancy is predicted by the 
aortic diameter itself 25-27. Several studies have focused on the potential growth of the 
aorta during pregnancy in Marfan patients. Rossiter prospectively observed 21 women with 
Marfan syndrome during 45 pregnancies and compared them to a control group of non-
pregnant Marfan patients. The aortic diameter did not increase in size faster in the pregnant 
group 18 but an important limitation of this study is that the reason for not embarking on 
pregnancy in the control group was not documented, so selection bias might be introduced 
with potentially more severe disease manifest in the non-pregnant group. 
Meijboom described 33 pregnancies in women with Marfan syndrome with an aortic 
root diameter equal to or smaller than 45mm 21. Their control group consisted of 22 age-
matched female childless Marfan patients. No evident aortic root growth was reported 
when compared to the control group, apart from a mildly increased growth of the aortic 
root during long-term follow-up, in the patients who had a diameter of the root equal to or 
more than 40 mm at baseline.
A similar comparative study 28 divided Japanese pregnant patients with Marfan into an 
event group and a non-event group. Aortic dilatation of more than 60mm in any part of 
aorta or dissection were considered events. The aortic diameter increased by 0.41 mm per 
month in the event group, versus 0.05mm (P<0.005) in the non-event group. The study 
did not report however on long-term outcome, i.e. whether the diameter decreased after 
pregnancy.
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The largest study by Donnelly et al compared patients with Marfan in 199 pregnancies 
with nulliparous Marfan patients 23. An increase of 3 mm in aortic diameter was seen dur-
ing pregnancy. Post-pregnancy the diameter decreased, but without full recovery during 
follow-up, up to 5 years, post-delivery. 
In these 4 studies the evidence for an increase in aortic diameter is contradictory. Draw-
ing firm conclusions is also made difficult because of a variable use of beta blockers and 
different follow-up duration. However there is some suggestion that aortic diameter growth 
could be partially irreversible. 
Long term outcome
Life expectancy in Marfan patients has substantially increased and was up to 72 years in 
1995. Although large series are still scarce, the literature shows that use of the current guide-
lines confers a favorable outcome in pregnancy in MFS, however evidence on long term 
outcome is needed. Donnelly et al found an increase of risk over the longer term (average 
about 5 years) with death, aortic dissection, severe symptomatic aortic regurgitation and 
need for urgent surgery defined as adverse outcomes in their study. Predictors of these 
outcomes are summarized in Table 2 23. 
Obstetric and fetal outcome:
The miscarriage rate in the normal population ranges from 10-20% before 20 weeks gesta-
tion. This rate can be higher in MFS with some patients experiencing habitual abortions 29. 
An important cause of fetal and neonatal morbidity and mortality is prematurity, which is 
the result of premature rupture of membranes (PROM). PROM occurs more often in Marfan 
patients: approximately 5% has been reported. There is a strong suggestion that if the 
fetus has connective tissue disease the integrity of the membranes is weakened causing 
a greater risk of preterm rupture 30. Small-for-gestational-age is also seen more frequently, 
with the frequent use of beta blockers implicated 17.  It appears that the obstetric outcome 
table 2 Risk factors for long term outcome after pregnancy in women with Marfan syndrome 
Associated factors with long term adverse outcome: Odds ratios
Aortic size 1.3 (1.11-1.61)
Number of pregnancies 1.5 (1.15-1.97)
Prospective care 0.1 (0.05-0.39)
Medication 0.3 (0.14-0.92)
Aorta>4cm 3.8 (1.11-13.3)
Independent correlates:
Initial aortic size 1.8 (1.07-3.07)
Rate of aortic change (log) 7.4 (1.32-41.22) 
Modified from: Donnelly et al23
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of patients diagnosed with Marfan after pregnancy, is no different from those with known 
Marfan syndrome 29. 
Ehlers-Danlos
The syndrome of Ehlers-Danlos is an autosomal dominant inherited disease. It is how-
ever more rare than Marfan syndrome with an incidence of approximately 1:5.000 31. The 
Villefranche classification consists of six different types: classical, hypermobility, vascular, 
kyphoscoliosis, arthrochalasia and dermatosparaxis EDS 32. The disease is characterized by 
hypermobility of large joints, hyperelastic skin, tissue fragility, easy bruising and poor wound 
healing. The vascular type is the most severe form of the syndrome. It is associated with a 
mutation in the gene for type III procollagen, 50% of which is a de novo mutation. This type 
of EDS involves the cardiovascular system and features like hypermobility and hyperelastic-
ity are less frequently seen. Patients suffering from the vascular type have an increased risk 
of aortic dissection, often not preceded by aortic dilation. Surgery is difficult due to the 
features associated with the disease, such as tissue fragility. There is also an increased risk 
of uterine rupture and hemorrhage peripartum. Consequently pregnancy is high risk with a 
peripartum mortality of 12% reported due to arterial or uterine rupture 33. 
Turner
Turner syndrome occurs in 1 per 2000 female births 34 and is caused by complete or partial 
monosomy for the X chromosome. It is characterized by short stature and premature ovar-
ian failure, but also associated with a variety of congenital heart diseases and aortic pathol-
ogy. Cardiovascular and aortic complications are the main reason for premature mortality 
in women with Turner syndrome. The highest prevalence of AOD is seen in women aged 20 
to 39. No information on previous gravidity was available in this study 35.  The risk of aortic 
dissection appears to be elevated by approximate 100-fold in TS 36, which might be partly 
related to the higher incidence of a bicuspid valve present in 20-30% of patients, as well as 
coarctation of the aorta (found in 12% of cases). In addition aortic arch abnormalities are 
described in up to 50% of patients. A recent cardiac magnetic resonance (CMR) imaging 
study of 102 Turner patients found an association between the aortic diameter and aortic 
growth with coarctation and bicuspid aortic valve 37. The aortic dilatation in TS tends to 
involve the ascending aorta.  Specific echo views are needed to image this region but CMR 
or CT can also assess this region along with the whole aorta so are useful assessment tools. 
It is important that all aortic measurements are adjusted for body surface area. One study of 
158 TS patients with a follow-up duration of 3 years showed 3 aortic dissections occurring 
in women all with a preexisting aortic diameter of larger than 25 mm/m2 and an abnormal 
aortic valve 38.
Infertility due to premature ovarian failure is an important clinical feature in Turner pa-
tients, although some mosaic Turner patients may be fertile. Subsequently, patients often 
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seek assisted conception with oocyte donation. There is limited data on the long-term 
cardiovascular risks associated with these treatments 39,40. A review of reported cases of 
AOD revealed a 58% mortality rate in Turner patients. Specifically 7 AOD during pregnancy 
have been described, causing 6 maternal deaths 41. Two retrospective national studies 
reported on mortality outcome in pregnancy. A French study showed 2 AOD, both fatal, 
in 93 pregnancies resulting from oocyte donation. Patients had not been treated using the 
recommended guidelines 42. More recently no AOD were reported in 124 deliveries in TS 
patients in Denmark 43. The exact incidence of AOD in pregnancy is not accurately defined, 
but mortality rate is definitely increased. Overall maternal mortality during pregnancy is 
estimated at 2% 44.
Other aortic syndromes
Other less common syndromes with a potential high risk for aortic dissection are Loeys-Dietz 
syndrome, Aneurysm-Osteoarthritis Syndrome (AOS) and Familial Thoracic Aortic Aneurysm 
and Dissection. The number of women with these syndromes contemplating pregnancy is 
unknown, but they are all associated with a high risk of dissection. 
Loeys-Dietz syndrome is caused by mutation of the genes TGFBR1 or TGFBR2 and shows 
some overlap with other syndromes of thoracic aortic aneurysm and dissection, such as 
vascular Ehlers-Danlos and Marfan syndrome. It is characterized by arterial tortuosity, hyper-
telorism and bifid uvula, along with a large range of other features 11. The mean age of death 
is 26 years, due to the vascular complications. Pregnancy has been reported in a few case 
reports 45,46. In addition Loeys et al described 21 pregnancies in 12 women with LDS. During 
pregnancy or postpartum there were 4 AOD and two uterine ruptures 47. 
Thoracic aneurysms resulting from SMAD3 mutations have been recently described often 
presenting with early-onset osteoarthritis, named Aneurysm-Osteoarthritis Syndrome. It is 
a spectrum consisting of arterial aneurysms, dissections and tortuosity, accompanied by 
skeletal, craniofacial and cutaneous features. The mutations are located on chromosome 
15q22.2-24.2 and are allied with the TGF-β pathway 48,49. AOS appears to be an aggressive 
phenotype, with AOD occurring in vessels with even smaller diameters than Marfan syn-
drome. With regard to the aortic size where there is increased risk of AOD it is similar to LDS 
where AOD can occur even with normal aortic root dimensions 49. Pregnancy outcomes 
have not been reported yet.
Familial Thoracic Aortic Aneurysm and Dissection syndrome is associated with a variety 
of gene mutations, and there is little data on pregnancy outcomes in this condition, they 
are however high risk and should be managed in the same way as other fragile aortic syn-
dromes 5. 
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folloW-uP
For all patients with aortopathy or fragile aorta’s blood pressure control must be optimal. 
Monthly review with echo evaluation of the aortic root diameter each trimester and prior to 
delivery is recommended. If the aortic arch or thoracic aorta is at risk MRI should be used. It 
is safe in the second and third trimester of pregnancy 50. Computed tomography should be 
avoided during pregnancy because of radiation exposure. 
The frequency of echocardiography will depend upon the nature of the underlying aor-
topathy and baseline aortic root size. If the aortic diameter is larger than 40 mm, or there is 
progressive aortic dilatation, a history of surgery or previous AOD it is justifiable to perform 
echocardiography every 4 to 8 weeks. If there is rapid progressive aortic dilatation, a diam-
eter exceeding 50 mm or aortic valve regurgitation, surgery during pregnancy may need to 
be considered. If the foetus is viable a caesarian section delivery should be undertaken prior 
to surgical intervention. The definition of rapid is not clear, but we would suggest aortic 
growth of more than 3-5 mm as significant 4,5. 
medicAtion
Retarding or preventing aortic dilatation is very important in patients with a fragile aorta. 
Current guidelines recommend using beta blockers as there is some evidence that beta 
blockers reduce aortic growth in pregnant Marfan patients 7. Beta blockers might contribute 
to slowing aortic root absolute growth and a reduced rate of complications such as aortic 
regurgitation, aortic dissection, cardiovascular surgery, congestive heart failure and death. 
Although it should be noted that evidence is limited and controversial 51. More research is 
needed to support the current use of beta blockers during pregnancy.
Easterling et al 7 found evidence for the benefit of atenolol in this perspective. However 
atenolol appeared to have an adverse fetal outcome, causing intrauterine fetal growth re-
striction 52. Other common side effects of beta blockers are fetal bradycardia and hypogly-
cemia. Propranolol can also be considered as it decreases both aortic growth and risk of 
dissection 53. Adverse effects in general are less common with propranolol or metoprolol so 
they are preferred for use in pregnancy54.  
In non-pregnant EDS patients a randomized controlled trial using celiprolol has been 
published. Celiprolol was given to 25 patients and outcomes compared with a control 
group of 28 patients, taking no medication. The trial showed a definite benefit of celiprolol 
with an incidence of arterial events in 20% of treated patients, versus 50% in the control 
group. No data exists with regards to the use of celiprolol in pregnancy in this patient popu-
lation 55. If beta blockers are used, the fetus will need more frequent growth scans to detect 
intrauterine growth restriction.
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Some authors state, beta blockers should be given in such dosage, that heart rate is 
minimized to a resting heart rate of below 60 beats per minute, or at least a decrease of 
20% 12. However, again no good data are available during pregnancy and the negative fetal 
effects of beta blockers must also be considered. Goland et al report on the excretion of 
beta blockers in breast milk and found the effects on the infant were not significant, unless 
there is a diminished hepatic function.
In MFS there is evidence that angiotensin-converting enzyme (ACE) inhibitors 56 and 
angiotensin receptor blockers (ARBs) are beneficial both reducing aortic growth 57,58, the 
latter due to the inhibitory effect on TGF-β. Currently both these drugs are contra-indicated 
during pregnancy, because of potential adverse effects for the fetus, including congenital 
malformations, intrauterine growth restriction, oligohydramnios and renal failure. A recent 
study however, has shown that ACE-inhibitors and ARBs, when used in the first trimester 
were not major teratogens and hypertension per se was as important in determining fetal 
outcome and not necessarily the medication 59. It is therefore suggested by the authors in 
this particular paper that these medications are relatively safe and can be continued until 
pregnancy is confirmed. 
The treatment of acute AOD is emergency surgery with adjunctive medical therapy to 
lower blood pressure. Medical therapy includes the use of intravenous beta blockers such 
as labetalol or metoprolol with additional hydralazine if needed 5,12. 
elective intervention Prior to or durinG PreGnAncy
For any patient with an aortopathy or fragile aorta syndrome imaging of the whole aorta is 
recommended prior to pregnancy.  Elective surgical aortic root replacement in non-preg-
nant patients is of significantly lower risk with a 30 day mortality of 1.5% compared to 11.7% 
in an emergency procedure 26. Exact numbers for surgical mortality in pregnant patients are 
lacking, but repair should preferably take place outside pregnancy.
Current guidelines advise elective aortic root replacement in Marfan patients if the 
aortic diameter exceeds 50 mm or 45 mm if there is a family history of aortic dissection. If 
pregnancy is considered, conception probably should be dissuaded until pre-pregnancy 
prophylactic surgery is performed. If there are additional risk factors such as a family history 
of AOD or for those with Loeys Dietz syndrome 11, some authors suggest the threshold for 
intervention should be less at an aortic diameter of 40 mm. In other patients pre-pregnancy 
surgery can be deliberated if the diameter exceeds 50mm, for instance in patients with a 
bicuspid aortic valve. In particular in Turner patients the diameter has to be adjusted for 
body surface area. Current guidelines advise prophylactic surgery in a diameter of larger 
than 27 mm/m24,5. General recommendations are summarized in Table 3. It must be borne 
in mind that prophylactic surgery before conception does not lower the risks of AOD to the 
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level of the normal population 4 and indeed there is no absolute safe diameter in patients 
with a fragile aorta. In addition, the risk of surgery in patients with Turner and especially 
Ehlers-Danlos syndrome is higher due to tissues being generally more friable with poor 
wound healing. A decision to proceed to surgery must therefore carefully be considered 
and the balance of risks discussed with the patient.
If the aortic size increases rapidly during pregnancy or if the root is over 50mm at pre-
sentation a multidisciplinary team should plan further management, depending on the 
underlying diagnosis, progression in aortic size and the viability of the child. If the fetus is 
viable, a caesarian section prior to cardiac surgery should be considered. Exact timing and 
sequence of delivery and thoracic surgery has not been specified yet. If cardiac surgery 
is going to be performed with the fetus in situ, the patient needs to be informed of the 
risks. Pomini states that hypothermia can induce uterine contractions and reduce placental 
blood flow, while rewarming can provoke uterine contractions and premature labor 60. It is 
therefore advised that cardiopulmonary bypass is undertaken in normothermic conditions, 
left lateral decubitus position, while monitoring fetal heart rate and tocometry. Further-
more a higher pump flow is needed to maintain placental perfusion 61. In anticipation of a 
possible preterm delivery, corticosteroids should be administered to accelerate fetal lung 
maturation 62. 
mAnAGement of Aortic dissection durinG PreGnAncy
There are several reports of a successful maternal outcome in AOD in pregnancy, although a 
publication bias of successful cases may exist. Zeebregt et al reported on the management 
and outcome of 6 patients presenting with acute AOD in pregnancy. Four presented with 
type A dissection, and two patients had undergone emergency caesarian section delivery 
immediately followed by thoracic surgery, with a favorable outcome for both mothers, 
table 3 Indications pre-pregnancy surgery and Caesarian section4,5
Syndrome
Indication
Pre-pregnancy Elective Surgery
Indication
Caesarian Section
Marfan ≥ 45 mm ≥ 45 mm
Ehlers-Danlos ≥ 45 mm all
Turner ≥ 27 mm/m2 ≥ 27 mm/m2
Loeys-Dietz ≥ 45 mm ≥ 45 mm
AOS ≥ 45 mm ≥ 45 mm
Others like associated BAV ≥ 50 mm ≥ 45 mm
AOS = Aneurysm-Osteoarthritis Syndrome
BAV = Bicuspid Aortic Valve
Level C evidence applicable for all recommendations 
216 Chapter 10
although only 1 infant survived. Two women had cardiac surgery performed with the  fetus 
in situ: one had caesarian section (CS) delivery 5 days after repair and the other had CS 16 
weeks after repair. Both infants survived.  Two women with type B AOD were managed 
medically without surgical intervention and survived but in both cases, the fetus’s died from 
asphyxia. The authors suggested that based on their reported outcomes, management 
should be individualized taking into account the gestational age of the fetus 63. A review of 
literature overall 64 shows that outcomes have improved in the past few decades. 
In a more recent review, Goland reported pregnancy complications in MFS. Of the pa-
tients described, 18 had a type A AOD during pregnancy. One fetus died before surgery and 
there was one maternal death post cardiac surgery, with subsequent death of the fetus as 
well 12. A combined maternal and fetal death occurred in a patient having aortic repair with 
the fetus in utero 65. 
The management of acute aortic dissection should follow the current guidelines for 
thoracic aortic disease 5, where emergency surgery is indicated for type A dissection. The 
management of acute type A AOD in pregnancy poses more of a challenge as both mother 
and fetus are at risk but in most cultures the health of the mother is prioritized over that 
of the unborn infant and this determines the management strategy. Reported maternal 
and fetal mortality after surgical repair of type A dissection is improving, however rates are 
difficult to estimate as the literature consists of case reports and small series. Acute type B 
AOD during pregnancy (Figure 1) is usually managed medically with blood pressure control, 
unless there is a state of malperfusion or aortic rupture 4,5. 
delivery
Patients with dilatation of the aorta should deliver in a center with cardiothoracic surgery. In 
general, vaginal delivery is appropriate in selected low risk patients with an aortic diameter 
figure 1 Type B dissection during pregnancy in Marfan syndrome
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less than 40mm. Epidural anesthesia and forceps or ventouse to assist the second stage 
is recommended. The optimal mode of delivery is not clear if the aortic root diameter is 
between 40 and 45mm: in the European guidelines a class IIa indication is given for a vaginal 
delivery and IIb for caesarian section 4. If the aorta is exceeding 45mm or if there is a severe 
aortic valve regurgitation, a caesarian section is advised. However, this is not based on solid 
data, but merely on expert opinion. An advantage of caesarian section is the possibility to 
plan the operation during working hours with all possible experts available. In addition cae-
sarian section is advised in all patients with vascular EDS to limit the risk of uterine rupture 4,5. 
Epidural anesthesia can be more difficult in Marfan patients due to the presence of dural 
ectasia.  This is caused by altered elastin composition of the dural sac. It is often asymptom-
atic, but will impede epidural anesthesia techniques 66. If a lumbosacral MRI has not been 
performed prior to delivery a lumbar spine ultrasound may be helpful in guiding epidural 
catheter placement.
A recent retrospective study on the anesthetic management of delivery in 15 Marfan 
patients, reported on neuraxial and general anesthesia. The authors state there is no 
evidence to support superiority of general anesthesia with opioids to titrated (combined) 
spinal-epidural anesthesia, however the final decision regarding mode of analgesia should 
be made based upon the experience and expertise of the anaesthetist involved in the care 
of the patient 66. 
summAry
The management of the patients with aortopathy and a fragile aorta is challenging and 
these conditions are all high risk in pregnancy. Pre-conceptional counseling is the first 
very important step making the patient aware of the risks of aortic dissection, based on 
both type of aortic disease or genetic predisposition, family history as well as the aortic 
diameter. Frequent follow-up is needed during and after pregnancy to evaluate aortic size. 
Cardiologists, obstetricians, cardiothoracic surgeons and anesthesiologists should collabo-
rate closely with a consensus on best management on an individualized case by case basis. 
Maternal and fetal outcomes are improving with better medical and surgical care and more 
adherence to guidelines. Nevertheless, there is a necessity for more research as current 
series are small. Multi-national and multi-centre prospective studies with adherence to the 
guidelines would supply us with more detailed and accurate information about and how to 
improve outcomes, risk and prognosis. Also, the advantages and disadvantages and dosage 
of medical therapy should be the focus of future research. 
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AbstrAct
Introduction Turner syndrome (TS) is associated with subfertility and infertility. Neverthe-
less, an increasing number of women become pregnant through oocyte donation. The 
wish to conceive may be negatively influenced by the fear of cardiovascular complications. 
The aim was to investigate the wish to conceive and the concerns about cardiovascular 
complications during pregnancy in women with TS.
Methods The patient association for TS invited all members of ≥18 years old (n=344) to 
complete a specifically developed, disease-specific questionnaire, including questions 
about fertility, wish to conceive, attempts and concerns. Results were compared with previ-
ously published results of this questionnaire in women with congenital heart disease.
Results The questionnaire was completed by 89 women (median age 30.1 years, Q1–
Q3=22.9–39.4). Of them, 51% had 45, X0-monosomy and 38% had ≥1 cardiac abnormality. 
Seventeen women (19%) had attempted to become pregnant and 12 of them succeeded 
to become pregnant. Women who had not undertaken attempts to conceive (81%), con-
sidered themselves mainly too young or had no partner. Of the total sample, 58% were 
concerned about the influence of pregnancy on their cardiovascular status. This was higher 
(75%) in the sample of women with TS and cardiac  abnormalities, than in women with 
congenital heart disease from a previously published cohort (21%), (p<.001). There were 
no differences in concerns about pregnancy complications between women with TS who 
respectively had or had not attempted to become pregnant.
Discussion Women with TS, especially those with cardiac abnormalities, show serious con-
cerns about the risks pregnancy may have. Patients should be timely counseled and specifi-
cally asked about their concerns. Psychosocial care should be provided when necessary.
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introduction
Turner syndrome (TS) is caused by a partial or total monosomy of the X-chromosome. One 
in 2000 live born girls is affected1,2. TS is characterized by short stature, webbed neck and 
gonadal dysgenesis. The phenotype varies considerably and some women have barely 
dysmorphic features. Awareness of TS from several disciplines has increased in the past 
decades and in the Netherlands it resulted in a multidisciplinary approach which is now 
part of standard care3. Cardiac or aortic abnormalities are present in 30–40% of women with 
TS1,4,5. Pregnancy in women with TS is an important challenge due to the gonadal dysgen-
esis, which may lead to premature ovarian failure. Only a small minority of women with TS 
is able to conceive spontaneously. Nevertheless, since oocyte donation became available, 
pregnancy became possible for a larger group of these women. The risk of complications 
during pregnancy in women with TS is suggested to be increased, in particular the risk of 
aortic dissection6. Pregnancy is assumed to decrease the integrity of the aortic wall7. The loss 
of structure may have deleterious consequences in women with an aortic syndrome and 
associated preexistent wall abnormalities. Several reports have described aortic dissection 
during pregnancy in patients with TS8,9. It is important to address this when counseling 
these women. So far, it is unknown how many women with TS are hesitant to become 
pregnant due to their knowledge about this specific cardiovascular risk during pregnancy.
The wish to conceive and concerns regarding pregnancy are rather unexplored and 
neglected field. Whether one wants to have children or not and concerns in this domain, 
are crucial subjects in a woman’s life. The surplus value of this study is that by gaining more 
specific knowledge on essential themes, counselling of women with TS can be attuned 
more to these women’s wishes. 
Since the past two decades the possibility to conceive increased and evolved in this group 
of women, the present study aims to investigate how many women with TS have a wish to 
conceive and how many actually undertake attempts to conceive. Also, the concerns and 
fear for cardiovascular complications during pregnancy are assessed.
methods
This is a cross-sectional observational study organized together with the Dutch patients 
association for women with TS (“Turner Contact Nederland”). All adult women with TS, who 
were the members of the association, were approached by the association in November 
2014. After giving informed consent, participants received a questionnaire. The medical 
status of all participants was checked to retrieve data on karyotype, cardiac abnormalities 
and conception or pregnancy outcomes. Institutional review board  approval was obtained 
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(MEC-2014–457). The study was conducted according to the Declaration of Helsinki (version 
October 2013).
Data
A validated questionnaire about concerns and fear for potential pregnancy complications 
in this specific group is lacking. Hence, we based our questionnaire as much as possible on 
an existing questionnaire for patients with congenital heart disease, with published data10. 
Questions are presented in the results section. The karyotypes were subdivided into the 
seven groups commonly used in the literature11: monosomy, mosaic, isochromosomes, 
deletions, polyploidy, ring chromosomes and Y material.
Statistical analysis
Age, karyotypes and cardiac abnormalities are described. Concerns and fears were analyzed 
for age groups, karyotypes and presence versus absence of cardiac abnormalities. We com-
pared women younger than 25 years of age with women over 25, because we hypothesized 
that the younger group may have been influenced by the rapid increase in the Netherlands 
of well organized and multidisciplinary care and the availability of oocyte donation in the 
past 10 years in particular. Continues variables were checked for normality and presented as 
mean with standard deviation, or as median with first and third quartile (Q1–Q3). Categorical 
variables are presented as frequencies and percentages, and compared using chi-squared 
tests providing a p value. The p values smaller than .05 was considered significant. The 
Bonferroni method was used to correct for multiple hypothesis testing, for each subgroup 
(corrected α=.05/n, with n=number of hypotheses tested). All analyses were performed 
using SPSS version 21.0 (IBM Corp., Armonk, NY).
results
Of the total 344 women with TS invited for this study, 104 women (30%) responded and 
gave informed consent. The questionnaire was completed by 89 women (86%). Median age 
was 30.1 years (Q1–Q3=22.9–39.4; range 18.0–65.7 years). Patient characteristics including 
bicuspid aortic valve, aortic dilatation and coarctation are presented in Table 1. One or more 
of these anomalies were presented in 28 women (37.8%). Nine women had other cardiac 
abnormalities: partial anomalous pulmonary venous return (n=4), abnormal origin of the 
right subclavian artery (n=2), corrected persistent arterial duct (n=1), right descending aorta 
and persistent left superior vena cava (n=1), dextroposition (n=1).
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Fertility and wish to conceive
The majority of the responders had been told by their physician that they probably needed 
oocyte donation to conceive (Table 2). Seventeen women (19.1%) were told they were 
infertile (median age of 22.6 years, Q1–Q3: 19.6–46.6, range: 18.5–62.6). Eleven patients did 
not know their fertility status (median age of 22.1 years, Q1–Q3: 19.1–41.3, range: 18.0–65.7). 
Seventeen patients (19.1%) had attempted to become pregnant. The reason for not trying 
to get pregnant in the remaining 72 patients, as shown in Table 3, was in the majority their 
young age and the fact that they felt a child would not (yet) fit into their lives. Patients that 
reported their young age as a reason for not trying to get pregnant (n=28), had a median 
age of 21.1 years (Q1–Q3: 19.0–22.9, range 18.0–26.4). Three patients (3.4%) did not have a 
wish for a child at all.
table 1 Patient characteristics
  n = 89 %
Age (median, Q1-Q3) median = 30.1 Q1-Q3=22.9-39.4
Cardiac abnormalities* (total) 28 37.8
Bicuspid aortic valve** 20 28.6
Aortic dilatation 9 12.2
Coarctation 6 8.1
Other 9 12.2
Karyotype***
Monosomy 37 51.4
Mosaic 9 12.5
Isochromosomes 11 15.3
Deletions 3 4.2
Polyploidy 7 9.7
Ring chromosomes 1 1.4
Y material 4 5.6
*Cardiac abnormalities: unknown in 15 (16.9%) of patients. 
**Valve morphology unknown in 19 (21.3%) of patients.
***Karyotype: unknown in 17 (19.1%) of patients.
table 2 Fertility
Patients awareness of their fertility:
If I would like to attempt pregnancy, then I would be dependent of an oocyte donation. 49 55.1%
I might have natural hormone production and thus I have a chance to conceive spontaneously. 12 13.5%
Doctors told me I could not get pregnant at all. 17 19.1%
I do not know about my fertility. 11 12.4%
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Of the 17 women, who had attempted to become pregnant, 14 women had been treated 
with assisted reproductive therapies. Five women failed to become pregnant, of whom two 
were still trying to get pregnant. Eventually, 12 women became at least once pregnant, 
which resulted in seven miscarriages before 20 weeks, one therapeutic abortion because of 
anencephaly, and eight live births. Preconception cardiac screening was performed in 12 of 
the 17 women; two patients had not been screened (in one of them it was 20 years ago) and 
in three patients TS had not been diagnosed at the time of their first attempt to conceive.
Concerns regarding pregnancy and cardiac complications
The results of the concerns questionnaire were available for 87 patients and are shown in 
Figure 1: more than half of the patients had concerns about the influence of pregnancy 
or delivery on their cardiovascular status. Figure 2 shows the presence of concerns in TS 
women with cardiac abnormalities compared to those without. There were no significant 
differences in the concerns of women with and without pregnancy attempts. Women 
younger than 25 years of age (n=31) seemed to have more concerns about the heredity 
of TS (36% versus 13%, p=.013), but less concerns about not having enough energy for 
raising a child (29% versus 55%, p=.022) and fewer concerns about a negative influence of 
pregnancy on their mental health (13% versus 36%, p=.023). After correction for multiple 
hypothesis testing (p<.0033 considered significant), none of these results were significantly 
table 3 Pregnancy attempts
  n %
Pregnancy attempt 17 19.1
No pregnancy attempt 72 80.9
Reason for no pregnancy attempts
Too young 18 20.2
Children do not fit (yet) into my life 14 15.7
Too young and combination of other reasons 10 11.2
Rather not by oocyte donation 6 6.7
Never tried due to small chances 5 5.6
Never had a partner, too old 5 5.6
For a medical reason I should not get pregnant 4 4.5
No partner yet 3 3.4
No desire to have children 3 3.4
Aims to start reproductive therapy 2 2.2
Other reasons 1 1.1
Unknown 1 1.1
Total 89  
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different. No significant differences were found in the answers to the questionnaire between 
patients with (n=37) versus without monosomy (n=34). 
Table 4 shows the results of the comparison of the questionnaires of the TS women with 
cardiac abnormalities in our cohort with the questionnaires of another cohort of women 
with congenital heart disease10. The table shows that women with TS and cardiac abnormali-
ties had more concerns than women with congenital heart disease regarding pregnancy 
risks, also related to the possible negative influence on their heart (75% versus 21%, p<.001).
discussion
In this study, we explored the wish to conceive and the concerns of cardiovascular compli-
cations during pregnancy in women with TS. Pregnancy had been attempted by 19.1% of 
all women, while only 3.4% had no wish for a child at all. More than half of all women with 
TS have or have had concerns about the influence of a potential pregnancy on their cardio-
vascular health. In women with TS and cardiac abnormalities this percentage was as high 
table 4 Concerns about pregnancy in Turner patients (with cardiac abnormalities) compared to other patients 
with congenital heart disease
Turner patients 
with cardiac/
aortic disease
CHD patients* p value**
N = 87 (%) (%)  
Have you ever felt concerns about fertility? 82 26 <0.001
Have you ever been afraid of any harmful effects of your 
disease on your child? 50 37 0.17
Have you ever been afraid of not having enough energy to 
raise a child? 50 11 <0.001
Do you feel a certain heart disease could be a limiting 
factor in having children? 75 22 <0.001
Have you ever been afraid pregnancy can have a negative 
influence on your heart? 75 21 <0.001
Have you ever been afraid pregnancy can have a negative 
influence on your overall health? 61 21 <0.001
Have you ever been afraid delivery can have a negative 
influence on your heart? 71 28 <0.001
Have you ever been afraid delivery can have a negative 
influence on your overall health? 46 22 0.005
*Percentages of CHD patients extracted from: Opic et al, 
2013 Int J Cardiology.
** p value of significance after Bonferroni correction: 
p=0.00625
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as 75%. Women with TS and cardiac abnormalities also had much more concerns regarding 
pregnancy and possible complications, than women with congenital heart disease.
Cardiovascular risks of reproductive therapy and Turner syndrome
Awareness of cardiovascular pregnancy risks in women with TS has evolved since 2003, 
when a study reported an estimated 2% risk of maternal mortality6 in pregnancy after 
oocyte donation. This percentage, however, was based on equivocal extrapolation of data. 
In the following 10 years, several papers were published containing retrospective data 
on pregnancy complications reporting aortic dissection rates during pregnancy of 0% 
(0/9; 0/13; and 0/18)12-14, 0.8% (1/122)9 and 2.2% (2/93)8. Most of these patients conceived 
through oocyte donation. In a national study that might have partially overlapped with 
one of these studies, one aortic dissection was found in 202 pregnancies (0.5%), where the 
majority conceived spontaneously15. Outside pregnancy, the presence of aortic dilatation, 
a bicuspid aortic valve and hypertension are risk factors for aortic dissection in women 
with TS16. However, also in the absence of these factors and with a normal diameter of the 
aorta, dissection has been reported. Hence, women with TS without aortic dilatation still 
need to be informed about these risks: not only about the risk of dissection but also about 
other pregnancy  complications, like hypertension and early onset preeclampsia. A large 
Scandinavian study has shown the substantial risk of hypertensive complications during 
pregnancy in women with TS, who conceived by oocyte donation9. In 35% of these patients, 
pregnancy induced hypertension or preeclampsia occurred, which might be both related 
to TS and oocyte donation. 
Since cardiac screening of women with TS prior to conception is advocated by the Eu-
ropean Society of Cardiology guidelines17, several studies have reported on the number 
of preconceptionally screened patients, which ranged from 37.6% to 48.7% 6,8,9. Apart from 
those that received the diagnosis of TS after pregnancy attempts or pregnancy, cardiac 
screening was performed in almost all women who attempted pregnancy in our cohort, 
except for one patient who delivered in 2009 and one patient who tried to become preg-
nant in the nineties.
Fertility and counseling
Fertility issues and TS are closely connected, and the majority of women in our cohort do 
seem to be informed about their situation. However, 12.4% of (mainly younger, median age 
22 years) patients did not know whether they are fertile or not. In a previous study, non-
disclosure or partial disclosure of the TS diagnosis or associated infertility appeared to be a 
common strategy of physicians toward their patients, mostly in consensus with the patient’s 
parents18. Withholding such important information may induce fear, isolation and depres-
sion18,19. However, in recent research it seemed that mainly parents of very young children 
had barriers to communicate about fertility20. Overprotective parents of the child with an 
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(cardiac) anomaly influences the evolvement of body image and self-esteem, and parents 
should be guided in how to communicate with their child about reproductive matters21.
Patients with sex development disorders were previously reported to have difficulties 
with social interaction and impaired cognition, fewer experiences with sexual relationships 
and lack of initiative to finding a partner22-24. Talking about these subjects may help to lower 
the thresholds for entering a relationship. Also, early puberty induction may optimize their 
psychosocial development25,26. When fertility is discussed, a patient should also be informed 
about her risks of pregnancy complications. Timing of this additional information should 
not be delayed to adult age. Although adolescents with TS are generally older when they 
become sexually active27, the age of onset of sexual intercourse decreases in the general 
population, and this may also happen in young patients with TS. In patients with congenital 
heart disease the (perceived) level of information regarding sexual activities and pregnancy 
seems to be deficient10. In Marfan syndrome, where the risk of aortic dissection during 
pregnancy is much better documented, women reported not having started a family partly 
because of the chances for an affected child, but also because of worries for personal health 
in 30% of the study cohort28. An increase in consciousness in reproductive decision-making 
was reported, similarly to some other genetic counseling populations. The authors do 
emphasize that this may also bring induce an undesired increased psychological burden. 
Education about fertility and cardiovascular risks in women with TS by cardiologists and 
gynaecologists should be adequately timed, and when necessary follow-up by a psycholo-
gist should be offered.
Anxiety and pregnancy
The women in this study seem to have much more concerns about pregnancy and delivery 
risks, particularly when they have a cardiac abnormality, than women with congenital heart 
disease assessed by the same questionnaire. The female patients in the reference cohort 
were older (median age 39) than in our study cohort, which could partly explain the fact 
that patients were less worried about pregnancy complications.
Women were older and hence, might remember fewer concerns. However, comparing 
patients younger than 25 years to those older than 25, revealed no significant differences. 
Also, fertility is less of an issue in women without TS, which should be taken into account 
when interpreting our results. 
It remains unknown if the difference between the two cohorts is due to information pro-
vided during counseling, or if this is associated with an underlying anxiety disorder or symp-
toms, which are known to be more common in women with TS1. Furthermore, a previous 
study described that women with congenital heart disease who thought they were unable 
to bear a child, often had expressions of self-hate and a feeling of inadequacy as women21. 
Regardless of the underlying cause, during pregnancy, stress symptoms have shown to be 
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associated with adverse pregnancy outcomes29-31. Thus, the presence of  anxiety symptoms 
does warrant extra psychosocial care.
Clinical implications
Young women with TS, should be adequately informed about fertility issues, but also about 
the risks of pregnancy, irrespective of conceiving by spontaneous conception or oocyte 
donation32-34. After full disclosure of risks, women should be offered not only psychosocial 
support regarding subfertility or infertility, but also regarding fear or concerns of pregnancy 
complications since this might influence their pregnancy outcome as well.
Limitations and future perspectives
Since a validated questionnaire about this topic was not available from literature, we derived 
questions from a questionnaire already used in a cohort study of women with congenital 
heart disease10. We added questions focusing on the aorta and also on mental health. The 
questions were based on literature and clinical experience of experts in this field (JR;EU). 
However, since this is the first study using this questionnaire, future studies are needed to 
replicate our findings. 
The initial response rate was quite low, which is probably related to the fact that people 
were approached through a nonmedical institution by airmail, so not in person, and first 
had to give their consent before questionnaires were sent. Since, we do not have data 
from nonresponders, we do not know to what extent a potential selection bias may have 
influenced our results. Overall, the age of women in our cohort was quite low, given the 
fact that all age categories are represented within the patient society. The topic of research 
is probably most appealing for women of young age who are considering their options 
of starting a family. Although this might induce a selection bias, the risk of recall bias is 
subsequently lower. 
Finally, we did not report the medical fertility status, as opposed to the perception about 
fertility of women with TS in our cohort. It would be interesting to know whether there is a 
discrepancy between fertility and perceived fertility.
Conclusion
In this cohort, half of the women with TS currently or previously experienced fears and 
concerns about cardiac or aortic complications during pregnancy. This holds particularly 
for women with a cardiac abnormality. Information about these risks should be given, and 
psychosocial support during fertility and pregnancy counseling should be provided without 
restraint.
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AbstrAct
Background and aims Turner syndrome (TS) is typically associated with subfertility and 
infertility due to gonadal dysgenesis, but an increasing number of women with TS do get 
pregnant since the introduction of oocyte donation. Cardiac anomalies and aortopathy are 
present in a significant part of women with TS, and they are at increased risk of aortic dilata-
tion and dissection. Therefore, we aimed to describe outcome of pregnancy in women with 
TS in our centre, with specific focus on cardiovascular outcome.
Methods This study included a retrospective cohort of women with Turner syndrome. All 
women who have a genetically proven diagnosis of Turner syndrome and have visited the 
obstetric or cardiac outpatient clinic at Erasmus Medical Centre, Rotterdam, between 2000 
and 2015 were included in this study. 
Results Data from 165 adult women who were diagnosed with Turner Syndrome were 
collected. Of them, 45 (27.3%) attempted to get pregnant at least once: 22 women had suc-
cessful attempts (74 conceptions ending in 31 full-term pregnancies) and 23 women had 
no conception. No aortic dissection was reported. One patient had aortic dilatation, but no 
significant aortic growth during pregnancy. Pregnancy induced hypertension occurred in 
10%, pre-eclampsia in 15% and HELLP in 10% of the patients who had a full-term pregnancy. 
One women had an uneventful pregnancy after aortic root replacement. 
Conclusion In our cohort of women with TS no major aortic complications occurred. How-
ever, hypertensive complications and miscarriage seems prevalent.
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introduction
Turner syndrome (TS) is characterised by a partial or complete monosomy of the X-chro-
mosome, with a wide variety in genotype and phenotype1. TS is typically associated with 
subfertility and infertility due to gonadal dysgenesis, but an increasing number of women 
with TS do get pregnant since the introduction of oocyte donation. Cardiac anomalies and 
aortopathy are present in a significant part of women with TS, and they are at increased 
risk of aortic dilatation and dissection2. How this influences pregnancy outcome, and more 
importantly how to deal with the wish for assisted reproductive therapy wish in this group 
of women remains subject of debate3. More data on the topic is clearly warranted, with the 
aim to better inform women with TS and a pregnancy wish, and to support present and 
future guidelines on TS and pregnancy.
Guidelines on pregnancy in Turner syndrome are not very well specified, mainly due to 
the fact that there are limited data. In other aortic syndromes such as Marfan syndrome, 
guidelines advice to consider prepregnancy prophylactic surgery in case of aortic dilatation4. 
But little data exists to ensure that this approach leads to a safe course of pregnancy without 
subsequent type B aortic dissection. An alarming series report described adverse pregnancy 
outcome in Loeys-Dietz syndrome (which is also often characterised by aortopathy) after 
prophylactic aortic surgery5. 
Therefore, we aimed to describe outcome of pregnancy in women with Turner syndrome 
in our centre, with specific focus on cardiovascular outcome, and specifically aortopathy.
methods
This study included a retrospective cohort of women with Turner syndrome. All women (>18 
years) who have a genetically proven diagnosis of Turner syndrome and have visited the 
obstetric or cardiac outpatient clinic at Erasmus Medical Centre, Rotterdam, between 2000 
and 2015 were included in this study. The medical status of all participants was checked to 
retrieve data on karyotype, cardiac abnormalities and conception or pregnancy outcomes. 
Institutional review board approval was obtained (MEC-2014-457).
Data
Data collection included: patient characteristics, pregnancy attempts, pregnancies and 
deliveries. Data were retrieved from electronic medical files by the first author. Patient char-
acteristics included age at diagnosis of TS and of congenital heart disease, age at the time of 
conception, age at the time of this study, karyotype, growth hormone, puberty induction, 
cardiac screening, cardiac abnormalities and prior cardiac interventions. Pregnancy data 
included type of conception (spontaneous or assisted reproductive therapy - ART), miscar-
242 Chapter 12
riage, therapeutic abortion, live births, pregnancy induced hypertension, pre-eclampsia, 
aortic dimensions, aortic dissection
A successful attempt was defined as an achieved conception, regardless of outcome such 
as miscarriage or live birth. Karyotypes were subdivided into seven groups6: monosomy, 
mosaic, isochromosomes, deletions, polyploidy, ring chromosomes, Y material.
Imaging data were collected for patients who conceived. Only those with images before 
and after pregnancy derived from the same modality (i.e. echocardiography before and after 
pregnancy, or magnetic resonance before and after pregnancy) were selected for graphical 
representation in this study.
Statistical analysis
A flowchart of included patients is provided. Patient characteristics are described. Women 
with successful pregnancy attempts and those with failed attempts are compared. Spon-
taneous conceptions are compared to conceptions induced by ART. Full term pregnancies 
will be described in detail, in particular in case of prior aortic surgery. Data from the general 
population in literature7-11 are provided, but do not allow for statistical comparison.
Continuous data are presented as median and first to third quartile (Q1-Q3) as appropri-
ate, and comparisons were made using Wilcoxon signed rank tests. Categorical data are 
presented as frequencies and percentages, and compared using chi-squared tests. P-values 
below 0.05 were considered significant. All analyses were performed with SPSS version 
21.0(IBM Corp., Armonk, NY).
results
Total cohort
Data from 165 adult women who were diagnosed with Turner Syndrome were collected 
(Figure 1). Of these women, 45 (27.3%) had reported at least one pregnancy attempt to 
their physician. Women who did not report any pregnancy attempts (n=120) were generally 
younger at the time of this study (28 years versus 39 years, p<0.001) but also at the time of 
their diagnosis (9 years versus 14 years, p<0.001), than those who did report a pregnancy 
attempt. There were more women with a monosomy in the group that did not report a 
pregnancy attempt than those who did (56% versus 33%, p=0.003). 
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Pregnancy attempts
Table 1 shows the baseline characteristics of the women with at least 1 pregnancy attempt. 
There were 22 women with successful attempts (ending in conception) and 23 women with 
no conception. Karyotype was not significantly different overall (p=0.35). But there seemed 
to be more women with mosaicism in the group with successful attempts (35.0% versus 
5.3%). Women with successful attempts had their diagnosis of Turner Syndrome more often 
during or after conception or fertility issues (50.0% versus 13.0%, p=0.008). 
Women who did not receive puberty induction were more likely to have a successful 
attempt than women who did receive puberty induction (68.8% versus 25.0%, p=0.009). 
Growth hormone did not significantly contribute to the chance of success or failure: 56% 
of women without growth hormone had a successful attempt, versus 30% of women with 
growth hormone treatment (p=0.11). 
165  
women with Turner Syndrome 
45  
reported pregnancy attempts  
120  
reported no pregnancy attempts  
Median age at time of study:  28 (21-36)  
Median age at diagnosis:  9 (0.8-12) 
 
Monosomy:  56% 
Mosaicism:   6% 
Other karyotype:  38% 
 
Adoption: 1 
Conception:  
22 women 
No conception:  
23 women 
ART:  5 
No donor found: 2 
 
Adoption: 1 
74 conceptions 
Spontaneous: 54 
ART: 20 
 
Therapeutic abortion: 2 
Miscarriages: 40 
Carrying: 1 
Live births: 31 (in 19 women) 
     Neonatal death: 1 
Median age at time of study:  39 (32-44) 
Median age at diagnosis:  14 (9-30) 
 
Monosomy:   33% 
Mosaicism:   21% 
Other karyotype:  46% 
figure 1 Flowchart
ART= assisted reproductive therapy
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Conceptions
Of the women who had at least one conception (n=22),  13 were screened by a cardiologist 
; 4 women had their TS diagnosis after pregnancy; 3 had no screening or follow-up at all 
despite their diagnosis of TS (2 with low-level mosaicism); 2 had their first cardiac screening 
years after diagnosis and conception. Of the 13 women that were screened, 11 received 
cardiac follow-up during pregnancy, and 2 did not.
In total, 74 conceptions were achieved, by 22 women. Table 2 shows the outcome of 
conceptions conceived either spontaneously (n=54) or through ART (n=20). Spontaneous 
conceptions were mainly achieved by women with mosaicism, and by women with deletion 
table 1 Women who attempted pregnancy
 
Women with successful 
attempts
Women with failed 
attempts
n=22 n=23 p value
Median age at the time of the study (Q1-Q3) 41.1 (35.5-45.0) 34.7 (30.0-42.0) 0.09
Median age at diagnosis (Q1-Q3) 24.2 (8.3-35.5) 12.8 (7.2-21.9) 0.17
Karyotype, % 0.23
Monosomy 5 25.0% 8 42.1%
Mosaic 7 35.0% 1 5.3%
Isochromosomes 2 10.0% 3 15.8%
Deletions 3 15.0% 3 15.8%
Polyploidy 3 15.0% 2 10.5%
Ring chromosomes 0 0.0% 1 5.3%
Y material 0 0.0% 1 5.3%
Diagnosis 0.008
before pregnancy attempts, % 10 50.0% 20 87.0%
at or after the time of attempts, % 10 50.0% 3 13.0%
Cardiac or aortic abnormality 4 21.1% 5 23.8% 1.00
BAV 2 10.5% 5 23.8% 0.41
Aortic dilatation 2 10.5% 2 9.5% 1.00
Coarctation 2 10.5% 1 4.8% 0.60
Other 3 15.8% 2 9.5% 0.65
Cardiac or aortic intervention 3 15.8% 1 4.8% 0.33
Growth hormone 6 40.0% 14 66.7% 0.11
Puberty induction 5 31.2% 15 75.0% 0.009
BAV = bicuspid aortic valve, Q1-Q3 = first to third quartile
Cardiovascular complications during pregnancy in Turner syndrome 245
12
or polyploidy. Outcome was quite similar, with 42.6% life births in spontaneous conceptions 
and 40.0% in conceptions achieved with ART.
Thirty-one conceptions ended in full term pregnancies in 19 women, shown in Table 3. 
Five of these women had a cardiac anomaly when they became pregnant: 1 patient required 
a mitral mechanical valve 7 years before conception (because of mitral valve regurgita-
tion); 1 patient had  a partial anomalous pulmonary venous return (PAPVR) but no other 
anomalies; 1 patient was diagnosed with TS 18 years after pregnancy and she appeared to 
have coarctation, a small perimembranous ventricular septal defect and a persistent left 
sided vena cava superior; 1 patient became pregnant while having a bicuspid aortic valve 
with aortic dilatation (40 mm); 1 patient became pregnant two years after ascending aortic 
surgery (case report below).
table 2 Conceptions: spontaneous versus ART
Conceptions
Spontaneous ART
  n=54 n=20 p value
Median age at conception (Q1-Q3) 31.0 (26.5-35.0) 32.9 (28.3-39.0) 0.48
Number of previous pregnancies (Q1-Q3) 3 (2-5) 1.5 (1-4) 0.059
Pregnancy outcome: 0.48
Miscarriage 29 53.7% 11 55.0%
Therapeutic abortion 2 3.7% 0 0.0%
Live births 23 42.6% 8 40.0%
Carrying 0 0.0% 1 5.0%
ART= assisted reproductive therapy, Q1-Q3 = first to third quartile
table 3 Full term pregnancies
 
Full term pregnancies
n= 31 %* Normal
Median age at conception(Q1-Q3) 31.0 (26.0-35.0)
Conceived by ART 8 25.8%
Karyotypes
Monosomy 4 12.9%
Mosaic 17 54.8%
Isochromosomes 1 3.2%
Deletions 3 9.7%
Polyploidy 3 9.7%
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Caesarean section was planned in 3 patients: one had breech presentation; one had 
preeclampsia; and one had an aortic diameter of 44mm in the presence of a bicuspid aortic 
valve. A secondary CS was performed because of fetal distress in two, and failure to progress 
in one patient. Mode of delivery was unknown in 5 pregnancies.
One patient had a baby with atresia ani and maldevelopment of scrotum. Another patient 
had a baby with cheilognathopalatoschisis. 
table 3 Full term pregnancies (continued)
 
Full term pregnancies
n= 31 %* Normal
Ring chromosomes 0 0.0%
Y material 0 0.0%
unknown 3 9.7%
Turner syndrome known before pregnancy 18 58.1%
Maternal mortalitya 0 0.0% <0.01%
Pregnancy induced hypertensionb 2 10.0% 2.5%
Pre-eclampsiac 3 15.0% 3.8%
HELLPd 2 10.0% <1.0%
Pregnancy duration, median (wks) 39 (38-40.5)
Induced vaginal delivery 3 11.5
Spontaneous vaginal delivery 17 65.4
Primary caesarean section 3 11.5
Secondary caesarean section 3 11.5
Neonates 33
Birth weighte, median (gr) 3285 (2975-3495) 3454
Small for gestational age (<10th percentile) 2 8.3% 10.0%
Neonatal deatha 1 3.2% 0.4%
Congenital anomaly 2 8.0%
*Frequencies are presented as percentages of valid cases. 
Obstetric complications unknown in 11 cases; small for gestational age unknown in 7; congenital anomalies un-
known in 6; birth weight and pregnancy duration unknown in 10.
aEuroperistat, bDrenthen 2007, cAbalos 2013, dStone 1998 Jama, eJaddoe 2008
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Cardiovascular complications
No aortic dissections were reported. One patient had aortic dilatation, but no significant 
growth during pregnancy. Hypertensive complications during pregnancy are shown in 
Table 3; one of these patients had pre-existent mild hypertension. 
In four patients, echo data were present before and after pregnancy(and during preg-
nancy in some of them). The course of aortic dimensions are presented in Figure 2.
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Case report of pregnancy after thoracic aortic surgery
The patient was a 32-year-old woman who had been diagnosed with Turner Syndrome at 
the age of 11 after growth failure. Karyotyping revealed a monosomy 45,X in all investigated 
blood cells. The patient was treated with growth hormone and estradiol. First cardiac evalu-
ation one year after diagnosis showed a bicuspid aortic valve and mild aortic regurgitation. 
At age 15, a dilated ascending aorta was noticed on echocardiogram with a diameter of 
38 mm. At age 18, the ascending aorta diameter was 35 mm, which further dilated to 40 
mm at the age of 25. The patient decided to opt for egg cell donation four years later and 
hormone therapy was initiated in the form of estradiol and medroxyprogesterone. The 
patient consulted a cardiologist and a cardiac and thoracic MRI showed an ascending aortic 
diameter of 47 mm, mild aortic regurgitation and a mild prolapse of the mitral valve. The 
patient was advised to delay pregnancy until after replacement of the ascending aorta. She 
underwent a supracoronary replacement of the ascending aorta. The sinus was not found 
to be dilated and the aortic valve was left in place. One year after aortic surgery, the egg 
cell donation procedure was continued. The patient was confirmed to be pregnant at the 
age of 32. She received a total of three single donor embryos transfers: one fresh embryo 
transfer and two frozen embryo transfers. The second frozen embryo transfer resulted in 
pregnancy. An echocardiogram at 26 weeks of gestation showed a stable cardiac status and 
good functioning of the aortic graft. The ascending aortic diameter remained stable at 31 
mm. The patient reported no complaints.  At 41 weeks of gestation, labour was induced us-
ing prostaglandin and oxytocin because of postterm pregnancy, and secondary caesarean 
section was required due to foetal distress. She gave birth to a boy of 4510 grams without 
congenital defects. Postpartum course was uneventful. Upon cardiac evaluation three 
months postpartum, the patient reported good recovery. Echocardiographic evaluation 
two and three years postpartum showed a stable aortic diameter and mild aortic regurgita-
tion. First postpartum CT scan of the thoracic aorta was performed three years postpartum 
and confirmed stable diameters. 
discussion
In this single centre cohort of women with Turner syndrome, no severe aortic complica-
tions occurred during or directly after pregnancy. Some women experienced hypertensive 
events, as expected based on literature. We presented a unique case of a woman with 
Turner syndrome who became pregnant after aortic root replacement. The pregnancy was 
uneventful and aortic diameters were stable years after delivery.
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Pregnancy and aortic complications
The aortic wall is subject to change during pregnancy. In post-mortem histopathology of 
the aorta in pregnant women, fragmentation of reticulum fibers and less corrugated elastic 
fibers were found in the intima media12. This leads to the hypothesis that pregnancy may 
lead to aortic dilatation or even rupture. Many case reports and series have been published, 
although restrained by low numbers and selection bias. Patients derived from these 
reports presumably overrepresent those with an unusual presentation of their disease13. 
An early review of literature did not reveal pregnancy as a risk factor. Also, only two out of 
346 women in the largest registry of aortic dissections, were pregnant14. The registry could 
not reveal pregnancy as a risk factor, while aortic syndromes were the most important risk 
factor for aortic dissection in young women15. However, in a population based cohort, a 
clear increased risk of aortic dissection existed in pregnant women compared to their non-
pregnant peers16.
Whether pregnancy further increases the risk of aortic dissection in patients with 
Turner Syndrome, although often suggested, has not yet been determined. Two case se-
ries described the dramatic course of aortic dissection in TS women; some of them were 
pregnant2,17. However, these findings might also be attributed to the fact that aortic dis-
section generally occurs at young adult age. Both research groups reported a mean age of 
approximately 30-35 years at the time of aortic dissection in Turner syndrome. 
Similar to our study, all studies on the incidence of aortic dissection during pregnancy 
in patients with Turner Syndrome were retrospective and one should be very cautious to 
draw any conclusion, as a high risk of selection and publication bias exists. The majority of 
pregnancies was conceived through assisted reproductive therapy18-23. Regardless of the risk 
being increased in pregnancy or not, aortic dissection is a potential devastating event and 
the most important cause of cardiovascular maternal mortality in the general population24. 
It requires a systematic approach of pregnancy counselling and follow-up in women who 
are at increased risk of aortic dissection, and thus also for women with Turner Syndrome. 
Evidence of other complications in Turner syndrome 
In addition to the potentially increased risk of aortic dilatation and dissection, women with 
Turner syndrome are at increased risk of hypertensive complications: in a Scandinavian 
cohort pregnancy induced hypertension occurred in 14.5% and pre-eclamptic toxaemia in 
20.5% of oocyte donation pregnancies23. In a Belgian report, pregnancy induced hyperten-
sion and pre-eclampsia have been reported in 17% and 23%, respectively, of oocyte donation 
pregnancies in Turner patients20. Pre-eclampsia and gestational hypertension in the general 
pregnant population are associated with several risk factors including nulliparity, older age, 
pre-existing diabetes, antiphospholipid antibodies and pre-existing hypertension25. Hyper-
tension is more common in women with Turner syndrome, which may contribute to the 
higher incidence of hypertensive complications during pregnancy. 
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Prophylactic aortic surgery and pregnancy
Currently, little is known about the risk of pregnancy after aortic surgery. In the European 
guidelines, prepregnancy surgery is advised in women with Marfan syndrome and a dilated 
ascending aorta (>45 mm in their case), and surgery should be considered in women with 
a bicuspid aortic valve and a diameter greater than 50mm or 27 mm/m2. However, a recent 
report described 3 cases of pregnancy in women with Loeys Dietz syndrome after aortic 
surgery and 2 of them suffered from aortic dissection shortly after delivery5. It is unknown 
whether this risk is isolated to syndromes such as Loeys Dietz, or whether we should be 
reluctant also to perform prophylactic surgery in women with Turner syndrome, or even no 
specific aortic syndrome at all. In our cohort, one woman underwent prepregancy aortic 
root replacement, without subsequent problems during or after pregnancy. In retrospect, 
it may have been useful to plan delivery at 38 or 39 weeks, to prevent the additional risk 
of prolonged pregnancy and of delivery in the presence of macrosomia. More studies are 
definitely required to support the current guidelines on pregnancy in women with aortic 
disease.
Cardiovascular management of pregnancy 
Prior to conception, all women with Turner syndrome should be screened for cardiac anom-
alies. Also, the risk of aortic dissection needs to be determined, just as outside pregnancy. 
Risk factors that have been found are: aortic dilatation, bicuspid aortic valve, hypertension, 
repaired or unrepaired coarctation, and history of aortic dissection2,26. The aortic size index 
should be evaluated by imaging of the aorta prior to conception, either with CT or MR. 
During pregnancy, at least one echocardiogram should be made (for instance at 20 weeks 
of gestation) to evaluate the aortic dimensions. If the aortic size index before pregnancy 
exceeded 2.0 cm/m2, regular assessment is advised with an interval of 4 to 12 weeks. An 
MRI is indicated in case of aortic dilatation or an increase of dimensions, and also may be 
considered if echocardiographic images are not sufficient. Gadolinium is not routinely used 
because it crosses the placental borders and the consequences for the fetus are unclear.
Vaginal delivery is the preferred mode of delivery in every patient. Fetal adverse outcome 
is more frequently encountered in women with a caesarean section compared to women 
with a vaginal delivery27. Specific evidence is lacking in patients with aortic disease or even 
Turner syndrome and associated aortopathy. Based on expert opinion, in patients with 
a dilated aorta, i.e. an aortic size index of greater than 2.7 cm/m2, a caesarean section is 
recommended, to prevent of large haemodynamic differences causing aortic wall stress4.
During the first six months after pregnancy careful evaluation and imaging is also indi-
cated, as aortic dilatation and dissection may still occur in the postpartum period. 
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Limitations
This study is limited by its retrospective nature and by the low number of included patients. 
The latter is difficult to overcome, as the number of women with Turner syndrome getting 
pregnant, is quite low and increasing slowly in the past decades since oocyte donation came 
available. Selection bias remains hard to prevent, with probably a large number of women 
with Turner syndrome being cared for in peripheral hospitals or not visiting a clinic at all. 
These women presumably have a milder phenotype of Turner syndrome. Large prospective 
multicentre and multinational studies are definitely required to investigate the absolute risk 
of aortic problems and maternal mortality in women with Turner syndrome3. 
Conclusion
This study aimed to determine the risk of cardiovascular complications in women with Turner 
syndrome. In our retrospective cohort no major complications occurred. One women had 
an uneventful pregnancy after aortic root replacement. Larger cohorts are required to study 
incidence of aortic and hypertensive complications in more detail.
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Women with genetic aortic disease, such as Marfan syndrome, are at increased risk of preg-
nancy complications, in particular aortic dissection1. Aneurysms-Osteoarthritis Syndrome 
(AOS) is an autosomal-dominant syndrome caused by SMAD3 mutations, and is character-
ized by arterial aneurysms and tortuosity in combination with osteoarthritis. There is a 
lack of data about the cardiovascular risks of pregnancy in women with SMAD3 mutation. 
Therefore, we collected data on the pregnancies of patients with SMAD3 mutation followed 
in our centers.
We included all women with a SMAD3 mutation that were previously enrolled in a prospec-
tive cohort study2. Data regarding pregnancy were collected retrospectively, both through 
the medical file and by interview. In two patients, with a recent pregnancy, aortic dimen-
sions measured with echocardiography or computed tomography before, during and after 
pregnancy were available. 
Seventeen women with SMAD3 mutation had 34 pregnancies. Two of them had two 
pregnancies after they were diagnosed with SMAD3 mutation. At the time of diagnosis, 
osteoarthritis and orthopedic lesions were present in all but one patient, and vascular 
anomalies present in at least 12 of the 17 patients. Mean age at first conception was 26 
years (SD±3.6;range 22-33 years). There were 6 miscarriages in 4 women (23.6%). Twenty-
eight pregnancies ended in live births, including two twins. No maternal mortality and no 
aortic dissection occurred. One patient developed pregnancy induced hypertension and 
preeclampsia, and another patient reported gestational diabetes. Hydronephrosis occurred 
in one other patient. At least 4 patients reported to have experienced severe pregnancy 
related pain in the pelvic area (24%). One patient had intrauterine growth restriction, result-
ing in a baby small-for-gestational age.
Three caesarean sections (CS) were performed. One woman delivered by secondary CS 
due to failure to progress, and two women had a planned CS: one was performed for breech 
position, and the other was planned at 35 weeks because of increasing aortic diameters 
(Patient 2, Figure 1). No uterine rupture was reported. One neonate had lower urinary tract 
obstruction, and another baby was reported to have a cleft palate. No postpartum hemor-
rhage or other complications were reported.
No major cardiovascular complications occurred postpartum. Imaging before and after 
pregnancy is shown in Figure 1.
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comment
Pregnancy not only induces hemodynamic changes, with a 30-50% increase of cardiac 
output and 10% increase in heart rate, but it may also influence the integrity of the aortic 
wall . This is suggested to be due to hormonal changes, that affect in particular the matrix 
profile resulting in decreased artery stiffness3. As AOS due to SMAD3 mutations is an ag-
figure 1 Aortic dimensions in two patients with SMAD3 mutation. 
Two women had been pregnant twice after being diagnosed with SMAD3 mutation. The evolvement of their aortic 
dimensions are shown in this figure. ST = sinotubular
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gressive aortic syndrome, concern exists around pregnancy in these patients. The current 
study describes 34 pregnancies in 17 women. No clear increased risk of aortic dissection or 
obstetric complications in these women was found. Conclusions of our results are limited 
by the retrospective nature of this study, with a risk of survivor bias, and the limited amount 
of patients included. Therefore, large prospective studies are warranted. In two patients with 
multiple aortic measurements, we observed no clear changes in Patient 1, while in Patient 
2 the dimensions at the level of the sinus of Valsalva showed a tendency to increase. Future 
research must focus on aortic growth to further determine whether pregnancy has an ef-
fect on aortic diameters and poses women to an increased risk of aortic dissection. Finally, 
uterine rupture was not observed, but a number of patients spontaneously reported severe 
pain in the pelvic area, suggesting a link with pelvic joint pain.
This report, in combination with existing evidence on aortic syndromes caused by muta-
tions in genes involved in the TGF-beta pathway like Loeys-Dietz, can provide guidance 
for preconception counseling and management of pregnancy in patients with SMAD3 
mutation. The guidelines on pregnancy and cardiovascular disease advise preconception 
surgery in women with SMAD3 mutation, when the aorta is ≥45mm4. Further management 
during pregnancy includes strict blood pressure control. CS in women with an aortic di-
ameter >45mm and vaginal delivery with epidural anesthesia when the aorta is <40mm 
is advised. Between 40 and 45mm bot strategies could be considered. We feel that these 
recommendations can be adapted to women with SMAD3 mutation. In our series only 1 
woman had a CS because of a dilated aorta. In the patients with vaginal delivery no aortic 
complications occurred.
In conclusion, in the absence of prospective studies, our retrospective study shows no ad-
verse outcome for pregnancy in women with SMAD3 mutation. However, counseling about 
the potential increased risk of pregnancy-related aortic complications remains warranted. In 
addition, pelvic joint pain might occur more often in these patients.
260 Chapter 13
references
 1. Immer FF, Bansi AG, Immer-Bansi AS, et al. Aortic dissection in pregnancy: analysis of risk factors and 
outcome. Ann Thorac Surg 2003; 76(1): 309-14.
 2. van der Linde D, van de Laar IM, Bertoli-Avella AM, et al. Aggressive cardiovascular phenotype of 
aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am Coll Cardiol 2012; 
60(5): 397-403.
 3. Natoli AK, Medley TL, Ahimastos AA, et al. Sex steroids modulate human aortic smooth muscle cell 
matrix protein deposition and matrix metalloproteinase expression. Hypertension 2005; 46(5): 1129-
34.
 4. Regitz-Zagrosek V, Lundqvist CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular 
diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases during 
Pregnancy of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(24): 3147-97.


PART IV
Cardiomyopathies and Pulmonary 
hypertension 

CHAPTER 14
Pregnancy in women with hypertrophic 
cardiomyopathy: data from the 
European Society of Cardiology 
initiated Registry of Pregnancy and 
Cardiac disease (ROPAC)
Sorel Goland
Iris M. van Hagen
Gabby Elbaz-Greener
Uri Elkayam
Avraham Shotan
Waltraut M. Merz
Sibel C. Enar
Ilshat R. Gaisin
Petronella G. Pieper
Mark R. Johnson
Roger Hall
Alexander Blatt*
Jolien W. Roos-Hesselink*.
Submitted
266 Chapter 14
AbstrAct 
Aims We report the maternal and fetal outcomes at birth and after 6 months in a cohort of 
pregnant women with hypertrophic cardiomyopathy (HCM).
Background Although most women with HCM tolerate pregnancy well, there is an increased 
risk of obstetric and cardiovascular complications.
Methods All pregnant women with HCM entered into the prospective worldwide Registry 
of Pregnancy and Cardiac disease (ROPAC) were included in this analysis. The primary end-
point was a major adverse cardiovascular event (MACE), which included death, heart failure 
(HF), thromboembolic event and arrhythmia. Baseline and outcome data were analysed and 
compared for patients with MACE versus without MACE and for patients with obstructive 
HCM versus non-obstructive HCM.
Results Sixty pregnant women (mean age 30.4±6.0 years) with HCM (41.7% obstructive) 
were included. No maternal mortality occurred in this cohort. In 14 (23%) patients at least 
one MACE occurred: 9 (15.0%) HF and 7 (12%) an arrhythmia (6 ventricular and 1 atrial fibril-
lation). MACE occurred most commonly during the 3rd trimester and postpartum period. 
In total, 3 (5.0%) women experienced fetal loss. Women with MACE had a higher rate of 
emergency Caesarean delivery for cardiac reasons (21.4% vs. 0%, p=0.01). No significant 
differences in pregnancy outcome were found between women with obstructive and 
non-obstructive HCM. NYHA functional class of ≥ II and signs of HF before pregnancy, were 
associated with MACE.
Conclusions Although most women with HCM tolerated pregnancy well, cardiovascular 
complications were not uncommon and predicted by pre-pregnancy status facilitating pre-
pregnancy counselling and targeted antenatal care.
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introduction 
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease and has 
a prevalence of 2% in the general population. The widespread use of echocardiography 
and genetic screening for HCM has led to a growing number of young women diagnosed 
with HCM where most of them desire pregnancy. HCM in the non-pregnant state is associ-
ated with an increased risk of sudden cardiac death, arrhythmia and heart failure and the 
pregnancy-associated changes in the cardiovascular system may exacerbate these risks, al-
though their impact on maternal hemodynamics is not well understood. During pregnancy, 
there is an initial fall in peripheral vascular resistance occurring predominantly during the 
1st and 2nd trimesters. This results in an increase in cardiac output of around 50% due to the 
combination of a greater stroke volume and higher heart rate1. The increase in blood volume 
and consequently of left ventricular size offsets the adverse effect of the fall in peripheral 
vascular resistance on the LVOT gradient. In addition, enhanced LV contractility and higher 
heart rate with a shortened diastolic filling time, could exacerbate or precipitate heart failure 
and may not be well tolerated. Moreover, at the time of delivery, the auto-transfusion from 
the contracting uterus into the systemic circulation and stress related tachycardia during 
delivery and early postpartum, may lead to clinical deterioration. Despite these potential 
complications, it appears that most women with HCM tolerate pregnancy well. Previous 
studies report widely differing rates of cardiovascular complications, varying between 2 and 
48%. However, most of the reports are retrospective or include small case series and may 
suffer from selection bias including more severe cases2-7.
This prospective study aims to provide information on the outcome of pregnancy in a 
cohort of pregnant women with HCM recruited to the observational, contemporary, world-
wide Registry of Pregnancy and Cardiac disease (ROPAC). Such information may be helpful 
in pre-pregnancy counseling of women with HCM and identifying women at high-risk of an 
adverse outcome.
methods
ROPAC is an ongoing prospective and worldwide registry initiated in 2007 by the European 
Society of Cardiology working groups on valvular heart disease and on congenital heart 
disease8. All consecutive pregnant women with structural heart disease, aortic pathology 
or pulmonary hypertension were included; non-structural heart diseases such as lone ar-
rhythmic disease were excluded. Data were prospectively collected, and centers could 
also retrospectively include all consecutive patients up to 6 months before study entry. For 
this interim analysis, pregnancies in women with hypertrophic cardiomyopathy who were 
included in the study from 2007 up to 2014 were selected. 
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Data
The patient characteristics collected at baseline (before pregnancy) included age, ECG 
rhythm, diagnosis, risk factors for cardiovascular disease (smoking, diabetes, hypertension), 
previous interventions, medication, parity, obstetric history and facultative echocardio-
graphic parameters. Follow-up was available for all patients up to one week after delivery; in 
addition follow-up at 6 months was available for part of the cohort. Patient characteristics 
and events were reported by the individual sites and did not undergo centralized adjudica-
tion. However, all events were predefined in the case report form.
Definitions
HCM was defined “by the presence of increased left ventricular wall thickness that is not 
solely explained by abnormal loading conditions”9. The diagnosis HCM was confirmed if 
one or more left ventricular (LV) myocardial segments showed a thickness of ≥15 mm on 
echocardiography, cardiac resonance imaging or computed tomography. Obstructive HCM 
was defined as “an instantaneous peak Doppler LV outflow tract pressure gradient ≥30 mm 
Hg at rest or during physiological provocation such as Valsalva maneuver, standing and 
exercise” (2014 ESC guidelines9).  These diagnostic features were confirmed in each patient 
by the local cardiologist. LVOT gradient was not collected as separate variable, and therefore 
could not be analyzed.
The primary endpoint was a major adverse cardiovascular event (MACE), collected up to 
1 week after delivery, including maternal death, heart failure (HF), thromboembolic events, 
and supraventricular or ventricular tachyarrhythmia. Heart failure was defined was defined 
according to ACC/AHA guidelines as a clinical syndrome that is characterized by specific 
symptoms (dyspnea and fatigue) and signs (of fluid retention, such as edema, or rales) on 
physical examination as judged by the treating cardiologist10. The heart failure episode was 
only registered when signs or symptoms of HF were present which required new treat-
ment, change of treatment or hospital admission. A ventricular tachyarrhythmia (VTA) 
was defined as three or more consecutive ventricular beats with a mean rate of more than 
100 beats per minute; however, only clinically relevant VTA (when the patient had physical 
complaints, needed treatment for VTA or when the patient had more than 100 consecutive 
beats) was included. Other endpoints of interest were hospitalization for a cardiac reason, a 
Caesarean delivery for a cardiac reason, birth weight, small for gestational age (birth weight 
<10th percentile), miscarriage (<24 weeks), fetal death (≥24 weeks), neonatal death, termina-
tion of pregnancy and preterm birth (<37 weeks). 
Baseline and outcome data were analyzed for the total group; patients with and without 
MACE were compared and those with obstructive HCM compared to those with non-
obstructive HCM.
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Statistical analysis
Continuous variables are presented as mean and standard deviation, or as median and 
quartiles where appropriate. Differences were assessed with Student’s t-test. Categorical 
variables are presented as percentages and differences were assessed using Chi-square 
tests. Predictors of MACE were identified by performing univariable logistic regression 
analyses. The number of events (n=15) did not allow for multivariable regression analysis. 
Statistical tests were considered significant if a p-value was less than 0.05 (two-sided). All 
analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY).
results
Sixty pregnancies in women with hypertrophic cardiomyopathy were included, from 28 
centers in 19 countries; the majority were from countries with an advanced economy (n= 
49, 81.7%). Mean age was 30.4 (±6.0) years and 30 (50.0%) were nulliparous. All pregnan-
cies were singleton. Baseline characteristics are presented in Table 1. Twenty-five patients 
(41.7%) were reported to have an obstructive hypertrophic cardiomyopathy. Eight patients 
(13.3%) had had a prior intervention (3 patients had undergone septal myectomy, 1 patient 
had had an alcohol septal ablation, 1 patient surgical repair of the mitral valve had been 
performed, and in 3 patients there had been an unspecified intervention). In 4 patients 
(6.7%) an implantable cardioverter-defibrillator (ICD) was implanted.
During pregnancy, 29 patients were treated with cardiac medication (48.3%); 24 were 
taking a beta-blocker (40.0%), five a calcium-antagonist (8.3%), four diuretics (6.7%), and 
three antiarrhythmic medications (5.0%).
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Maternal outcome
No maternal mortality occurred in this cohort. In 14 patients, at least one MACE occurred 
(23.3%, Figure 1); 9 developed HF (15.0%), 6 patients had a ventricular tachyarrhythmia 
(10%), and 1 patient had atrial fibrillation (1.7%). Two patients had two major adverse cardiac 
events: one developed both HF and ventricular tachycardia at five weeks of gestation and 
one developed HF at gestational age 23 weeks followed by a ventricular arrhythmia at 32 
weeks. The timing of the first MACE was mainly in the third trimester (n=6) or postpartum 
(n=4) (Figure 1). 
In Table 2, the management of patients who suffered a MACE during pregnancy is 
presented. Before the event, four patients were taking a beta-blocker and in another four 
patients, a beta-blocker had been stopped. After the event, 9 of 14 started or continued a 
beta-blocker, in some in addition to diuretics or antiarrhythmic medication. One patient 
with a ventricular tachyarrhythmia in the third trimester had an ICD implantation two days 
postpartum.
Results of the univariable analysis for MACE are shown in Table 3. NYHA functional class of 
≥ 2 and signs of HF before pregnancy were significantly associated with MACE. The number 
of events was too small to allow for multivariable analysis.
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figure 1 Timing and type of first Major Adverse Cardiac Event during pregnancy in women with hypertrophic 
cardiomyopathy
No maternal mortality or thromboembolic events occurred.
AF= atrial fibrillation; HF= heart failure; MACE= Major Adverse Cardiac Event; VTA= ventricular tachyarrhythmia
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Obstetric and fetal outcome
Table 4 shows the obstetric and fetal outcome for the total HCM group and for women 
with MACE versus those without MACE. Three fetal losses occurred; 1 miscarriage and 2 fetal 
deaths after 24 weeks. The miscarriage occurred at 23 weeks and the growth-restricted fetus 
was suspected of a mitochondrial cardiomyopathy. In the patient who had developed HF 
and a ventricular tachyarrhythmia at 5 weeks, intrauterine fetal death occurred at 29 weeks 
of gestation. One patient with pre-existing permanent atrial fibrillation, was treated with 
disopyramide, digoxin and unfractionated heparin and had an intrauterine fetal death at 27 
weeks. Pregnancy duration in women with MACE was significantly shorter than in women 
without MACE. An emergency Caesarean delivery for a cardiac reason was performed 
in three of the 14 women with MACE:  in 2 after HF (of whom one also had a ventricular 
tachyarrhythmia) and in 1 after atrial fibrillation.
Five neonates (8.3%) were diagnosed with an inherited hypertrophic cardiomyopathy: 3 
babies of women with non-obstructive HCM (8.6%) (in 1 of these 3, fetal loss at 23 weeks 
occurred), and 2 of the women with obstructive HCM (8.0%).
Obstructive and non-obstructive HCM
No significant differences in pregnancy outcome were found between women with ob-
structive and non-obstructive HCM. The data are presented in Table 5.
table 3 Univariable analysis of predictors of MACE during pregnancy in women with hypertrophic cardiomy-
opathy
Predictors of MACE
  OR 95%CI p-value
Nulliparity 1.46 (0.44-4.86) 0.54
Hypertension before pregnancy 4.56 (0.96-21.7) 0.057
NYHA  class >1 8.55 (2.26-32.4) 0.002
Signs of heart failure 17.2 (1.73-171) 0.015
Obstructive cardiomyopathy 0.48 (0.13-1.74) 0.26
Mitral regurgitation 1.01 (0.29-3.52) 0.99
RVSP>30 mmHg 5.73 (0.85-38.6) 0.073
Septum thickness 1.03 (0.95-1.12) 0.48
LV posterior wall thickness 1.15 (0.94-1.42) 0.18
CI = confidence interval; NYHA = New York Heart Association functional class; OR= odds ratio; RVSP = right 
ventricular systolic pressure.
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table 4 Obstetric and fetal outcome of pregnancy in the presence of hypertrophic cardiomyopathy, in women 
with and women without MACE
All women with 
HCM Women with MACE
Women without 
MACE
  n= 60 n= 14 (23.3%) n= 46 (76.7%) p-value
   
(pre-)eclampsia or HELLP 3 5.0% 2 14.3% 1 2.2% 0.13
Pregnancy-induced hypertension 0 0.0% 0 0.0% 0 0.0% na
Postpartum haemorrhage 1 1.7% 1 7.1% 0 0.0% 0.23
Caesarean section 36 60.0% 12 85.7% 24 52.2% 0.031
Emergency CS for a cardiac 
reason 3 5.0% 3 21.4% 0 0.0% 0.011
   
Miscarriage <24 weeks 1 1.7% 0 0.0% 1 2.2% 1.00
Fetal death ≥24 weeks 2 3.3% 1 7.1% 1 2.2% 0.42
Termination of pregnancy 0 0.0% 0 0.0% 0 0.0% na
Small-for-gestational age 9 16.1% 2 14.3% 7 16.7% 1.00
Preterm birth (<37 weeks) 14 24.6% 4 30.8% 10 22.7% 0.72
Low Apgar (<7) 6 11.1% 1 7.7% 5 12.2% 1.00
Pregnancy duration, weeks 
(Q1-Q3) 38.3 (36.9-39.1) 37.4 (34.6-38.3) 38.6 (36.9-39.9) 0.037
Birthweight, grams (Q1-Q3) 3000 (2500-3280) 2900 (2555-3228) 3045 (2488-3389) 0.56
Neonatal death, ≤1 week 0 0.0% 0 0.0% 0 0.0% na
CS = Caesarean section; HELLP = Hemolysis Elevated Liver enzymes and Low Platelets; MACE = Major Adverse 
Cardiac Event; na = not applicable; Q1-Q3 = first to third quartile 
*2 patients with heart failure also developed a ventricular arrhythmia
table 5 Outcome in women with obstructive and non-obstructive hypertrophic cardiomyopathy
 
Women with obstructive 
HCM
Women with non-obstructive 
HCM
n= 25 (41.7%) n= 35 (58.3%) p-value
MACE*
Maternal mortality 0 0% 0 0% na
Heart failure 2 8.0% 7 20.0% 0.28
Supraventricular tachyarrhythmia 1 4.0% 0 0% 0.42
Ventricular tachyarrhythmia 1 4.0% 5 14.3% 0.39
Thromboembolic complication 0 0% 0 0% na
Hospital admission 8 32.0% 13 38.2% 0.62
Cardiac hospital admission 4 16.0% 8 22.9% 0.51
(pre-)eclampsia or HELLP 0 0.0% 3 8.6% 0.26
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Follow-up
Follow-up at 6 months was available in 49 of the 60 pregnancies (81.7%) and no maternal 
mortality occurred during follow-up. One patient, with non-obstructive HCM and good LV 
function prior to pregnancy, was found to have severe LV dysfunction with apical thrombus 
formation - along with signs and symptoms of overt HF - at 4 months after delivery with a 
gradual recovery of LV function after heart failure medication was started. 
discussion
The results of our study demonstrate a favorable maternal and fetal outcome in the ma-
jority of women with HCM who tolerated pregnancy well without maternal mortality. At 
the same time, however, 23% of the patient still developed important MACE including HF 
and arrhythmias. In addition, women with cardiac complications had a shorter duration of 
pregnancy and higher rates of emergency cesarean delivery. Functional status and signs of 
HF prior to pregnancy were associated with these complications. 
Mortality in pregnant women with HCM 
The results of this study support data obtained from few retrospective studies reporting 
low mortality rate (0%-2%) related to pregnancy in women with HCM4,11,12. In the study by 
table 5 Outcome in women with obstructive and non-obstructive hypertrophic cardiomyopathy (continued)
 
Women with obstructive 
HCM
Women with non-obstructive 
HCM
n= 25 (41.7%) n= 35 (58.3%) p-value
Postpartum haemorrhage 0 0.0% 1 2.9% 1.00
Caesarean section 14 56.0% 22 62.9% 0.59
Emergency CS for a cardiac reason 2 8.0% 1 2.9% 0.57
Miscarriage <24 weeks 0 0.0% 1 2.9% 1.00
Fetal death ≥24 weeks 1 4.0% 1 2.9% 1.00
Small-for-gestational age 4 16.7% 5 15.6% 1.00
Preterm birth (<37 weeks) 4 16.7% 10 30.3% 0.24
Low Apgar (<7) 5 21.7% 1 3.2% 0.073
Pregnancy duration, weeks (Q1-Q3) 38.6 (37.0-39.1) 38.1 (36.4-39.6) 0.70
Birthweight, grams (Q1-Q3) 3014 (2568-3258) 3000 (2420-3450) 0.80
CS = Caesarean section; HELLP = Hemolysis Elevated Liver enzymes and Low Platelets; MACE = Major Adverse 
Cardiac Event; na = not applicable; 
Q1-Q3 = first to third quartile
*2 patients with heart failure also developed a ventricular arrhythmia
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Autore et al, 2 women (out of 100) with very high-risk profiles died during pregnancy. Both 
had been advised against becoming pregnant4. One had a septum thickness of more than 
30 mm, a very high LVOT gradient and a poor functional class with deterioration during 
her previous pregnancies and the other had an extremely strong familial history of sudden 
death and had experienced prolonged runs of VT prior to death. A recent review presented 
the pooled analysis of 408 pregnancies including these two cases, which were the only 
deaths in the series, giving a maternal mortality rate of 0.5%13. It seems likely, if current rec-
ommendations9 had been followed, that both of these deaths would have been prevented. 
Indeed, in our contemporaneous data, there was no maternal mortality, although at least 7 
patients had a septal thickness of more than 30 mm.
MACE in pregnant women with HCM
A number of complications such as HF, arrhythmias, syncope and thromboembolic com-
plications have been described in women with HCM during pregnancy. The rates of these 
vary from 15% to 48% depending on the study design and patient population4,6,7,13. In the 
most recent retrospective study by Lima et al, which included 52 women with HCM, the 
reported rate of MACE was 23% at time of delivery, which was significantly lower compared 
to women with peripartum or dilated cardiomyopathy14. In our contemporary registry, 
almost a quarter of pregnant women with HCM developed either HF or arrhythmia and 
most of these complications occurred during the 3rd trimester or postpartum, consistent 
with the reported literature.
Heart failure and timing of occurrence
Autore et al identified 98 survivors among 100 women with HCM (199 pregnancies)4.   In 
their study, most of the patients were asymptomatic before pregnancy and clinical dete-
rioration during pregnancy was uncommon. HF symptoms tended to worsen more often 
in those with LVOT obstruction (25% vs 11%), this difference however, was not statistically 
significant. In our registry, 15% of women experienced HF, mainly during the 3rd trimester, 
but there was no difference in pregnancy outcome between women with obstructive and 
non-obstructive HCM. These data are consistent with two other studies where the presence 
of LVOT obstruction had no influence on maternal outcome5,6. Avila et al compared 12 non-
pregnant and 23 pregnant women with HCM, and found that similar to our findings, 30% of 
pregnant women experienced HF mainly during the 3rd trimester6.
Arrhythmia 
Recently, in a retrospective review of 27 pregnancies in 23 women with HCM, Tanaka et al 
reported a cardiovascular event rate of 48%; the vast majority involved an arrhythmia and 
occured during the third trimester7. In contrast, Avilla et al reported an  arrhythmia rate of 
only 13% among 23 pregnant women with HCM, a rate lower than found in non-pregnant 
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women with HCM6. In a series of 8 high risk women with HCM who had  an implantable 
cardioverter defibrillator (ICD), 2 patients had VT (1 sustained and 1 non-sustained) and 2 
had SVT15. Notably,  all events but one, which required anti-tachycardia rapid pacing, were 
detected by interrogation of the ICD without any intervention by the device. In a recent 
review of the existing literature Schinkel et al reported ventricular arrhythmias in 5% and 
supraventricular arrhythmias in 7% of the patients13. Similar to this review, in our registry 
we found that 11.7 % of patients developed arrhythmia, 10% ventricular tachyarrhythmia 
and 1.7% atrial fibrillation (1.7%). In one woman ICD-implantation was necessary because of 
studies reported episodes of palpitations and arrhythmia during pregnancy in women with 
HCM which were similar to those experienced before their pregnancy5,6. More information 
is needed in order to define the effect of pregnancy on the incidence and severity of ar-
rhythmias in women with HCM.
Predictors of complications in pregnant women with HCM 
Several studies reported that symptomatic women deteriorated more often during 
pregnancy than asymptomatic women with HCM5-7. In a large retrospective study (using 
questionnaires), Thaman et al described 271 pregnancies in 127 women with HCM and 
found that the majority (90%) of women with symptoms during pregnancy had been 
symptomatic before7. Similarly, Autore et al found that those who had symptoms prior to 
pregnancy were more likely to deteriorate then those who did not (42% vs. 4%)4. Tanaka 
et al identified the use of cardiac medication prior to pregnancy as a predictor of maternal 
complications in a retrospective study of 27 pregnancies in 23 women with HCM7. In line 
with ESC risk stratification guidelines9, the results of our contemporary registry show that 
NYHA functional class of ≥2 and signs of HF prior to pregnancy are associated with the 
occurrence of MACE.
Obstetric and fetal outcome 
Schinkel reported a 25% Caesarean section rate for predominantly  obstetric indications 
and a 15% rate of spontaneous abortion 5%  therapeutic abortions and a 2% stillbirth rate13. 
In our study , the most frequently observed fetal morbidity was premature birth (26%), 
followed by being small for gestational age (8%) and developing fetal bradycardia (3%). 
Another study described termination of pregnancy in 4 out of 27 pregnancies, all due to 
cardiovascular complications7. In our registry, pregnancy duration in women with MACE was 
significantly shorter than in women without MACE and emergency Caesarean delivery for 
cardiac reasons was performed in 3 women, all of whom had a MACE. Three fetal losses oc-
curred, 1 in a woman with MACE, 1 in a woman with pre-existing atrial fibrillation and 1 due 
to a mitochondrial cardiomyopathy in the fetus itself. As in the current series, fetal mortality 
in all available reports is comparable with the general population16 although it seems to 
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occur mostly in women with cardiac complications, emphasizing the need for appropriate 
follow-up and management of women after a MACE, including close fetal monitoring. 
Conclusion 
Over the last decades, considerable progress has been made in the diagnostic evaluation, 
risk assessment and clinical management in patients with HCM. Results of this contempo-
raneous, multicenter, prospective, worldwide registry showed that most women with HCM 
tolerated pregnancy well and there was no mortality. However, cardiovascular complications 
such as heart failure and arrhythmias were not uncommon and influenced fetal outcome 
and delivery. Functional status and signs of heart failure prior to pregnancy are important 
risk factors for cardiac complications in pregnant women with HCM. Pre-pregnancy counsel-
ing, close monitoring and optimal care are mandatory to prevent complications in women 
with HCM.
Limitations
Our study has a number of limitations mostly related to missing information such as the 
LVOT gradient and its changes during pregnancy. However, obstructive HCM was defined 
as the presence of an LVOT gradient >30 mmHg, so we could characterize the group of 
women with obstructive HCM. In addition, there was incomplete information regarding 
family history, syncope and arrhythmias prior to pregnancy. Despite these limitations, this 
prospective registry included a large number of women with HCM, managed according to 
on contemporary guidelines, providing important information related to the maternal and 
fetal outcome in women with HCM.
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AbstrAct
Aims To describe the outcomes of pregnancy in women with pulmonary hypertension. 
Methods and Results In 2007 the European Registry on Pregnancy and Heart Disease was 
initiated by the European Society of Cardiology. Consecutive patients with all forms of 
cardiovascular disease, presenting with pregnancy, were enrolled with the aim of investi-
gating the pregnancy outcomes. This sub-group of the cohort included 151 women with 
pulmonary hypertension (PH) either diagnosed by right heart catheterization or diagnosed 
as possible PH by echocardiographic signs, with 26% having pulmonary arterial hyperten-
sion (PAH), in 3 subgroups: idiopathic (iPAH), associated with congenital heart disease 
(CHD-PAH) or associated with other disease (oPAH); and 74% having PH due to left heart 
disease (LHD-PH, n=112). Maternal mean age was 29.2±5.6years and 37% were nulliparous. 
The right ventricular systolic pressure was <50mmHg in 59.6% of patients, 50-70 mmHg 
in 28.5% and >70mmHg in 11.9%. In more than 75% of patients, the diagnosis of PH had 
been made prior to pregnancy. Maternal death up to 1 week after delivery occurred in 5 
patients (3.3%), with another 2 out of 78 patients who presented for follow-up (2.6%), dy-
ing within 6 months after delivery. Highest mortality was found in iPAH (3/7, 43%). During 
pregnancy, heart failure occurred in 27%. Caesarean section was performed in 63.4% (23.9% 
as emergency). Therapeutic abortion was performed in 4.0%. Complications included mis-
carriage (5.6%), fetal mortality (2%), premature delivery (21.7%), low birth weight (19.0%) 
and neonatal mortality (0.7%). 
Conclusion Mortality in this group of patients with various forms of PH was lower than 
previously reported as specialised care during pregnancy and delivery were available.  How-
ever, maternal and fetal mortality remains prohibitively high in women with iPAH, although 
this conclusion is restricted by limited numbers. Early advice on contraception, pregnancy 
risk and fetal outcome remains paramount. 
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introduction
Pulmonary hypertension (PH) is a pathophysiological condition often leading to debilitat-
ing symptoms and shortened overall life expectancy, due to narrowing of the pulmonary 
vasculature and often leading to right heart failure. Pregnancy in women with PH, including 
idiopathic pulmonary arterial hypertension (iPAH), PH associated with congenital heart 
disease (CHD-PAH) or PAH due to other conditions (oPAH), are known to be associated 
with a high maternal mortality - between 25-56%1,2. PH in pregnant women is a modified 
World Health Organization (WHO) Class IV indication and, therefore, pregnancy should be 
avoided3. Pregnancy outcome is poor with high rates of preterm delivery (85-100%), fetal 
growth restriction (3-33%) and fetal/neonatal loss (7-13%)1,2,4. However, despite the advice 
to avoid pregnancy3,5 some women with PH choose to become pregnant or to continue 
with an unplanned pregnancy. 
Due to absence of larger (>20 cases) prospective outcome studies on PH in pregnancy, 
many questions remain. The aim of this report was to investigate maternal and fetal out-
comes in women with pulmonary hypertension including all subtypes of PH, according to 
the most recent guidelines 6 and to document the outcomes in the different subpopulations. 
The specific impact of comorbidities, type of anesthesia, mode of delivery and medication 
were evaluated, as well as the risk of developing heart failure and thrombotic events in 
the mother. The data were collected by the European Registry of Pregnancy and Cardiac 
Disease (ROPAC). This registry was initiated by the European Society of Cardiology in 2007. 
Consecutive patients with all forms of cardiovascular disease presenting with pregnancy 
were enrolled7. By 2014, 151 women with elevated pulmonary artery pressures, either di-
agnosed by right heart catheterization or diagnosed as possible PH by echocardiographic 
signs,  were included. 
methods
Study design 
A detailed description of study design and data collection was previously reported7. ROPAC 
is an ongoing worldwide registry that includes all pregnant women with congenital and 
structural cardiac disease. Patients with arrhythmic disease in the absence of structural heart 
disease are excluded. Prospective inclusion of patients commenced in January 2008. This 
interim analysis concerns patients enrolled between January 2008 and April 2014.
For this study, outcomes of pregnancy were analysed for patients with PH. All patients 
with right ventricular systolic pressure (RVSP) >30 mmHg at rest, measured by echocar-
diography or right heart catheterization, were included. Patients with elevated RVSP due to 
outflow tract obstruction/pulmonary stenosis were excluded.
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Data
Information was collected regarding age, parity, cardiovascular risk factors, type of heart dis-
ease, etiology of PH, previous interventions, New York Heart Association (NYHA) functional 
class, signs of heart failure, rhythm disturbance, medication, maternal or fetal mortality, 
cardiac events such as heart failure or arrhythmias, obstetric events such as preeclamptic 
toxaemia or postpartum haemorrhage, timing and mode of delivery, neonatal sex and birth 
weight and postpartum events. Follow-up data included vital status, cardiac events and 
neonatal status. Follow-up was available in all patients up to one week. If available, follow-
up was reported up to six months. 
Information on pulmonary hypertension was collected via the following ROPAC Registry 
website CRF variables: Under echocardiographic assessment the value of the peak velocity 
tricuspid regurgitation, as well as the right ventricular systolic pressure could be entered. 
Right ventricular systolic pressure could be entered via a tick box in the following categories 
of <30, 30-50, 50-70, 70-90 and more than 90 mmHg or unavailable. Amongst the param-
eters for the cardiac function the right ventricular function could be entered as normal, 
moderately impaired and severely impaired. 
The question if full right heart catheterization confirming pulmonary hypertension via 
standard criteria was performed prior to pregnancy, could be answered with either a yes 
(26%) or no. No other parameters such e.g. cardiac output, pulmonary vascular resistance 
were collected in this data base.
Pregnant women were categorised based on the PH etiology as classified in the most 
recent consensus document8. Patients with PAH in case of iPAH, CHD-PAH or oPAH due 
to diseases such as connective tissue disease or vascular malformations were classified as 
group 1. Patients with PH due to left heart disease (LHD-PH) in case of left ventricular sys-
tolic dysfunction, valvular disease or congenital/acquired left heart inflow or outflow tract 
obstructions or congenital cardiomyopathies were classified as group 2. Other diagnoses 
mentioned in the consensus documents were not present in our study population. 
Patients were stratified by RVSP level in three groups: RVSP 30-50 mmHg, 50-70 mmHg, 
and >70 mmHg. 
Heart failure was defined according to ESC guidelines, as a clinical syndrome that is 
characterised by specific symptoms (dyspnea and fatigue) and signs (fluid retention, such 
as oedema, rales) on physical examination, as judged by the treating cardiologist. A heart 
failure episode during or after pregnancy was only registered when signs or symptoms of 
HF were present which required new treatment, change of treatment or hospital admission.
Statistical analysis
Baseline characteristics, as well as cardiac, obstetric and fetal outcome are presented for the 
total PH group. We compared baseline characteristics and outcome of PH in group 1 and 
group 2. Categorical data are presented as frequencies and percentages, and chi-square 
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tests were used for comparison. If there are less than five cases in a group Fisher’s exact test 
was used. Normality of continuous data was checked with Kolmogorov-Smirnov tests and 
presented either as mean ± standard deviation, or as median and first and third quartiles 
(Q1-Q3) as appropriate. Differences between groups were assessed using Student’s t tests 
or, in case of non-normality, using Mann Whitney tests. P values are considered statistically 
significant if less than 0.05 (2-sided test). All analyses were performed in SPSS 21.0 (IBM SPSS 
21.0, SPSS Inc., Chicago IL, USA).
results
Baseline characteristics
In total 2966 pregnancies were enrolled in this interim analysis and 151 (5.1%) had PH 
(flowchart: online supplemental Figure S1). Of these women, 39 (26%) had PAH (Table 1). PAH 
was either idiopathic, associated with congenital heart disease or associated with other 
disease (e.g. connective tissue disease or vascular malformations). LHD-PH was present in 
112 (74%) patients. LHD-PH was associated with valvular heart disease in 100 women and 
with cardiomyopathy in 12 women (Table 1). Mean age of the 151 PH patients was 29.2±5.6 
years and 56 of them (37%) were nulliparous. The majority (59.6%) had a mildly elevated 
RVSP between 30 and 50 mmHg. Further baseline characteristics are presented in Table 2. 
In more than 75% of the patients the diagnosis of PH had been made prior to pregnancy. 
There were no differences between women diagnosed before and during pregnancy. 
Management
Management of PH patients is presented in Table 2. In six women (4.0%), therapeutic abor-
tion was performed because of the pulmonary hypertension in the mother. This occurred in 
two (28.6%) of the iPAH patients; three (10.7%) of the CHD-PH patients; none (0.0%) of the 
oPAH patients; and one (0.9%) of the LHD-PH patients (p=0.003). 
There were 41 patients (27.2%) who were administered diuretics during pregnancy (34 
were LHD-PH patients). Fourteen patients (9.3%) took digoxin during pregnancy (13 were 
LHD-PH patients). Four of these used digoxin temporarily (only one trimester).
During pregnancy nine patients received advanced PH medication (online Table S1) - all 
of them were given a phosphodiesterase type 5 inhibitor (PDE5-i). In addition, four of 
these nine patients were administered an endothelin-receptor antagonist (ERA), and three 
patients were given a prostacyclin analogue. One of these patients used all three. Of the 
patients on ERA, one patient developed a postpartum pulmonary embolism as well as heart 
failure, and one patient was reported to have a thromboembolic complication leading 
to temporary blindness for five days. Heart failure occurred in three other patients - all of 
whom were taking PDE5-i.
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Maternal Outcomes
Hospitalization was needed in 75 patients with 26 of them being admitted more than once. 
In 52 patients there was a cardiac reason for admission. Median timing of admission (known 
in 73% of cases) was 27 weeks (Q1-Q3 = 19.6 – 35.1). Admission for cardiac reasons occurred 
at a median of 25.1 weeks (Q1-Q3 = 19.2-31.2) and mainly for heart failure (42 patients).
No deaths occurred during pregnancy. Five women (3.3%) died peripartum up to one 
week after delivery. Another 2 (2.6%) of 78 women in whom follow-up was available died 
within six months after delivery. Details of maternal mortality are presented in Table 3. 
Death most commonly occurred in the group of iPAH (3/7, 43%), followed by patients with 
LHD-PH (3/112, 2.7%). One of the patients with CHD-PAH died (1/28, 3.6%).  The five patients 
who died in the first week postpartum died shortly after a preterm spontaneous or induced 
delivery and cause of death was acute cardiac failure. In two patients this was induced by 
an infection (patient numbers 4 and 6) and in one patient by mechanical valve thrombosis 
(patient number 5). Two patients died during an intervention (abortion in patient number 2 
table 1 Classification of pregnant women with pulmonary hypertension
Etiology of pulmonary hypertension n %
Group 1 (n=39, 25,9%)      
Idiopathic PAH 7 4.6%
PAH in Congenital heart disease
Eisenmenger syndrome 6 4.0%
PAH in Left-to-right shunts 7 4.6%
Post-operative PAH 15 9.9%
Other PAH 4 2.6%
Group 2 (n=112, 74.1%)      
Left heart disease 
Valvular    
Aortic stenosis 11 7.3%
Aortic regurgitation 7 4.6%
Mitral stenosis 54 35.8%
Mitral regurgitation 26 17.2%
Other valve disease 2 13.2%
Cardiomyopathy    
Dilated CMP 1 0.7%
Hypertrophic CMP 2 1.3%
PPCM 4 2.6%
Myocarditis 2 1.3%
other CMP 2 1.3%
ccTGA, with systemic ventricle dysfunction 1 0.7%
ccTGA = congenitally corrected transposition of the great arteries, CMP = cardiomyopathy, PAH=pulmonary 
arterial hypertension, PPCM = peripartum cardiomyopathy.
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and hysterotomy in patient number 3). One of these seven patients reached term pregnancy 
and died 24 weeks after delivery of cardiogenic shock (patient number 1). One patient died 
of sudden death 24 weeks after therapeutic abortion performed because of maternal heart 
failure (patient number 7).
Some women suffered from thrombotic events. One patient, with a closed arterial duct, 
had a pulmonary embolism and four patients suffered from other thrombotic complica-
tions (prosthetic valve thrombosis, n=1; ischemic cerebrovascular event, n=3).  The ischemic 
cerebrovascular events occurred in the presence of a mechanical aortic valve (n=1), mitral 
valve stenosis (n=1) and an unrepaired arterial duct.
Figure 1 shows the outcome of pregnancy in three different RVSP level groups: mildly, 
moderately and severely elevated RVSP. Maternal mortality at 6 months follow-up was 
significantly different in the three groups (0% in mild PH, 0% in moderate PH, 25% in severe 
PH). There were non-significant differences in the rate of low birth weight (<2500g) in the 
children of women with severe PH (p=0.09, Figure 1). However, in the analysis of the data 
by type of PH, more women with CHD-PAH and oPAH had babies with a birthweight of less 
than 2500g (Figure 2).
figure 1 Outcome of pregnancy and level of RVSP
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Delivery
Details of delivery were reported in 145 patients (96.0%). Caesarean section (CS) was per-
formed in 92 patients (63.4%) and it was initially planned in 83 of them (90.2%), mainly 
for cardiac reasons (65.1%). In ten patients a spontaneous start of labor was reported. 
Anesthesia was reported in 65 CS patients. In 21 patients (32.3%), CS was performed under 
general anesthesia and in 44 patients (67.7%), under local anesthesia. Emergency CS was 
reported in 21 patients, and in eight of them this was for cardiac reasons:  heart failure or 
anticoagulation. Heart failure occurred in five (11.4%) patients after general anesthesia and 
in three (14.3%) patients after local anesthesia in the peripartum period and up to one week 
postpartum. Maternal death occurred in 2 patients (9.1%) after emergency CS, 2 patients 
(2.9%) died after planned non-emergency CS within one week after delivery and one patient 
died during therapeutic abortion (p=0.25, Table 3).
Vaginal delivery was performed in 53 patients (36.6%). Twenty-three patients (43.4%) had 
an induced vaginal labor. Heart failure peripartum or in the first week postpartum occurred 
in two (3.8%) patients after vaginal delivery and in 12 (13.0%) patients after CS (p=0.07). No 
maternal mortality within one week postpartum occurred in patients after vaginal delivery 
versus 4.3% in the CS group (p=0.19).
figure 2 Outcome of pregnancy per PH group
iPAH, idiopathic pulmonary arterial hypertension; CHD-PAH, pulmonary arterial hypertension associated with con-
genital heart disease; oPAH, pulmonary arterial hypertension associated with other disease; LHD-PH, pulmonary hy-
pertension caused by left heart disease.
Epilogue
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Fetal outcome
Fetal or neonatal death up to one week after delivery occurred in 14 pregnancies (9.3%). 
There were 20 neonates (13.8%) who were small for gestational age (Table 4). Of these, 
thirteen babies had a birthweight below 2500 grams. A birthweight below 2500 grams oc-
curred in 28 (19.3%) neonates. Twenty-five of them were delivered by CS, which accounts 
for 27.2% of CS deliveries versus three (5.7%) of vaginal deliveries (p=0.002). Eight of these 
25 were emergency Caesarean sections.
Six neonates (4.0%) were reported to have cardiac anomalies: one persistent ductus 
arteriosus; one, a combination of persistent ductus arteriosus and atrial septal defect; one, 
a combination of persistent ductus arteriosus, atrial septal defect and pulmonary stenosis; 
one hypertrophic cardiomyopathy; one pulmonary valve stenosis; one combination of total 
anomalous pulmonary venous return and atrial septal defect. Of these 6 neonates, 4 had 
a mother with LHD-PH (4 out of 99 live births in LHD-PH, 4%) and 2 had a mother with 
CHD-PAH (2 out of 25 live births in CHD-PAH, 8%). The atrial septal defect (ASD) was found 
in a mother with CHD-PAH that used a PDE5-i.
Six other neonates were reported to have the following non-cardiac anomalies: congenital 
hemophagocytic syndrome; hydrocele; respiratory distress syndrome; rhesus isoimmuniza-
tion; wet lung.
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Follow-up six months postpartum
In 78 patients (51.7%) follow-up at six months postpartum was available. Baseline character-
istics of patients with and without follow-up are presented in online supplemental Table S2. 
Two of these patients (2.6%, Table 2 and Table 3) died 24 weeks after delivery. Heart failure 
occurred in one of the patients who died, as well as in five other patients (7.8%) and two 
patients (2.6%) had an arrhythmic event.
In 22 patients (14.6%) echocardiography before and after pregnancy was available and no 
significant change in the RVSP category was found.
discussion
In this prospective, contemporary, international registry of 151 pregnant women with PH, 
the incidence of maternal cardiac and neonatal complications was high. However, with a 
maternal mortality for the entire group of less than 5%, the overall outcome was substan-
tially better than previously reported. It is the first larger cohort including pregnant women 
with PH categorised according to the most recent consensus document. A clear distinction 
in maternal morbidity and mortality could be made between the different forms. PH due 
to left heart disease was the most common form of PH in this cohort and, to a large extent, 
caused by mitral valve disease or complicated peripartum cardiomyopathy. 
PH due to left heart disease, classified as group 2 of the most recently updated classifi-
cation on PH8, is believed to be the most common cause of PH globally. Epidemiological 
studies of group 2 PH are less exhaustive than for the rarer causes of PH such as iPAH9. Group 
2 PH is likely to be caused by passive downstream elevation in the left heart pressures (post 
capillary), but may progress to reactive  changes of the pulmonary arteries (precapillary), 
leading to mixed PH10.  For reasons unknown, only a certain proportion of patients progress 
to develop reactive pulmonary vasoconstriction, despite the presence of chronic heart 
failure.  Our data show that the diagnosis of PH was made in the majority of cases prior to 
pregnancy, with more than 80% of women having no or minimal symptoms (NYHA FC I or 
II). We found a lower mortality in women with LHD-PH (3 of 112 cases) and CHD-PAH (1 of 
28 cases) compared to a mortality of 43% (3 of 7 cases) in women with iPAH, with most of 
the deaths occurring postpartum. The latter deserves special attention as it implies that 
all women with PH should remain under close supervision for at least a week after having 
given birth. Heart failure occurred in almost 30% and arrhythmias were common. Forty-one 
patients received diuretics during pregnancy, but advanced PH therapy was only given to 
9 cases (8 of 39 cases in group 1, predominantly with iPAH, and 1 of 112 cases in group 2). 
Tabarsi and colleagues11 recently reported their experience with Epoprostenol, the first 
approved therapy shown to improve morbidity and mortality in PAH, in a woman with 
severe PAH and right ventricular dysfunction. The outcome for this woman was satisfactory 
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up to 2 years post-delivery. However, the authors stress the importance of early contact 
with a highly experienced obstetrician in the course of a pregnancy and management by 
a multi-disciplinary team. This team will also prepare a delivery plan, balancing the advan-
tages of vaginal birth (lower blood loss, lower risk of infection and thrombus formation) 
versus Caesarean section (better hemodynamic monitoring). The 2015 ESC/ERS guidelines 
for the diagnosis and treatment of pulmonary hypertension6, as well as the ESC guidelines 
on cardiac disease in pregnancy3, state that pregnancy in all women with PH should be 
avoided or terminated early. Our data suggests that such advice should be focused on the 
high-risk subgroups, namely PAH. However, if pregnancy occurs very close expert follow-up 
is needed with at least monthly review. Serial echocardiography should be used to screen 
for right heart failure.
Altogether, little is known about the outcome of PH in the peripartum period. There are 
only 2 systematic overviews and selected case series (< 20 patients). The case series have 
mainly focused on PAH, e.g. the study by Xavier Jais et al12 reporting on the outcome of 26 
pregnancies in 13 participating centres, during a 3-year period. Three women (12%) died 
and one woman needed urgent heart-lung transplantation. Women with well controlled 
PAH and a low pulmonary vascular resistance in modern therapy had a better outcome in 
this cohort. A study by Weiss et al2, reported on the pooled analysis of publications from 
1978 through 1996, on a total of 125 cases, including 73 with Eisenmenger syndrome, 27 
with primary arterial PH and 25 with secondary PH, with a mortality of 36%, 30% and 56% 
respectively.  Of the total number of reported deaths (n=48), 20% occurred late (as late as 
several months post-delivery). Hemoglobin was only reported for 43 and pulmonary artery 
pressure (PAP) for 81 of the 125 patients. A more recent study by Bedard et al1 summarised 
the findings from 73 pregnant patients with PAH, with 29 having iPAH, 29 CHD-PAH and 
15 oPAH, with a 90-day reported mortality of 17%, 28% and 33%. More than two-thirds 
of the deaths occurred within the first month after delivery. Patients with PH-LHD were 
not included in this analysis. As most of the cases in this cohort came from individual case 
reports, mean pulmonary artery pressure (MPAP), when not reported, was approximated or 
echocardiographic data utilised, using the Bernoulli formula (MPAP=systolic PAP estimated 
by echocardiogram/4x2.4). In the study by Bedard1, therapies for PAH were used during 
pregnancy and delivery in 72% of iPAH, 52% of CHD-PAH and 47% of oPAH.  Patients receiv-
ing general anesthesia were four times more likely to die, compared to patients receiving 
regional anesthesia. 
Recommendations for the management of pregnant women with PAH have been 
published recently in a state-of-the-art review13.  However, this may not be applicable to 
pregnancy in women with other forms of pulmonary vascular disease as the use of PDE5 
inhibitors and prostacyclin have not been investigated in those types of pregnancies6.
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Role of echocardiography in our cohort estimating the degree of PH
According to the 2015 ESC/ERS guidelines for the diagnosis of pulmonary hypertension 6, 
right heart catheterization is recommended as a Class IC indication in patients with pulmo-
nary arterial hypertension. Right heart catheterization for patients with PH due to left heart 
disease has an IIB indication and is indicated only to support treatment decisions.  Right 
heart catheterization would therefore not have been indicated in pregnant women in PH 
groups II-V. The challenges to diagnose the most frequent causes of PH have recently been 
summarised in a paper by Hoeper et al, A global view of pulmonary hypertension 14.
The recently published guidelines highlight also the use of echocardiographic probability 
of PH in symptomatic patients with a suspicion of PH. The authors of the guidelines preferred 
the use of peak tricuspid regurgitation velocity over the estimated PASP or RVSP. However, 
in the ROPAC data base peak tricuspid regurgitation velocity was only rarely entered by the 
investigators. It was not a mandatory field.
The majority of the women in the ROPAC registry had mildly to moderately elevated RVSP 
with more than 80% having a RVSP <70mmHg. Transthoracic echocardiography allows esti-
mation of the RVSP from the velocity of the tricuspid regurgitation by adding the right atrial 
pressure10. This diagnostic module has led to widespread use and increased documentation 
of the burden of PH in patients with heart disease and its association with a high morbidity 
and mortality. PH is often a neglected issue and the importance of long-term follow-up has 
recently been highlighted15. 
A rationale for using echocardiography in the diagnosis of PH in patients from low-to-
middle income countries, where RHC is often not available, has been summarised recently16. 
According to our knowledge, the impact of the haemodynamic changes of pregnancy on 
the measurement of the RVSP by echocardiography has not been formally evaluated. How-
ever, in more than 75% of patients the diagnosis of PH had been made prior to pregnancy 
using standard criteria.
Recommendations for the management of pregnant women with PAH have been pub-
lished in the ESC/ERS guidelines for the treatment and management of PH 6. Patients with 
PAH that choose to continue pregnancy should be treated with disease-targeted therapy. 
However, this may not be applicable to pregnancy in women with other forms of pulmo-
nary hypertension as the use of PDE5 inhibitors and prostacyclin has not been investigated 
in these types of pregnancies. This may have been the reason why only 9 patients in our 
cohort have received PH medication during pregnancy.
Fetal complications and outcomes 
Perinatal complications were common, with fetal or neonatal demise occurring in almost 
10%. Further, a birthweight of less than 2500 gram occurred in one fifth of the babies, reflect-
ing the high rates of growth restriction and preterm birth. The long-term impact of chronic 
maternal hypoxia on fetal outcome remains unknown, but fetal growth restriction is known 
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to programme increased rates of diabetes, heart disease and hypertension in later life17. 
Poor fetal growth has been noted in most reports relating heart disease with pregnancy 
outcome, with the combination of hypoxia and impaired cardiac output having the most 
deleterious effect. 
Data about the pulmonary circulation during pregnancy and its influence on the pla-
cental flow is scarce. However, it is known that the mean pulmonary arterial pressure in 
a normal pregnancy does not change18, while the pulmonary flow increases. This implies 
that the pulmonary vascular resistance has to decrease. In women with pulmonary hy-
pertension, it is likely that there is a limited ability of the pulmonary vascular resistance to 
change throughout pregnancy and, hence, the pulmonary flow, might decrease. In a recent 
systematic review, cardiac output during pregnancy was significantly lower in women with 
heart disease and predicted a poor perinatal outcome (hypertension, pre-eclampsia, fetal 
growth restriction, stillbirth and placental growth abruption)19. However, although the poor 
pregnancy outcome may be a reflection of the limited cardiac output, it is also possible that 
other factors present in women with pre-existing heart disease may influence placental de-
velopment, leading to poor pregnancy outcome. We found a high frequency of congenital 
heart disease in the newborn, which warrants further research. 
Limitations
This registry, as most other registries, has numerous limitations such as incomplete (<5%) 
and biased data. Specifically the timing of diagnosis has not been reported in 25% of cases. 
This is a global registry with some centres having dedicated high-risk obstetric clinics and 
much higher volumes than others, which is likely to affect the outcome.  In general, centres 
in ROPAC are typically tertiary centres with well-organised pregnancy clinics. Thus, all con-
clusions must be drawn with caution. 
In addition, the diagnosis of PH was not made with heart catheterisation in all patients. 
As highlighted by others14, many patients had echocardiographic diagnosis of probably PH 
because an invasive test would neither be feasible or indicated. The interpretation of our 
data must take into account that echocardiography as a diagnostic modality has limitations 
in PH. 
This is a relatively large series of patients with PH, but mortality occurred in only a limited 
number of cases. Therefore, interpretation of mortality rates per subgroup should be done 
cautiously. In many countries patients are unable to return for 6-month follow-up visits 
due to financial constraint, e.g. having to pay for the clinic visit and all investigations and 
transport to the hospital. As late (6-month) follow-up was only reported in about 50% of the 
patients, the number of late deaths is likely to have been underestimated. Therefore only 
limited conclusion can be drawn from these data. 
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Conclusion
Despite the advent of a number of therapeutic options for patients with PH, pregnancy 
remains a substantial risk and commonly leads to heart failure. Mortality remains high, 
particularly in women with iPAH (although limited number of patients: 3/7, 43%). However, 
there are marked differences in the maternal and fetal outcome of women with iPAH, CHD-
PAH, oPAH and LHD-PAH, which need to be highlighted and investigated further. Our data 
differ from previous systematic overviews and pooled cases series as we included all sub 
groups of PH including a high number of LHD-PH. As most deaths occurred postpartum, 
women should be kept in hospital for at least a week post-delivery and possibly longer, 
being monitored for arrhythmia, heart failure and uterine hemorrhage in particular. Vaginal 
delivery is usually the preferred mode of delivery. Pre-conception, women need to be coun-
selled, not only about the risk to their health in the short and longer term, but also about the 
overall poor outcome for their children. However, if pregnancy occurs, close follow-up with 
a minimum of monthly visits and echocardiograms to screen for and treat right heart failure 
are essential.  Larger, prospective, carefully conducted multi-centre studies in patients with 
PH are required to determine the exact pregnancy-related risk, the role of supportive care 
and advanced PH therapy, as well as predictors of outcome for each sub-group.  
Online Supplementary Information
Figure S1 Flowchart of inclusion
Table S1 Pulmonary hypertension medication
Table S2 Characteristics of patients with and without follow-up
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Discussion
summAry
Cardiac disease is the most important cause of maternal mortality1. The overall maternal 
mortality rate declines,  but there is a remarkable increasing trend for cardiac death during 
pregnancy and after delivery. This thesis investigated the risks of pregnancy in women with 
cardiac disease. The majority of the chapters is based on the global prospective Registry 
for Pregnancy And Cardiac disease (ROPAC), which was designed to study large groups of 
women with all sorts of heart disease, aortic pathology and pulmonary hypertension2. From 
previous studies we know that risk stratification is important to distinguish between those 
women at low, intermediate or high risk3-5. The guidelines for pregnancy and heart disease 
recommend to use the modified World Health Organization (WHO) risk classification6. It is 
based on expert opinion. Women are stratified by their cardiac lesion, systolic function and 
New York Heart Association (NYHA) classification. Women with a simple cardiac lesion such 
as a repaired atrial septal defect, are in class I which is associated with a low risk of morbidity 
and mortality, comparable to pregnant women without cardiac disease. Women in class IV 
(pulmonary arterial hypertension, NYHA class 3 or 4) have an extremely high risk and are 
advised to avoid pregnancy. The complication risk is thought to increase in modified WHO 
class II and III.
In Chapter 1, we validated the modified WHO risk classification, in the largest cohort to 
date and also in emerging countries for the first time. We showed that the modified WHO 
classification has a moderate discriminative power with a c-statistic of 0.71 and is therefore 
quite useful but there is room for improvement. First of all, there is a noteworthy incidence 
of events in WHO class I, assumed to be a group with no increased risk. Women in this group 
should not be told that the risk is negligible, and we need to further define which class-I-
women have an elevated risk compared to their peers. The difference in accuracy of the tool 
in emerging and advanced countries is also remarkable. The event rate shows the expected 
gradual increase in advanced countries, while the event rate varies in emerging countries. 
This is partly explained by the different underlying diagnoses: predominantly congenital 
heart disease in advanced countries, and valvular heart disease in emerging countries. We 
added more clinical parameters to the modified WHO-risk tool. Adding atrial fibrillation and 
signs of heart failure to the risk tool enables a better prediction of risks, in particular in 
countries with an emerging economy, and we introduced a revised risk tool for clinical use. 
In Chapter 2 it appeared that the modified WHO risk tool has a poor value for prediction 
of obstetric and fetal risks. It seems that the ‘usual suspects’ like multiple pregnancy and 
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preconception hypertension are better predictors to evaluate risks just like in other preg-
nant women. Twin pregnancy had a major influence on outcome (OR 6.4 for fetal/neonatal 
death; OR 5.0 for small-for-gestational age), but we do not know whether this influence is 
more distinct than in women without cardiac disease. It does raise the question how to deal 
with multiple pregnancy. A preventive approach is probably a sensible choice, by avoid-
ing multiple embryo transfer and restrict ovulation induction. It is impossible, however, to 
prevent spontaneous multiple pregnancies. Reduction of multiple pregnancy just because 
of the presence of maternal cardiac disease seems a step too far, but definitely should be 
considered in case of deterioration of the mother’s condition.  Other associations found, 
were maternal complex congenital heart disease being predictive of fetal growth restric-
tion, and more interestingly aortic disease being related to pre-eclampsia. These findings 
may help to better understand pathophysiology of pregnancy complications.
We investigated the impact of several specific complications: supraventricular and ven-
tricular arrhythmia’s. The results are described in Chapter 3 and 4. Fortunately, the incidence 
of arrhythmic complications was relatively low. Ventricular arrhythmias occurred in 1.4% of 
women and were associated with heart failure, but it is difficult to conclude on cause and 
effect based on the data we have. As previously described, heart failure indeed is a much 
bigger problem with an incidence of approximately 13%7. We found that most patients with 
ventricular arrhythmia had heart failure, but not all patients with heart failure developed 
ventricular arrhythmias. Patients with NYHA class 2 or higher were at highest risk. Clearly, 
efforts should be made to prevent ventricular tachyarrhythmia’s, not only because of the 
maternal risks, but also because of the clear impact on fetal outcome, expressed as higher 
rates of preterm birth (36%), low birth weight (33%) and neonatal death (4.8%). While atrial 
fibrillation and flutter are considered quite benign events in the general population, we 
showed an alarming trend towards higher maternal death rate. In our large database of 
patients with structural heart disease we found an incidence of 1.3%. Atrial fibrillation and 
flutter were found mainly in patients with mitral valve disease and women with other left 
sided lesions, and occurred typically by the end of the second trimester. Heart failure and 
arrhythmias form the major complications during pregnancy.
Other potential hazardous situations during pregnancy such as acute coronary syndrome, 
aortic dissection or prosthetic valve thrombosis are discussed in Chapter 5.Women suffering 
from these life-threatening events often present ‘de novo’, and thus did not have preconcep-
tion counselling, simply because they were not known to have a cardiac or aortic disease. 
We know from the “Confidential enquiries” in the United Kingdom, an obligatory registry of 
all maternal deaths, that these diseases are the most important cause of maternal cardiac 
mortality1. Doctors working in the emergency department should have knowledge of this 
specific high-risk group of patients. Practical flow charts are provided to assist in urgent 
treatment decision making.
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We conclude part 1 of this thesis with a study describing the impact of socioeconomic fac-
tors on the outcome of pregnancy in women with cardiac disease. The results are presented 
in Chapter 6. While maternal condition appeared the main denominator of pregnancy 
outcome in women with heart disease, some socioeconomic influence cannot be denied. 
Access to advanced health care, with dedicated ‘pregnancy and heart disease clinics’, is not 
the norm in many countries and rural areas. Women may present at a later stage, because 
of costs but also because of their cultural background, with pregnancy providing a certain 
status. For instance, in Egypt it is so important to have children that women often do not 
mention their heart defect. Only when pregnancy is already in an advanced state or when 
severe problems arise, these women seek help, making early intervention (let alone preven-
tion) very difficult. It is important to bear in mind the interregional differences in outcome, 
not only when interpreting the ROPAC results, but also when aiming for improvement of 
general maternal outcome.  
Part II focusses on pregnancy in women with valvular heart disease. In Chapter 7 and 
Chapter 8 we studied women with left-sided valve disease. We describe a cohort of 96 
patients with moderate or severe aortic stenosis. The pregnancy related mortality rate 
was low in these women, compared to older studies. However, women with symptomatic 
severe aortic stenosis in our study had a considerable risk of developing heart failure (26%) 
throughout pregnancy. Probably at least some of them should have been treated pre-
pregnancy anyway. It remains a difficult decision whether we should treat women with 
asymptomatic severe stenosis pre-pregnancy or not. Valve replacement introduces a new 
dilemma. In case of choosing a mechanical valve, we know pregnancy is a risky period when 
it comes to bleeding and thrombosis (see chapter 9). In case of choosing a bioprosthetic 
valve, we know this valve will deteriorate over time and another valve intervention will be 
unavoidable after 10-15 years. As we are discussing young patients they typically will need 
many reinterventions in that situation. 
In Chapter 7, we have shown that women with rheumatic mitral valve disease, specifically 
those with severe mitral stenosis, are at very high risk of adverse outcome. This was not sur-
prising, with the current guidelines advising to avoid pregnancy in those with a severe and 
symptomatic stenosis (heart failure in 36%). But the evidently increased risk of pregnancy in 
women with moderate mitral stenosis (heart failure in 23%), and even those with isolated 
significant regurgitation (heart failure in 23%), is a finding that needs closer attention in 
future recommendations: how to deal with women who are formally not an intervention 
candidate yet, but do have a pregnancy wish in the presence of moderate mitral stenosis? 
Does the risk of pregnancy outweigh the risk of early intervention or not? And what type of 
intervention is safest? Balloon dilatation during pregnancy was associated with an unevent-
ful course of further pregnancy in most women. 
In Chapter 9, pregnancies in the presence of a mechanical and/or bioprosthetic valve are 
described. Women with a mechanical valve had a dissatisfactory 58% chance of having an 
310 Discussion
uncomplicated pregnancy with a live child, while women with a bioprosthetic valve had a 
much better outcome. But the question remains whether there is a long-term deteriorating 
effect of pregnancy on bioprosthetic substitute functioning. Also, there is much room for 
improvement when it comes to anticoagulant treatment during pregnancy in the presence 
of a mechanical valve. Guidelines advice different strategies, with a switch to low-molecular-
weight heparin or unfractionated heparin in the first trimester, and continuation of vitamin 
K antagonists in high-risk pregnancies6. In the second and third trimester, a vitamin K an-
tagonist is recommended. As of 36 weeks it should be replaced with some sort of heparin 
to prevent major fetal bleedings during vaginal delivery. Currently, none of the reported 
strategies in our cohort appeared superior. Vitamin K in the first trimester was related with 
a high rate of fetal deaths in the second and third trimester, while the use of low molecular 
weight heparin seems to increase the risk of valve thrombosis. The newer direct thrombin 
inhibitors (such as apixaban) are not safe for prevention of mechanical valve thrombosis.
The effects of pregnancy on the aortic wall are delineated in Chapter 10, the first chapter 
of Part III. These effects generally do not lead to severe aortic problems in women without 
underlying aortic pathology, but women with an aortic syndrome such as Marfan, Loeys 
Dietz or Turner syndrome may be at increased risk of aortic dissection. An overview of litera-
ture is presented, with focus on specific etiologies, medical treatment and surgical approach 
during pregnancy.
Turner syndrome is characterised by a partial or total monosomy of the X-chromosome. 
It is associated with short stature, sub- or infertility due to gonadal dysgenesis, and cardiac 
and aortic anomalies. Pregnancy has been out of reach for the vast majority of women with 
Turner syndrome for decades due to infertility. But since oocyte donation has become avail-
able, the number of pregnancies in this group has expanded. In Chapter 11, we described 
pregnancy wish, reasons for not (yet) attempting pregnancy and number of attempts 
ending in conceptions. A significant number of women had (had) concerns about the risk 
of cardiovascular complications during pregnancy and delivery, which we feel deserves 
attention from treating physicians. In Chapter 12 we show the outcome of pregnancy in 
women with Turner syndrome from our centre. We found  that the number of miscarriages 
was high, but that the full-term pregnancies had a quite low cardiovascular event rate. How-
ever, much more research is required, given the fact that studies describing cardiovascular 
events in Turner syndrome, including ours, are limited by the lack of statistical power. A large 
multicentre global prospective registry such as ROPAC, with a focus on Turner syndrome 
an d(very) long-term follow-up, would be the only way to discover the exact aortic growth 
and incidence of aortic dissection related to pregnancy. While the same lack of statistical 
power issue plays a role in women with SMAD3 mutations, our report in Chapter 13 is the 
first and largest case series describing pregnancy in this recently discovered genotype of 
patients with aggressive aortic pathology, associated with aneurysms and aortic dissection 
and rupture. No severe cardiovascular problems were found in 17 pregnancies in women 
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with SMAD3 mutations, almost all having at least some clinical findings of the phenotype 
(some several years after pregnancy), and this retrospective study can be seen as a starting 
point for further investigations in this group of women. 
Chapter 14 shows the relatively favourable outcome of pregnancy in 60 women with 
hypertrophic cardiomyopathy. No maternal deaths occurred, but 15% of women suffered 
from heart failure and 10% had a ventricular tachyarrhythmia. Events occurred mainly dur-
ing the 3rd trimester, and directly postpartum. Women with pre-pregnancy dyspnea or signs 
of heart failure were at highest risk. Surprisingly, no differences were found between women 
with obstructive disease and those with non-obstructive cardiomyopathy. However, the 
overall cardiac event rate of 23% should be definitely mentioned when counselling women 
with hypertrophic cardiomyopathy. 
Pulmonary hypertension is a whole other story: as previously mentioned, pulmonary 
arterial hypertension (PAH) is a reason to avoid pregnancy according to the guidelines. We 
demonstrated in Chapter 15 that the existing concerns about this group of patients is justi-
fied. But until now, little was known about the risk of pregnancy in women with elevated 
right ventricular systolic pressures due to left-sided heart disease. We studied a cohort of 
151 with elevated right ventricular systolic pressures (RVSP), of whom 26% had PAH and 74% 
had pulmonary hypertension due to left-sided heart disease. Heart failure occurred in 36% 
and 25%, respectively. Maternal death occurred mainly in women with idiopathic PAH (3 out 
of 7: 43%), while the maternal mortality rate in left-sided heart disease was not zero either 
(2.7%). Women with severely elevated pressures (RVSP>90 mmHg) were at highest risk of 
maternal death, thrombotic events and delivery of a small baby (<2500gr), although low 
numbers prevented statistical significance. The results of our study imply that pulmonary 
hypertension due to left sided heart disease may carry a lower risk of pregnancy related 
events, but that they should be carefully counselled about the associated risks. It would be 
reasonable to distinguish between mildly, moderately and severely elevated right ventricu-
lar systolic pressures in future guidelines.
conclusions And future directions
Leading a ‘normal’ life is important to young women with heart disease, just as it is for their 
healthy peers, and pregnancy is one important aspect of that normal life. This thesis investi-
gated the risk of pregnancy in women with several types of cardiac and aortic disease. Apart 
from some high risk groups, women with cardiac disease tolerate pregnancy reasonably 
well in the current era. The majority of young girls and women with heart disease can be 
reassured about these improving prospects, provided that we accurately search for the ones 
with a substantial higher risk. 
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Every woman with cardiac disease and a pregnancy wish, needs to be stratified and 
informed accordingly about her risk for adverse cardiac and fetal outcome. We recommend 
the use of the modified WHO classification, which we amended in Chapter 1 along with a 
risk chart that is easy to use in practice. But the advice and management plan is still a matter 
of individualized medicine. All women should therefore be evaluated before pregnancy, and 
in case of modified WHO class II or higher, this should be done in a multidisciplinary team 
of at least a cardiologist and obstetrician. Once a woman is pregnant, this multidisciplinary 
approach needs to be continued, with close collaboration with an anesthesiologist, who 
has expertise in the field of obstetrics and cardiac dysfunction. Other specialties should be 
involved with low threshold, such as a haematologist in case of therapeutic anticoagulation 
indications, or a pulmonologist in case of pulmonary arterial hypertension.
Young women with valvular stenosis will benefit in particular from close echocardio-
graphic evaluation before preconception advise. We have shown the high risk of pregnancy 
complications, specifically in those with moderate or severe mitral stenosis. The imminent 
pregnancy wish of these women preferably is discussed in a team with valve intervention 
cardiologists and valve surgeons. A lower threshold towards intervention may be the result. 
However, whether the risk of pregnancy with valve stenosis outweighs the risk of valve 
surgery remains an important question. And in case of mechanical valve implantation, one 
should be aware of the risk of pregnancy complications in the presence of any anticoagula-
tion strategy. Perhaps newer interventional approaches offer a solution: is there a future for 
trans-catheter valve replacement in these young women?
Several diagnosis groups need further investigation in the future, to determine whether 
women may tolerate pregnancy in the current era and to select clinical predictors or 
biomarkers to reveal the group that may be better off, avoiding pregnancy. Examples 
are ischemic heart disease, certain aortic syndromes (as explained later) and complex 
congenital heart disease with interventions such as Fontan circulation. Ischemic heart 
disease in pregnant women is quite rare but an expanding problem in young women, as 
a result of wealth-related epidemic issues such as smoking, obesity and increasing age at 
childbirth. Acute myocardial infarction during pregnancy is associated with high rates of 
maternal morbidity and mortality8. First and above all, coronary artery disease in young 
women should be prevented by all means.  But there is also a need for further research 
about the therapeutic strategies in pregnant women: percutaneous coronary intervention 
is first choice. But little is known about the use of antiplatelet therapy such as ticagrelor and 
glycoprotein IIb/IIIa inhibitors such as eptifibatide. Their use in pregnant women and also 
the (hopefully improving) outcome of pregnancy in the presence of ischemic heart disease 
need to be studied in more depth.
It is only since a few decades that the life expectancy of children with complex congenital 
heart disease improves rapidly: the majority of patients with a Fontan circulation for instance 
now reach adulthood, and thus fertile age. Although fertility issues seem to be present, 
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some women with a Fontan circulation do get pregnant9. And it will be just a matter of time 
until we start to see the first reports about pregnancy in Fontan patients with hypoplastic 
left heart syndrome, a very complex entity. Current studies in Fontan are rather small and/
or retrospective, and show a high miscarriage rate and significant cardiac event rate in the 
remaining women10,11. Prospective long-term follow-up studies are required to study the 
exact risks and the influence of pregnancy on these women’s life expectancy. 
Echocardiographic changes during pregnancy have been described by several studies, 
both in ‘normal’ pregnancies, as well as in women with structural heart disease12-17. Car-
diac output increases up to 50% during pregnancy, but an even bigger impact has been 
described during delivery, as also depicted in Chapter 5, figure 1. It is a period of risk for 
developing heart failure, specifically in women with diminished left ventricular function, 
and close monitoring of hemodynamic parameters such as cardiac output would be desir-
able. Echocardiographic measurement of cardiac output has been validated in pregnant 
women18. But echocardiographic measurements during delivery are quite hard to achieve. 
Non-invasive cardiac output measurements have been proposed in this setting, but require 
validation studies during pregnancy and in particular during delivery. It would be very 
interesting to study this method in women with structural heart disease and a high risk of 
developing heart failure.
Also, long term effect of pregnancy on the structural abnormal heart needs further in-
vestigation. Clinical follow-up studies showed an increased event rate 1 year postpartum, 
mainly in women who experienced a cardiac event during pregnancy19,20. A prospective 
cohort study showed reduction of systolic and diastolic function after 6 months in women 
with cardiac disease21. Little is known about which underlying diagnosis carries the highest 
risk, and more importantly, whether it is related to more events later in life and reduces life 
expectancy of the mother. This may influence a patient’s pregnancy wish and in selected 
cases maybe even the physician’s advice regarding assisted reproductive therapy. Large 
prospective cohort studies with long-term echocardiographic follow-up are required. 
In Chapter 2 we have shown an association between aortic disease and preeclampsia. 
Preeclampsia during pregnancy in general is predictive for cardiovascular disease in later 
life, with an increased risk of hypertension, ischemic heart disease, stroke and death22,23. It is 
suggested that this increased risk results from arterial changes, but others hypothesize that 
there is no causal relationship between preeclampsia and cardiovascular disease in later life, 
but that these women were predisposed anyway24,25. Still it poses us to the question: are 
women with pre-existent aortic disease, who develop pre-eclampsia during pregnancy, at 
much higher risk of aortic dissection well after pregnancy, at an earlier age, than their peers 
with an uncomplicated pregnancy? Would these women benefit from preventive strategies 
for preeclampsia such as low-dose aspirin therapy? 
The additive risk of pregnancy in women with Turner syndrome when it comes to aortic 
dissection is very hard to determine. Available evidence comes from small cohorts, mainly 
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of retrospective nature. Of course these studies are the basis of future research. But single 
centers and nations are not able to collect numbers of patients large enough to draw 
firm conclusions about the exact risk of aortic dissection. There is a clear need of a large 
international collaboration26. Hopefully, a recent taskforce on new guidelines will accelerate 
such initiatives (expected in 2017).  A research question we are eager to get an answer 
to is whether women with Turner syndrome can safely get pregnant, after prophylactic 
aortic surgery. Braverman and colleagues wrote an alarming report describing 3 cases of 
pregnancy after aortic surgery in Loeys-Dietz syndrome, ending up in a dissection in two 
cases27. Currently, we do not have much other evidence on pregnancy after aortic surgery, 
let alone in Turner syndrome. Also, we do not know whether pregnancy induces a signifi-
cant increase of aortic dimension in Turner syndrome. It would be very interesting to know 
if these women benefit from beta-blockers, used to limit aortic growth rate in some forms 
of aortic aneurysms such as Marfan syndrome, and this needs further investigation both 
during and outside pregnancy.
While the goal of this thesis was to answer a lot of questions, undoubtedly it raised even 
more questions as mentioned in this chapter. And we could continue forever about topics 
that deserve or require attention: what are the risks of pregnancy in women with arrhythmic 
disease? What is the effect of preconception counselling in the different WHO classes? Is 
assisted reproductive therapy an option in women with a complex cardiac disease, that 
have an improved life expectancy in the current era of medical technologies? We are still 
at the beginning of elucidating this interesting research area. By shedding a light on these 
issues, young women with heart disease will have a chance to lead a life as close to normal.
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Voor jonge mensen met een hartafwijking is het belangrijk om een zo normaal mogelijk 
leven te leiden, net als hun leeftijdsgenoten zonder een hartafwijking. Zwangerschap is 
daar een onderdeel van. Maar zwangerschap vormt een belasting voor het hart: om de 
baarmoeder en het kind te kunnen voorzien van voldoende zuurstof en voedingsstoffen, 
neemt het bloedvolume sterk toe. Dat betekent dat het hart zo’n 50% meer bloed rond dient 
te pompen per minuut1-3. Een gezond hart kan deze fysiologische veranderingen aan. Maar 
een hart dat afwijkend is, kan zich niet altijd aanpassen. Daarnaast hebben de hormonale 
veranderingen tijdens de zwangerschap impact op de bloedvaten en kan zwangerschap 
leiden tot een hogere bloeddruk. Hartziekte (cardiovasculaire ziekte) vormt de belangrijkste 
oorzaak van moedersterfte4. Terwijl moedersterfte door andere oorzaken wereldwijd juist 
afneemt is er in de laatste decennia een toename van moedersterfte door cardiovascu-
laire ziekte5. Dit is een zorgwekkende trend, en het maakt onderzoek naar de risico’s van 
zwangerschap in vrouwen met een hartafwijking noodzakelijk. Wie zijn de vrouwen met 
het hoogste risico, en moeten zij afgeraden worden om zwanger te worden? Wat zijn de 
risico’s voor het kind als de moeder een hartafwijking heeft en wat gebeurt er als zij een 
complicatie doormaakt? Het doel van dit proefschrift is dan ook het inzichtelijk maken van 
de risico’s van zwangerschap, middels de volgende onderwerpen:  
- risico stratificatie voor de uitkomst van zowel moeder als kind
- incidentie en impact van complicaties zoals ritmestoornissen 
- bestuderen van patiënten met een hoog-risico aandoening zoals een kunstklep 
- invloed van socio-economische factoren op de uitkomst van zwangerschap in deze 
groep vrouwen 
- bestuderen van de zwangerschapswens bij vrouwen met het syndroom van Turner
Het voornaamste gedeelte van dit proefschrift is gebaseerd op de Registry Of Pregnancy 
And Cardiac disease, de ROPAC studie6. Deze wereldwijde registratie werd in 2007 opgezet, 
door Professor Roger Hall uit Norwich, Verenigd Koninkrijk, en Professor Jolien Roos-
Hesselink, uit Rotterdam, met als doel een grote groep vrouwen met een hartafwijking te 
verzamelen, en de uitkomst van hun zwangerschappen te bestuderen. Vrouwen met allerlei 
soorten structurele hartafwijkingen worden geïncludeerd. Tot op het moment van schrijven 
zijn er al meer dan 4000 vrouwen geïncludeerd, in meer dan 100 verschillende centra uit 
meer dan 60 verschillende landen. 
In Deel I van dit proefschrift hebben we het voorkomen van verschillende acute hartproble-
men (cardiale complicaties) bestudeerd. Welke vrouwen hebben het hoogste risico op een 
problematisch verloop van de zwangerschap? In de Europese richtlijnen wordt de gemodi-
318 Nederlandse samenvatting
ficeerde World Health Organization (WHO) risicoscore geadviseerd om het risico van een 
patiënte in te schatten7,8. Het is gebaseerd op de onderliggende diagnose (bijvoorbeeld een 
gerepareerd gaatje in het boezem tussenschot of een verhoogde druk in het longvaatbed). 
WHO klasse 1 houdt in dat er een laag risico bestaat op het ontwikkelen van een com-
plicatie tijdens de zwangerschap, vergelijkbaar met het risico van zwangerschap bij een 
vrouw zonder hartafwijking. In klasse 2 en 3 loopt dat risico op, en in WHO klasse 4 worden 
vrouwen geplaatst met een ernstig verhoogd risico op complicaties en sterfte, hetgeen een 
reden is om hen absoluut af te raden om zwanger te worden. Deze classificatie is ontwikkeld 
op basis van expertise. Grote onderzoeken ontbraken tot op heden om de waarde van de 
classificatie aan te tonen middels statistische analyses. In hoofdstuk 1 laten we zien dat 
de classificatie redelijk in staat is om het risico op een cardiale complicatie te voorspellen. 
Er zijn echter duidelijk verschillen in de voorspellende waarde in ontwikkelingslanden en 
in ontwikkelde landen. Tot op heden was er weinig bekend over de uitkomst en dus ook 
de voorspellers van uitkomst van zwangerschap in vrouwen met een hartafwijking uit 
ontwikkelingslanden. We stellen voor om een aantal klinische parameters aan de WHO risico 
classificatie toe te voegen, om de voorspelling nauwkeuriger te laten verlopen: met name 
in ontwikkelingslanden voorspelt het hebben van een boezemritmestoornis (fibrilleren) of 
tekenen van hartfalen vóór de zwangerschap in belangrijke mate het risico op een cardiale 
complicatie tijdens zwangerschap.
In Hoofdstuk 2 gaan we op zoek naar de waarde van de WHO classificatie voor het voor-
spellen van obstetrische en foetale complicaties, zoals pre-eclampsie, laag geboorte gewicht 
en foetale sterfte. Het blijkt dat de WHO classificatie niet goed in staat is om deze uitkomsten 
te voorspellen. Zodoende gingen we op zoek naar voorspellers van specifieke complica-
ties in vrouwen in de ROPAC studie. Het blijkt bijvoorbeeld dat een complexe aangeboren 
hartafwijking bij de moeder veel vaker gepaard gaat met een te laag geboorte gewicht bij 
het kind, relatief tot de duur van de zwangerschap. Ook zien we dat pre-eclampsie vaker 
voorkomt bij vrouwen met een ziekte van de aorta. Dit zijn interessante bevindingen die ons 
in de toekomst wellicht ook meer inzicht kunnen bieden in het ontstaan van de betreffende 
complicaties. Een ander belangrijke associatie is tweelingzwangerschap: in onze studie 
eindigden deze zwangerschappen zorgwekkend vaak tot foetale sterfte, en het is de vraag 
of verlies van de foetus zelfs vaker voor komt dan in tweelingzwangerschappen in vrouwen 
zonder een hartafwijking. Maar hoe om te gaan met meerlingzwangerschappen in deze 
vrouwen? Het lijkt verstandig om in het geval van fertiliteitsbehandeling terughoudend te 
zijn met ovulatie inductie en met multipele embryo terugplaatsingen en de voorkeur te 
geven aan ‘single embryo transfer’. Maar spontane meerlingzwangerschappen zijn moe-
ilijk te voorkomen, en het lijkt een brug te ver om actief over te gaan tot reductie van de 
zwangerschap tot een eenling, enkel omdat het een zwangerschap betreft bij een vrouw 
met een hartafwijking. Maar in het geval dat de conditie van de vrouw ernstig achteruit 
dreigt te gaan, zal dit zeker overwogen moeten worden.
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Hartfalen is een bekend probleem in patiënten met een hartafwijking: het hart is onvol-
doende in staat om het bloed de aorta in te pompen, en doordat het daarin faalt, kan een 
patiënt last krijgen van longoedeem (‘vocht achter de longen’), met kortademigheid en 
moeheid, en oedeem in de benen. Bij vrouwen met een hartafwijking komt het  voor in 13% 
van de zwangerschappen, zoals collega dr. Ruys reeds beschreef in een eerder artikel over 
de ROPAC9. Het is één van de complicaties die we probeerden te voorspellen in hoofdstuk 
1. In hoofdstuk 3 en 4 gaan we op zoek naar het voorkomen van ritmestoornissen in de 
zwangerschap. Zowel supraventriculaire (boezem) als ventriculaire (kamer) ritmestoornissen 
komen gelukkig niet vaak voor: respectievelijk in 1.3% en in 1.4% van de zwangerschappen. 
Ventriculaire ritmestoornissen waren vaak geassocieerd met het optreden van hartfalen. 
Patiënten met kortademigheid voor de zwangerschap hadden het hoogste risico op een 
ventriculaire ritmestoornis. Verder blijkt dat vrouwen die een ritmestoornis hebben tijdens 
de zwangerschap, een hoger risico hebben op een slechte afloop: ze verliezen iets vaker 
hun baby, en er is vaker sprake van een laag geboorte gewicht. We moeten zo’n ritmestoor-
nis dus zo goed mogelijk proberen te vermijden of in ieder geval zo vroeg mogelijk op te 
sporen. De behandeling is tijdens de zwangerschap lastiger dan buiten de zwangerschap 
omdat sommige medicijnen kwaad kunnen bij de baby. Van sommige medicijnen is dit 
goed uitgezocht, maar hier is duidelijk nog meer onderzoek nodig.
In hoofdstuk 5 beschrijven we welke acute en potentieel levensgevaarlijke complica-
ties er op kunnen treden tijdens de zwangerschap, en vooral hoe daar het beste mee om 
gegaan kan worden. Voorbeelden zijn acuut coronair syndroom (dat is, in het ergste geval, 
een hartinfarct), aorta dissectie (een scheur in de grote lichaamsslagader) of kunstklep trom-
bose (een stolsel op de kunstklep). Vrouwen die zich met zo’n complicatie presenteren, zijn 
vaak vooraf nog niet bekend met een/hun hartafwijking, en hebben daarom voorafgaand 
aan de zwangerschap ook geen consult met een cardioloog gehad om te spreken over de 
potentiele risico’s van zwangerschap ten aanzien van het hart of de aorta. We weten van de 
‘Confidential enquiries’ in het Verenigd Koninkrijk, een nationale verplichte registratie voor 
moedersterfte, dat deze hartproblemen de belangrijkste oorzaken zijn van moedersterfte4. 
Artsen op de spoedeisende hulp zouden zoveel mogelijk kennis in huis moeten hebben 
over deze specifieke groep risico patiënten om tijdig de diagnose te kunnen herkennen. Om 
snelle behandelingskeuzes mogelijk te maken, worden in hoofdstuk 5 flow diagrammen 
voor diagnostiek en behandelingsstrategie per diagnose aangeboden. 
We besluiten Deel I van dit proefschrift met het bekijken van de invloed van socio-
economische factoren op de uitkomst van zwangerschap in vrouwen met een hartafwi-
jking. De invloed van dit soort factoren is nog onvoldoende onderzocht. Onze resultaten 
zijn weergegeven in hoofdstuk 6. Terwijl maternale conditie de belangrijkste noemer voor 
uitkomst van zwangerschap bleek, kan socio-economische invloed op de uitkomst in deze 
groep vrouwen niet ontkend worden. Toegang tot de juiste vorm van gezondheidszorg, 
met toegewijde ‘zwangerschap en hartafwijkingen – klinieken’, is niet de standaard in veel 
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landen en afgelegen gebieden. Vrouwen presenteren zich vaak in een later stadium, van-
wege de kosten, maar ook vanwege hun culturele achtergrond, waarbij zwangerschap een 
vorm van status is. In Egypte bijvoorbeeld, is het dusdanig belangrijk om kinderen te krijgen, 
dat vrouwen vaak niet praten over hun hartafwijking. Alleen wanneer zwangerschap al in 
een ver gevorderd stadium is, of wanneer er serieuze problemen ontstaan, zoeken deze 
vrouwen hulp. En dat bemoeilijkt vroege interventie, laat staan preventie. Het is belangrijk 
om die interregionale verschillen in uitkomst in het achterhoofd te houden, niet alleen bij de 
interpretatie van ROPAC resultaten, maar ook wanneer men als doel heeft om de uitkomst 
van zwangerschap wereldwijd te verbeteren.
Deel II richt op zwangerschap in vrouwen met een hartklep afwijking. In hoofdstuk 7 en 
hoofdstuk 8 hebben we vrouwen bestudeerd met linkszijdige hartklep afwijkingen, te 
weten van  de aortaklep (tussen de linker kamer en de aorta) en de mitralisklep (tussen de 
linker boezem en de linker kamer). We beschrijven een cohort van 96 vrouwen met matige 
of ernstige aortaklep stenose (vernauwing). Zwangerschap gerelateerde sterfte bij aortaklep 
stenose kwam in onze studie niet voor, en het voorkomen van sterfte is daarmee veel lager 
dan in oudere studies. Echter, vrouwen met symptomatische ernstige aortaklepstenose in 
onze studie hadden een aanzienlijk risico op het ontwikkelen van hartfalen: in 26% van de 
zwangerschappen. Een aantal van hen had waarschijnlijk reeds voor de zwangerschap al 
een indicatie om klepvervanging te ondergaan. Het blijft een moeilijke beslissing of we 
vrouwen met een asymptomatische ernstige klepstenose voor de zwangerschap moeten 
behandelen of niet. Klepvervanging neemt namelijk een nieuw dilemma met zich mee: 
moet de klep vervangen worden door een biologische of een mechanische kunstklep? 
Wanneer gekozen wordt voor een mechanische kunstklep, weten we dat zwangerschap een 
risicovolle periode is wat betreft bloedingen en trombose (stolselvorming op de kunstklep, 
zie ook hoofdstuk 9). Wanneer gekozen wordt voor een biologische kunstklep, dan weten 
we dat die klep niet veel langer dan 10-15 jaar mee gaat en dat in deze jonge populatie dus 
een klepvervanging na die periode onvermijdelijk is, hetgeen ook niet zonder risico is. Onze 
studie laat zien dat bij vrouwen met een matig tot ernstige aortastenose er wel complicaties 
optreden, maar deze waren goed te behandelen en er was gelukkig geen sterfte in onze 
groep. Dat ondersteunt het beleid om bij de meeste vrouwen niet eerder te gaan opereren 
vanwege een zwangerschapswens. 
In hoofdstuk 7 laten we zien dat vrouwen met reumatische mitralisklep afwijkingen (door 
acuut reuma in de jeugd), en met name de vrouwen met mitralisklep stenose, een heel 
hoog risico hebben op een problematische zwangerschap. Dat kwam niet als een verass-
ing, aangezien de huidige richtlijnen adviseren om zwangerschap te vermijden in het geval 
van ernstige en symptomatische stenose. Deze laatste groep ontwikkelde hartfalen in 36% 
van de gevallen in onze studie. Maar het evident verhoogde risico van zwangerschap in 
vrouwen met matige mitralisklep stenose (hartfalen in 23%) en zelfs in vrouwen met een 
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significante mitralisklep insufficiëntie (eveneens hartfalen in 23%), is een bevinding die meer 
aandacht behoeft in de toekomstige richtlijnen: hoe moeten we omgaan met de situatie 
waarin een vrouw formeel nog geen kandidaat is voor klepvervanging, maar die wel een 
zwangerschapswens heeft in de aanwezigheid van bijvoorbeeld een matige mitralisklep 
stenose? Weegt het risico van zwangerschap zwaarder dan het risico van een interventie 
die eerder dan noodzakelijk wordt verricht? En welk type interventie is het veiligst, zoals 
hierboven op een rij gezet? Tijdens de zwangerschap hadden 14 vrouwen in onze studie 
een ballon dilatatie ondergaan (verwijding van de klepvernauwing via de bloedbaan met 
een ballon). Dit was geassocieerd met weinig problemen gedurende het verdere verloop 
van de zwangerschap en lijkt dus veilig.
In hoofdstuk 9 worden zwangerschappen beschreven bij vrouwen die een mecha-
nische of biologische kunstklep hebben. Vrouwen met een mechanische kunstklep 
hadden slechts een teleurstellende 58% kans op een ongecompliceerde zwangerschap 
resulterend in een levend geboren baby, terwijl vrouwen met een biologische prothese 
een veel gunstigere uitkomst hadden. De vraag blijft of er op langere termijn sprake is van 
een snellere achteruitgang van het functioneren van zo’n biologische prothese. Tevens is 
er veel ruimte voor verbetering wat betreft de behandeling met anticoagulantia (sterke 
‘bloedverdunners’) tijdens de zwangerschap. Bij mensen met een mechanische kunstklep 
moeten bloedverdunners (anticoagulantia) levenslang gebruikt worden in verband met 
het risico op stolselvorming op de mechanische kunstklep. Er zijn verschillende soorten 
anticoagulantia, bijvoorbeeld tabletten acenocoumarol (‘oraal’, vitamine K antagonisten) 
of subcutaan of intreveneus heparine (via de huid of de bloedbaan). De tabletten kunnen 
aangeboren afwijkingen bij de baby veroorzaken, maar zijn wel het veiligst voor de moeder. 
De spuitjes zijn veilig voor de baby, maar waarschijnlijk iets minder veilig voor de moeder 
en als er iets met de moeder gebeurt, heeft dit ook direct nadelige consequenties voor de 
baby. Richtlijnen voor zwangerschap in deze vrouwen adviseren verschillende strategieën, 
met een switch van orale naar subcutaan of intraveneus heparine in het eerste trimester, 
en voortzetten van de orale anticoagulantia gedurende het tweede en derde trimester. 
De switch wordt aanbevolen in verband met ernstige aangeboren afwijkingen bij de baby 
in geval van doorgebruik van orale anticoagulantia. Vanaf 36 weken zal er weer geswitcht 
moeten worden naar een subcutaan of intraveneus middel, om ernstige bloedingen bij het 
kind tijdens vaginale bevalling met name te voorkomen. In ons cohort bleek dat geen van 
de strategieën beduidend beter was. Wel bleek dat gebruik van het orale middel (vitamine 
K antagonist) in het eerste trimester, geassocieerd was met een hoog aantal foetale sterftes 
in het tweede en derde trimester, terwijl het gebruik van subcutaan heparine het risico op 
klep trombose leek te verhogen. De nieuwere orale middelen, zoals apixaban, hebben we 
niet onderzocht, maar zijn in het algemeen niet bruikbaar bij patiënten met een kunstklep 
omdat het niet veilig genoeg is om kunstklep trombose te voorkomen.
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De effecten van zwangerschap op de aorta vaatwand hebben we beschreven in hoofdstuk 
10, het eerste hoofdstuk van Deel III. Deze effecten leiden in principe niet tot ernstige prob-
lemen bij vrouwen zonder een onderliggende aortaziekte, maar vrouwen met een aorta 
syndroom zoals Marfan, Loeys Dietz of Turner syndroom hebben wel een verhoogd risico op 
een aorta dissectie (een scheur in de aorta). Een overzicht van de literatuur wordt gegeven 
in dit hoofdstuk, met de focus op specifieke aorta ziekten, farmacologische behandeling en 
chirurgische benaderingen tijdens de zwangerschap.
Turner syndroom wordt gekarakteriseerd door een partiële of totale afwezigheid van een 
X-chromosoom (monosomie). Het is geassocieerd met een korte gestalte, sub- of infertiliteit 
(verminderde/afwezige) vruchtbaarheid, en hart- en aorta afwijkingen. Zwangerschap was 
voorheen niet aan de orde voor het grootste deel van deze vrouwen. Maar sinds het mo-
gelijk is zwanger te worden na ontvangst van eiceldonatie, is het aantal vrouwen met Turner 
syndroom dat zwanger wordt toegenomen. Natuurlijk zijn er nog niet veel Turner vrouwen 
zwanger en er speelt nog veel onzekerheid en angst. In hoofdstuk 11 beschrijven we de 
zwangerschapswens, redenen om (nog) niet te proberen om zwanger te worden, en het 
aantal pogingen dat eindigt in een werkelijke zwangerschap. Een aanzienlijk aantal vrou-
wen had zorgen (gehad) rondom het risico op problemen van het hart en de aorta tijdens 
zwangerschap en bevalling, hetgeen duidelijk aandacht behoeft van de behandelende 
artsen die betrokken zijn bij de zorg rondom vrouwen met Turner syndroom. In hoofdstuk 
12 tonen we de uitkomst van zwangerschap in vrouwen met het Turner syndroom in ons 
centrum. Het aantal miskramen was hoog, maar bij de voldragen zwangerschappen, was 
er sprake van een relatief laag aantal cardiovasculaire complicaties. Echter, er is veel meer 
onderzoek noodzakelijk, aangezien de onderzoeken naar cardiovasculaire complicaties 
tijdens zwangerschap bij vrouwen met het Turner syndroom, inclusief onze studie, sterk 
beperkt worden door het kleine aantal patiënten dat geïncludeerd werd. Dit probleem 
geldt ook voor vrouwen met een SMAD3 mutatie: een recent ontdekte genetische afwijking 
waarbij patiënten een agressieve aorta ziekte ontwikkelen, geassocieerd met aneurysmata 
(verwijdingen van de aorta) en dissectie. De groep patiënten beschreven in hoofdstuk 13 in 
de eerste serie van zwangerschappen in SMAD3 patiënten. Geen ernstige cardiovasculaire 
problemen werden gevonden in 34 zwangerschappen in 17 vrouwen met zo’n genmutatie, 
die bijna allemaal een klinische uiting van het syndroom hadden of hadden ontwikkeld 
(sommigen enkele jaren na de zwangerschap). Deze retrospectieve studie kan gezien wor-
den als het startpunt voor verder onderzoek naar zwangerschap in deze vrouwen.
Hypertrofische cardiomyopathie is een aandoening waarbij de hartspier verdikt is, meestal 
door een genetische mutatie. Het wordt steeds vaker ontdekt op jonge leeftijd dankzij 
genetische screening. Over het algemeen wordt gedacht dat zwangerschap redelijk verdra-
gen kan worden, maar er is tot op heden nog weinig onderzoek naar gedaan. Hoofdstuk 
14 toont de relatief gunstige uitkomst van zwangerschap in vrouwen met hypertrofische 
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cardiomyopathie. In onze studie was er geen sprake van maternale sterfte, maar 15% van 
de vrouwen ontwikkelde hartfalen en 10% had een ventriculaire ritmestoornis gedurende 
de zwangerschap. Deze problemen traden meestal op tijdens het derde trimester, en direct 
postpartum. Vrouwen met kortademigheid of tekenen van hartfalen voorafgaand aan de 
zwangerschap hadden het hoogste risico op een complicatie. Er waren geen verschillen 
tussen vrouwen met obstructieve hartziekte (een situatie waarbij de hartspier zo verdikt 
is dat het de uitstroom van het bloed belemmert) en vrouwen zonder obstructieve ziekte. 
Het is van belang dat een vrouw met hypertrofische cardiomyopathie en een zwangersc-
hapswens op de hoogte is van het voorkomen van een cardiale complicatie in 23% van de 
gevallen.
Pulmonale hypertensie is een heel ander verhaal: zoals eerder benoemd is pulmo-
nale arteriële hypertensie (PAH, een verhoogde druk in het longvaatbed) een reden om 
zwangerschap te vermijden. Echter de studies waarop dit advies is gebaseerd, zijn over het 
algemeen retrospectieve studies. In hoofdstuk 15 tonen we dat de bestaande terughou-
dendheid gerechtvaardigd is. Maar tot op heden was er weinig bekend over het risico van 
zwangerschap in vrouwen met een verhoogde druk in de rechterkamer door linkszijdige 
hartziekte, hetgeen formeel gezien pulmonale hypertensie heet (omdat het niet arterieel 
bepaald is, maar primair een probleem van de linkerkant en dus het long veneuze vaatbed). 
In ons cohort hebben we 151 vrouwen met een verhoogde rechts druk (right ventricular 
systolic pressure, of RVSP) bestudeerd, van wie 26% PAH had en 74% verhoogde longdruk-
ken door linkszijdige hartafwijkingen. Hartfalen kwam respectievelijk voor in 36% en 25% 
van de zwangerschappen. Maternale sterfte kwam met name voor bij vrouwen met PAH 
zonder duidelijke oorzaak (idiopathisch): 3 uit 7 patiënten, 43%. Echter onder vrouwen uit 
de tweede groep, met linkszijdige hartafwijkingen, kwam ook sterfte voor in 2.7% van de 
zwangerschappen. Vrouwen met ernstig verhoogde drukken (RVSP>90 mmHg) hadden het 
hoogste risico op sterfte, trombotische problemen en bevalling van een baby met laag 
geboortegewicht (<2500gr), hoewel één en ander niet statistisch significant was bij te lage 
aantallen. De resultaten van onze studie impliceren dat pulmonale hypertensie door linkszij-
dige hartafwijkingen wellicht een lager risico met zich mee brengt tijdens de zwangerschap 
dan in het geval van PAH, maar dat deze vrouwen zeker goed geïnformeerd moeten worden 
over de risico’s. Het zou aan te bevelen zijn om in de toekomstige richtlijnen een duidelijk 
onderscheid te maken in adviezen voor vrouwen met mild, matig en ernstig verhoogde 
rechts drukken.
Het doel van dit proefschrift was om een aantal vragen te beantwoorden, maar er zijn nog 
zoveel vragen te beantwoorden. Wat zijn de risico’s van zwangerschap in vrouwen met een 
ritmestoornis zonder onderliggende structurele hartafwijking? Wat is het effect van het 
preconceptioneel advies van artsen in de verschillende WHO klasses? Is fertiliteitsbehandel-
ing een optie in vrouwen met een complexe aangeboren hartafwijking, die inmiddels een 
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langere levensverwachting hebben dan vroeger dankzij de verbeterde medische technolo-
gien? We staan aan het begin van de ontwikkeling van een zeer interessant onderzoeks-
gebied. Door deze vragen te beantwoorden krijgen jonge vrouwen met een hartafwijking 
steeds meer een kans hun leven op een zo normaal mogelijke manier te leiden. Voorop staat 
dat zij voorafgaand aan pogingen om zwanger te worden in ieder geval goed geinformeerd 
moeten worden over hun risico op problemen tijdens en na de zwangerschap. Goede 
informatie en een gedegen besluitvorming zullen bijdragen aan een veiligere situatie voor 
moeders met een hartafwijking en hun toekomstige kinderen.
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Leading a ‘normal’ life is important to young women 
with heart disease, just as it is for their healthy peers, 
and pregnancy is one important aspect of that normal 
life. This thesis investigated the risk of pregnancy in 
women with several types of cardiac and aortic disease. 
Apart from some high risk groups, women with cardiac 
disease tolerate pregnancy reasonably well in the cur-
rent era. The majority of young girls and women with 
heart disease can be reassured about these improving 
prospects, provided that we accurately search for the 
ones with a substantial higher risk. We are still at the 
beginning of elucidating this interesting research area. 
By shedding a light on these issues, young women with 
heart disease will have a chance to lead a life as close 
to normal.
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